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With	  9	  million	  people	  in	  the	  UK	  alone	  suffering	  from	  deafness	  or	  hearing	  impairment,	  
there	   is	   a	   concerted	   effort	   to	   develop	   effective	   treatments.	   To	   address	   this,	   one	  
strategy	   is	   to	   recruit	  mechanisms	   naturally	   occurring	   during	   inner	   ear	   development,	  
but	  this	  first	  requires	  a	  clear	  picture	  of	  the	  normal	  molecular	  mechanisms	  underlying	  
this	  developmental	  process.	  	  
	  
Fibroblast	   growth	   factors	   (FGFs)	   are	   short-­‐range	   extracellular	   signalling	   molecules,	  
with	   Fgf3	   and	   Fgf10	   already	   shown	   to	   be	   critical	   for	   the	   earliest	   event	   of	   inner	   ear	  
induction.	   Interestingly	   these	   ligands	   are	   also	   expressed	   in	   the	   inner	   ear	   itself,	   and	  
mutations	   in	   both	   Fgf3	   and	   Fgf10	   have	   independently	   been	   linked	   to	   sensorineural	  
deafness	  in	  humans.	  This	  project	  is	  focused	  on	  unravelling	  the	  molecular	  mechanisms	  
controlling	  their	  expression	  in	  the	  inner	  ear.	  
	  
Bioinformatic	  analysis	  of	   the	  Fgf3	  and	  Fgf10	  enhancer	  regions	  revealed	  the	  presence	  
of	  putative	  binding	  sites	  for	  retinoic	  acid	  (RA).	  RA	  is	  a	  key	  signalling	  molecule	  in	  inner	  
ear	  development	  with	  both	  excess	  and	  deficit	  leading	  to	  inner	  ear	  abnormalities.	  First,	  
a	   novel,	   non-­‐invasive	   method	   of	   RA	   administration	   via	   sugar	   pellet	   was	   tested	   and	  
proved	   to	   be	   an	   efficient	   and	   reliable	   alternative	   to	   gavage.	   	   Using	   an	   Fgf3-­‐lacZ	  
reporter	   mouse,	   the	   effects	   of	   RA	   excess	   on	   Fgf3	   expression	   were	   investigated	   in	  
detail.	  In	  addition,	  preliminary	  studies	  of	  the	  effects	  of	  RA	  on	  Fgf10	  were	  also	  carried	  
out.	   Both	   Fgf3	   and	   Fgf10	   were	   downregulated	   with	   high	   doses	   of	   RA,	   confirming	  
previous	  in	  vitro	  studies.	  In	  addition,	  detailed	  analysis	  of	  Fgf3-­‐lacZ	  embryos	  exposed	  to	  
RA	   revealed	   that	   downregulation	   critically	   depends	   on	   the	   dose	   and	   time	   of	  
administration.	  
	  
To	   further	   explore	   other	   direct	   regulators	   of	   Fgf10	   expression,	   additional	   reporter	  
constructs	  were	  also	  generated	  for	  functional	  analysis	  in	  mouse	  and	  in	  chick.	  To	  date,	  
analysis	  of	  electroporated	  chick	  embryos	  shows	  that	  ear	  specific	  Fgf10	  regulation	  may	  
not	  be	  conserved	  between	  these	  two	  species.	  
  
4	  






1	  	   INTRODUCTION…………………………………………………………………………………………..13	  
1.1 Ear	  structure	  and	  function	  ……………………………………...………………………………......	  14	  
1.2 Development	  of	  the	  mammalian	  inner	  ear	  ……………………………………………………	  22	  
1.3 The	  role	  of	  FGFs	  in	  inner	  ear	  development	  .………………………………………………....	  31	  
1.4 Retinoic	  acid	  signalling	  ......................................................................................	  39	  
1.5 Other	  putative	  upstream	  regulators	  of	  Fgf10	  ...................................................	  49	  
1.6 Treating	  hearing	  impairment	  ............................................................................	  52	  
1.7 Project	  aims	  ......................................................................................................	  54	  
	  
2 MATERIAL	  AND	  METHODS	  ...............................................................................	  55	  
2.1 Mouse	  genotyping	  ............................................................................................	  55	  
2.2 Retinoic	  acid	  administration	  to	  pregnant	  mice	  	  ................................................	  59	  
2.3 Staining	  embryos	  for	  β-­‐Galactosidase	  activity	  	  .................................................	  62	  
2.4 Histological	  methods	  ........................................................................................	  63	  
2.5 General	  DNA	  manipulation	  ...............................................................................	  63	  
2.6 Reporter	  vectors	  ...............................................................................................	  71	  
2.7 Fgf10	  reporter	  constructs	  .................................................................................	  74	  
2.8 In	  situ	  hybridization	  ..........................................................................................	  78	  
2.9 Immunohistochemistry	  .....................................................................................	  81	  
2.10 Chick	  otic	  vesicle	  electroporation	  .....................................................................	  82	  






3 RETINOID	  CONTROL	  OF	  FGF3	  EXPRESSION	  .....................................................	  85	  
3.1 Development	  of	  an	  improved	  method	  for	  RA	  administration	  .........................	  86	  
3.2 Validation	  of	  the	  new	  protocol	  for	  administering	  RA	  using	  sugar	  pellets	  ........	  87	  
3.3 Fgf3	  expression	  in	  9.5dpc	  embryos	  exposed	  to	  RA	  at	  7.75dpc	  ........................	  91	  
3.4 RA-­‐induced	  downregulation	  of	  Fgf3	  expression	  is	  maintained	  at	  10.5dpc	  ......	  99	  
3.5 Semi-­‐quantitative	  analysis	  of	  downregulation	  of	  otic	  Fgf3	  expression	  ..........	  101	  
3.6 Fgf3	  expression	  in	  9.5dpc	  embryos	  exposed	  to	  RA	  at	  8.5dpc	  ........................	  104	  
3.7 Generation	  of	  RA-­‐induced	  phenotypes	  in	  other	  organ	  systems	  .....................	  109	  
3.8 Fgf3/Fgf10	  crossregulation	  .............................................................................	  111	  
	  
4 INVESTIGATING	  FGF10	  TRANSCRIPTIONAL	  REGULATION	  	  ...............	  .............115	  
4.1 The	  endogenous	  Fgf10	  expression	  pattern	  ....................................................	  115	  
4.2 Generation	  of	  Fgf10-­‐reporter	  constructs	  for	  analysis	  in	  mice	  ........................	  118	  
4.3 Candidate	  upstream	  regulators	  of	  Fgf10	  expression	  ......................................	  132	  
4.4 Reporter	  constructs	  to	  investigate	  Fgf10	  regulation	  by	  the	  Ngn1	  pathway	  ...	  140	  
4.5 Generation	  and	  analysis	  of	  an	  Fgf10-­‐reporter	  transgenic	  mouse	  line	  ...........	  153	  
4.6 Investigation	  of	  mouse	  Fgf10	  regulation	  in	  the	  chick	  inner	  ear	  	  ....................	  157	  
4.7 Regulation	  of	  Fgf10	  by	  retinoic	  acid	  ...............................................................	  169	  
	  
5 DISCUSSION	  ....................................................................................................	  172	  
5.1 Regulation	  of	  Fgf3	  by	  retinoids	  .......................................................................	  172	  
5.2 Regulatory	  analysis	  of	  Fgf10	  ...........................................................................	  192	  
5.3 Conclusion	  ......................................................................................................	  202	  
	  
APPENDIX……………………………………….	  ........................................................................	  204	  
	  







TABLE	  OF	  FIGURES	  
	  
	  
Figure	  1.1	  Gross	  anatomy	  of	  the	  ear	  ............................................................................	  15	  
Figure	  1.2	  Structure	  of	  the	  inner	  ear	  ............................................................................	  18	  
Figure	  1.3	  Transduction	  of	  sound-­‐induced	  vibration	  into	  neural	  signals	  …...................	  20	  
Figure	  1.4	  Fgfs	  expression	  during	  inner	  ear	  induction	  in	  mouse	  ..................................	  24	  
Figure	  1.5	  A	  model	  of	  otic	  patterning	  and	  axis	  specification	  ........................................	  24	  
Figure	  1.6	  Inner	  ear	  development	  ................................................................................	  28	  
Figure	  1.7	  FGFs	  signalling	  ..............................................................................................	  33	  
Figure	  1.8	  Retinoic	  acid	  signalling	  .................................................................................	  40	  
Figure	  1.9	  RA	  synthetic/catabolic	  enzymes	  and	  nuclear	  receptors	  distribution	  	  
in	  the	  developing	  inner	  ear	  ...........................................................................................	  40	  
Figure	  1.10	  Differential	  effects	  of	  RA	  on	  hindbrain	  signalling	  ......................................	  46	  
Figure	  1.11	  Conceptual	  drawing	  of	  a	  normal,	  damaged	  and	  repaired	  organ	  of	  Corti...	  53	  
Figure	  2.1	  Genotyping	  of	  Fgf10	  knockout	  embryos	  .....................................................	  56	  
Figure	  2.2	  pZsGreen1-­‐1	  vector	  .....................................................................................	  72	  
Figure	  2.3	  pDsRed-­‐Express2-­‐1	  vector	  ...........................................................................	  72	  
Figure	  2.4	  PCR	  primers	  location	  within	  the	  7.0kb	  Fgf10	  upstream	  region	  ...................	  74	  
Figure	  3.1	  Dose-­‐dependant	  embryo	  malformations	  following	  RA	  administration	  
	  via	  sugar	  pellets	  ...........................................................................................................	  89	  
Figure	  3.2	  Analysis	  of	  Fgf3-­‐lacZ	  expression	  pattern	  in	  9.5dpc	  embryos	  	  
following	  administration	  of	  increasing	  doses	  of	  RA	  at	  7.75dpc	  ....................................	  92	  
Figure	  3.3	  Effect	  of	  RA	  on	  otic	  Fgf3	  expression	  following	  administration	  at	  7.75dpc...	  96	  
Figure	  3.4	  Early	  time	  course	  of	  Fgf3-­‐lacZ	  expression	  ...................................................	  98	  
Figure	  3.5	  Effects	  of	  RA	  exposure	  at	  7.75dpc	  on	  10.5dpc	  embryos	  ...........................	  100	  
Figure	  3.6	  Image	  analysis	  of	  Fgf3	  expression	  in	  the	  9.5dpc	  otic	  vesicle	  	  
exposed	  to	  increasing	  doses	  of	  RA	  at	  7.75dpc	  ...........................................................	  102	  
Figure	  3.7	  Effects	  of	  RA	  administration	  after	  hindbrain	  patterning	  ..........................	  105
	   	  
  
7	  
Figure	  3.8	  Image	  analysis	  of	  Fgf3	  expression	  in	  the	  9.5dpc	  otic	  vesicle	  	  
exposed	  to	  increasing	  doses	  of	  RA	  at	  8.5dpc	  .............................................................	  108	  
Figure	  3.9	  Generation	  of	  identical	  RA	  phenotypes	  using	  gavage	  or	  sugar	  pellets	  	  
in	  other	  organ	  systems	  ...............................................................................................	  110	  
Figure	  3.10	  Wholemount	  analysis	  of	  early	  Fgf3-­‐lacZ	  expression	  	  
in	  a	  Fgf10	  null	  background	  .........................................................................................	  113	  
Figure	  3.11	  Analysis	  of	  early	  Fgf3-­‐lacZ	  expression	  on	  sections	  	  
in	  a	  Fgf10	  null	  background	  .........................................................................................	  113	  
Figure	  4.1	  Early	  Fgf10	  mRNA	  expression	  in	  the	  developing	  mouse	  embryo	  .............	  	  117	  
Figure	  4.2	  Schematic	  of	  the	  Fgf10	  upstream	  region	  and	  constructs	  generated	  ........	  119	  
Figure	  4.3	  The	  7F7R-­‐DsRed	  reporter	  construct	  ………………………………………………………	  120	  
Figure	  4.4	  Reconstruction	  of	  the	  7F7R	  enhancer	  .......................................................	  122	  
Figure	  4.5	  Modification	  of	  the	  pDsRed-­‐Express2-­‐1	  reporter	  vector	  ..........................	  124	  
Figure	  4.6	  The	  7F3F-­‐3R7R-­‐ZsGreen	  reporter	  construct	  …………………………………………..	  125	  
Figure	  4.7	  Generation	  of	  a	  7F7R	  enhancer	  specifically	  deleted	  from	  3F3R	  ...............	  127	  
Figure	  4.8	  The	  7F3F	  and	  3R7R-­‐DsRed	  reporter	  constructs	  ………………………………………	  129	  
Figure	  4.9	  Generation	  of	  the	  7F3F-­‐DsRed	  construct	  ..................................................	  130	  
Figure	  4.10	  Generation	  of	  the	  3R7R-­‐DsRed	  construct	  ................................................	  131	  
Figure	  4.11	  Generation	  and	  trial	  of	  Gata3	  riboprobes	  ...............................................	  134	  
Figure	  4.12	  Early	  pattern	  of	  Gata3	  expression	  in	  the	  developing	  inner	  ear	  ...............	  136	  
Figure	  4.13	  Presence	  of	  conserved	  putative	  binding	  sites	  for	  neurogenic	  	  
factors	  upstream	  Fgf10	  ..............................................................................................	  138	  
Figure	  4.14	  Comparative	  analysis	  of	  NeuroD	  and	  Fgf10	  expression	  	  
in	  wholemount	  in	  situ	  mouse	  embryos	  at	  9.5dpc	  and	  10.5dpc	  .................................	  138	  
Figure	  4.15	  The	  Neuro2.5-­‐DsRed	  reporter	  construct	  ……………………………………………..	  140	  
Figure	  4.16	  Generation	  of	  a	  Neurod2.5-­‐DsRed	  reporter	  construct	  ...........................	  142	  
Figure	  4.17	  The	  Neuro1.1-­‐DsRed	  reporter	  construct	  ……………………………………………..	  144	  
Figure	  4.18	  Generation	  of	  a	  Neuro1.1-­‐DsRed	  reporter	  construct	  .............................	  145	  
Figure	  4.19	  The	  3F-­‐Neuro-­‐DsRed	  reporter	  construct	  ……………………………………………..	  148	  
Figure	  4.20	  Generation	  of	  3F-­‐Neuro-­‐DsRed	  construct	  ...............................................	  149	  
Figure	  4.21	  The	  7F-­‐Neuro-­‐DsRed	  reporter	  construct	  ………………………………………………	  151	  
Figure	  4.22	  Generation	  of	  7F-­‐Neuro-­‐DsRed	  construct	  ...............................................	  152	  
  
8	  
Figure	  4.23	  Genotyping	  and	  in	  vivo	  analysis	  of	  7F7R-­‐DsRed	  transgenic	  mice	  ............	  154	  
Figure	  4.24	  MiniBglobin-­‐ZsGreen	  and	  MiniZsGreen-­‐DsRed	  reporter	  vectors	  ............	  159	  
Figure	  4.25	  Electroporation	  of	  mouse	  Fgf10	  constructs	  in	  chick	  	  
using	  a	  dual	  reporter	  system	  ......................................................................................	  161	  
Figure	  4.26	  Regulation	  of	  Fgf10	  mouse	  enhancers	  in	  chick	  .......................................	  164	  
Figure	  4.27	  Effect	  of	  exogenous	  RA	  administration	  on	  Fgf10	  expression	  ..................	  170	  
Figure	  5.1	  Effects	  of	  RA	  and	  FGFs	  signalling	  on	  the	  expression	  of	  anterior	  and	  posterior	  
otic	  genes	  ………………………………………………………………………………………………………………	  182	  
Figure	  5.2	  Model	  of	  exogenous	  retinoic	  acid	  effect	  on	  otic	  patterning	  .....................	  189	  

























TABLE	  OF	  TABLES	  
	  
Table	  2.1	  Set	  of	  primers	  used	  for	  the	  genotyping	  of	  the	  4	  transgenic	  mice	  lines	  	  
used	  in	  this	  study	  ..........................................................................................................	  56	  
Table	  2.2	  PCR	  conditions	  for	  LacZ	  genotyping	  ..............................................................	  57	  
Table	  2.3	  Standard	  PCR	  conditions	  ...............................................................................	  58	  
Table	  2.4	  PCR	  reaction	  mix	  for	  genotyping	  of	  Fgf10neo	  embryos	  ..................................	  58	  
Table	  2.5	  Reaction	  mix	  for	  blunting	  using	  T4	  DNA	  polymerase	  ....................................	  64	  
Table	  2.6	  Plasmid	  dephosphorylation	  reaction	  mix	  ......................................................	  65	  
Table	  2.7	  Typical	  ligation	  set	  up	  	  ...................................................................................	  67	  
Table	  2.8	  List	  of	  primers	  used	  to	  generate	  Fgf10	  enhancer	  fragments	  ........................	  74	  
Table	  2.9	  Conditions	  used	  for	  3R7R	  fragment	  amplification	  with	  Phusion	  ..................	  75	  
Table	  2.10	  Reaction	  mix	  used	  for	  3R7R	  fragment	  amplification	  ..................................	  75	  
Table	  2.11	  Conditions	  used	  for	  7F3F	  and	  Neuro2.5	  fragments	  amplification	  
with	  Expand	  Long	  Template	  .........................................................................................	  76	  
Table	  2.12	  Reaction	  mix	  used	  for	  7F3F	  and	  Neuro2.5	  fragments	  amplification	  ...........	  76	  
Table	  2.13	  Conditions	  used	  for	  Neuro1.1	  amplification	  with	  Phusion	  .........................	  77	  
Table	  2.14	  Reaction	  mix	  used	  for	  Neuro1.1	  fragment	  amplification	  ............................	  77	  
Table	  2.15	  Riboprobe	  synthesis	  ....................................................................................	  78	  
Table	  2.16	  Riboprobe	  purification	  by	  precipitation	  in	  Lithium	  Chloride	  	  ......................	  79	  
Table	  3.1	  Range	  of	  doses	  used	  to	  investigate	  the	  role	  of	  RA	  in	  the	  development	  of	  
different	  organ	  systems	  ................................................................................................	  87	  
Table	  3.2	  Incidence	  of	  phenotypes	  and	  changes	  in	  Fgf3	  expression	  	  
with	  increasing	  dose	  of	  RA	  administered	  at	  7.75dpc	  and	  8.5dpc	  .................................	  90	  
Table	   S1	   Range	   of	   all-­‐trans	   retinoic	   acid	   doses	   administrated	   to	   pregnant	   mice	   via	  






















I	  would	   like	  to	  thank	  the	  people	  who	  gave	  me	  the	  opportunity	  to	  carry	  out	  the	  work	  
reported	  in	  this	  thesis.	  First,	  I	  would	  like	  to	  thank	  Sussex	  University	  for	  supporting	  me	  
through	  my	  first	  3	  years	  of	  PhD	  with	  a	  GTA	  studentship.	  I	  would	  also	  like	  to	  thank	  my	  
supervisor,	  Mark	  Maconochie,	  for	  his	  support,	  especially	  during	  the	  last	  months	  of	  my	  
experimental	  work,	  and	  for	  his	  critical	  reading	  and	  suggestions	  on	  this	  thesis.	  I	  am	  also	  
grateful	  to	  Androulla	  Economou	  for	  her	  help	  and	  advices,	   in	  particular	  with	  the	  chick	  
electroporations.	  
	  
I	  would	   also	   like	   to	   thank	   other	   researchers	   and	   students	  working	   in	   the	   laboratory	  
during	  my	  PhD	  for	  their	  help	  and	  friendship:	  Vassilis,	  Preeta,	  Fara,	  Maria	  and	  Prathu;	  or	  
in	  adjacent	  laboratory:	  Richard,	  Julia	  and	  Nicola.	  I	  would	  also	  like	  to	  express	  my	  thanks	  
to	  Vince	  Edwards	   for	   excellent	   animal	  husbandry	  and	  his	  help	  with	  mouse	  handling;	  
and	  I	  am	  also	  grateful	  to	  all	  the	  undergraduate	  students	  who	  made	  my	  teaching	  duty	  
really	  enjoyable	  with	  their	  kindness	  and	  enthusiasm.	  
	  
I	  am	  also	  grateful	  to	  all	  of	  the	  teachers	  and	  teaching	  assistants	  who	  communicated	  me	  
their	   passion	   for	   science	   during	  my	   degree	   in	   France:	   Francois	   Cretin,	   Remy	   Sadoul,	  
Rabah	  Iratni,	  Claire	  Vourc’h,	  Thierry	  Gauthier	  and	  Anne-­‐Laure	  Mahul.	  
	  
I	  want	  to	  thanks	  as	  well	  all	  the	  people	  I	  have	  been	  working	  with	  at	  American	  Express	  
during	  the	  writing	  of	  my	  thesis	  for	  their	  cheerful	  company:	  Sarah,	  Elodie,	  Ndjimi,	  Pat,	  
Vero,	  Aylin,	  William,	  Adrien,	  Ben,	  Jerome,	  Laurent,	  Donald,	  Elias,	  Emma…	  to	  name	  just	  
a	  few.	   I	  would	  have	  never	  finished	  that	  thesis	  without	  all	  your	  positive	  energy!	   I	  also	  
want	  to	  thank	  my	  team	  leader	  Yves	  Tillieux	  for	  his	  flexibility	  when	  I	  needed	  last	  minute	  
days	  off	  to	  finish	  my	  thesis.	  	  
	  
To	  finish	  I	  am	  obviously	  grateful	  to	  my	  family	  and	  friends	  for	  their	  understanding	  and	  











Hearing	  loss	  is	  one	  of	  the	  most	  common	  sensory	  deficits	  with	  over	  200	  million	  people	  
worldwide	  suffering	  from	  deafness	  or	  experiencing	  severe	  hearing	   impairment	  either	  
induced	   or	   inherited.	   In	   the	   UK	   alone,	   1	   in	   850	   children	   is	   born	   with	   significant	  
sensorineural	  deafness	  (Fortnum	  et	  al.,	  2001)	  and	  in	  Europe,	  roughly	  30%	  of	  men	  and	  
20%	  of	  women	  suffer	  from	  presbycusis,	  or	  age-­‐related,	  bilateral	  hearing	  loss	  (ARHL),	  by	  
age	  70	  years,	  with	  a	  loss	  of	  30	  dB	  or	  more.	  	  These	  numbers	  keep	  increasing	  as	  people	  
age,	  with	  55%	  of	  men	  and	  45%	  of	  women	  by	  age	  80	  years	  suffering	  from	  ARHL	  (Roth	  et	  
al.,	  2001).	  Presbycusis	  in	  the	  aged	  has	  been	  correlated	  with	  a	  decreased	  quality	  of	  life	  
and	  depression	  (Mulrow	  et	  al.,	  1990),	  and	  hearing	  loss	  in	  children	  has	  been	  shown	  to	  
affect	   behaviour,	   confidence	   and	   social	   integration	   (Moeller,	   2007).	   Furthermore,	  
hearing	  loss	  costs	  billions	  in	  healthcare	  each	  year	  (Frisina,	  2009;	  Shield,	  2006).	  Thus	  in	  
addition	  to	  the	  challenges	  faced	  every	  day	  by	  people	  affected	  to	  adapt	  to	  this	  sensory	  
deficit,	  hearing	  loss	  has	  serious	  financial	  consequences	  for	  everyone.	  	  
	  
Current	  treatment	  options	  for	  hearing	  impairment,	  such	  as	  hearing	  devices	  (aids)	  and	  
cochlear	   implants,	  do	  not	  restore	  hearing	  to	  a	  normal	   level	   (www.nidcd.nih.gov)	  and	  
thus	  more	  effective	  treatments	  need	  to	  be	  found.	  One	  alternative	  long-­‐term	  strategy	  is	  
to	  recruit	  biological	  mechanisms	  naturally	  occurring	  during	  inner	  ear	  development,	  but	  
this	  first	  requires	  a	  clear	  picture	  of	  the	  normal	  molecular	  mechanisms	  underlying	  this	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developmental	  process.	  Fibroblast	  growth	  factors	  (FGFs)	  are	  short-­‐range	  extracellular	  
signalling	  molecules,	  with	  Fgf3	  and	  Fgf10	  already	  shown	  to	  be	  critical	  for	  the	  earliest	  
events	  of	  inner	  ear	  induction	  (Alvarez	  et	  al.,	  2003;	  Zelarayan	  et	  al.,	  2007).	  In	  addition,	  
they	  are	  also	  expressed	  in	  the	  inner	  ear	  itself	  (Ohuchi	  et	  al.,	  2005;	  Pauley	  et	  al.,	  2003;	  
Powles	  et	  al.,	  2004)	  and	  mutations	   in	  both	  Fgf3	   and	  Fgf10	  have	   independently	  been	  
linked	  to	  sensorineural	  deafness	  in	  human	  (Shams	  et	  al.,	  2007;	  Tekin	  et	  al.,	  2008).	  This	  
thesis	   addresses	   the	   lack	   of	   knowledge	   regarding	   the	   molecular	   mechanisms	  
controlling	  their	  expression	  in	  the	  inner	  ear.	  
	  
1.1 Ear	  structure	  and	  function	  
For	  someone	  able	  to	  perceive,	  interpret	  and	  appreciate	  sounds	  every	  day,	  hearing	  may	  
feel	   like	   a	   rather	   banal	   phenomenon;	   but	   it	   actually	   depends	   on	   really	   complex	  
mechanisms	  that	  are	  presented	   in	  this	  section.	  To	  start	  with,	  we	  first	  need	  to	  define	  
how	  ‘hearing’	  happens.	  A	  sound	  is	  essentially	  a	  longitudinal	  wave	  causing	  an	  oscillation	  
of	  pressure	  or	  vibrations	  of	  air	  molecules	  (Purves	  and	  Williams,	  2001).	  The	  concept	  of	  
‘noise’	  or	  the	  concept	  of	  ‘talking’	  only	  exists	  because	  we	  come	  naturally	  equipped	  with	  
a	   transducer	   that	   converts	   these	   mechanical	   waves	   into	   neural	   signals	   that	   can	   be	  
interpreted	   by	   the	   auditory	   cortex.	   But	   how	   does	   this	   actually	   happen?	  Mechanical	  
waves	   will	   undergo	   multiple	   modifications	   before	   being	   processed	   by	   the	   brain	   to	  
extract	   the	  useful	   information	   from	   the	  original	   signal.	   	  Most	   of	   these	  modifications	  
will	   occur	   in	   the	   ear	   that	   itself	   is	   composed	   of	   3	   distinct	   parts;	   the	   outer	   ear,	   the	  
middle	  ear	  and	  the	  inner	  ear	  (Figure	  1.1),	  and	  thus	  their	  characteristics	  and	  functions	  
are	  presented	  below.	  
	  
Figure	  1.1	  –	  Gross	  anatomy	  of	  the	  ear.	  The	  ear	  is	  composed	  of	  the	  outer	  ear,	  middle	  ear	  and	  
inner	   ear.	   	   The	   outer	   ear	   can	   be	   subdivided	   into	   the	   pinna,	   concha	   and	   external	   auditory	  
meatus	  (or	  ear	  canal)	  and	  is	  separated	  from	  the	  middle	  ear	  by	  the	  tympanic	  membrane.	  The	  
pinna	  and	  concha	  gather	  sound	  wave	  and	  focus	  them	  on	  the	  ear	  canal	  that	  boosts	  sound	  up	  to	  
100	  fold,	  causing	  the	  tympanic	  membrane	  to	  vibrate.	  The	  middle	  ear	  transmits	  and	  ampliﬁes	  
the	  movement	  of	  the	  tympanic	  membrane	  	  to	  the	  inner	  ear	  through	  a	  lever	  system	  consis@ng	  
of	  3	   interconnected	  auditory	  ossicles.	  The	  cochlea	  ampliﬁes	  and	  decomposes	   these	  complex	  
acous@cal	  waveforms	  into	  their	  cons@tuents.	  These	  are	  then	  transduced	  to	  electrical	  energy	  in	  
cochlear	   hair	   cells	   and	   transmiBed	   to	   the	   brain	   via	   the	   statoacous@c	   nerve.	   Adapted	   by	  
permission	   from	   Macmillan	   Publishers	   Ltd:	   Nature	   Reviews	   Neuroscience	   (Kelley,	   2006),	  
copyright	  (2006)	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1.1.1	  	  The	  outer	  ear	  
The	  outer	  ear	  can	  be	  subdivided	  into	  the	  pinna,	  the	  concha	  and	  the	  external	  auditory	  
meatus	   (EAM)	   or	   ear	   canal	   (Figure	   1.1).	   Each	   of	   these	   parts	   plays	   a	   specific	   and	  
important	   role	   in	   hearing.	   The	   pinna	   and	   the	   concha	   gather	   sound	   waves	   and	  
participate	   in	   their	   localisation.	   The	   ear	   canal	   boosts	   the	   sound	   30-­‐	   to	   100-­‐fold	   for	  
frequencies	   around	   3kHz	   and	   focuses	   it	   on	   the	   tympanic	   membrane.	   The	   tympanic	  
membrane	   is	   composed	  of	   two	  apposed	  epithelia;	   one	  provided	  by	   the	  external	   ear	  
meatus	  and	  the	  other	  by	  the	  middle	  ear	  cavity.	  A	  fibrous	  layer	  located	  between	  these	  
two	  epithelia	   gives	   the	  membrane	   consistency	   and	  elasticity	   (Mallo,	   2001).	   This	   thin	  
membrane	   is	   stretched	   between	   the	   air	   compartments	   of	   the	   outer	   and	  middle	   ear	  
(Figure	   1.1),	   causing	   it	   to	   vibrate	   in	   reaction	   to	   the	   acoustic	   pressure	   wave	   that	  
impinges	  on	  it	  (Purves	  and	  Williams,	  2001).	  
	  
1.1.2	  	  The	  middle	  ear	  
The	  airborne	  sound-­‐induced	  vibrations	  captured	  by	  the	  external	  ear	  then	  need	  to	  be	  
transmitted	  to	  the	  inner	  ear,	  where	  they	  will	  be	  converted	  into	  neural	  signals	  that	  can	  
be	   interpreted	   by	   the	   auditory	   cortex.	   The	   middle	   ear	   not	   only	   transfers	   sound	  
pressure	   waves	   to	   the	   inner	   ear	   but	   it	   also	  matches	   the	   relatively	   low	   impendence	  
airborne	   sounds	   to	   the	   higher	   impendence	   fluid	   of	   the	   inner	   ear	   and	   enhances	  
important	  frequencies	  (Pickles,	  1988).	  	  The	  middle	  ear	  transmits	  the	  vibrations	  of	  the	  
tympanic	  membrane	  to	  the	  inner	  ear	  through	  a	  lever	  system	  consisting	  of	  three	  small,	  
interconnected,	   skeletal	  elements	  or	  auditory	  ossicles:	   the	  malleus,	   incus	  and	   stapes	  
(Figure	  1.1).	  The	  malleus	  provides	  the	  physical	  link	  between	  the	  ossicle	  chain	  and	  the	  
tympanic	  membrane.	  The	  incus	  then	  makes	  the	  link	  between	  the	  body	  of	  the	  malleus	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and	  a	  small	  head	  in	  the	  middle	  of	  the	  stapedial	  arch.	  The	  stapes	  eventually	  provide	  the	  
connection	  of	  the	  ossicles	  to	  the	  inner	  ear.	  	  Due	  to	  this	  spatial	  arrangement,	  vibration	  
of	  the	  tympanic	  membranes	  results	  in	  a	  piston-­‐like	  movement	  of	  these	  ossicles,	  which	  
in	   turn	   initiates	   waves	   in	   the	   inner	   ear	   fluids	   (the	   inner	   ear	   compartments	   and	   the	  
consequences	   of	   these	   waves	   are	   described	   in	   section	   1.1.3).	   Without	   the	   ossicles,	  
only	  a	  small	  portion	  of	  sound	  would	  reach	  the	  inner	  ear	  (Kurokawa	  et	  al.	  1995).	  As	  well	  
as	  transferring	  sound	  energy	  from	  the	  outer	  to	  the	  inner	  ear,	  the	  middle	  ear	  therefore	  
plays	  a	  significant	  role	  in	  amplifying	  the	  vibrations	  set	  up	  on	  the	  tympanic	  membrane.	  	  
This	  role	  in	  amplification	  is	  estimated	  to	  increase	  by	  200-­‐fold	  the	  pressure	  measured	  at	  
the	  tympanic	  membrane	  (Mallo,	  2001;	  Purves	  and	  Williams,	  2001)	  
	  
1.1.3	  The	  inner	  ear	  
The	   inner	  ear	   is	   arranged	  as	  a	  highly	   complex	  membranous	   labyrinth	  encased	   in	   the	  
petrous	   part	   of	   the	   temporal	   bone	   in	   the	   skull.	   The	   inner	   ear	   can	   be	   functionally	  
subdivided	  into	  two	  regions:	  	  the	  vestibule	  and	  the	  cochlea	  (Figure	  1.2).	  Both	  of	  these	  
divisions	   of	   the	   inner	   ear	   contain	   regions	   of	   sensory	   hair	   cells.	   Hair	   cells	   act	   as	  
mechanotransducers	   that	  are	   connected	   to	   the	  auditory	  and	  vestibular	  nuclei	  of	   the	  
brain,	  through	  bipolar	  neurons.	  The	  vestibule	  is	  located	  dorsally	  and	  is	  responsible	  for	  
the	   sense	   of	  motion	   and	   gravity	   (Alsina	   et	   al.,	   2009).	   The	   cochlea,	   which	   is	   located	  
ventrally,	   is	   the	  most	   critical	   structure	   in	   the	   auditory	   pathway.	   	   Not	   only	   does	   the	  
cochlea	  amplify	   the	   incoming	  sound	  wave	  but	   it	  also	  acts	  as	  a	  mechanical	   frequency	  
analyser,	  by	  decomposing	  complex	  acoustical	  waveforms	  into	  its	  constituents,	  before	  
converting	  them	  into	  neural	  signals	  (Alsina	  et	  al.,	  2009).	  	  
(A)	  
(B)	  
Figure	   1.2	   Structure	   of	   the	   Inner	   Ear.	  The	   inner	   ear	   can	   be	   subdivided	   into	   two	   func@onally	  
dis@nct	  regions	  :	  the	  ves@bule	  and	  the	  cochlea.	  (A)	  A	  cross-­‐sec@on	  of	  the	  cochlea	  reveals	  three	  
ﬂuid-­‐ﬁlled	   chambers.	   The	   organ	  of	   Cor@	   that	   is	   responsible	   for	   hearing	   runs	  within	   the	   scala	  
media.	  (B)	  The	  organ	  of	  Cor@	  is	  composed	  of	  a	  tectorial	  membrane	  in	  which	  are	  embedded	  the	  
stereocilia	  of	  the	  sensory	  hair	  cells,	  laying	  on	  top	  of	  another	  important	  membrane,	  the	  basilar	  
membrane.	  Purves	  (2001)	  Neuroscience	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Thus,	  along	  the	  cochlea,	  different	  frequencies	  are	  detected	  and	  corresponding	  signals	  
are	  sent	  to	  the	  auditory	  centres	  for	  processing.	  
	  
	  Structural	  organization	  of	  the	  mammalian	  cochlea	  
In	  mammals,	  the	  cochlea	  is	  a	  small,	  coiled	  structure;	  making	  2.75	  turns	  around	  its	  axis	  
in	  human	   (Kingsley,	  1999).	  The	  number	  of	   turns	  varies	  according	   to	   the	  species.	  The	  
cochlea	   consists	   of	   three	   fluid-­‐filled	   chambers	   arranged	   in	   a	   parallel	   spiral.	   Two	   of	  
these	  chambers,	  the	  scala	  vestibuli	  and	  the	  scala	  tympani,	  run	  on	  each	  side	  of	  the	  scala	  
media	   or	   cochlear	   duct.	   The	   organ	   responsible	   for	   hearing	   (the	   organ	   of	   Corti)	   runs	  
within	   the	   cochlear	   duct	   (Figure	   1.2).	   The	   organ	   of	   Corti	   is	   composed	   of	   a	   basilar	  
membrane	  upon	  which	  lay	  several	  layers	  of	  epithelial	  cells,	  and	  apically,	  several	  rows	  
of	  hair	  cells.	  	  Sensory	  hair	  cells	  are	  the	  mechanotransducer	  cells,	  and	  display	  stereocilia	  
on	  their	  apical	  surface	  that	  are	  embedded	  in	  the	  overlying	  tectorial	  membrane	  (Figure	  
1.2).	  The	  scala	  vestibuli	  and	  tympani	   join	  at	  the	  apical	  end	  of	  the	  cochlea	  so	  that	  the	  
fluid	   movement,	   triggered	   by	   the	   oval	   window	   through	   vibration	   of	   the	   stapes,	  
eventually	  causes	  the	  round	  window	  located	  at	  the	  basal	  end	  of	  the	  scala	  tympani	  to	  
bulge	  out	  at	  the	  end	  of	  the	  passage	  of	  the	  travelling	  wave.	  The	  vibrations	  or	  travelling	  
waves	   are	   subsequently	   translated	   into	   a	   shearing	   motion	   between	   the	   basilar	  
membrane	   (BM)	   and	   the	   overlying	   tectorial	   membrane	   (TM)	   of	   the	   organ	   of	   Corti	  
(Figure	   1.3).	   The	   stereocilia	   located	   at	   the	   apical	   end	   of	   the	   hair	   cells	   contains	  
transducer/ion	   channels	   that	   open	   when	   they	   are	   stretched,	   leading	   to	   a	   voltage	  
change	  across	  the	  hair	  cell	  membrane.	  Action	  potentials	  generated	  travel	  through	  the	  
bipolar	  neurons	   linking	   the	  hair	   cells	   to	   the	  brain,	  where	   the	  signal	   is	  processed	  and	  
perceived	  (Purves	  and	  Williams,	  2001;	  Vander	  et	  al.,	  2001).	  
Figure	  1.3	  Transduc=on	  of	  sound-­‐induced	  vibra=ons	  into	  neural	  signals.	  (A)	  Travelling	  waves	  
result	   into	   shearing	  mo@on	  between	   the	   tectorial	   and	  basilar	  membrane.	  This	   shearing	   force	  
bends	  the	  stereocilia	  of	  the	  hair	  cells.	  (B)	  Deﬂec@on	  of	  the	  stereocilia	   leads	  to	  the	  opening	  of	  
ion	  channels,	  depolariza@on	  of	  the	  hair	  cell,	  release	  of	  neurotransmiBer	  onto	  the	  nerve	  endings	  
of	  auditory	  neurons	  and	  genera@on	  of	  ac@on	  poten@al.	  Purves	  (2001)	  Neuroscience	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The	  morphology	  and	  structure	  of	  the	  basilar	  membrane	  (BM)	  varies	  along	  the	  cochlea,	  
from	  wide	  and	  flexible	  apically	  to	  small	  and	  stiff	  basally.	  These	  differences	  in	  stiffness	  
and	   size	   result	   in	   different	   positions	   of	   the	   BM	   vibrating	   maximally	   with	   different	  
stimulus	  frequencies:	  the	  BM	  resonates	  to	  low	  frequency	  at	  his	  wide,	  flexible	  apex	  and	  
high	   frequencies	   at	   its	   thin,	   stiff	   base	   (Patuzzi,	   1996).	   Therefore	   a	   complex	   sound	  
composed	  of	  different	  frequencies	  will	  lead	  to	  a	  pattern	  of	  BM	  vibration	  equivalent	  to	  
the	  superposition	  of	  vibrations	  generated	  by	  the	  individual	  tones	  composing	  it.	  The	  BM	  
is	  said	  to	  be	  tonotopically	  organized	  (Purves	  and	  Williams,	  2001).	  
	  
The	  vestibular	  system	  
The	   vestibular	   system	   is	   composed	  of	   a	   series	   of	   interconnected	   canals	   (Figure	   1.2),	  
the	  semi-­‐circular	  canals	   (scc)	   link	  to	  two	  additional	  chambers,	  the	  utricle	  and	  saccule	  
(Purves	  and	  Williams,	  2001).	  	  Within	  these	  regions	  are	  located	  five	  sensory	  patches	  of	  
hair	  cells,	  cristae	  in	  the	  ampulla	  of	  each	  scc	  and	  2	  otolith	  organs	  or	  maculae,	  located	  in	  
the	   utricule	   and	   the	   saccule	   (Figure	   1.6).	   Similarly	   to	   cochlear	   hair	   cells,	   all	   the	  
vestibular	  sensory	  epithelia	  send	  neural	  signal	  to	  the	  brain,	  via	  the	  movement	  of	  their	  
stereocillia,	  leading	  to	  the	  transduction	  of	  currents	  (Kingsley,	  1999).	  The	  nature	  of	  the	  
message	   to	   the	   brain	   is	   different	   though,	   with	   the	   vestibular	   system	   allowing	  
interpreting	  of	   linear	   acceleration	   and	  head	  position.	   These	   signals	   are	   integrated	   in	  







1.2	  Development	  of	  the	  mammalian	  inner	  ear	  
The	  entire	  mammalian	  inner	  ear,	  with	  all	  its	  different	  specialised	  cell	  types	  such	  as	  hair	  
cells	  and	  neurons,	  derive	  from	  a	  patch	  of	  cranial	  ectoderm	  called	  the	  otic	  placode.	  This	  
patch	   invaginates	   to	   first	   form	   the	   otic	   cup	   and	   subsequently	   the	   otic	   vesicle.	   This	  
initially	   simple	   hollow	   vesicle	   then	   undergoes	   a	   series	   of	   complex	   remodelling	   to	  
eventually	  give	  rise	  to	  the	  highly	  sophisticated	  adult	  inner	  ear.	  This	  section	  describes	  in	  
more	  details	  the	  process	  of	  inner	  ear	  formation	  along	  with	  the	  signalling	  mechanisms	  
involved.	  
	  
1.2.1	  Formation	  of	  the	  preplacodal	  domain	  
	  Several	  lines	  of	  evidence,	  morphological,	  experimental	  and	  molecular,	  suggest	  that	  all	  
craniofacial	   sensory	   organs	   belong	   to	   a	   group	   of	   related	   structures,	   the	   sensory	  
placodes,	  that	  all	  originate	  from	  the	  ‘preplacodal	  region’	  (Ohyama	  et	  al.,	  2007;	  Streit,	  
2007).	  Morphologically,	  regions	  from	  which	  the	  sensory	  placode	  will	  originate	  appear	  
like	   a	   continuous	   thickened	   band	   of	   ectoderm	   in	   mice,	   human	   and	   amphibians	  
(Ohyama	   et	   al.,	   2007).	   In	   addition,	   transplantation	   experiments	   show	   that	   this	  
thickened	   region	   is	   competent	   to	   form	   multiple	   placodes	   (Jacobson,	   1963).	  
Furthermore,	  the	  preplacodal	  domain	  is	  characterized	  by	  a	  particular	  set	  of	  molecular	  
markers;	  and	  alteration	  of	  the	  expression	  of	  these	  genes	  results	  in	  variation	  in	  the	  size	  
of	  the	  preplacodal	  domain	  (Glavic	  et	  al.,	  2004).	  	  
	  
According	   to	   this	   model,	   the	   first	   step	   toward	   inner	   ear	   formation	   is	   to	   form	   the	  
preplacodal	  domain,	  a	  region	  of	  competence	  for	  all	   the	  sensory	  placode.	  The	  second	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step	   is	   the	   induction	   of	   a	   ‘pre-­‐otic	   field’	   within	   the	   preplacodal	   domain.	   As	  
development	   proceeds,	   the	   preplacodal	   region	   gets	   gradually	   divided	   into	   smaller	  
domains,	  in	  response	  to	  specific	  molecular	  signals	  (Streit,	  2007).	  The	  ‘pre-­‐otic	  field’	  is	  
subsequently	  refined	  into	  the	  otic	  placode	  and	  surrounding	  epidermis	  (Ohyama	  et	  al.,	  
2007)	  
	  
1.2.2	  Inner	  Ear	  Induction	  
The	  induction	  of	  the	  inner	  ear,	  that	  is	  to	  say	  the	  specification	  of	  one	  particular	  patch	  of	  
cranial	   ectoderm	  as	  otic,	   depends	  on	  FGF	   signalling	   from	   the	   surrounding	  hindbrain,	  
mesoderm	  and	  endoderm.	  The	   identity	  and	  source	  of	  FGFs	  may	  vary	  from	  species	  to	  
species	   but	   they	   always	   play	   a	   central	   role	   in	   the	   induction	   of	   the	   otic	   placode	  
(Ohyama	  et	  al.,	  2007).	  
	  
The	   induction	   of	   the	   inner	   ear	   can	   be	   subdivided	   into	   3	   steps	   with	   regard	   to	   the	  
dynamic	  expression	  of	  Fgf3,	  Fgf8	  and	  Fgf10	  during	  this	  process	  (Figure	  1.4;	  rewieved	  in	  
Schimmang,	  2007).	  Step	  1	  -­‐	  expression	  of	  Fgf8	  and	  Fgf10	  in	  the	  lateral	  plate	  mesoderm	  
(that	  will	  later	  give	  rise	  to	  the	  heart)	  at	  8dpc	  marks	  the	  start	  of	  the	  induction	  process.	  
Step	  2	  -­‐	  Fgfs	  starts	  to	  be	  expressed	  in	  neural	  tissues	  as	  evidenced	  by	  Fgf3	  expression	  in	  
the	  hindbrain	  and	  preplacodal	  domain	  (Wright	  and	  Mansour,	  2003),	  Fgf10	  expression	  
in	  the	  hindbrain	  (Alvarez	  et	  al.,	  2003),	  and	  transient	  Fgf8	  expression	  in	  the	  preplacodal	  
ectoderm	   (Lahder	   et	   al.,	   2005).	   Fgf8	   is	   also	   transiently	   detected	   in	   the	   pharyngeal	  





Figure	  1.4	  Fgfs	  expression	  during	  inner	  ear	  induc=on	  in	  
mice.	   (A)	   During	   the	   1st	   step	   of	   the	   induc@on	   process,	  
Fgf8	  and	  Fgf10	  are	  expressed	  in	  the	  mesoderm.	  (B)	  The	  
2nd	   step	   of	   induc@on	   is	   characterized	   by	   the	   onset	   of	  
Fgfs	   expression	   in	   neural	   @ssues,	   with	   Fgf3	   and	   Fgf10	  
expression	   in	   the	   hindbrain.	   Fgf3	   also	   starts	   to	   be	  
expressed	  in	  the	  preplacodal	  ectoderm	  and	  Fgf10	  in	  the	  
endoderm.	   (C)	   Finally,	   during	   the	   3rd	   step	   of	   induc@on	  
the	   o@c	   placode	   is	   fully	   formed	   and	   start	   invagina@ng.	  
At	   this	   stage	   Fgf3	   and	   Fgf10	   are	   s@ll	   expressed	   in	   the	  
hindbrain	   and	   Fgf10	   is	   now	   expressed	   in	   the	   o@c	  
placode.	   In	  addi@on	  all	   three	  Fgfs	   are	  expressed	   in	   the	  
endoderm.	  Abbrevia>ons:	  m,	  mesoderm;	  n,	  neural	  tube;	  
op,	   o>c	   placode;	   pp,	   preplacodal	   domain.	   Reproduced	  
from	   (Schimmang,	   2007)	   with	   permission	   from	   The	  
Interna@onal	   Journal	   of	   Developmental	   Biology	   (Int.	   J.	  
Dev.	  Biol.)	  (2007)	  Vol	  51:	  473-­‐481	  
Figure	  1.5	  A	  model	  on	  o=c	  paGerning	  and	  axis	  speciﬁca=on.	  (A)	  O@c	  placode	  is	  induced	  by	  Fgfs,	  
Wnts	   and	   possibly	   Bmps	   signalling	   from	   the	   hindbrain	   and	   surrounding	   @ssues.	   (B,C)	   The	  
invagina@ng	   o@c	   placode	   receives	   AP	   (Wnts,	   Bmps)	   and	   DV	   signals	   (Shh)	   from	   surrounding	  
@ssues.	  AP	  speciﬁca@on	   is	   thought	   to	   involves	   the	   induc@on	  of	  Tbx1	   in	   the	  posterior	  o@c	  cup.	  
Tbx1	   may	   in	   turn	   restrict	   the	   anterior	   neurosensory	   region	   that	   is	   characterized	   by	   the	  
expression	  of	  Ngn1,	  NeuroD	  and	  Lfng.	  Postero-­‐ventral	  cells	  then	  migrates	  to	  form	  most	  of	  the	  
lateral	   wall,	   with	   the	   excep@on	   of	   the	   anterior	   neurosensory	   domain.	   (D)	   The	   lateral	   wall	  
con@nues	  receiving	  AP	  and	  DV	  signals	  is	  subdivided	  in	  domains	  characterized	  by	  the	  expression	  
of	   speciﬁc	   genes.	   Abbrevia>ons:	   M,	   medial;	   L,	   lateral;	   A,	   anterior;	   P,	   posterior;	   D,	   dorsal;	   V,	  
ventral.	   Reproduced	   from	   (Bok,	   2007)	   with	   permission	   from	   The	   Interna@onal	   Journal	   of	  
Developmental	  Biology	  (Int.	  J.	  Dev.	  Biol.)	  (2007)	  Vol	  51:	  521-­‐533	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Fgf8	   expression	  disappears	   from	   the	  preplacodal	  domain	  with	  only	  a	   few	   transcripts	  
still	  expressed	  in	  the	  ventral	  surface	  ectoderm,	  pharyngeal	  endoderm	  and	  mesoderm	  
(Lahder	  et	  al.,	  2005).	  Shortly	  before	  placode	  invagination,	  Fgf3	  is	  now	  detected	  in	  the	  
pharyngeal	   endoderm,	   as	   well	   as	   in	   rhombomeres	   5	   and	   6	   (r5-­‐r6)	   and	   in	   the	   otic	  
placode	  (Mahmood	  et	  al.,	  1996).	  Fgf10	  also	  starts	  to	  be	  expressed	  in	  the	  invaginating	  
placode	   at	   this	   stage,	   as	   well	   as	   in	   the	   pharyngeal	   endoderm	   with	   Fgf3	   and	   Fgf8	  
(Pirvola	  et	  al.,	  2000;	  Alvarez	  et	  al.,	  2003;	  Wright	  and	  Mansour.,	  2003).	  	  
	  
1.2.3	  Patterning	  and	  axis	  specification	  
As	  the	  otic	  ectoderm	  becomes	  specified,	   it	  starts	  expressing	  specific	  combinations	  of	  
genes	  (Figure	  1.5;	  reviewed	  in	  Bok	  et	  al.,	  2007).	  The	  earliest	  molecular	  markers	  of	  the	  
otic	  placode	  in	  mice	  are	  paired	  box	  genes	  (Pax);	  Pax8	   is	  expressed	  first	  (Ohyama	  and	  
Groves,	   2004),	   shortly	   followed	   by	   Pax2	   (Oywama	   et	   al.,	   2007).	   Importantly,	   early	  
molecular	   asymmetries	   prefigure	   axis	   formation,	   with	   for	   instance	   expression	   of	  
several	  neurosensory	  markers	   in	  the	  anterior	  region	  of	  the	   invaginating	  otic	  placode:	  
Fgf10,	  Lunatic	  Fringe	  (Lfng),	  Neurogenin1	  (Ngn1)	  and	  NeuroD	  (Bok	  et	  al.,	  2007).	  In	  the	  
posterior	   region	   of	   the	   otocyst,	   expression	   of	  Tbx1	  delimits	   the	   neurogenic	   domain.	  
However,	   this	   pattern	   of	   expression	   is	   only	   prefiguring	   future	   axis	   formation,	   not	  
determining	  it,	  as	  evidenced	  by	  otic	  transplantation	  studies	  in	  chick	  that	  showed	  that	  
despite	  a	  clear	  molecular	  patterning,	  otic	  vesicle	  transplanted	  in	  the	  wrong	  orientation	  
adopt	  the	  correct	  antero-­‐posterior	  (AP)	  identity	  (Wu	  et	  al.,	  1998).	  What	  are	  the	  signals	  
responsible	  for	  conferring	  this	  AP	  axial	   identity	  to	  the	  otic	  placode?	  Due	  to	  its	  crucial	  
role	   in	   inner	   ear	   induction,	   and	   its	   arrangement	   in	   rhombomeres	   each	   expressing	   a	  
particular	   set	   of	   gene,	   the	   hindbrain	   seems	   a	   good	   candidate.	   However,	   hindbrain	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rotation	  experiments	  in	  chick	  that	  switched	  the	  position	  of	  rhombomeres	  5	  and	  6	  (r5	  
and	   r6)	   did	   not	   affect	   the	   AP	   identity	   of	   the	   inner	   ear	   (Bok	   et	   al.,	   2005).	   AP	   axis	  
formation	  is	  discussed	  further	  in	  later	  sections	  of	  this	  thesis	  (see	  section	  5.1.5).	  
	  
The	   inner	  ear	   is	  also	  divided	   into	  different	  domains	  along	   its	  dorso-­‐ventral	   (DV)	  axis,	  
with	  the	  dorsal	  region	  of	  the	  otic	  vesicle	  that	  will	  give	  rise	  to	  the	  vestibular	  structures	  
and	  the	  ventral	  region	  that	  will	  give	  rise	  to	  the	  auditory	  component	  of	  the	  inner	  ear.	  
Proper	   formation	  of	   these	   two	  different	   structures	  depends	  on	   the	  establishment	  of	  
the	  dorso-­‐ventral	  axis.	  Here	  again	  each	  compartment	  is	  characterised	  by	  a	  different	  set	  
of	  molecular	  markers	   (Figure	   1.5),	   for	   the	   vestibular	   system	   it	   for	   instance	   includes	  
Dlx5	  (Distal-­‐Less	  homeobox	  5),	  Hmx3	  (H6	  family	  homeobox	  3)	  and	  Gbx2	  (Gastrulation	  
brain	   homeobox	   2),	   and	   for	   the	   auditory	   system	   Lfng	   (Lunatic	   Fringe),	   Ngn1	  
(Neurogenin1),	  NeuroD1,	  Sox2	  (Sex	  Determining	  Region	  Y-­‐Box	  2)	  and	  Six1	  (Sine	  Oculis	  
Homeobox	  Homolog	  1)(Fekete	  and	  Wu,	  2002).	  As	   for	   the	  AP	  axis,	   the	  onset	  of	  gene	  
expression	   is	   not	   concomitant	   with	   the	   establishment	   of	   the	   DV	   axis.	   The	   lack	   of	  
correlation	  between	  gene	  expression	  pattern	  and	  axis	  formation	  is	  consistent	  with	  the	  
AP	   axis	   being	   established	   before	   the	   DV	   axis,	  whereas	  molecular	  marker	   expression	  
appears	  at	  the	  same	  time	  along	  the	  AP	  and	  DV	  axis	  (Wu	  et	  al.,	  1998)	  
	  
In	   contrast	   to	  what	   has	   been	   shown	   for	   the	  AP	   axis,	   transplantation	   experiments	   in	  
chick	  embryos	  where	  the	  hindbrain	  is	  rotated	  in	  VD	  instead	  of	  DV	  orientation	  results	  in	  
the	   expression	   of	   several	   ventral	   genes	   including	   NeuroD	   dorsally,	   whereas	   the	  
expression	   of	   dorsal	   gene	   such	   as	   Gbx2	   is	   abolished	   (Bok	   et	   al.,	   2005).	   This	  
demonstrates	   that	   the	  establishment	  of	   the	  DV	  axis	  depends	  on	  hindbrain	   signalling	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and	   is	   thought	   that	   the	   effects	   of	   the	   hindbrain	   on	   DV	   axis	   formation	   are	   partly	  
mediated	  by	  Sonic	  Hedgehog	  (Shh)	  signalling	  from	  the	  floor	  plate/notochord	  and	  Wnt	  
signalling	  from	  the	  dorsal	  neural	  tube	  (Figure	  1.5;	  reviewed	  in	  Bok	  et	  al.,	  2007).	  
	  
Along	   these	  molecular	   changes,	  morphological	   changes	   also	   happen;	   starting	  with	   a	  
thickening	  of	  the	  otic	  placode	  (Figure	  1.6)	  at	  8.0dpc	  (days	  post	  coitum).	  Half	  a	  day	  later	  
the	  otic	  placode	  already	  starts	  to	  invaginate	  and	  will	  have	  formed	  a	  hollow	  vesicle	  by	  
9.5dpc.	  At	  this	  stage,	  the	  first	  sign	  of	  elongation	  can	  also	  be	  seen,	  which	  correspond	  to	  
the	   future	   endolymphatic	   duct	   (Reviewed	   in	   Romand	   et	   al.,	   2006).	   The	   first	  
neuroblastes	   also	   start	   delaminating	   from	   the	   antero-­‐ventral	  wall	   of	   the	   otic	   vesicle	  
(OV)	  (Figure	  1.6)	  and	  can	  be	  identified	  by	  the	  expression	  of	  specific	  neuronal	  markers	  
such	  as	  NeuroD	  (Romand	  et	  al.,	  2006).	  By	  10.5dpc,	  the	  endolymphatic	  duct	  can	  now	  be	  
observed	   dorsally	   (Figure	   1.6)	   and	  morphogenesis	   of	   the	   cochlea,	   vestibular	   canals,	  
utricule	   and	   saccule	   also	   starts.	   These	   will	   adopt	   a	   more	   mature	   appearance	   by	  
12.5dpc	   and	   eventually	   reach	   their	   almost	   adult	   form	   at	   17.5dpc	   (Figure	   1.6).	  
Interestingly,	  the	  otic	  epithelium	  gives	  rise	  to	  a	  wide	  spectrum	  of	  specialised	  cell	  types	  
including	   epithelial,	   neural,	   sensory	   and	   supporting	   cells,	   thus	   providing	   the	   major	  
contribution	  to	  inner	  ear	  cells.	  	  Additional	  cells	  are	  however	  provided	  by	  melanocytes	  
(in	   the	  stria	  vascularis)	  and	  Schwann	  cells;	   the	  vestibulo-­‐acoustic	  ganglion	  also	  partly	  

















































































































































































































































































































































1.2.4	  Molecular	  basis	  of	  inner	  ear	  morphogenesis	  
Most	   inner	   ear	   structures	   consist	   in	   both	   sensory	   and	   non-­‐sensory	   regions	   and	  
reciprocal	   interactions	  between	   these	   sensory	   and	  non-­‐sensory	   tissues	   is	   thought	   to	  
coordinate	  the	  morphogenesis	  of	  these	  regions	  during	  inner	  ear	  development	  (Bok	  et	  
al.,	   2007).	   One	   example	   of	   such	   molecular	   interplay	   between	   a	   sensory	   and	   non-­‐
sensory	  compartment	  involves	  Fgf10	  and	  its	  receptor,	  Fgfr-­‐2(IIIb).	  Fgf10	  is	  expressed	  in	  
the	  presumptive	  sensory	  domain,	  whereas	  Fgfr-­‐2(IIIb)	  is	  expressed	  in	  a	  complimentary	  
pattern	   into	   the	   non-­‐sensory	   epithelium	   (Pirvola	   et	   al.,	   2000).	   Interestingly,	   despite	  
being	  expressed	  exclusively	  in	  non-­‐sensory	  epithelia,	  targeted	  mutation	  of	  Fgfr-­‐2(IIIb)	  
resulted	   in	   a	   dysgenesis	   of	   the	   cochleovestibular	   labyrinth	   as	   well	   as	   in	   defects	   in	  
sensory	  patches	  and	  vestibulo-­‐acoustic	  ganglion	  formation;	   in	  addition	  to	  the	  defects	  
in	   the	   non-­‐sensory	   epithelium.	   Since	   the	   lack	   of	   Fgfr-­‐2(IIIb)	   cannot	   explain	   by	   itself	  
defects	   in	   areas	  where	   it	   is	   not	   expressed,	  we	  might	   assume	   that	  what	   is	   lacking	   in	  
these	   organs/tissues,	   is	   a	   signal	   normally	   generated	   in	   response	   to	   FGFR-­‐2(IIIb)	  
activation	  by	  ligand	  binding	  (Bok	  et	  al.,	  2007).	  	  
	  
Cochlea	  formation	  
The	   cochlear	   duct	   forms	   in	   the	   postero-­‐lateral	   wall	   of	   the	   otic	   vesicle	   and	   descend	  
ventro-­‐medially.	   It	  then	  extends	  and	  coils	  to	  1	  and	  ¾	  turns	  in	  mice.	  Initially	  thick	  and	  
wide,	  it	  is	  thought	  to	  reach	  its	  final	  shape	  via	  convergent	  extension	  along	  its	  axis	  (Bok	  
et	  al.,	  2007;	  Chacon	  et	  al.,	  2012).	  Proper	  development	  of	  the	  cochlear	  duct	  depends	  on	  
the	  coordination	  of	  numerous	  factors,	  such	  as	  Pax2	  and	  Otx1	  that	  play	  a	  critical	  role	  in	  
cochlea	   formation	   by	   regulating	   differential	   proliferation	   and	   growth	   (Burton	   et	   al.	  
2004).	   Thus,	   targeted	   mutation	   of	   Otx1	   mutation	   results	   in	   abnormal	   growth	   and	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coiling	  and	  Pax2	  null	  mutations	  results	  in	  agenesis	  of	  the	  cochlea	  and	  of	  the	  auditory	  
ganglion	  (Burton	  et	  al.,	  2004).	  Tissue-­‐specific	  deletion	  of	  Tbx1	  in	  the	  mesenchyme	  also	  
results	   in	   malformation	   of	   the	   cochlear	   duct	   (Xu	   et	   al.,	   2007),	   demonstrating	   that	  
changes	   in	   the	  expression	  of	   gene	   in	   the	  mesenchyme	  can	  also	   cause	  defects	   in	   the	  
inner	   ear	   epithelium,	   probably	   as	   a	   result	   of	   abnormal	   epithelial/mesenchymal	  
interactions.	  This	   further	  supports	   the	  hypothesis	   that	   the	   formation	  of	   the	  different	  
components	  of	  the	  inner	  ear	  is	  interdependent.	  	  
	  
Crista	  and	  canal	  formation	  
The	  semicircular	  canals	  are	  induced	  in	  the	  dorso-­‐lateral	  region	  of	  the	  otic	  vesicle.	  Crista	  
and	   canal	   formation	   involves	   Bmp4	   and	   Fgf10	   signalling	   in	   a	   ‘canal	   genesis	   zone’	  
adjacent	   to	   the	   presumptive	   crista.	   Targeted	   inactivation	   of	   Fgf10	   in	  mice	   results	   in	  
abnormal	  crista	  development	  and	  absence	  of	  semi-­‐circular	  canals	  (Pauley	  et	  al.,	  2003).	  
Interestingly	  gain	  of	  function	  experiments	  using	  Fgf10	  loaded	  beads	  in	  chick	  embryos,	  
suggest	   that	   Fgf10	   also	   promotes	   canal	   formation	   (Chang	   et	   al.,	   2004).	   Thus,	   in	  
addition	  to	  its	  crucial	  role	  during	  inner	  ear	  induction,	  Fgf10	  appears	  to	  also	  be	  involved	  










1.3 The	  role	  of	  Fgfs	  in	  Inner	  ear	  development	  
Fibroblast	  growth	  factors	  (FGFs)	  are	  short-­‐range	  extracellular	  signalling	  molecules	  that	  
control	  normal	  development	  of	  the	  mammalian	  embryo	  in	  a	  large	  number	  of	  different	  
developmental	   contexts	   and	   their	   role	   during	   the	   induction	   of	   the	   otic	   placode	  was	  
already	   introduced	   in	   section	  1.2.2.	   	  The	  characteristics	  of	  FGF	  signalling	  and	   its	   role	  
during	  inner	  ear	  development	  are	  presented	  in	  more	  details	  in	  the	  following	  sections.	  
	  
1.3.1 The	  Fibroblast	  Growth	  Factors	  family	  
The	   fibroblast	   growth	   factor	   protein	   was	   described	   for	   the	   first	   time	  more	   than	   40	  
years	  ago,	  when	  it	  was	  found	  to	  be	  mitogenic	  for	  cultured	  fibroblasts	  (Gospodarowicz	  
and	   Moran,	   1975).	   So	   far,	   a	   total	   of	   22	   Fgfs	   have	   been	   reported	   following	   the	  
sequencing	  and	  bioinformatic	  analysis	  of	  the	  human	  and	  mouse	  genomes.	  Human	  and	  
mouse	   Fgfs	   are	   homologous	   in	   sequence,	   share	   similar	   binding	   specificities	   to	  
receptors	   and	   can	   be	   classified	   into	   subgroups	   according	   to	   their	   structure,	  
biochemical	   properties	   and	   expression	   (Bottcher	   and	   Niehrs,	   2005;	   Guillemot	   and	  
Zimmer,	   2011).	   Most	   Fgfs,	   including	   Fgf3,	   Fgf8	   and	   Fgf10,	   are	   classical	   short-­‐range	  
extracellular	   signalling	  molecules	   acting	   in	   an	   autocrine	   and/or	   paracrine	   fashion	   by	  
interacting	  with	  receptors	  present	  in	  the	  membrane	  of	  the	  target.	  There	  are	  however	  
two	   other	   subsets	   of	   Fgfs	   with	   different	   properties.	   	   Fgf15/19,	   Fgf21	   and	   Fgf23,	  
comprise	  a	  second	  subset	  that	  acts	   in	   long-­‐distance	  signalling,	   in	  a	  manner	  similar	  to	  
endocrine	   factors	   that	   regulate	   metabolism,	   and	   thus	   display	   ‘hormone-­‐like’	  
properties.	   A	   third	   subset,	   including	   Fgf11	   to	   Fgf14,	   are	   not	   secreted	   and	   do	   not	  
activate	  FGF	  receptors,	  but	  instead	  interact	  with	  voltage	  gated	  channels	  or	  localize	  to	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the	  nucleus	  (Itoh	  and	  Ornitz,	  2008).	  With	  all	   these	  different	   functions	   it	  comes	  as	  no	  
surprise	   that	   members	   of	   the	   FGF	   family	   control	   normal	   development	   of	   the	  
mammalian	  embryo	  in	  almost	  all	  developmental	  contexts.	  	  
	  
Members	  of	   the	   first	  and	  best	   characterised	  subset	  of	  FGF	  signalling	  molecules,	   that	  
display	  short-­‐range	  ligand-­‐receptor	  interactions,	  were	  in	  particular	  shown	  to	  be	  critical	  
for	   early	   inner	   ear	   development,	   with	   Fgf3,	   Fgf10	   and	   Fgf8	   all	   collaborating	   in	   the	  
earliest	   events	   of	   inner	   ear	   induction	   (Zelarayan	   et	   al.,	   2007).	   	   Therefore	   the	  
characteristics	  of	   the	   receptors	  with	  which	   they	   interact,	   as	  well	   as	   the	  downstream	  
signalling	  pathways	  they	  activate,	  are	  discussed	  in	  more	  detail	  in	  the	  next	  section.	  
	  
1.3.2 Fgfs	  signalling	  
The	   FGF	   ligands	   signal	   through	   cognate	   FGF	   receptors	   (FGFRs)	   that	   compose	   a	  
subfamily	  of	   receptor	   tyrosine	  kinases	   (RTKs).	   There	  are	  4	  different	  FGF	   receptors	   in	  
vertebrates,	   FGFR1	   to	  4	   that	   all	   exist	   in	  multiple	   isoforms	  due	   to	  alternative	   splicing	  
and	  that	  exhibit	  different	  FGF-­‐binding	  specificities	  (Zhang	  et	  al.	  2006;	  Guillemot,	  2011).	  
Interaction	  of	  FGFs	  with	  their	  receptors	  is	  also	  strongly	  influenced	  by	  cofactors	  such	  as	  
heparan	   sulfate	   proteoglycans	   (HSPGs),	   which	   are	   also	   considered	   low	   affinity	  
receptors	  (Sugaya,	  2008).	  FGFRs	  are	  single	  spanning	  transmembrane	  proteins	  with	  an	  
extracellular	  domain	  composed	  of	  three	  immunoglobulin-­‐like	  loops	  that	  bind	  the	  FGF	  
ligand	  (Figure	  1.7).	  	  The	  intracellular	  domain	  has	  tyrosine	  kinase	  activity	  that	  interacts	  
with	   intracellular	   substrates	  and	   signal	   transduction	  molecules	   (Bottcher	  and	  Niehrs,	  
2005).	  
Figure	   1.7	   Fgfs	   signalling.	   Dimerisa@on	   of	   the	   FGF	   receptor	   following	   FGF	   binding	   results	   in	  
autophosphoryla@on	  of	  tyrosine	  kinase	  residues.	  Phosphorylated	  residues	  aBract	  proteins	  such	  
as	   FRS2,	  PLCγ	  or	   STAT1/3,	   resul@ng	   in	   the	   recruitment	  and	  assembly	  of	   signalling	   	   complexes.	  
Fgfs	  signaling	   is	   involved	   in	  numerous	  events	  such	  as	  cytoskeleton	  dynamic,	  apoptosis	  and	  cell	  
prolifera@on,	   diﬀeren@a@on	   and	   migra@on.	   Fgfs	   signalling	   also	   auto-­‐regulates	   itself	   via	   the	  
ac@va@on	   of	   several	   feedback	   inhibitors	   such	   as	  Sef	   and	  Sprouty.	  Reprinted	   from	  Neuron,	   71,	  
(Guillemot	  et	  al.,	  2011).	  From	  Cradle	  to	  Grave:	  The	  Mul@ple	  Roles	  of	  Fibroblast	  Growth	  Factors	  in	  








Binding	   of	   FGFs	   to	   their	   respective	   FGFR,	   triggers	   the	   dimerisation	   of	   the	   receptors,	  
which	   results	   in	   the	   auto-­‐phosphorylation	   of	   a	   number	   of	   tyrosine	   kinase	   residues.	  
Phosphorylation	  of	  FGFR	  intracellular	  domain	  leads	  to	  the	  recruitment	  and	  assembly	  of	  
signalling	   complexes	   (Figure	   1.7).	   One	   of	   the	   proteins	   recruited	   by	   FGFR	  
phosphorylation	   is	   FGFR	   substrate	   2	   (FRS2),	   which	   then	   allows	   the	   recruitment	   of	  
Grb2,	  SOS	  and	  eventually	  the	  activation	  of	  an	  important	  protein,	  Ras,	  which	  then	  goes	  
on	   and	   phosphorylates	  MAPK	   ERK,	   thus	   turning	   on	   the	   pathway	   of	   the	   same	   name	  
(Figure	  1.7).	  G	  Ras	  plays	  a	  critical	  role	  in	  controlling	  cell	  growth	  and	  differentiation	  via	  
the	  activation	  or	  upregulation	  of	  several	  transcription	  factors	  such	  as	  Ets	  proteins,	  AP1,	  
Gata,	  c-­‐myc	   and	  CREB.	   Thus,	  deregulation	  of	   this	  pathway	   is	  usually	   associated	  with	  
the	   development	   of	   cancer	   (De	   Luca	   et	   al.,	   2012).	   Under	   normal	   conditions,	   this	  
pathway	   regulates	   itself,	   via	   the	  activation	  of	   several	   feedback	   inhibitors	   such	  as	  Sef	  
and	   Sproutys	   (Figure	   1.7).	   	   FGF	   signalling	   can	   also	   activate	   the	   phosphoinositide-­‐3	  
kinase	  pathway,	  which	  in	  turn	  activate	  the	  serine/threonine	  kinase	  Akt/protein	  kinase	  
B.	   This	   pathway	   is	   also	   involved	   in	   the	   regulation	   of	   cell	   survival	   and	   growth	   and	  
associated	  with	  cancer	  when	  misregulated.	  JAK-­‐STAT	  pathway	  is	  another	  downstream	  
target	   of	   FGF3	   signalling	   and	   is	   for	   instance	   involved	   in	   limb	   growth,	   and	   blood	   cell	  
differentiation	  (Gilbert,	  2006).	  
	  
FGF	   signalling	   has	   been	   shown	   to	   be	   important	   for	   many	   cellular	   roles	   that	   are	  
important	   in	   development,	   such	   as	   animal-­‐vegetal	   pole	   specification	   in	   Xenopus	  
(Kumano	  et	  al.,	  2001);	  maintenance	  of	  the	  stem	  zone	  during	  posterior	  axial	  elongation	  
in	   chick	   and	   mouse	   (Dorey	   and	   Amaya,	   2010);	   induction	   of	   the	   peripheral	   nervous	  
system	  (PNS),	  patterning	  of	  the	  neural	  primordium,	  proliferation	  of	  neural	  progenitors,	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neuronal	   migration,	   axon	   navigation,	   synaptogenesis	   (Streit	   et	   al.,	   2007;	   Guillermot	  
and	  Zimmer,	  2011);	  differentiation,	  apoptosis,	  cell	  adhesion	  and	  cell	  survival	  (Bottcher	  
and	  Niehrs,	  2005)	  
	  
1.3.3 Fgfs	  and	  inner	  ear	  induction	  
The	  dynamically	  changing	  patterns	  of	  Fgf3,	  Fgf8	  and	  Fgf10	  at	  the	  time	  of	  otic	  placode	  
induction	   (described	   in	   section	   1.2.2)	   suggest	   they	   are	   important	   factors	   in	   this	  
process.	   In	   agreement	   with	   that	   hypothesis,	   the	   sufficiency	   of	   Fgfs	   to	   ectopically	  
induce	  the	  otic	  placode	  has	  been	  demonstrated	  for	  Fgf10,	  where	  its	  misexpression	  in	  
the	   hindbrain	   leads	   to	   ectopic	   vesicle	   formation	   next	   to	   r3-­‐r5	   (Alvarez	   et	   al,	   2003).	  
Misexpression	  of	  Fgf3	   also	   leads	   to	   the	  generation	  of	   ectopic	  otic	   vesicle	  but	  with	  a	  
lower	  occurrence	  than	  Fgf10	  (Alvarez	  et	  al.,	  2003).	  
	  
Requirement	   for	   FGF	   signalling	   was	   first	   assessed	   in	   single	   mutants.	   Targeted	  
inactivation	  of	  Fgf3	  resulted	  in	  almost	  half	  the	  embryos	  not	  presenting	  any	  phenotype.	  
Remaining	   embryos	   were	   affected	   in	   various	   degrees	   and	   developmental	  
abnormalities	  included	  poorly	  coiled	  and	  swollen	  cochlear	  duct,	  lack	  of	  endolymphatic	  
duc	   and	   sac,	   and	   abnormal	   fusion/truncation	  of	   the	   vestibular	   canals	   (Alvarez	   et	   al.,	  
2003;	  Wright	  and	  Mansour,	  2003).	  Fgf10	  null	  embryos	  were	  also	  analysed.	  The	  saccule	  
and	   cochlea	   were	   smaller	   but	   otherwise	   unchanged.	   However	   the	   posterior	   canal	  
system	   and	   the	   crista	   were	   completely	   lacking	   (Pauley	   et	   al.,	   2003).	   Furthermore,	  
targeted	   mutation	   of	   Fgfr-­‐2(IIIb),	   the	   receptor	   through	   which	   both	   Fgf3	   and	   Fgf10	  
signal	   to	   their	   target	   cells,	   lead	   to	   even	  more	   developmental	   abnormalities,	   such	   as	  
severely	   disrupted	   cochleovestibular	   membranous	   labyrinth,	   absence	   of	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endolymphatic	   duct,	   and	   non	   sensory	   epithelium,	   sensory	   patches	   and	   vestibulo-­‐
cochlear	  ganglion	  staying	  at	  rudimentary	  stage	  (Pirvola	  et	  al.,	  2000).	  	  
	  
1.3.4 Fgfs	  in	  inner	  ear	  morphogenesis	  
It	   is	  now	  well	  established	  that	  redundant	  FGF	  signalling	  from	  tissues	  surrounding	  the	  
future	  otic	  placode	  is	  required	  for	  inner	  ear	  induction	  (see	  section	  1.2.2).	  But	  is	  it	  the	  
only	  role	  for	  FGF	  signalling	  during	  inner	  ear	  development?	  Interestingly	  Fgf3	  and	  Fgf10	  
are	  also	  expressed	  within	   the	  developing	   inner	  epithelium	   itself	   at	   later	   stages,	  with	  
their	  expression	  overlapping	  in	  the	  antero-­‐ventral	  wall	  of	  the	  otic	  vesicle.	  This	  antero-­‐
ventral	  domain	  is	  thought	  to	  be	  the	  proneurosensory	  region	  that	  will	  later	  give	  rise	  to	  
all	  the	  sensory	  patches	  and	  neurons	  of	  the	  inner	  ear	  (Pirvola	  et	  al.,	  2000),	  suggesting	  
Fgf3	   and	   Fgf10	   may	   play	   a	   role	   in	   later	   aspects	   of	   development,	   such	   as	   inner	   ear	  
neurogenesis.	  
	  
A	  brief	  review	  of	  the	  literature	  indeed	  revealed	  some	  circumstantial	  evidence	  for	  the	  
role	  of	  FGF	  signalling	  in	  neurogenesis.	  According	  to	  a	  review	  (Sanchez-­‐Calderon	  et	  al.,	  
2007),	   Fgf2,	   Fgf3,	   Fgf8,	   Fgf10	   and	   Fgf19	   have	   been	   shown	   to	   participate	   in	   otic	  
neurogenesis	   (Adamska	  et	  al.,	  2001;	  Alsina	  et	  al.,	  2004;	  Wright	  and	  Mansour,	  2003).	  
For	   instance	   in	  chick,	  ectopic	  expression	  of	  Fgf3	   in	  combination	  with	  Fgf2	   resulted	   in	  
an	  enlarged	  vestibulo-­‐acoustic	  ganglion	  (Adamska	  et	  al.,	  2001),	  suggesting	  a	  potential	  
involvement	   of	   Fgf3	   in	   ganglion	   formation.	   In	   addition,	   overexpression	   of	   Fgf10	   in	  
chick	  gives	  rise	  to	  a	  larger	  number	  of	  cells	  expressing	  the	  neurogenic	  markers	  NeuroD	  
and	  NeuroM	  (Alsina	  et	  al.,	  2004),	  whereas	  targeted	  mutation	  of	  Fgf10	  in	  mice	  results	  in	  
a	   reduction	   in	   the	   number	   of	   otic	   neurons	   (Pauley	   et	   al.,	   2003).	   Mutation	   of	   Fgfr-­‐
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2(IIIb),	  the	  receptor	  used	  both	  by	  Fgf3	  and	  Fgf10,	  also	  lead	  to	  the	  failure	  of	  forming	  a	  
vestibulo-­‐acoustic	   ganglion	   (Pirvola	   et	   al.,	   2000).	   Furthermore,	   Fgf10	   is	   involved	   in	  
neurogenesis	  in	  other	  organ	  systems.	  In	  particular,	  in	  the	  mouse	  forebrain,	  Fgf10	  has	  
been	  shown	  to	  promote	  the	  maturation	  of	  glial	  cells	  and	  the	  initiation	  of	  neurogenesis	  
(Sahara	  and	  O'Leary,	  2009).	  Fgf10	  was	  also	  shown	  to	  promote	  synaptogenesis	  in	  chick	  
motoneuron	   cultures	   (Umemori	   et	   al.,	   2004).	   All	   together	   these	   suggest	   that	   FGF	  
signalling	   is	   not	   only	   important	   for	   inner	   ear	   induction,	   but	   actually	   plays	   a	   role	   in	  
every	  aspect	  of	  inner	  ear	  development,	  including	  neurosensory	  development.	  
	  
This	   hypothesis	   is	   further	   supported	   by	   a	   recent	   study	   (Chen	   et	   al.,	   2012),	   where	  
human	   Embryonic	   Cells	   (heSCs)	   cultured	  with	   both	   Fgf3	   and	   Fgf10	   gave	   rise	   to	   two	  
types	  of	  otic	  progenitors,	   that	  where	   then	  able	   to	  differentiate	   in	  vitro	   into	  auditory	  
neurons	  and	  hair-­‐cell-­‐like	  cells.	  	  
	  
1.3.5 Fgfs	  redundancy	  and	  compensation	  mechanisms	  
As	  explained	  above,	  Fgf3	  and	  Fgf10	  are	  both	  expressed	   in	   the	  prosensory	  domain	  of	  
the	   developing	   otic	   vesicle	   and	   they	   have	   been	   showed	   to	   play	   crucial	   roles	   in	  
numerous	   aspects	   of	   inner	   ear	   development.	   However,	   surprisingly,	   Fgf10	   null	  mice	  
only	   display	   mild	   defects	   in	   inner	   ear	   morphogenesis	   and	   innervation	   (Wright	   and	  
Mansour,	  2003)	  and	  only	  around	  50%	  of	  Fgf3	  null	  mice	  display	  a	  phenotype	  (Alvarez	  et	  
al.,	   2003).	   Since	   Fgf3	   and	   Fgf10	   signal	   through	   the	   same	   Fgfr-­‐2(IIIb)	   receptor	   this	  
suggests	  that	  the	  two	  Fgfs	  may	  compensate	  for	  each	  other.	  Such	  a	  phenomenon	  may	  
be	  masking	  further	  roles	  of	  Fgf10	  and/or	  Fgf3	  in	  later	  events	  of	  inner	  ear	  development	  
within	   the	   otic	   epithelium,	   suggesting	   a	   comparative	   study	   of	   both	   these	   factors	   is	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required	   to	   get	   the	   whole	   picture	   of	   Fgfs	   control	   of	   inner	   ear	   development.	  
Importantly,	  both	  Fgf3	  mutations	  and	  Fgf10	  mutations	  have	  separately	  been	  reported	  
to	  underlie	  sensorineural	  deafness	  in	  humans	  (Shams	  et	  al.,	  2007;	  Tekin	  et	  al.,	  2008).	  
This	  demonstration	  of	  Fgf3	  and	  Fgf10	  roles	  in	  deafness	  in	  mice	  and	  humans,	  makes	  it	  
timely	   to	  establish	  a	  more	  detailed	  picture	  of	   their	  expression	  and	   regulation	  during	  
inner	  ear	  development.	  
	  
To	   investigate	   the	   regulation	   of	   Fgf	   signalling	   regulation	   during	   development,	   a	  
bioinformatic	  analysis	  of	  the	  7.4kb	  region	  upstream	  Fgf10	  was	  performed.	  It	  revealed	  
the	   presence	   of	   several	   putative	   binding	   sites	   for	   transcription	   factors	   and	   other	  
signalling	   complexes	   involved	   in	   inner	   ear	   development,	   such	   as	   retinoic	   acid	   (RA),	  
GATA3,	  NEUROD,	  NEUROGENIN1	  and	  NSCL1	  (Appendix	  Figure	  S1).	  The	  Fgf3	  enhancer	  
also	  contains	  7	  putative	  RA	  binding	  sites,	  including	  one	  that	  was	  shown	  to	  bind	  RA	  in	  
vitro	  (Frenz	  et	  al.,	  2010).	  The	  next	  sections	  present	  in	  more	  detail	  these	  candidates	  for	  












1.4 Retinoic	  Acid	  signaling	  
Retinoic	  acid	  (RA)	  is	  a	  small	  lipophilic	  molecule,	  derived	  from	  the	  breakdown	  of	  vitamin	  
A.	  The	  circulating	  form	  of	  vitamin	  A	  (retinol)	   is	  taken	  up	  into	  cells	  by	  diffusion	  across	  
the	   cell	  membrane,	  where	   it	   is	   converted	   into	  RA	  by	   two	  oxidative	   reactions	   (Figure	  
1.8).	   The	   first	   reaction	   involves	   alcohol	   dehydrogenase	   and	   retinol	   dehydrogenase	  
(RoDH)	   that	   convert	   the	   physiologically	   inactive	   retinol	   into	   retinal.	   The	   second	  
reaction	   involves	  members	  of	  the	  retinaldehyde	  dehydrogenase	  family	  (RALDH1,	  2,	  3	  
and	   4)	   that	   converts	   retinal	   into	   either	   all	   trans-­‐RA	   or	   9-­‐cis	   RA.	   	   RA	   then	   exerts	   its	  
effects	  by	  binding	  to	  two	  families	  of	  nuclear	  receptors,	  the	  RARs	  (α,	  β	  and	  γ)	  and	  the	  
RXRs	   (α,	   β	   and	   γ).	   RARs	   and	   RXRs	   can	   form	   both	   homodimeres	   and	   heterodimeres.	  
Complex	   formed	   by	   the	   RA	   ligand	   and	   these	   receptors	   then	   directly	   regulate	   gene	  
expression	   via	   binding	   to	   RA-­‐binding	   sites	   (RAREs)	   located	   on	   the	   DNA	   regulatory	  
sequences	  of	  RA’s	  target	  genes	  (Figure	  1.8).	  	  
	  
Normal	   embryonic	   development	  depends	  on	  homeostatic	   concentrations	  of	   RA	  with	  
both	   excess	   and	   deficiency	   resulting	   in	   developmental	   anomalies	   (McCaffery	   et	   al.,	  
2003)	   and	   thus	   RA	   signalling	   must	   be	   tightly	   controlled.	   First	   of	   all	   RA	   signalling	  
depends	  on	  the	  availability	  of	  vitamin	  A,	  as	  shown	  for	  instance	  by	  the	  study	  of	  Vitamin	  





Figure	   1.8	   Re=noic	   acid	   signalling.	   RA	   is	   a	  
small	   lipophilic	   molecule	   derived	   from	   the	  
breakdown	   of	   the	   vitamin	   A	   (re@nol).	   	   The	  
vitamin	  A	   is	   taken	  up	   	   into	   	   the	   	   cells	   	   and	  	  
then	   converted	   into	   re@nal	   by	   re@nol	  
dehydrogenases	  (RoDHs).	  The	  re@nal	   is	   later	  
converted	   into	   all-­‐trans	   RA	   or	   9-­‐cis-­‐RA	   by	  
re@nol	   dehydrogenases	   (RALDHs).	   (CRBP/	  
CRABP	   are	   cellular	   re@nol/RA	   binding	  
proteins	   that	   are	   thought	   to	   be	   involved	   in	  
regula@ng	  the	  concentra@on	  of	  RA).	  RA	  binds	  
to	   nuclear	   receptors	   (RXR,	   RAR)	   and	   these	  
complexes	   regulate	   gene	   expression	   by	  
binding	  to	  RA	  responsive	  sites	  (RAREs).	  
Figure	  1.9	  RA	  synthe=c/catabolic	  enzymes	  and	  nuclear	  receptors	  distribu=on	  in	  the	  inner	  ear.	  
RA	  synthe@c	  (RALDHs)	  and	  catabolic	  enzymes	  (CYP26)	  are	  restricted	  to	  a	  speciﬁc	  region	  of	  the	  
o@c	   epithelium/perio@c	   mesenchyme.	   At	   10.5dpc,	   Cyp26	   expression	   are	   predominantly	  
expressed	  in	  the	  latero-­‐ventral	  mesenchyme,	  and	  Raldhs	  in	  the	  dorso-­‐medial	  o@c	  epithelium.	  At	  
12.5dpc,	   Raldhs	   and	   Cyp26	   con@nue	   to	   have	   a	   rather	   complementary	   paBern,	   with	   the	  
excep@on	   of	   some	   overlapping	   region	   of	   expression,	   for	   instance	   in	   the	   ventral	   region.	   RA	  
nuclear	  receptors	  RARα,β	  and	  γ	  are	  also	  expressed	  in	  speciﬁc	  regions	  of	  the	  o@c	  epithelium	  and/
or	  perio@c	  mesenchyme.	  At	  10.5dpc,	  they	  are	  predominantly	  restricted	  to	  a	  dorso-­‐lateral	  region.	  
At	   12.5dpc,	   their	   expression	   	   encompasses	   more	   inner	   ear	   domains.	   Abbrevia>ons:	   Ed,	  
endolympha>c	   duct;	   G,	   ves>bulo-­‐acous>c	   ganglion;	   Apsc,anterior	   and	   posterior	   semi-­‐circular	  
canals;	  Hsc,	  horizontal	  semi-­‐circular	  canal;	  Cc,	  cochlear	  duct.	  Reproduced	  from	  (Romand	  et	  al.,	  
2006)	  with	  permission	  from	  John	  Wiley	  and	  Sons.	  Copyright	  ©	  2006	  Wiley	  Periodicals,	  Inc.	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Similarly	  to	  its	  active	  metabolite,	  RA,	  both	  deficiency	  and	  excess	  of	  Vitamin	  A	  itself	  also	  
results	   in	   congenital	  malformations	   (Zile,	   1998)	   as	   shown	   through	   the	   shortening	   of	  
the	   caudal	   hindbrain	   in	   VAD	   rat	   embryos	   (White	   et	   al.,	   2000)	   and	   craniofacial	  
abnormalities	   in	  mice	  and	  rats	  fed	  with	  excess	  RA	  (Alles	  and	  Sulik,	  1992;	  Emmanouil-­‐
Nikoloussi	   et	   al.,	   2000).	   However,	   excess	   of	   dietary	   vitamin	   A	   has	   less	   dramatic	  
consequences	   than	   RA	   excess	   or	   Vitamin	   A	   deficiency,	   since	   the	   availability	   of	   RA	  
synthesizing	  enzymes	  will	  be	  a	  limiting	  factor	  in	  the	  generation	  of	  RA	  from	  the	  ingested	  
vitamin	  A.	  	  
	  
This	   illustrates	   that	   at	   the	   level	   of	   the	   organism,	   the	   first	   element	   of	   control	   of	   RA	  
signalling	   is	  the	  biosynthesis	  step	  to	  produce	  RA.	  A	  second	  element	  of	  control	  that	   is	  
common	   to	   all	   chemical/biochemical	   reactions	   is	   the	   half-­‐life	   of	   the	   active	  molecule	  
and	  the	  time	  taken	  before	  RA	  becomes	  degraded.	  In	  the	  case	  of	  a	  biological	  metabolite	  
like	  RA,	  degradation	  is	  a	  crucial	  regulatory	  control	  mechanism	  rather	  than	  just	  loss	  of	  
activity.	  	  Control	  of	  degradation	  is	  ensured	  by	  three	  members	  of	  the	  cytochrome	  P450	  
superfamily	  CYP26A1,	  CYP26B1	  and	  CYP26C1	   (Rhinn	  and	  Dolle,	  2012;	  Romand	  et	  al.,	  
2006).	   Homeostatic	   supply	   of	   RA	   in	   the	   embryo	   is	   thus	   tightly	   controlled	   by	   precise	  
stage	   and	  –tissue-­‐specific	   expression	  of	   both	   synthesizing	   (RALDHs)	   and	  degradation	  
enzymes	  (CYP26).	   	   Interestingly,	  and	  consistent	  with	  their	  essential	  regulatory	  role	  to	  
ensure	   the	  appropriate	   local	  RA	  concentrations,	   synthetizing	  and	  degrading	  enzymes	  
are	  expressed	  in	  a	  mostly	  complementary	  pattern	  in	  the	  developing	  inner	  ear	  (Figure	  
1.9;	  Romand	  et	  al.,	  2006).	  This	  control	  of	  RA	  signalling	  is	  in	  addition	  to	  spatiotemporal	  
control	   of	   receptor	   expression	   that	   comes	   as	   a	   last	   step	   in	   the	   signalling	   cascade	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through	  which	  RA	   regulates	   gene	  expression	   through	  DNA	  binding	  as	   a	  RA/RAR/RXR	  
complex.	  
	  
The	   crucial	   functions	   of	   RA	   signalling	   during	   vertebrate	   development	   were	   first	  
inferred	  by	   studying	   the	   teratogenic	   effects	  of	   excess	  RA,	   either	   indirectly	   by	  dosing	  
pregnant	  mice	  or	  directly	   in	  chick	  embryo	  using	  RA-­‐soaked	  beads	  (reviewed	   in	  Rhinn	  
and	   Dolle,	   2012).	   These	   experiments	   revealed	   profound	   craniofacial	   malformations	  
illustrating	   that	   RA	   is	   a	   key	   signalling	  molecule	   in	   vertebrates	   (Yasuda	   et	   al.,	   1986).	  
Later	   it	  was	  shown	  that	  excess	  RA	  affects	  a	  wide	  range	  of	  organ	  systems	  such	  as	  the	  
hindbrain	  (Marshall	  et	  al.,	  1992),	   forebrain	  (Simeone	  et	  al.,	  1995),	  heart	   (Wasiak	  and	  
Lohnes,	  1999),	  limb	  (Kochhar	  et	  al.,	  1984),	  eye	  (Sulik	  et	  al.,	  1995)	  palate	  (Dempsey	  and	  
Trasler,	  1983)	  and	  the	  ear	  (Frenz	  et	  al.,	  1996).	  The	  study	  of	  VAD	  (Vitamin	  A	  deficient)	  
quails	  and	  mouse	  knockout	  for	  RA	  receptors	  then	  showed	  that	  lack	  of	  RA,	  similarly	  to	  
excess	  of	  RA,	   lead	   to	  developmental	   abnormalities.	  Mutant	   analysis	   and	   subsequent	  
phenotypes	   affecting	   all	   the	   above	   organ	   systems	   revealed	   RA	   is	   an	   essential	  
morphogen	   for	   normal	   embryonic	   development,	   with	   the	   lack	   of	   RA	   resulting	   in	  
developmental	   defects	   (reviewed	   in	   Rhinn	   and	  Dolle,	   2012).	   Interestingly,	   due	   to	   its	  
broad	   spectrum	  of	  effects	   in	  embryonic	  development,	  RA	  has	  been	   referred	   to	  as	   ‘a	  
master	  differentiation	  factor’	  (Romand	  et	  al.,	  2006).	  This	  highlights	  the	  likelihood	  that	  
RA	   will	   either	   control	   a	   large	   number	   of	   developmental	   genes,	   or	   some	   of	   the	   key	  
developmental	  genes	  that	  are	  used	  in	  a	  large	  number	  of	  developmental	  contexts	  (such	  
as	   the	   Hox	   genes	   for	   instance	   in	   patterning	   multiple	   developmental	   fields	   –	   limb,	  
hindbrain,	  gut),	  in	  order	  to	  have	  such	  extensive	  effects	  in	  so	  many	  organs	  (reviewed	  in	  
Romand	  et	  al.,	  2006).	  Elucidating	  the	  identity	  of	  the	  genes	  acting	  downstream	  of	  RA	  in	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the	   different	   tissues	   is	   the	   first	   step	   toward	   understanding	   how	   RA	   controls	  
development.	  	  
	  
1.4.1 RA	  signaling	  in	  the	  developing	  hindbrain	  	  
Although	   RA	   exerts	   its	   effects	   in	   multiple	   tissues,	   the	   molecular	   mechanisms	  
underlying	   embryonic	   development	   normally	   controlled	   by	   RA	   in	   the	   developing	  
hindbrain	  are	  specifically	  discussed	   in	  more	  detail	  here	  for	  two	  major	  reasons.	   	  First,	  
the	   hindbrain	   is	   one	   of	   the	   organs/tissues	   where	   the	   effects	   of	   RA	   excess	   and	  
deficiency	   have	   been	   best	   described	   at	   a	   molecular	   level,	   making	   the	   hindbrain	   a	  
paradigm	  for	  understanding	  RA	  regulatory	  effects	  (reviewed	  in	  Rhinn	  and	  Dolle,	  2012).	  
Second,	   inner	   ear	   induction	   and	   cochlear	   coiling,	   two	  major	   inductive	   events	   in	   the	  
developing	   inner	   ear,	   have	   been	   shown	   to	   be	   dependent	   on	   signalling	   from	   the	  
hindbrain.	  Thus,	  any	  RA-­‐induced	  changes	  in	  hindbrain	  patterning	  (described	  below)	  are	  
potentially	   likely	   to	   indirectly	   influence	   inner	   ear	   development	   (Frenz	   et	   al.,	   2010).	  	  
Clearly	   then,	  an	  understanding	  how	  RA	  affects	  hindbrain	  patterning	  will	  be	  crucial	   in	  
the	   interpretation	  of	  phenotype	  and	  gene	  expression	   changes	   following	  aberrant	  RA	  
signalling.	  
	  
Hindbrain	   development	   involves	   the	   generation	   of	   7	   (mammalian)	   or	   8	   (avian)	  
transient	   neuroepithelial	   compartments	   called	   rhombomeres	   (r),	   which	   all	   have	   a	  
distinct	  molecular	   identity	   according	   to	   their	  position	  along	   the	  AP	  axis	   (Kiecker	   and	  
Lumsden,	  2005)	  and	  are	  units	  of	  cell	  lineage	  restriction.	  Rhombomere	  formation	  leads	  
to	   the	   generation	   of	   specific	   molecular	   patterns	   along	   the	   hindbrain	   that	   vary	   at	  
different	  axial	  levels.	  Therefore	  rhombomeres	  can	  be	  each	  characterized	  by	  a	  specific	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combination	   of	   Hox	   gene	   expression.	   Disruption	   of	   this	   pattern	   of	   expression	   by	  
exposure	  to	  excess	  vitamin	  A	  was	  first	  demonstrated	  40	  years	  ago	  (Morriss,	  1972).	  In	  
mouse	  embryos	  exposed	  to	  RA	  at	  7.75dpc,	  at	  a	  stage	  before	  hindbrain	  patterning,	  the	  
hindbrain	   appears	   shortened	   and	   adopts	   a	   r4-­‐like	   identity	   according	   to	   molecular	  
markers	   (Morriss-­‐Kay	   et	   al.,	   1991).	   Interestingly,	   studies	   of	   embryos	   deficient	   in	   RA,	  
such	  as	  VAD	  quails	  embryos	  (Gale	  et	  al.,	  1999),	  and	  also	  more	  recently	  VAD	  rat	  (White	  
et	   al.,	   2000)	  also	   showed	  misspecification	  of	   the	   caudal	  hindbrain,	  where	   the	   region	  
from	  r4	   to	   r8	   is	   transformed	   into	  an	  enlarged	   r3,	  while	  more	  anterior	   rhombomeres	  
extended	   posteriorly	   (reviewed	   in	   Rhinn	   and	   Dolle,	   2012).	   Thus,	   correct	   hindbrain	  
patterning	   requires	   RA	   concentrations	   along	   the	   anterior-­‐posterior	   axis	   to	   be	   at	   a	  
specific	  equilibrium	  (homeostatic),	  with	  excess	  RA	  affecting	  the	  rostral	  hindbrain	  and	  
RA	  deficiency	  affecting	  the	  caudal	  hindbrain.	  This	  suggested	  the	  existence	  of	  a	  spatially	  
controlled	  RA	  gradient	   in	  the	  hindbrain,	  with	  specific	  concentrations	  of	  RA	  specifying	  
different	   rhombomere	   compartments.	   This	   RA	   gradient	   hypothesis	   assumes	   the	  
somitic	  mesoderm	  up	  to	  and	   including	  the	  1st	  somite	   is	  the	  main	  source	  of	  RA	   in	  the	  
hindbrain	  region	  due	  to	  its	  high	  concentration	  in	  RALDH2	  (one	  of	  the	  enzyme	  involved	  
in	  the	  2nd	  step	  of	  RA	  biosynthesis	  from	  vitamin	  A).	  	  RA	  is	  then	  envisaged	  to	  diffuse	  from	  
this	   source	   creating	   a	   gradient	   with	   high	   caudal	   RA	   concentration	   and	   low	   rostral	  
concentrations.	  This	  hypothesis	  gained	  further	  support	  from	  the	  work	  of	  dissecting	  the	  
regulatory	   pathway	   controlling	   Hox	   and	   other	   segmentally	   expressed	   genes	   in	   the	  
hindbrain	   that	   were	   used	   as	   molecular	   markers	   for	   the	   RA	   excess	   and	   deficiency	  




However,	  RALDH2	  is	  not	  the	  only	  enzyme	  involved	  in	  RA	  biosynthesis	  and	  in	  addition,	  
the	   specificity	   of	   RA	   concentration	   at	   a	   particular	   level	   is	   not	   determined	   by	   its	  
synthesis	   alone,	   but	   rather	   by	   the	   equilibrium	   between	   synthesis	   and	   degradation.	  
Thus,	  on	  top	  of	  this	  RA	  gradient	  that	  was	  so	  far	  presented	  like	  a	  passive	  mechanism,	  is	  
likely	  superimposed	  an	  active	  process,	  which	  maintains	  and	  refines	  this	  gradient	  along	  
the	   hindbrain	   through	   the	   specific	   expression	   of	   synthesizing	   and	   catabolizing	  
enzymes.	   The	   highly	   dynamic	   expression	   of	   the	   RALDHS	   and	   CYP26	   genes	   in	   the	  
hindbrain	   during	   its	   formation	   is	   in	   agreement	   with	   this	   hypothesis	   (Glover	   et	   al.,	  
2006).	  
	  
The	  effect	  of	  timing	  of	  RA	  administration	  on	  hindbrain	  patterning	  
The	   teratogenicity	   described	   thus	   far	   in	   RA	   excess	   experiments	   is	   a	   consequence	   of	  
administration	  at	  7.75dpc,	  prior	   to	  hindbrain	  patterning,	  but	   interestingly	   the	  effects	  
of	  RA	  were	  also	  studied	  by	  administering	  RA	  following	  hindbrain	  patterning,	  at	  8.5dpc.	  
Are	   homeostatic	   concentrations	   of	   RA	   only	   required	   during	   hindbrain	   formation	   or	  
could	   excess	   RA	   also	   disrupt	   the	   patterning	   of	   the	   hindbrain	   after	   it	   has	   been	  
specified?	  In	  other	  words,	  is	  the	  hindbrain	  pattern	  e.g.	  Hox	  code	  plastic?	  	  In	  embryos	  
exposed	  to	  RA	  at	  8.5dpc	  there	  was	  no	  apparent	  change	  of	  brain	  morphology	  (Wood	  et	  
al.,	  1994)	  but	  further	  detailed	  molecular	  analysis	  revealed	  the	  change	  in	  expression	  of	  
some	  molecular	  markers,	  with	  r2	  ectopically	  expressing	  Hoxb2	  and	  Hoxb1	  (Figure	  1.10;	  
Morriss-­‐Kay	   et	   al.,	   1991).	   The	   combined	   expression	   of	   these	   two	   genes	   is	   normally	  
found	   in	   r4,	   suggesting	   that	   r2	   had	   adopted	   a	   r4-­‐like	   identity	   following	   RA	  
administration	  after	  hindbrain	  patterning	  (Morriss-­‐Kay	  et	  al.,	  1991).	  However,	  the	  Hox	  
gene	  expression	  pattern	  of	  other	  rhombomeres	  and	  in	  particular	  r4	  and	  r5,	  from	  which	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emanate	   the	   inner	   ear	   inductive	   signals,	   appears	   unaltered.	   This	   is	   thus	   strikingly	  
different	   from	   embryos	   exposed	   to	   RA	   at	   7.75dpc,	   which	   all	   displayed	   a	   highly	  
disrupted	  hindbrain	   identity	   (Figure	  1.10).	  This	  difference	  between	  embryos	  exposed	  
to	   RA	   prior	   to,	   or	   after,	   hindbrain	   patterning	   will	   thus	   likely	   play	   a	   major	   factor	   in	  
differentiating	  direct	  and	  indirect	  effects	  of	  RA	  on	  the	  developing	  otocyst	  and	  on	  the	  








Figure	   1.10	   Differential	   effects	   of	   retinoic	   acid	   on	   hindbrain	   patterning.	   In	   control	   embryos	   the	  
hindbrain	   is	   characterized	  by	   the	  expression	  of	   specific	   gene	  combinations	  along	   the	  antero-­‐posterior	  
axis.	   For	   instance	   rhombomere	   4	   (r4)	   is	   characterized	   by	   the	   expression	   of	   Hoxb-­‐2	   and	   Hoxb-­‐1.	   In	  
embryos	  exposed	  to	  RA	  at	  8.5dpc,	  after	  hindbrain	  patterning.	  Hindbrain	  formation	  is	  almost	  unaltered	  
apart	   from	   r2	   adopting	   a	   r4	   like	   identity,	   with	   the	   misexpression	   of	  Hoxb-­‐2	   and	  Hoxb-­‐1	   In	   embryos	  
exposed	  to	  RA	  at	  7.75dpc,	  prior	  to	  hindbrain	  patterning,	  the	  hindbrain	  appears	  shortened	  and	  adopt	  an	  





1.4.2 Effects	  of	  RA	  on	  the	  developing	  inner	  ear	  
Inner	   ear	  development	   also	   requires	  optimal	  homeostatic	   concentrations	  of	  RA	  with	  
both	   excess	   and	   deficiency	   leading	   to	   inner	   ear	   dysmorphogenesis	   –	   a	   so-­‐called	  
“Goldilocks”	  phenomenon	  (Frenz	  et	  al.,	  2010).	   Interestingly,	  the	  developing	   inner	  ear	  
epithelium	   itself	  contains	  all	   the	  elements	  of	   the	  RA	  pathway,	  with	  RALDH,	  RAR/RXR	  
and	   CYP26	   expression	   distributed	   according	   to	   a	   dynamic	   and	   restricted	   pattern	  
(Romand	   et	   al.,	   2006).	   Thus,	   in	   addition	   to	   the	   RA	   diffusing	   from	   the	   somatic	  
mesoderm,	  in	  situ	  sources	  of	  RA	  synthesis	  in	  the	  inner	  ear	  epithelium	  are	  also	  likely	  to	  
play	  a	  role	  in	  inner	  ear	  development.	  To	  summarize,	  there	  are	  two	  sources	  of	  RA:	  RA	  
from	   the	   somitic	   mesoderm	   may	   affect	   the	   inner	   ear	   directly,	   but	   also	   indirectly	  
through	   reprogramming	   the	   hindbrain,	   and	   a	   second	   source	   of	   RA	   within	   the	   otic	  
epithelium	  itself	  that	  may	  affect	  inner	  ear	  development	  directly.	  
	  
Although	  some	  ear	  abnormalities	  have	  been	  reported	  among	  the	  multiple	  craniofacial	  
abnormalities	  mentioned	  in	  early	  RA	  teratogenic	  studies	  in	  mice	  (Yasuda	  et	  al.,	  1986)	  
and	  humans	  (Lammer	  et	  al.,	  1985),	  the	  first	  conclusive	  demonstration	  of	  a	  role	  for	  RA	  
in	   inner	   ear	   development	   was	   in	   cochlear	   cultures.	   In	   these	   in	   vitro	   experiments,	  
exposure	  to	  excess	  RA	  during	  early	  postnatal	  development	  lead	  to	  the	  development	  of	  
supernumerary	  rows	  of	  hair	  cells,	  suggesting	  RA	  may	  play	  a	  crucial	  role	  in	  cochlear	  hair	  
cell	  differentiation	  (Kelley	  et	  al.,	  1993).	  Detailed	  in	  vivo	  studies	  of	  the	  effects	  of	  excess	  
RA	  on	  the	  inner	  ear	  have	  subsequently	  revealed	  a	  number	  of	  developmental	  anomalies	  
of	  the	  inner	  ear	  (Frenz	  et	  al.,	  1998;	  Frenz	  and	  Liu,	  2000;	  Frenz	  et	  al.,	  2010;	  Frenz	  et	  al.,	  
1996).	  For	  instance,	  the	  otic	  vesicle	  seemed	  shifted	  anteriorly	  in	  some	  9.5dpc	  embryos	  
(Frenz	   et	   al.,	   1996).	   At	   11.5dpc,	   developing	   inner	   ears	   displayed	   elongating	   ovoid	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shapes	   with	   almost	   half	   of	   them	   lacking	   the	   vestibulo-­‐acoustic	   ganglion	   and	  
endolymphatic	   duct.	   At	   13.5dpc,	   in	   RA-­‐treated	   embryos	   the	   developing	   inner	   ears	  
showed	  an	  uncoiled	  rudimentary	  cochlear	  projection	  and	  the	  vestibular	  portion	  of	  the	  
ear	  was	  disorganised;	  e.g.	  a	  common	  utriculo-­‐saccular	  space	  in	  more	  than	  half	  of	  the	  
ears	  analysed.	   In	  addition,	   the	  pattern	  of	  capsular	  chondrogenesis	  was	   irregular,	  and	  
the	   vestibulo-­‐acoustic	   ganglion	   was	   highly	   reduced	   or	   even	   absent,	   with	   a	   lack	   of	  
neuritic	  projections	  to	  the	  cochlea	  (Frenz	  et	  al.,	  1996).	  Similar	  defects	  are	  observed	  in	  
human	  embryos	  following	  exposure	  to	  RA	  during	  the	  first	  trimester	  of	  pregnancy,	  and	  
these	  have	  been	  linked	  to	  sensorineural	  deafness	  (Lammer	  et	  al.,	  1985).	  
	  
Interestingly,	  these	  defects	  mimic	  some	  of	  the	  phenotypes	  observed	  in	  Fgf3	  and	  Fgf10	  
knockout	  mice.	   For	   instance,	   anomalies	  of	   the	   inner	  ear	   in	  Fgf3	   null	  mice	   includes	  a	  
failure	   of	   endolymphatic	   duct	   formation	   and	   reduced	   cochlear	   coiling	   (Wright	   and	  
Mansour,	   2003),	   whereas	   anomalies	   of	   the	   inner	   ear	   in	   Fgf10	   null	   mice	   includes	  
agenesis	  or	  reduction	  of	  the	  semi-­‐circular	  canals	  and	  their	  innervations	  (Pauley	  et	  al.,	  
2003).	   Interestingly,	   alterations	   in	   Fgf3	   expression	   in	   the	   brain	   had	   previously	   been	  
reported	   in	  mice	   in	  which	  RA	  signalling	   is	   impaired	  by	  the	  target	  mutation	  of	  Raldh2	  
(Niederreither	  et	  al.,	  1999)	  and	  in	  mice	  exposed	  to	  excess	  RA	  (Mahmood	  et	  al.,	  1996).	  
Raldh2	   null	   mice	   present	   segmentation	   defects	   and	   altered	   gene	   expression	   in	   the	  
posterior	   hindbrain,	   including	   downregulation	   and	   lack	   of	   proper	   restriction	   of	   Fgf3	  
(Niederreither	  et	  al.,	  1999).	  In	  mouse	  embryos	  exposed	  to	  excess	  RA	  at	  7.75dpc,	  Fgf3	  
expression	   in	   the	   caudal	   hindbrain/rostral	   hindbrain	  was	   patchy,	   irregular	   and	  more	  
extensive	   than	   normal.	   Upregulation	   of	   Fgf3	   expression	   at	   the	   midbrain/hindbrain	  
junction,	  along	  with	  ectopic	  expression	  in	  the	  midbrain,	  were	  also	  reported	  following	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RA	  administration	  at	  8.25dpc	  (Mahmood	  et	  al.,	  1996).	  All	  together,	  this	  suggests	  that	  
Fgf3,	  and	  perhaps	  also	  Fgf10,	  may	  be	  downstream	  targets	  through	  which	  RA	  exerts	  its	  
effects	   during	   development.	   Given	   the	   importance	   of	   RA	   signalling	   and	   Fgf3	   in,	   not	  
only	  inner	  ear	  development,	  but	  in	  human	  deafness,	  a	  thorough	  investigation	  of	  how	  
RA	  leads	  to	  dysmorphology	  is	  required.	  	  	  
	  
	  
1.5 Other	  putative	  upstream	  regulators	  of	  Fgfs	  signalling	  
1.5.1 Gata3	  
Members	  of	  the	  GATA	  family	  are	  transcription	  factors	  that	  bind	  to	  a	  consensus	  ‘GATA’	  
DNA-­‐motif	  (A/T-­‐GATA-­‐A/G).	  Six	  factors	  (GATA1-­‐6)	  have	  been	  identified	  in	  vertebrates.	  
These	   factors	   are,	   similar	   to	   members	   of	   the	   FGF	   family,	   involved	   in	   cell-­‐fate	  
specification	   as	   well	   as	   cell	   differentiation,	   proliferation	   and	   motility	   during	  
development	   (Patient	  and	  McGhee,	  2002).	   Interestingly,	   two	   family	  members,	  Gata2	  
and	  Gata3,	  are	  expressed	  in	  inner	  ear	  (Lillevali	  et	  al.,	  2006).	  Their	  expressions	  initially	  
overlap	   in	   the	   mouse	   otic	   vesicle	   (around	   9.5–10.5dpc)	   but	   become	   increasingly	  
distinct	   during	   subsequent	   development	   with	  Gata2	   being	   mainly	   expressed	   in	   the	  
nonsensory	  areas	  of	  the	  vestibular	  epithelium,	  whereas	  Gata3	  expression	   is	  confined	  
to	   the	   sensory	   domains	   and	   is	   restricted	   to	   the	   cochlea	   by	   18.5dpc	   (Lillevali	   et	   al.,	  
2004).	  Mutation	   in	  either	  Gata2	   (Haugas	  et	  al.,	  2010)	  or	  Gata3	   (Lillevali	  et	  al.,	  2006)	  




Gata3,	  which	  is	  expressed	  throughout	  the	  otic	  placode	  at	  8.5dpc,	  is	  one	  of	  the	  earliest	  
markers	   of	   the	   inner	   ear	   (Lawoko-­‐Kerali	   et	   al.,	   2002).	   Its	   expression	   has	   also	   been	  
reported	   later	   on	   in	   the	  migrating	   auditory	   neuroblasts	   (Lawoko-­‐Kerali	   et	   al.,	   2004).	  
Fgf10	   also	   appears	   to	   be	   expressed	   in	   the	   delaminating	   neuroblasts	   (Pauley	   et	   al.,	  
2003)	  although	  it	  has	  not	  yet	  been	  determined	  whether	  it	  is	  expressed	  in	  the	  auditory	  
or	   vestibular	  neuroblasts	  only	  or	   in	  both	   types.	  Gata3	   is	   known	   to	   regulate	  multiple	  
events	   during	   inner	   ear	   development	   with	   Gata3	   deficiency	   leading	   to	   severe	  
abnormalities	   during	   otic	   placode	   invagination.	   The	   utricule,	   cochlea	   and	  
endolymphatic	  duct	  are	  also	  strongly	  reduced	  in	  Gata3	  null	  embryos,	  suggesting	  Gata3	  
also	  plays	  an	  important	  role	  in	  later	  morphogenetic	  events	  (Karis	  et	  al.,	  2001;	  Lillevali	  
et	   al.,	   2006).	   In	   addition,	  Gata3	   is	   also	   thought	   to	   be	   involved	   in	   cochlear	   hair	   cell	  
development	  and	  neurogenesis	  (Karis	  et	  al.,	  2001).	  The	  molecular	  basis	  of	  the	  defects	  
observed	   in	  Gata3	  deficient	   inner	  ears	  are	  not	  yet	  understood,	  but	   the	   loss	  of	  Fgf10	  
expression	   in	   otic	   epithelium	   and	   auditory	   ganglion	   suggests	   Gata3	   may	   be	   an	  
important	   regulator	   of	   FGF	   signalling	   during	   development	   (Lillevali	   et	   al.,	   2006).	   In	  
silico	  analysis	  of	   the	  Fgf10	  enhancer	  reveals	   the	  presence	  of	  putative	  GATA3	  binding	  
sites	   (Ohuchi	   et	   al.,	   2005)	   and	   GATA3	  was	   shown	   to	   transactivate	   a	   Fgf10	   reporter	  
construct	   in	   vitro	   in	   NIHT3T3	   fibroblaste	   cell	   line	   (Lillevali	   et	   al.,	   2006).	   All	   together	  
these	   data	   suggest	   that	   Fgf10	   is	   one	   of	   the	   targets	   through	   which	  Gata3	   exerts	   its	  
effect	   on	   inner	   ear	   development.	   However	   the	   nature	   of	   this	   regulation	   –	   direct	   or	  
indirect	   –	   is	   still	   to	   be	   determined.	   Although	   the	   transactivation	   experiment	   could	  





1.5.2 The	  Neurogenin	  Pathway	  
Ngn1	  and	  NeuroD	  are	  proneural	  genes	   that	  encode	  transcription	   factors	  of	   the	  basic	  
Helix-­‐Loop-­‐Helix	   (bHLH)	  class	  and	  bind	   to	  a	  common	  DNA	  sequence	  called	   the	  E-­‐box	  
sequences	   (Abello	   and	   Alsina,	   2007).	   The	   term	   proneural	   relate	   to	   their	   role	   in	  
neurogenesis.	  
	  
In	   vertebrate,	   inner	   ear	   neurogenesis	   first	   involves	   the	   specification	   of	   a	   proneural	  
field	   characterised	   by	   the	   expression	   of	  Ngn1	   in	   the	   antero-­‐ventral	   wall	   of	   the	   otic	  
placode.	   Following	  Ngn1	   expression,	   the	   expression	   of	  NeuroD1	   is	   switched	   on	   and	  
neuroblasts	   start	   to	   delaminate	   and	  differentiate.	  Members	   of	   the	   FGF	   family	   (Fgf3,	  
Fgf8	  and	  Fgf10)	  are	  also	  expressed	  in	  the	  antero-­‐ventral	  area	  and	  might	  be	  involved	  in	  
the	  recruitment	  of	  cells	  into	  the	  neurosensory	  lineage	  (Abello	  and	  Alsina,	  2007).	  	  
	  
Functional	   analysis	   of	   Ngn1	   and	   NeuroD	   mutants	   suggests	   they	   are	   sufficient	   for	  
neurogenesis,	  with	  Ngn1	  being	  involved	  in	  neuronal	  determination,	  and	  NeuroD	  being	  
involved	  in	  neuronal	  differentiation	  and	  survival	  (reviewed	  in	  Abello	  and	  Alsina,	  2007).	  
In	  Ngn1	  mutant	  the	  proximal	  cranial	  sensory	  ganglia	  are	  lost	  (Ma	  et	  al.,	  2000)	  whereas	  
ectopic	   neurons	   form	   in	   Xenopus	   if	   Ngn1	   is	   overexpressed	   (Perron	   et	   al.,	   1999).	  
Disruption	   of	   NeuroD	   function	   also	   results	   in	   a	   severe	   loss	   of	   sensory	   neurons	  
associated	  with	  the	  inner	  ear	  (Kim	  et	  al.,	  2001)	  as	  well	  as	   in	  the	  formation	  of	  ectopic	  
hair	   cells	  within	   the	   auditory	   ganglia	   (Jahan	   et	   al.,	   2010).	   Interestingly,	  mutations	   in	  
either	  Ngn1	  or	  NeuroD	  also	  affect	  the	  formation	  of	  the	  organ	  of	  Corti	  that	  is	  shortened	  
in	  both	  mutants	  and	  presents	  multiple	  (ectopic)	  rows	  of	  hair	  cells	  (HC)	  (Fritzsch	  et	  al.,	  
  
52	  
2011).	  Thus,	  these	  two	  genes	  seem	  to	  play	  a	  crucial	  role	  both	  in	  neuron	  and	  hair	  cell	  
formation.	  
	  
These	  roles	  of	  Ngn1	  and	  NeuroD	   in	  the	  antero-­‐ventral	  wall	  of	  the	  otic	  vesicle	  (Bok	  et	  
al.,	  2007),	  where	  Fgf10	  is	  also	  expressed	  (Pauley	  et	  al.,	  2003;	  Abello	  and	  Alsina,	  2007),	  
suggest	  that	  these	  members	  of	  the	  Neurogenin	  pathway	  represent	  good	  candidates	  for	  
regulating	  Fgf10	  expression	  in	  vivo.	  	  	  
	  
	  
1.6 Treating	  hearing	  impairment	  
How	  could	  we	  use	  the	  mechanisms	  naturally	  occurring	  during	  development	  to	  restore	  
hearing?	   To	   illustrate	   that,	   a	   schematic	   example	   of	   a	   damaged	   organ	   of	   Corti	   is	  
presented	  in	  Figure	  1.11.	  In	  such	  case,	  the	  hair	  cells	  are	  lost	  and	  progressively	  replaced	  
by	   epithelial	   cells.	   The	   idea	   is	   that	   if	  we	   could	   expose	   this	   damaged	  epiderm	   to	   the	  
same	   set	   of	   signals	   allowing	   the	   differentiation	   of	   hair	   cells	   and	   neurons	   during	  
embryogenesis	   then	  we	  may	  be	  able	   to	   force	   the	  differentiation	  of	  new	  hair	   cells	   to	  
replace	  the	  one	  that	  had	  been	  lost.	  This	  could	  be	  done	  by	  direct	  delivery	  of	  the	  gene	  
required	   for	   hair	   cell	   and	   neuron	   differentiation	   to	   the	   epiderm	   or,	   as	   depicted	   in	  
Figure	  1.11,	  by	  grafting	  cells	  that	  were	  induced	  to	  differentiate	  as	  hair	  cells/neurons	  in	  






































































































































































































































































































































































































































































































































































































Such	  changes	  in	  the	  identity	  of	  differentiated	  cells	  are	  not	  just	  speculation;	  they	  have	  
been	  achieved	  in	  vitro.	  Six	  years	  ago	  already,	  Shina	  Yamanaka	  (Nobel	  Prize	  2012)	  and	  
Kazutsochi	  Takahashi	  turned	  differentiated	  fibroblasts	  into	  pluripotent	  cells	  in	  vitro	  by	  
exposing	  them	  to	  a	  combination	  of	  only	  4	  genes:	  Oct4,	  Sox2,	  Klf4	  and	  c-­‐Myc	  (Takahashi	  
and	   Yamanaka,	   2006).	   This	   demonstrates	   that	   a	   couple	   of	   key	   genes	   can	   have	   a	  
tremendous	  effect	  on	  cell	  differentiation.	  	  Even	  more	  recently,	  human	  embryonic	  stem	  
cells	  induced	  in	  vitro	  to	  differentiate	  into	  auditory	  neuron	  progenitors	  were	  shown	  to	  
restore	  auditory	  evoked	  responses	  when	  transplanted	  in	  gerbils’	  cochlea	  (Chen	  et	  al.,	  
2012).	   Interestingly,	  hair	   cell	   and	  auditory	  neuron-­‐like	   features	  had	  been	   induced	  by	  
exposure	   to	   Fgf3	   and	   Fgf10,	   putting	   these	   two	   genes	   in	   the	   regulatory	   pathway(s)	  
controlling	  hair	  cell	  and	  neuron	  differentiation.	  
	  
	  
1.7 Project	  aims	  
In	  this	  project	  I	  thus	  took	  Fgf3	  and	  Fgf10	  as	  a	  starting	  point	  from	  which	  to	  investigate	  
the	   network	   involved	   in	   hair	   cell	   and	   neuron	   formation.	   Bioinformatic	   analysis	   of	  
Fgf3/10	   genomic	   regions	   revealed	   the	  presence	  of	  putative	  binding	   sites	   for	   retinoic	  
acid	   (RA).	   However	   the	   spatial	   and	   dose-­‐dependent	   effects	   of	   RA	   on	   Fgf3/Fgf10	  
expression	   in	  vivo	  are	  unknown.	   	  Thus	  a	  major	   focus	  of	   this	  study	  was	  to	   investigate	  
whether	  abrogated	  Fgf3/10	  signalling	  could	  in	  part	  explain	  the	  genesis	  of	  RA-­‐induced	  
inner	   ear	   phenotypes.	   	   In	   addition,	   this	   study	   also	   looked	   to	   investigate	   regulatory	  





MATERIAL	  AND	  METHOD	  
2.1	  Mouse	  Genotyping	  
2.1.1	  Transgenic	  mouse	  lines	  and	  primers	  used	  for	  genotyping	  
Four	  different	  genetically	  modified	  mouse	  strains/lines	  were	  used	  in	  this	  study:	  
(i)	  An	  Fgf3-­‐lacZ	  reporter	   line	  that	  has	  been	  previously	  described	  (Powles	  et	  al.,	  2004)	  
and	   is	   able	   to	   recapitulate	  Fgf3	   pattern	   of	   expression	   in	   all	   endogenous	   domains	   of	  
Fgf3	  expression,	  with	  the	  exception	  of	  rhombomeres	  5	  and	  6.	  	  
(ii)	   An	   Fgf10	   mutant	   mouse	   line	   where	   a	   PGK-­‐neo	   cassette	   had	   been	   inserted	   in	  
reverse	  orientation	  in	  the	  Fgf10	  coding	  region	  (Min	  et	  al.,	  1998).	  	  
(iii)	  An	  Fgf10-­‐reporter	  line	  (3f3r-­‐ZsGreen)	  able	  to	  recapitulate	  the	  endogenous	  pattern	  
of	  Fgf10	  expression	   in	  the	   inner	  ear	  and	  that	  was	  generated	   in	  the	   laboratory	  during	  
the	  course	  of	  this	  study	  as	  part	  of	  an	  independent	  project	  (Economou	  et	  al.,	  2013).	  	  	  
(iv)	   A	   second	   Fgf10-­‐reporter	   line	   (7f7r-­‐DsRed)	   generated	   as	   part	   of	   this	   project	   and	  
hypothesized	   to	   contain	   all	   enhancers’	   elements	   required	   to	   recapitulate	   the	   full	  
pattern	  of	  Fgf10	  expression.	  
Each	  of	  these	  transgenic	  lines	  was	  genotyped	  by	  PCR	  amplification	  using	  one	  of	  the	  set	  




Table	  2.1	  –	  Set	  of	  primers	  used	  for	  the	  genotyping	  of	  the	  4	  transgenic	  mouse	  lines	  used	  in	  this	  study	  
Transgenic	  mice	  line	   Forward	  primer	   Reverse	  primer	  
Fgf3-­‐lacZ	   5’-­‐GCGACTTCCAGTTCAACATC-­‐3’	   5’-­‐CTGGAATTCCGCCGATACTG-­‐3’	  
Fgf10neo	   5’-­‐TCCAGCTGTCTCTCTGCCTCGCAG-­‐3’	  
5’-­‐GGAGAACAGCAGCCTTCTCCAGCGGACA-­‐3’	  
5’-­‐CATCTGCACGAGACTAGTGAGACGTGC-­‐3’	  
3F3R-­‐ZsGreen	   5’-­‐GGAGATGACCATGAAGTACCGCATGG-­‐3’	   5’-­‐GCTTGTGCTGGATGAAGTGCCAGTC-­‐3’	  
7F7R-­‐DsRed	   5’-­‐GCGATCGCAGGAAAGTGCGTAGGCT-­‐3’	   5’-­‐GCTTGATGACGTTCTCAGTGCTATCCATGG-­‐3’	  
	  
Genotyping	  of	  Fgf10	  mutant	  embryos	  required	  making	  the	  difference	  between	  embryo	  
homozygous	  or	  heterozygous	   for	   the	  mutation.	  Fgf10+/-­‐	   and	  Fgf10-­‐/-­‐	   and	  WT	  embryos	  
were	  identified	  using	  a	  set	  of	  three	  different	  primers	  (See	  Table	  2.1	  and	  Figure	  2.1).	  	  	  
	  
	  
Figure	   2.1	   –	   Genotyping	   of	   mouse	   embryos	   homozygote,	   hetozygote	   or	   wild-­‐type	   for	   the	   Fgf10	   mutation.	  
Annealing	  of	  Fgf10	   forward	  and	  reverse	  primers	   	   (blue	  arrows)	  to	  the	  wild-­‐type	  Fgf10	  allele	  gives	  rise	  to	  a	  450bp	  
DNA	   fragment	   following	   PCR	   amplification.	   In	   the	   mutant	   allele	   a	  Neo	   cassette	   inserted	   in	   reverse	   orientation	  
results	  in	  the	  Fgf10	  forward	  primer	  (blue	  arrow	  in	  broken	  line)	  to	  be	  1.8kb	  apart	  from	  the	  Fgf10	  reverse	  primer.	  This	  
1.8kb	  fragment	  cannot	  be	  generated	  under	  the	  PCR	  conditions	  used	  for	  genotyping.	  However	  the	  second	  forward	  
primer	  (indicated	  in	  italic	  in	  Table	  2.1),	  in	  combination	  with	  the	  Fgf10	  reverse	  primer,	  results	  in	  the	  generation	  of	  a	  
350bp	  DNA	  fragment.	  Thus,	  wild-­‐type	  alleles	  are	  predicted	  to	  amplify	  a	  450bp	  fragment,	  whereas	  in	  the	  presence	  of	  
the	  mutant	  allele	  a	  350bp	  fragment	  is	  amplified.	  This	  permitted	  the	  identification	  of	  wild-­‐type	  (one	  band	  of	  350bp),	  




2.1.2	  DNA	  preparation	  from	  mouse	  ear	  notches	  
DNA	   was	   prepared	   from	   ear	   notches	   by	   digestion	   at	   55oC	   overnight	   in	   400µg/ml	  
proteinase	   K	   (PK)	   in	   20µL	   ear	   notch	   buffer	   (20mM	   Tris-­‐Cl	   pH8.0,	   10mM	   EDTA).	   The	  
next	  day	  180µL	  of	  ddH20	  was	  added	  to	  the	  mix	  and	  the	  PK	  was	  heat	  inactivated	  at	  95°C	  
for	  15min.	  	  1-­‐2µL	  of	  DNA	  solution	  was	  then	  used	  to	  set	  up	  PCR	  reactions.	  
	  
2.1.3	  PCR	  conditions	  
Typically	  PCR	  conditions	  were	  similar	  to	  the	  one	  used	  for	   lacZ	  genotyping	  (Table	  2.2)	  
with	  the	  exception	  of	  the	  annealing	  temperature	  that	  was	  70.6°C	  for	  Fgf10neo,	  65.5°C	  
for	  3F3R-­‐Zsgreen	  and	  63°C	  for	  7F7R-­‐DsRed	  PCR	  reactions	  were	  set	  up	  as	  described	  in	  
table	  2.3	  with	  the	  exception	  of	  Fgf10neo	  genotyping,	  due	  to	  the	  presence	  of	  3	  primers	  
instead	  of	  2	  (table	  2.4)	  
	  
Table	  2.2	  PCR	  conditions	  for	  LacZ	  genotyping	  
Description	   Temperature	   Time	   Cycles	  
Initial	  denaturation	   95°C	   2min	   1	  
Denaturation	   95°C	   30s	   	  
Annealing	   59°C	   30s	   x	  35	  
Elongation	   72°C	   1min	   	  
Final	  Elongation	   72°C	   2min	   1	  







Table	  2.3	  Standard	  PCR	  reaction	  mix	  
Reagents	   V	  (in	  μL)	   Volume	  (in	  μL)	  
Ultra-­‐pure	  water	   7.8	  
10x	  buffer	   2.0	  
2.5	  mM	  dNTPs	   2.0	  
Forward	  primer	  	   0.5	  
Rev	  primer	  	   0.5	  
Mg2+	   4.0	  
DMSO	   1.0	  
DNA	  Taq	  polymerase	   0.2	  
DNA	   2.0	  
TOTAL	   20.0	  µL	  
	  
Table	  2.4	  -­‐	  PCR	  reaction	  mix	  for	  genotyping	  of	  Fgf10neo	  embryos	  
Reagents	   V	  (in	  μL)	  
Ultra-­‐pure	  water	   6.8	  
10x	  buffer	   2.0	  
2.5mM	  dNTPs	   2.0	  
Fgf10MutFor	   1.0	  
Fgf10MutRev	   0.5	  
PGKRev	  (315)	   0.5	  
Mg2+	   4.0	  
DMSO	   1.0	  
DNA	  Taq	  polymerase	   0.2	  
DNA	   2.0	  





2.1.4	  Confirmation	  of	  in	  vitro	  genotyping	  results	  
Whenever	   possible,	   PCR	   results	   were	   confirmed	   in	   vivo	   by	   analyzing	   reporter	   gene	  
expression,	  or,	  through	  the	  visualization	  of	  morphological	  features	  of	  mutants,	  such	  as	  
the	   lack	  of	   limb	  bud	  in	  Fgf10-­‐/-­‐	  mice	  that	   is	  detectable	  by	  10.5dpc.	  Additionally,	  male	  
homozygotes	  for	  a	  specific	  reporter	  gene	  were	  bred	  and	  identified	  as	  those	  giving	  rise	  
to	  litters	  where	  all	  the	  embryos	  express	  the	  transgene	  when	  backcrossed	  to	  wild-­‐type	  
females.	   Ideally,	   each	  male	   should	   have	   been	   tested	   13	   times,	   because	   if	   out	   of	   13	  
litters	  all	  embryos	  carry	  the	  transgene,	  then	  the	  probability	  the	  male	  is	  heterozygous	  is	  
less	   than	   one	   in	   a	   thousand;	   as	   determined	   by	   a	   Chi-­‐squared	   test	   with	   a	   Yates	  
correction	  factor	  of	  0.5	  (www.informatics.jax.org).	  However	  with	  just	  5	  litters	  for	  each	  
male	  we	   can	  already	  be	  95%	  confident	   that	   they	  were	  homozygotes.	   In	   addition,	   all	  
Fg3-­‐lacZ	  embryos	  (as	  presented	  in	  Chapter	  3)	  showed	  visible	  X-­‐GAL	  staining,	  with	  the	  
exception	  of	  one	  (Figure	  3.5G)	  for	  which	  genotype	  was	  further	  confirmed	  by	  a	  PCR	  on	  
its	  yolk	  sac.	  
	  
2.2	  Retinoic	  Acid	  Administration	  to	  pregnant	  mice	  
2.2.1	  Preparation	  of	  chocolate/sugar	  pellets	  
Chocolate	  pellets.	   To	  prepare	   chocolate	  pellets,	   chocolate	   spread	   (regular	   chocolate	  
spread	   for	  human	  consumption	  available	   from	  supermarkets,	  1.25g)	  was	  mixed	  with	  
800ml	  water	  and	  5.6g	  icing	  sugar.	  	  Using	  a	  10.0ml	  syringe,	  small	  pellets	  of	  around	  50-­‐
150mg	   weights	   were	   made	   and	   allowed	   to	   set	   at	   4oC	   on	   plastic	   Petri	   dishes.	  	  
Experimental	  results	  (see	  section	  3.1)	  showed	  that	  ideal	  size	  pellets	  weighed	  between	  
70	  and	  110mg	  for	  complete	  ingestion.	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Sugar	  pellets.	  Writing	  icing	  sugar	  (Dr.Oekter	  brand)	  was	  used	  directly	  to	  make	  pellets	  
in	   a	   Petri	   dish	   with	   setting	   at	   4oC.	   Although	   this	   was	   not	   statistically	   tested,	   mice	  
seemed	   to	   show	   a	   preference	   toward	   the	   green-­‐coloured	   pellets	   during	   control	  
feeding	   experiments	   with	   sugar	   only,	   and	   thus	   the	   green	   icing	   sugar	   was	   then	  
preferentially	  used	  to	  generate	  RA-­‐laced	  pellets.	  This	  apparent	  preference	  was	  based	  
on	   the	   shorter	   time	   between	   exposure	   to	   the	   pellet	   and	   consumption	   by	   the	  mice	  
(n=6).	  Since	  mice	  have	  next	  to	  no	  colour	  perception	  but	  a	  particularly	  developed	  sense	  
of	  smell,	  this	  putative	  preference	  is	  more	  likely	  be	  due	  to	  the	  green	  paste	  scent.	  
	  
Retinoic	  acid-­‐laced	  chocolate/sugar	  pellets.	  To	  make	  retinoic	  acid	   (RA)-­‐laced	  pellets,	  
all-­‐trans	  retinoic	  acid	  powder	  (Sigma)	  was	  added	  either	  to	  the	  chocolate	  mix	  or	  to	  icing	  
sugar	  and	  mixed	   thoroughly	  until	  homogenous.	  The	  yellow	  RA	  powder	   is	  particularly	  
easily	   visible	   when	   mixed	   with	   green	   icing	   sugar	   making	   it	   easy	   to	   monitor	   for	  
homogenous	  RA	  mixing.	  Pellets	  were	  then	   left	  to	  set	  at	  4oC	  for	  2	  hours	  before	  being	  
transferred	  to	  -­‐20oC	  where	  they	  were	  stored	  for	  up	  to	  a	  week	  without	  any	  noticeable	  
decrease	   in	   efficiency	   (judged	   by	   reproducible	   generation	   of	   phenotypes).	   RA	  
concentrations	   in	   the	   sugar/chocolate	   mix	   was	   adjusted	   according	   to	   the	   desired	  
administration	  dose,	  ranging	  from	  4.5mg/kg	  to	  25mg/kg,	  in	  order	  to	  keep	  the	  pellets	  in	  








2.2.2	  RA	  administration	  to	  mice	  via	  chocolate/sugar	  pellets	  
Fgf3-­‐lacZ	  homozygous	  males	  were	  crossed	  with	  wild-­‐type	  females	  and	  pregnant	  mice	  
were	   identified	  by	   the	  presence	  of	   a	   vaginal	   plug.	  RA	  administration	  was	  performed	  
according	   to	   the	  protocol	   already	  described	   in	   detail	   elsewhere	   (Cadot	   et	   al.,	   2012).	  
Briefly,	  for	  inner	  ear	  analysis,	  pregnant	  mice	  of	  mean	  weight	  of	  25g	  received	  a	  dose	  of	  
0mg,	  4.5mg,	  6mg,	  7mg,	  8mg,	  10mg	  or	  25mg/kg	  RA	  mixed	  in	  either	  a	  chocolate	  or	  sugar	  
pellet	  of	  the	  appropriate	  size	  either	  at	  4pm	  on	  day	  7	  of	  gestation	  (for	  administration	  at	  
7.75dpc)	  or	  at	  10:30am	  on	  day	  8	  of	  gestation	  (for	  administration	  at	  8.5dpc).	  	  For	  doses	  
of	  2x25mg/kg	  of	  RA,	  time	  of	  exposure	  was	  10:30am	  and	  2:30pm	  on	  day	  8.	  Clean	  cages	  
without	  sawdust	  or	  bedding	  were	  used	  to	  allow	  visualization	  of	  pellet	  ingestion.	  	  These	  
mice	   were	   then	   humanely	   killed	   by	   cervical	   dislocation	   at	   9.5dpc	   or	   10.5dpc	   as	  
required	   for	   analysis,	   and	   their	   embryos	   processed	   as	   described	   in	   section	   2.3.	  
Embryos	  were	   examined	   on	   a	   Zeiss	   (Thornwood,NY)	   Stemi	   SVII	   stereomicroscope	   or	  
Nikon	  (Melville,NY)	  Steromicroscope.	  	  For	  phenotype	  analysis	  of	  other	  organ	  systems,	  
RA	  doses	   and	   timing	  of	   administration	  used	  were	  100mg/kg	   at	   11.5dpc	   for	   the	   limb	  
and	   palate;	   and	   10mg/kg	   at	   7dpc	   for	   the	   heart.	  Mice	  were	   then	   humanely	   killed	   as	  
described	   above	   and	   embryos	   examined	   at	   18.5dpc	   (limb	   and	   palate	   analysis)	   or	  
9.5dpc	  	  (heart	  analysis).	  	  
	  
2.2.3	  RA	  administration	  via	  oral	  gavage	  
For	   administration	   of	   RA	   via	   oral	   gavage,	   all-­‐trans	   RA	   (Sigma)	   was	   resuspended	   in	  
sesame	  seed	  oil	   at	  5mg/ml	  and	  stored	   in	   the	  dark	  at	  4oC	  until	  use	   the	  next	  day.	  For	  
analysis	  of	  inner	  ear	  phenotypes,	  pregnant	  mice	  of	  mean	  weight	  25mg	  received	  either	  
one	   dose	   of	   25mg/kg	   of	   RA	   at	   10:30am	   or	   two	   consecutive	   doses	   of	   25mg	   each	   at	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10:30am	   and	   2:30pm	   on	   day	   8	   as	   previously	   described	   (Frenz	   et	   al.	   1996).	  
Administration	  was	  performed	  using	  a	  blunt	  feeding	  needle	  with	  terminal	  ball	  bearing	  
to	  reduce	  oesophageal	  abrasion.	  Mice	  were	  humanely	  killed	  by	  cervical	  dislocation	  at	  
9.5dpc	  and	  embryos	  processed	  as	  described	  in	  section	  2.3.	  For	  limb,	  palate	  and	  heart	  
phenotype	   analysis,	   doses	   and	   timing	   of	   administration	   were	   as	   described	   in	   the	  
previous	  section	  2.2.3.	  	  	  
	  
2.3 	  Staining	  embryos	  for	  for	  ß-­‐Galactosidase	  activity	  
Fgf3-­‐lacZ	   reporter	   expression	   was	   detected	   by	   staining	   for	   ß-­‐galactosidase	   activity.	  
Pregnant	  mice	  were	  humanely	  killed	  by	  cervical	  dislocation	  and	   the	  uterus	  dissected	  
and	  chilled	   immediately	  on	   ice	   in	  1X	  PBS	   (Phosphate	  Buffer	  Saline,	  pH	  7.4).	  Embryos	  
were	  carefully	  dissected	  out	  of	  embryonic	  membranes	  and	  fixed	  by	  immersion	  in	  LacZ	  
fixative	   (1%	   Formaldehyde,	   0.2%	   Gluteraldehyde,	   2mM	   MgCl2,	   5mM	   EGTA,	   0.02%	  
Nonidet	  P40	  in	  PBS)	  for	  30	  minutes	  on	  ice.	  Embryos	  were	  then	  rinsed	  in	  PBS	  +	  0.02%	  
NP40	   for	   three	   30	  minute	  washes.	   	   Embryos	  were	   then	   incubated	   overnight,	   in	   the	  
dark	   at	   room	   temperature,	   in	   LacZ	   staining	   solution	   (5mM	   K3Fe(CN)6,	   5mM	  
K4FE(CN)6.3H2O,	  2mM	  MgCl2,	  0.01%	  sodium	  deoxycholate,	  0.02%	  NP40)	  to	  which	  had	  
been	  freshly	  added	  1mg/mL	  of	  Xgal	  (5-­‐bromo-­‐4-­‐chloro-­‐indolyl-­‐β-­‐D-­‐	  galactopyranoside)	  
in	  DMF	  (dimethylformamide).	  After	  development	  of	  the	  blue	  signal	  (around	  18hours),	  
embryos	  were	  rinsed	  3	  times	  in	  PBS	  and	  then	  post-­‐fixed	  in	  4%	  PFA	  (paraformaldehyde	  
in	  PBS)	  at	  4°C	  for	  45-­‐60min.	  Embryos	  were	  rinsed	  again	  3	  times	   in	  PBS	  before	  taking	  




2.4	  Histological	  methods	  
Some	   embryos	   were	   selected	   for	   further	   detailed	   analysis	   as	   wax	   sections.	   Such	  
embryos,	   typically	   9.5dpc	   to	   11.5dpc	   in	   age,	   were	   first	   dehydrated	   in	   an	   increasing	  
ethanol	   dilution	   series	   (25%,	   50%,	   75%,	   95%,	   100%	   x2)	   using	   5	   to	   10	   minute	  
incubations	   according	   to	   their	   size.	   Next|,	   embryos	  were	   cleared	   in	   two	   changes	   of	  
Histoclear	  (National	  Diagnostic)	  for	  20-­‐45	  minute	  incubation,	  followed	  by	  incubation	  in	  
molten	  wax	   at	   55-­‐60oC	   for	   5-­‐30	  minutes.	   Embryos	  were	   then	   transferred	   to	  moulds	  
and	   set	   at	   4oC.	   10-­‐20µM	   thick	   ribbons	   were	   cut	   on	   a	   microtome	   (Leica	   RM2135),	  
sections	   floated	   on	   a	   waterbath	   and	   collected	   on	   TESPA	   (3-­‐
aminopropyltriethoxysilane)	  treated	  slides.	  For	   lacZ	  embryos,	  wax	  was	  removed	  from	  
sections	   by	   brief	   immersion	   in	   Histo-­‐Clear,	   sections	   rehydrated	   through	   a	   reverse	  
ethanol	  series	  (100%,	  95%,	  70%	  ethanol	  and	  tap	  water	  etc)	  for	  3	  minute	  incubations,	  
counterstained	  in	  0.25%	  eosin	  for	  10	  seconds	  and	  dehydrated	  again	  before	  mounting	  
in	  DPX	  mount.	  	  For	  in	  situ	  hybridization	  (ISH)	  embryos,	  sections	  were	  washed	  from	  the	  
wax	  by	  brief	   immersion	   in	  Histoclear	  and	  they	  were	  mounted	   in	  DPX	  mount	  without	  
counterstaining.	  	  
	  
2.5	  General	  DNA	  manipulation	  
2.5.1	  DNA	  digestion	  by	  restriction	  endonucleases	  
1	   to	   10µg	   of	   plasmid	   DNA	   was	   digested	   with	   3-­‐5	   units/µg	   of	   DNA	   of	   restriction	  
endonuclease(s),	  with	  the	  appropriate	  buffer	  at	  1x	  concentration	  in	  a	  final	  volume	  of	  
20	   to	   50µL.	   Buffers	   and	   enzymes	   were	   in	   general	   purchased	   from	   New	   England	  
Biolabs.	   	  DNA	   incubation	   time	  varied	  depending	  on	   the	  purpose	  of	   the	  experiments.	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For	   subsequent	   cloning,	   DNA	   digestions	   were	   incubated	   1	   to	   2	   hours	   maximum	   at	  
37°C;	  for	  minipreps,	  digestions	  were	  incubated	  for	  2	  hours	  to	  overnight.	  
	  
2.5.2	  Blunting	  DNA	  fragments	  	  	  
Typically,	  fragments	  were	  first	  prepared	  by	  restriction	  endonuclease	  digestion	  and	  the	  
enzyme	  was	  first	   inactivated	  by	  denaturation	  for	  20min	  at	  65oC	  or	  80oC	  according	  to	  
the	   endonucleases	   used	   (NEB	   appendix).	   	   If	   the	   enzymes	   used	   could	   not	   be	   heat	  
inactivated,	  then	  DNA	  fragments	  were	  purified	  using	  the	  Geneclean	  kit	  	  (section	  2.5.5)	  
to	  purify	  DNA	  from	  a	  solution.	  The	  fill-­‐in	  reaction	  using	  T4	  DNA	  polymerase	  was	  then	  
set	  up	  as	  described	  in	  table	  2.9.	  	  
	  
Table	  2.5	  Reaction	  mix	  for	  blunting	  using	  T4	  DNA	  polymerase	  
Reagents	   Quantities	  
Restriction	  digest	  or	  purified	  DNA	  fragment	   15-­‐47	  µL	  
100x	  BSA	   0.5µL	  
2.5mM	  dNTPs	   2µL	  
T4	  DNA	  polymerase	   1U/µg	  of	  DNA	  
dH2O	   up	  to	  50µL	  
	  
The	  reaction	  mix	  was	  incubated	  for	  15min	  at	  12°C.	  The	  reaction	  was	  then	  stopped	  by	  
the	   addition	   of	   100mM	   of	   EDTA	   and	   heat	   inactivation	   of	   T4	   for	   20min	   at	   75°C.	  






2.5.3	  Plasmid	  dephosphorylation	  
Plasmid	   dephosphorylation	   was	   performed	   using	   the	   CIP	   alkaline	   phosphatase	   from	  
Roche.	   Following	   plasmid	   digestion	   the	   DNA	   fragments	   to	   dephosphorylate	   were	  
incubated	  for	  1	  hour	  at	  37oC	  with	  1U	  of	  CIP	  for	  1pmol	  of	  DNA	  ends	  (Table	  2.6)	  	  
	  
Table	  2.6	  Plasmid	  dephosphorylation	  reaction	  mix	  
Reagents	   Volume	  
Restriction	  digest	  or	  purified	  DNA	  fragment	   15-­‐37	  µL	  
10X	  CIP	  Buffer	   5µL	  
Calf	  Intestine	  Phosphatase	  (CIP)	   1U/1pmol	  of	  end	  
dH2O	   up	  to	  50µL	  
	  
The	  phosphatase	  reaction	  was	  stopped	  by	  adding	  1/10	  vol	  of	  200mM	  EGTA,	  followed	  
by	  heat	   inactivation	  for	  20min	  at	  65oC.	  DNA	  fragments	  were	  then	  run	  on	  an	  agarose	  
gel	  and	  purified	  using	  the	  Geneclean	  kit	  according	  to	  the	  protocol	  presented	  in	  section	  
2.5.5.	  	  
	  
2.5.4	  Agarose	  gel	  electrophoresis	  
Typically	   0.5-­‐10µg	   of	   DNA	   fragments	   were	   resolved	   by	   agarose	   gel	   electrophoresis	  
using	  0.8-­‐2%	  agarose	  gels	  containing	  0.01%	  	  (2-­‐5µl/100ml	  of	  10mg/ml	  stock)	  ethidium	  
bromide	  at	  approximately	  75mA	  for	  30-­‐60	  minutes.	  Agarose	  gels	  were	  prepared	  with,	  
and	  run	  into,	  1XTAE	  buffer	  obtained	  from	  freshly	  diluting	  50X	  TAE	  buffer	  stock	  (40mM	  




2.5.5	  Extraction	  of	  DNA	  from	  agarose	  gel	  using	  the	  Geneclean	  protocol.	  
DNA	  for	  extraction	  was	  run	  on	  an	  agarose	  gel	  at	  0.8-­‐1.5%.	  The	  required	  bands	  were	  cut	  
out	  using	  a	  scalpel	  under	  long	  wave	  UV	  illumination.	  Exposure	  to	  ultra-­‐violet	  was	  kept	  
to	   a	  minimum	   since	   it	   is	  mutagenic	   for	   the	  DNA.	  DNA	  was	   then	   extracted	   from	   the	  
bands	   using	   the	   Geneclean	   kit	   with	   some	   modifications	   to	   the	   manufacturer	  
instructions.	  Briefly,	  gel	  slices	  were	  weighed	  in	  1.5mL	  Eppendorf	  tubes.	  3X	  volume	  6M	  
NaI	  (sodium	  iodide)	  were	  added	  and	  tubes	  were	  put	  to	  incubate	  for	  5min	  at	  55°C	  (or	  
till	   dissolution	   of	   all	   the	   gel).	   2.5µL	   of	   Glass	  milk	   were	   then	   added	   and	   tubes	   were	  
incubated	   at	   room	   temperature	   (RT)	   on	   roll	   for	   30min	   (an	   additional	   overnight	  
incubation	  step	  at	  4°C	  was	  performed	  for	  DNA	  fragments	  with	  sizes	  inferior	  to	  800bp).	  
Tubes	   were	   then	   centrifuged	   for	   30sec	   at	   13000rpm	   and	   supernatants	   discarded.	  
Pellets	  were	  resuspended	  in	  500µL,	  centrifuged	  for	  5sec	  at	  13000rpm	  and	  supernatant	  
discarded.	   This	   step	  was	   performed	   a	   second	   time,	   following	   that,	   the	   pellets	   were	  
centrifuged	  for	  5sec	  to	  remove	  all	  traces	  of	  liquids	  and	  dried	  at	  37°C	  for	  5min.	  Pellets	  
were	  then	  resuspended	  in	  10µL	  of	  10mM	  Tris	  pH8	  and	  incubated	  for	  1min	  at	  RT.	  Tubes	  
were	  then	  centrifuged	  at	  full	  speed	  for	  30sec	  and	  supernatants	  carefully	  transferred	  to	  
a	   0.5µL	   Eppendorf.	   Pellets	  were	   resuspended	   in	   another	   10µL	   of	   Tris,	   incubated	   for	  
1min	  at	  55°C	  and	  centrifuged	  at	   full	   speed	   for	  30sec.	  The	  supernatants	  were	  pooled	  
with	  the	  previous	  10µL	  in	  the	  0.5µL	  Eppendorf	  tube.	  1µL	  of	  each	  tube	  was	  checked	  on	  
gel	  for	  quantification.	  
	  
2.5.6 Ligations	  
Ligations	  were	  usually	  set	  up	  at	  3	  different	  vector:insert	  ratios	  (Table	  2.7),	  except	  for	  
ligations	  known	  to	  be	  particularly	  efficient	  and	  for	  which	  only	  one	  ligation	  reaction	  was	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set	   up	   at	   the	   ratio	   that	   seemed	   the	  most	   appropriate.	   A	   control	  without	   insert	   also	  
allowed	  monitoring	  whether	  the	  vector	  had	  been	  fully	  digested	  and	  dephosphorylated	  
when	  applicable.	  	  
	  
Table	  2.7	  –	  Typical	  ligation	  reaction	  set	  up	  
Reagents	   1:1	   1:2	   1:3	   1:0	  
Linearised	  plasmid	   5-­‐50ng	  
Insert	   5-­‐50ng	   NONE	  
	  T4	  DNA	  Ligase	  buffer	   1	   1	   1	   1	  
T4	  DNA	  ligase	   0.5	   0.5	   0.5	   0.5	  
dH2O	   up	  to	  10µL	  
	  
Ligations	  were	  always	  incubated	  overnight	  at	  12-­‐16°C	  and	  sometimes	  left	  to	  incubate	  a	  
couple	   of	   hours	   more	   at	   4oC	   before	   being	   transferred	   at	   -­‐20°C	   for	   storage	   till	  
transformation.	  	  
	  
2.5.7 Generation	  of	  supercompetent	  cells	  
The	   transformation	   efficiency	   of	   supercompetent	   cells	   is	   usually	   much	   better	   than	  
what	  can	  be	  obtained	  with	  bacterial	   cells	   induced	  with	  calcium	  chloride.	   In	  addition,	  
cells	   could	   be	   prepared	   in	   bulk	   and	   conserved	   at	   4oC	   for	   months	   while	   being	  
immediately	   available	   for	   transformation	   at	   any	   time.	   In	   order	   to	   generate	  
supercompetent	   cells,	   a	   SOB	   plate	   was	   streaked	   with	   a	   frozen	   stock	   of	   DH5α	   and	  
incubated	  overnight	  at	  37°C	  until	  the	  colonies	  were	  2-­‐3mm	  in	  diameter.	  The	  next	  day,	  
one	  of	  these	  colonies	  was	  picked	  and	  incubated	  in	  10mL	  of	  SOB	  medium	  (2%	  tryptone,	  
0.5%	   yeast	   extract,	   10mM	   NaCl,	   2.5mM	   KCL	   in	   dH2O)	   overnight	   with	   moderate	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agitation	   (240rpm).	   On	   day	   3,	   4	   x	   50mL	   of	   SOB	  medium	  were	   inoculated	  with	   100-­‐
500µL	   of	   overnight	   bacterial	   culture	   in	   a	   500mL	   Erlen.	   Bacteria	   were	   then	   further	  
incubated	   with	   moderate	   agitation	   at	   37°C	   until	   the	   cell	   density	   is	   6.9	   x	   107	   viable	  
cells/mL,	  as	  evidenced	  by	  an	  OD	  =	  0.3-­‐0.4.	  It	  usually	  took	  2hours	  for	  the	  bacterial	  cells	  
to	  reach	  this	  stage.	  Cultures	  were	  then	  transferred	  to	  50mL	  Falcon	  tubes	  and	  chilled	  on	  
ice	   for	   10-­‐15min,	   before	   being	   centrifuged	   at	   4°C	   for	   20min	   at	   3000rpm.	   Bacterial	  
pellets	  should	  stay	  on	  ice	  at	  all	  times.	  Thus,	  they	  were	  quickly	  and	  thoroughly	  drained	  
by	  inverting	  the	  tubes	  on	  some	  paper	  towels	  for	  a	  few	  seconds	  only.	  Pellets	  were	  then	  
resuspended	   in	   1/3	   (17mL)	   of	   the	   original	   culture	   volume	   (50mL)	   in	   FSB	   (Frozen	  
Storage	  Buffer:	  10mM	  potassium	  acetate,	  10%	  redistilled	  glycerol,	  100mM	  KCl,	  45mM	  
MnCl2.4H2O,	  10mM	  CaCl2.2H2O,	  3mM	  HACoCl3)	  using	  a	  10mL	  pipette	  and	  incubated	  on	  
ice	   for	   10-­‐15min	   before	   being	   centrifuged	   again	   at	   4C	   for	   20min	   at	   3000rpm.	   After	  
thoroughly	   draining	   the	   pellets,	   cells	   were	   resuspended	   in	   FSB	   to	   1/12.5	   of	   their	  
original	  culture	  volume	  (thus	  into	  4mL	  of	  FSB	  for	  an	  original	  culture	  volume	  of	  50mL).	  
3.5%	  of	  DMSO	  (dimethyl	  sulfoxide,	  140µL)	  was	  then	  squirted	  into	  the	  center	  of	  the	  cell	  
suspension	  that	  was	   immediately	  swirled	  for	  5-­‐10sec.	  Tubes	  were	  then	   incubated	  on	  
ice	   for	   5min,	   after	   that	   a	   second	   aliquot	   of	   DMSO	   (140µL)	   was	   added,	   giving	   a	   7%	  
DMSO	  final	  concentration.	  Cells	  were	  swirled	  and	  incubated	  on	  ice	  again	  for	  10-­‐15min.	  
Cells	  were	  then	  transferred	  to	  chilled	  screw	  cap	  tubes	  to	  make	  aliquots	  of	  400-­‐600µL.	  
To	   finish,	   they	   were	   flash	   frozen	   in	   dry	   ice	   or	   in	   dry	   ice/alcohol	   bath	   before	   being	  
transferred	  to	  the	  -­‐80°C	  fridge	  for	  storage.	  Transformation	  efficiencies	  in	  the	  different	  





2.5.8 Transformation	  of	  supercompetent	  cells	  
One	   or	   several	   supercompetent	   cell	   aliquots	   (according	   to	   the	   number	   of	  
transformations	  to	  perform)	  were	  thawed	  on	  ice	  for	  10min.	  In	  the	  meantime,	  2-­‐4µL	  of	  
DNA	  ligations	  (between	  10ng	  and	  80ng	  of	  DNA)	  were	  added	  to	  50mL	  falcons	  chilled	  on	  
ice.	  As	  soon	  as	  thawed,	  100µL	  of	  supercompetent	  cells	  were	  added	  to	  each	  falcon	  and	  
swirled	  briefly.	  After	  a	  30min	  incubation	  on	  ice,	  the	  cells	  with	  DNA	  were	  heat-­‐shocked	  
for	  1	  min	  25sec	  at	  42°C,	  and	   then	   left	   to	   rest	   for	  2min	  on	   ice.	  500µL	  of	  SOC	   (10mM	  
MgCl2,	   10mM	   MgSO4,	   20mM	   Glucose	   in	   SOB	   medium)	   was	   then	   added	   to	   each	  
transformation	   and	   the	   cells	   were	   incubated	   at	   37°C	   with	   moderate	   agitation	   for	  
1hour.	  Following	  that,	  100µL	  of	  cells	  were	  plated	  on	  LB	  plates	  +	  100mg/mL	  Ampicilline	  
or	  50mg/ml	  Kanamycin	  depending	  on	  the	  construct	  being	  cloned.	  
	  
2.5.9 	  Plasmid	  DNA	  purification	  and	  analysis	  
A	   successful	   transformation	   of	   supercompetent	   cells	   with	   ligations	   means	   that	   a	  
certain	  number	  of	  colonies	  will	  have	  grown	  on	  the	  LB+antibiotic	  plates	  that	  have	  been	  
incubated	  overnight.	   In	  order	  to	  determine	  whether	  these	  colonies	  have	  really	  taken	  
up	  the	  DNA	  construct	  under	  investigation,	  the	  plasmid	  DNA	  needs	  to	  be	  amplified	  and	  
then	  extracted	  from	  the	  bacteria	  for	  analysis.	  To	  do	  so,	  up	  to	  24	  colonies	  were	  used	  to	  
inoculate	  each	  5mL	  of	  LB	  +	  antibiotic.	  Overnight	  incubation	  with	  moderate	  agitation	  at	  
37oC	  will	  allow	  amplification	  of	  the	  plasmid	  for	  DNA	  analysis.	  The	  following	  day,	  1.5mL	  
of	   each	  miniculture	  was	   transferred	   to	   a	   1.5mL	   Eppendorf	   tube	   and	   centrifuged	   for	  
1min	   at	   13000rpm.	   The	   supernatant	   was	   discarded	   and	   the	   pellets	   centrifuged	   for	  
30sec	  more	  in	  order	  to	  eliminate	  all	  traces	  of	  LB	  medium	  that	  could	  interfere	  with	  DNA	  
analysis	   later	   on.	   First	   the	   pellets	  were	   resuspended	   in	   100µL	   of	   Solution	   I	   (50	  mM	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Glucose,	  25mM	  Tris-­‐Cl,	  0.5mM	  EDTA	  in	  dH2O),	  then	  200µL	  of	  freshly	  made	  Solution	  II	  
(0.2N	  NaOH,	  1%	  SDS	  in	  dH2O)	  was	  added	  and	  the	  tubes	  inverted	  6	  times	  each.	  To	  finish	  
150µL	  of	  SolIII	   (3M	  potassium	  acetate,	  11.5%	  glacial	  acid	  acetic	   in	  dH2O)	  was	  added,	  
the	   tubes	   were	   inverted	   6	   times	   again,	   and	   then	   incubated	   for	   5min	   on	   ice	   before	  
being	  centrifuged	  again	  for	  5min	  at	  13000rpm.	  The	  supernatants	  were	  transferred	  to	  
new	   tubes	   and	   the	   pellets	   discarded.	   Once	   bacteria	   have	   been	   harvested,	   and	   the	  
plasmid	  released,	  it	  has	  to	  be	  precipitated	  and	  purified.	  To	  do	  so,	  1mL	  of	  100%	  Ethanol	  
was	   added	   to	   the	   1.5mL	   Eppendorfs.	   Tubes	  were	   inverted	   several	   times	   to	  mix	   the	  
DNA	  with	  ethanol	  and	  then	  incubated	  at	  room	  temperature	  for	  5min,	  the	  time	  needed	  
for	  the	  DNA	  to	  precipitate.	  Tubes	  were	  then	  centrifuged	  at	  13000rpm	  for	  5min	  and	  the	  
ethanol	  discard.	  DNA	  pellets	  were	  then	  rinsed	  with	  250µL	  of	  70%	  ethanol,	  centrifuged	  
again	   for	   1min	   to	   get	   rid	   of	   all	   traces	   of	   ethanol	   and	   then	   dried	   at	   55°C	   for	   10min.	  
Pellets	  were	  then	  resuspended	  in	  20-­‐40µL	  of	  TE	  (pH8)	  depending	  on	  their	  size.	  
	  
Midipreps	  
The	  plasmid	  DNA	  obtained	  from	  miniprep	  extraction	  is	  neither	  pure	  nor	  concentrated	  
enough	   to	   allow	   for	   any	   experiments	   to	   be	   performed.	   Large	   Scale	   Plasmid	  
Preparations,	   or	  Midipreps,	   thus	   needed	   to	   be	   performed.	   To	   do	   so	   4	   x	   50mL	  of	   LB	  
with	  the	  appropriate	  antibiotic	  were	  inoculated	  with	  500µL	  of	  miniculture	  and	  grown	  
for	  around	  16hours,	  or	  till	  OD	  =	  3.	  Each	  50mL	  culture	  was	  poured	  into	  a	  50mL	  Falcon	  
and	  centrifuged	  at	  3000rpm	  for	  20	  minutes	  at	  4oC.	  Pellets	  were	  then	  processed	  using	  
the	   Promega	   or	   Roche	  Midiprep	   kit	   according	   to	  manufacturer’s	   protocol.	   DNA	  was	  




	  Restriction	  analysis	  
Restriction	   analysis	   was	   usually	   performed	   in	   two	   steps.	   First,	   a	   screening	   for	   DNA	  
fragment	   of	   expected	   construct	   size	   versus	   plasmid	   alone	   using	   an	   enzyme	   that	   cut	  
once	   in	   the	  vector.	   Second,	   the	   identity	  and	  orientation	  of	   the	   fragment	   cloned	  was	  
confirmed	  by	  digesting	  the	  clone	  both	  with	  an	  enzyme	  cutting	  in	  the	  plasmid,	  and	  an	  
enzyme	  cutting	   in	  the	   insert.	  Even	  when	  an	  enzyme	  cutting	  both	   in	  the	   insert	  and	   in	  
the	   vector	  was	  available,	   thus	  allowing	   the	   identification	  of	  positive	   clones	   from	   the	  
first	  step,	  at	   least	  one	  more	  restriction	  digest	  was	  performed	  to	  confirm	  this	  positive	  
result.	  
	  
2.6 Reporter	  vectors	  	  
Two	  reporter	  vectors	  were	  used	  in	  this	  study.	  pZsGreen	  1-­‐1	  that	  encodes	  an	  optimized	  
variant	  of	  wild-­‐type	  Zoanthus	  sp.	  Green	  fluorescent	  protein,	  ZsGreen1	  (Figure	  2.2)	  and	  
pDsRed-­‐Express2-­‐1	  that	  encodes	  DsRed-­‐Express2,	  a	  variant	  of	   the	  Discosoma	   sp.	  Red	  
fluorescent	  protein,	  DsRed	  (Figure	  2.3).	  Both	  vectors	  are	  promotorless	  and	  were	  thus	  





Figure	   2.2	   	   pZsGreen1-­‐1	   vector.	   Restriction	  map	   and	  multiple	   cloning	   site	   (MCS)	   of	   the	  promotorless	  




Figure	   2.3	   pDsRed-­‐Express	   2-­‐1	   vector.	   Restriction	   map	   and	   multiple	   cloning	   site	   (MCS)	   of	   the	  
promotorless	  DsRed2	  reporter	  vector.	  ©	  Clonetech	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2.6.1	  Reporter	  vectors	  used	  in	  mice	  
The	  pZsGreen	  vector	  had	  been	  modified	  prior	  to	  the	  start	  of	  this	  doctoral	  project	  with	  
the	   insertion	   of	   a	   minimal	   human	   βglobin	   promoter	   as	   a	   BamHI	   fragment:	  
5’GGATCCCCCGGGCTGGGCATAAAAGTCAGGGCAGAGCCATCTATTGCTTACATTTGCTTCTA
GCCTGCAGGTCGAGGAGCGCAGCCTTCCAGAAGCAGAGCGCGGCGCCATGGGGGATCC-­‐3’	  
Black	   letters	   represent	   the	   human	   βglobin	   promoter	   sequence	  whereas	   blue	   letters	  
are	   plasmid	   sequences	   originating	   from	   the	   plasmid	   from	  where	   the	   promoter	   was	  
taken	  out.	  The	  TATA	  box	  is	  highlighted	  in	  red	  and	  the	  +1	  in	  green.	  In	  addition,	  an	  SpeI	  
restriction	  site	  had	  been	  generated	  upstream	  of	   the	  promoter	  by	  the	  cloning	  of	  SpeI	  
linkers	   in	   the	   SmaI	   restriction	   site	   in	   the	  MCS.	   The	   βglobin-­‐pZsGreen1-­‐1	   vector	   has	  
been	  shown	  to	  drive	  reporter	  expression	  in	  mice	  if,	  and	  only	  if,	  a	  suitable	  enhancer	  is	  
cloned	   upstream	   (Economou	   et	   al.,	   2012).	   The	   pDsRed	   vector	   was	   thus	   modified	  
similarly,	  except	  that	  SpeI	  linkers	  were	  cloned	  into	  the	  SalI	  restriction	  site.	  
	  
2.6.2	  Reporter	  vectors	  used	  for	  chick	  electroporation	  
Three	   reporter	   constructs	   were	   used	   for	   analysis	   into	   chick:	   miniβglobin-­‐ZsGreen,	  
CMV-­‐DsRed	  and	  a	  dual	  reporter	  including	  both	  miniβglobin-­‐ZsGreen	  and	  CMV-­‐DsRed	  in	  
a	  single	  construct.	  The	  miniβglobin	  promoter	  used	  in	  the	  chick	  reporter	  constructs	  is	  a	  
shortened	  version	  of	  the	  one	  used	  in	  mice	  reporter	  constructs,	  where	  only	  sequences	  
indispensable	   for	  expression	  have	  been	  kept.	   In	  particular,	  plasmid	  backbone	  DNA	   is	  
cut	   out:	   5’GGGCATAAAAGTCAGGGCAGAGCCATCTATTGCTTACA-­‐3’.	   CMV-­‐DsRed	  
contains	  a	  chicken	  β-­‐actin	  promoter	  that	  drives	  constitutive	  expression	  of	  DsRed	  and	  




2.7 Fgf10	  reporter	  constructs	  
Fgf10	  enhancer	  fragments	  were	  amplified	  with	  High	  Fidelity	  PCR	  polymerase	  using	  the	  
PCR	  primers	  listed	  in	  table	  2.8.	  The	  location	  of	  the	  primers	  is	  schematised	  in	  Figure	  2.4.	  
The	   generation	   and	   cloning	   of	   Fgf10	   reporter	   constructs	   is	   detailed	   in	   the	   results	  
(sections	  4.2	  and	  4.4).	  
	  
	  
Figure	  2.4	  PCR	  primers	   location	  within	  the	  7.0kb	  Fgf10	  upstream	  region.	   In	  orange	  are	   indicated	  the	  
primers	  to	  amplify	  the	  7f3f	  fragment	  while	  adding	  SpeI	  and	  NdeI	  restrictions	  sites.	  In	  red	  are	  indicated	  
the	   primers	   to	   amplify	   the	   3r7r	   fragments	   while	   adding	   SpeI	   and	  NdeI	   restrictions	   sites.	   In	   blue	   are	  
indicated	   the	   primers	   to	   amplify	   the	   Neuro2.5	   fragment	   and	   in	   green	   the	   primers	   to	   amplify	   the	  
Neuro1.1	  fragment.	  Plain	  red	  circles	  mark	  the	  position	  of	  putative	  Gata3	  binding	  sites	  and	  plain	  green	  
circles	  the	  position	  of	  putative	  binding	  sites	  for	  NGN11,	  NEUROD	  or	  NSCL1.	  	  
	  
	  
Table	  2.8	  List	  of	  primers	  used	  to	  generate	  Fgf10	  enhancer	  fragments	  
Enhancer	  fragment	   Forward	  primer	   Reverse	  primer	  
Neuro2.5	   5’-­‐TGTACTGAAACTCTCGGCACTG-­‐3’	   5’-­‐AGTGTTGGGCTGAAGAAGTGTC-­‐3’	  











*SpeI	  sites	  are	  indicated	  in	  blue	  and	  NdeI	  sites	  in	  red	  
	  
DNA	  fragments	  were	  amplified	  from	  mouse	  genomic	  DNA	  or	  from	  a	  FGF10	  BAC	  clone	  
using	   high-­‐fidelity	   PCR	   with	   Phusion	   DNA	   polymerase	   (Thermoscientific)	   or	   Expand	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Long	  Template	  PCR	  system	  (Roche).	  PCR	  conditions	  and	  reaction	  mixes	  are	  listed	  in	  the	  
tables	   below,	   3R7R	   fragment	   amplification	   (Table	   2.9	   and	   2.10),	   7F3F	   and	  Neuro2.5	  
fragment	  amplification	  (Table	  2.11	  and	  2.12),	  Neuro1.1	  fragment	  amplification	  (Table	  
2.13	  and	  2.14).	  
	  
Table	  2.9	  Conditions	  used	  for	  3R7R	  fragment	  amplification	  with	  Phusion	  
Description	   Temperature	   Time	   Cycles	  
Initial	  denaturation	   98°C	   2min	   1	  
Denaturation	   98°C	   30s	   	  
Annealing	   55°C	   30s	   x	  35	  
Elongation	   72°C	   30s	   	  
Final	  Elongation	   72°C	   10min	   1	  
Hold	   6°C	   -­‐-­‐	   	  
	  
	  
Table	  2.10	  Reaction	  mix	  used	  for	  3R7R	  fragment	  amplification	  
Reagents	   V	  (in	  μL)	  
Ultra-­‐pure	  water	   11.8	  
10x	  HF	  buffer	   2.0	  
2.5mM	  dNTPs	  (200	  μM)	   2.0	  
3R7R	  forward	  primer	  (500	  μM)	   1.0	  
3R7R	  reverse	  primer	  (500	  μM)	   1.0	  
DMSO	  (3%)	   1.0	  
Phusion	  DNA	  polymerase	  (1U)	   0.2	  
Fgf10	  BAC	  DNA	  	   1.0	  





Table	  2.11	  Conditions	  used	  for	  7F3F	  and	  Neuro2.5	  amplifications	  with	  Expand	  Long	  Template	  
Description	   Temperature	   Time	   Cycles	  
Initial	  denaturation	   94°C	   2min	   1	  
Denaturation	   94°C	   30s	   	  
Annealing	   54°C	   30s	   x	  30	  
Elongation	   68°C	   3min	  30s	   	  
Final	  Elongation	   68°C	   10min	   1	  
Hold	   6°C	   -­‐-­‐	   	  
	  
	  
Table	  2.12	  Reaction	  mix	  used	  for	  7F3F	  and	  Neuro2.5	  fragment	  amplification	  
Reagents	   V	  (in	  μL)	  
Ultra-­‐pure	  water	   14.2	  
10x	  buffer2	   2.0	  
2.5	  mM	  dNTPs	  	   1.5	  
7F3F	  or	  Neuro2.5	  forward	  primer	  	   0.6	  
7F3F	  or	  Neuro2.5	  reverse	  primer	  	   0.6	  
DMSO	  	   0.4	  
Expand	  Long	  Template	  Polymerase	  	   0.2	  
Fgf10	  BAC	  DNA	   0.5	  









Table	  2.13	  Conditions	  used	  for	  Neuro1.1	  amplification	  with	  Phusion	  
Description	   Temperature	   Time	   Cycles	  
Initial	  denaturation	   98°C	   2min	   1	  
Denaturation	   98°C	   30s	   	  
Annealing	   66°C	   30s	   x	  35	  
Elongation	   72°C	   30s	   	  
Final	  Elongation	   72°C	   10min	   1	  
Hold	   6°C	   -­‐-­‐	   	  
	  
	  
Table	  2.14	  Reaction	  mix	  used	  for	  Neuro1.1	  fragment	  amplification	  
Reagents	   V	  (in	  μL)	  
Ultra-­‐pure	  water	   21.4	  
5X	  GC	  buffer	   8.0	  
2.5	  mM	  dNTPs	   3.2	  
Neuro1.1	  forward	  primer	  	   2.0	  
Neuro1.1	  reverse	  primer	  	   2.0	  
DMSO	   1.2	  
Phusion	  DNA	  polymerase	   0.4	  
Fgf10	  BAC	  DNA	  	   2.0	  








2.8 In	  situ	  hybridization	  
2.8.1	  Riboprobes	  synthesis	  
In	  situ	  hybridizations	  were	  carried	  out	  according	  to	  standard	  methods.	  Single-­‐stranded	  
DIG-­‐labelled	  sense	  and	  anti-­‐sense	  Fgf10,	  Gata3	  and	  NeuroD	  riboprobes	  were	  prepared	  
using	  RNA	  polymerase	  T7	  and	  T3.	   	   In	  order	  to	  generate	  riboprobes	  and	  sens	  control,	  
5µg	  of	  cDNA	  were	  first	  digested	  in	  a	  final	  volume	  of	  50L,	  and	  this	  until	  full	  linearization	  
of	   the	   construct.	   Riboprobes	   synthesis	   was	   then	   performed	   overnight	   at	   37°C	   as	  
indicated	  in	  table	  2.15.	  
	  
Table	  2.15.	  Riboprobes	  synthesis	  
Reagents	   Volume	  
Linearised	  cDNA	  clone	  (~1ug)	   10µL	  
10x	  Transcription	  Buffer	   2.0µL	  
0.1M	  DTT	   2.0µL	  
DIG	  Labelling	  Mix	   2.0µL	  
RNAsin	   0.5µL	  
T3/T7	  polymerase	   0.5µL	  
DEPC	  H2O	   up	  to	  20µL	  
	  
	  
2.8.2	  Riboprobes	  purification	  
Riboprobes	  were	  purified	  by	  precipitation	  in	  Lithium	  Chloride	  in	  presence	  of	  Linearised	  
Acrylamide.	   For	   lithium	   chloride	   precipitation,	   the	   reaction	  mix	   shown	   in	   table	   2.16	  
was	  added	  to	  the	  transcription	  reaction,	  mixed	  well	  and	  left	  to	  precipitate	  overnight	  at	  
-­‐80°C.	  The	  next	  day,	  the	  samples	  were	  centrifuged	  at	  full	  speed	  for	  20min	  at	  4°C.	  The	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supernatants	   were	   then	   removed	   and	   replaced	   with	   70%	   Ethanol.	   Samples	   were	  
centrifuged	  again	   for	  10min	  at	  4oC.	  After	   the	   supernatant	  was	  discarded,	   the	  pellets	  
were	  dried	  at	  37oC,	  and	  then	  resuspended	  in	  1X	  TE.	  
	  
Table	  2.16	  Riboprobes	  purification	  by	  precipitation	  in	  Lithium	  Chloride	  
Reagents	   Volume	  
Linearised	  Acrylamide	   1µL	  
1X	  TE	  DEPC	   100µL	  
4M	  LiCl	   10µL	  
100%	  Ethanol	   300µL	  
	  
	  
2.8.3	  Wholemount	  In	  Situ	  Hybridization	  protocol	  
At	   the	   appropriate	   gestational	   stage	   (8.5-­‐11.5dpc),	   pregnant	   female	   mice	   were	  
humanely	  killed	  by	  cervical	  dislocation	  and	  embryos	  dissected,	  rinsed	  in	  DEPC-­‐PBS,	  and	  
fixed	  at	  4oC	  in	  4%	  PFA	  in	  DEPC	  PBS	  for	  30	  minutes	  to	  2	  hours,	  depending	  on	  the	  size	  of	  
the	  embryos.	  Embryos	  were	  subsequently	  rinsed	  in	  DEPC-­‐PBS	  and	  dehydrated	  through	  
a	  methanol	   series	   at	   4°C	   (25%,	  50%,	  75%	  and	  2x100%	  methanol	   in	  PBT	   (PBS	  +	  0.1%	  
Tween)	  and	  stored	  at	  -­‐20°C	  prior	  to	  wholemount	  in	  situ	  hybridization.	  	  
	  
Pre-­‐treatment	  and	  RNA	  hybridization	  
On	  day	   1	   of	   in	   situ	   hybridization	   (ISH),	   selected	   embryos	  were	   transferred	   to	   RNase	  
free	  2mL	  Eppendorf	  tubes	  and	  rehydrated	  through	  a	  methanol	  serie	  at	  RT	  in	  5-­‐10min	  
steps	  (75%,	  50%,	  25%	  methanol)	  followed	  by	  two	  washes	  in	  PBT.	  Embryos	  were	  then	  
incubated	  at	  RT	  for	  5	  to	  20min	  in	  10µg/mL	  Proteinase	  K,	  according	  to	  the	  size	  of	  the	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embryos.	   The	   Proteinase	   K	   reaction	  was	   stopped	   by	   re-­‐fixing	   the	   embryos	   at	   RT	   for	  
20min	   in	   fresh	   0.2%	   gluteraldehyde/4%	   PFA	   in	   PBT.	   Embryos	   were	   then	   washed	   3	  
times	  in	  PBT	  for	  5min	  and	  twice	  for	  5min	  in	  hybridization	  buffer	  (50%	  formamide,	  5X	  
SCC	   pH5,	   1%	   SDS,	   50µg/mL	   yeast	   DNA,	   50µg/mL	   heparine,	   5mM	   DEPC	   EDTA,	   0.2%	  
Tween,	   0.5%	   CHAPS	   in	   dH2O).	   Embryos	   were	   then	   prehybridized	   for	   2	   hours	   in	  
hybridization	  buffer,	  and	  then	  hybridized	  overnight	  at	  63°C	  in	  hybridization	  buffer	  with	  
riboprobe	  at	  a	  concentration	  of	  1µg/mL.	  
	  
Washes	  and	  immunohybridization	  
On	  day	  2,	   the	  embryos	  were	   rinsed	   twice,	   incubated	   for	  30min	  at	  68°C	   in	   Solution	   I	  
(50%	   formamide,	   5X	   SCC	   pH5,	   1%	   SDS	   in	   dH2O),	   and	   transferred	   to	   new	   2.0mL	  
Eppendorfs.	  Embryos	  were	   then	  washed	   twice	   for	  30min	  at	  65°C	   in	  Solution	   III	   (50%	  
formamide,	   2X	   SCC	   pH5,	   1%	   SDS	   in	   dH2O).	   Following	   that,	   embryos	  were	  washed	   3	  
times	   in	   1X	   TBST	   (0.14M	   NaCl,	   2.7mM	   KCl,	   1%	   Tween	   in	   dH2O)	   and	   incubated	   for	  
3hours	  in	  pre-­‐Ab	  solution	  (2%	  blocking	  reagent,	  10%	  lamb	  serum	  in	  TBST).	  They	  were	  
then	   incubated	   overnight	   at	   4°C	   in	   pre-­‐Ab	   solution	   with	   riboprobe	   at	   a	   1/2500	  
concentration.	  
	  
Washes	  and	  immunodetection	  
On	  day	  3,	  the	  embryos	  were	  transferred	  to	  new	  2.0mL	  Eppendorfs	  and	  washed	  in	  1X	  
TBST	  three	  times	  for	  5min	  each,	  and	  then	  five	  times	  for	  1hour	  at	  RT.	  Before	  initiating	  
the	   staining	   reaction	  embryos	  were	  equilibrated	   in	   freshly	  made	  NTMT	   (100mM	  Tris	  
pH9.5,	   1.4M	   NaCl,	   50mM	  MgCl2,	   0.1%	   Tween	   20	   in	   dH2O)	   via	   two	   20min	   washes.	  
Embryos	  were	   then	  stained	   in	   the	  dark	   in	  NTMT	  +	  4.5µL	  NBT	   (nitro-­‐blue	   tetrazolium	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chloride)	  and	  3.5µL	  BCIP	  (5-­‐Bromo-­‐4-­‐chloro-­‐3-­‐indolyl	  phosphate)	  for	  20min	  on	  roll	  and	  
then	  at	  37°C	  until	  properly	  stained.	  Development	  of	  the	  staining	  reaction	  was	  checked	  
regularly	   under	   a	   Nikon	   SMZ1500	   stereomicroscope.	   For	   most	   embryos	   further	  
staining	  in	  PVA	  (polyvynil	  acetate)	  was	  required.	  Staining	  reaction	  was	  then	  stopped	  by	  
three	  washes	  in	  PBT	  +	  1mM	  EDTA	  and	  post-­‐fixed	  for	  1hour	  in	  4%	  PFA	  in	  PBS.	  
	  
2.9 Immunohistochemistry	  
Immunolabelling	  was	  carried	  out	  according	  to	  standard	  methods.	  Briefly	  9.5,	  10.5	  and	  
11.5dpc	  embryos	  were	  dissected	  out	  of	  their	  embryonic	  membranes	  and	  fixed	  for	  1	  to	  
2	  hours	  in	  4%	  PFA.	  Embryos	  were	  then	  washed	  3	  times	  in	  PBS-­‐1%	  Triton	  for	  30	  minutes	  
each	   time,	  before	  being	   incubated	   for	  1	  hour	   in	  block	  solution	   (PBS	  1%	  triton	  +	  10%	  
lamb	   serum	   +	   0.2%	   sodium	   azide).	   An	   alpha-­‐red	   primary	   antibody	   raised	   in	   rat	  
(Chromotek)	  was	  used	  at	  a	  1/1000	  in	  block	  solution	  for	  labelling	  at	  4°C	  for	  2	  days	  with	  
gentle	  rotation.	  After	  several	  washes	   in	  PBS-­‐1%	  Triton	  and	  block	  solution	   for	  1	  hour,	  
the	  secondary	  anti-­‐goat	  antibody	  was	  added	  at	  a	  1/500	  dilution	  in	  block	  solution	  and	  
embryos	  were	   incubated	   for	   2	   days	  with	   gentle	   rotation	   at	   4°C.	   Embryos	  were	   then	  
washed	   in	  PBS-­‐Triton	  and	  stored	   in	   the	  dark	  at	  4°C.	  Photographs	  were	  taken	  using	  a	  









2.10 Chick	  otocyst	  electroporation	  
2.10.1 	  DNA	  preparation	  
The	  day	  before	  electroporating,	  Fgf10-­‐reporter	  constructs	  were	  precipitated	  overnight	  
in	  ethanol	  and	  resuspended	  in	  20µL	  of	  Tris	  pH7.5	  at	  a	  concentration	  of	  3-­‐4µg/µL.	  
	  
2.10.2 	  Eggs	  preparation	  and	  incubation	  
Fertilized	  eggs	  were	  ordered	  (from	  Henry	  Stewart)	  and	  stored	  at	  10°C	  for	  use	  within	  a	  
week.	   On	   day	   1,	   eggs	  were	   arranged	   horizontally	   and	   incubated	   at	   37°C	   for	   around	  
40hrs	  or	  until	  the	  embryos	  reached	  HH	  stage	  11	  (Hamburger	  and	  Hamilton,	  1992).	  	  On	  
day	  3,	  5-­‐10ml	  of	  albumin	  was	  removed	  from	  the	  egg	  with	  a	  10ml	  syringe	  needle.	  Using	  
cellotape,	   the	   top	   of	   the	   eggs	  was	   then	   covered	   to	   prevent	   the	   shell	   from	   cracking	  
when	   cutting	   out	   a	   little	   re-­‐sealable	  window	  on	   the	   top	   of	   the	   eggs.	   This	   process	   is	  
called	   windowing.	   No	   more	   than	   5	   embryos	   were	   windowed	   at	   once	   to	   prevent	  
embryos	   from	   drying	   out	   during	   electroporation.	   Black	   ink	   was	   injected	   under	   the	  
embryo	  to	  visualize	  whether	  they	  had	  reached	  the	  appropriate	  embryonic	  stage;	  if	  not,	  
the	   egg	   was	   resealed	   using	   parafilm	   and	   left	   to	   incubate	   for	   few	  more	   hours.	   	   The	  
incubator	  was	  kept	  humidified	  with	  sterile	  water.	  
	  
2.10.3 	  DNA	  injection	  and	  electroporation	  
Needles	   were	   stored	   in	   a	   square	   Petri	   Dish,	   using	   stripes	   of	   blue	   tack	   as	   needle	  
holders/rests.	   Injection	   needles	   were	   loaded	   with	   DNA/FastGreen	   mix	   and	   held	   in	  
place	  on	  the	  side	  of	  the	  microscope	  using	  blue	  tack.	  On	  the	  day	  of	  electroporation,	  2µL	  
of	  each	  enhancer	  constructs	   (3-­‐4µg/µL)	  were	  mixed	  with	  2µL	  of	  CMV-­‐DsRed	   control,	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and	  Fast	  Green	  was	  added	  to	  the	  mix	  at	  1/10	  volume.	  When	  using	  the	  dual	  reporter	  
(which	  already	  include	  an	  internal	  CMV-­‐DsRed	  control),	  Fast	  Green	  was	  added	  at	  1/10	  
volume	  to	  4µL	  of	  construct.	  DNA	  was	  then	  mixed	  and	  centrifuged	  at	  full	  speed	  for	  30	  
seconds.	   The	   supernatant	   was	   transferred	   to	   a	   clean	   tube	   and	   stored	   on	   ice	   until	  
loading	  of	  the	  electroporation	  needle.	  Embryos	  were	  electroporated	  with	  a	  BTX	  ECM	  
830	   electroporator	   with	   the	   following	   settings:	   Voltage,	   15V;	   Pulse	   length,	   50msec;	  
Pulse	   number,	   5.	   Following	   electroporation,	   eggs	   were	   immediately	   re-­‐sealed	   with	  
parafilm.	  
	  
2.10.4 	  Chick	  embryos	  harvesting	  and	  analysis	  
12	  to	  18	  hours	  after	  electropration,	  chick	  embryos	  were	  dissected	  out	  of	  all	  embryonic	  
membranes	   and	   fixed	   in	   4%	   PFA	   for	   1hour.	   Photographs	   were	   taken	   with	   a	   Nikon	  
AZ100	  steromicroscope	  and	  imaged	  captures	  using	  a	  Nikon	  Ds-­‐Fi1	  digital	  camera.	  
	  
2.11 Mouse	  pronuclear	  injections	  	  
Transgenic	  mice	  were	  generated	  by	  Mark	  Maconochie	  by	  pronuclear	  microinjection	  of	  
linearised	  DNA	  constructs	  into	  pronuclei	  of	  F2	  eggs	  produced	  by	  superovulation	  of	  28-­‐
38	  day	  F1	  (CBAxC57/BL6)	  females	  crossed	  with	  F1	  stud	  males	  as	  described	  in	  Hogan	  et	  
al.,	   1994.	   	   Injected	   embryos	   were	   then	   transferred	   to	   pseudopregnant	   F1	  
(CBAxC57/BL6)	   females.	   F1	   mice	   were	   used	   because	   they	   possess	   hybrid	   vigor	  
(Research.jax.org).	   In	  particular,	   they	  have	   larger	   litters	  and	   thus	  produce	  more	  eggs	  
for	   injection	  and	   later	  more	   transgenic	  embryos	   to	  analyse.	   They	  also	   survive	  better	  
under	  stress,	  such	  as	  the	  one	  imposed	  by	  the	  transfer	  of	  the	  injected	  embryos	  to	  the	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pseudopregnant	  females.	   	  Founder	  embryos	  were	  used	  to	  generate	  stable	  transgenic	  
lines.	  Genotyping	  for	  the	  presence	  of	  reporter	  transgenes	  was	  performed	  as	  described	  
in	   section	   2.1.	   The	   embryos	   examined	   were	   F2.	   Contrary	   to	   F1	   hybrid,	   they	   are	  













RETINOID	  CONTROL	  OF	  FGF3	  
EXPRESSION	  
	  
Endogenous	   retinoic	   acid	   (RA)	   plays	   a	   key	   role	   during	   inner	   ear	   development,	   with	  
both	   excess	   and	  deficiency	  of	   RA	   resulting	   in	   developmental	   abnormalities	   (Frenz	   et	  
al.,	  2010).	  RA	  was	  first	  shown	  to	  affect	  ear	  development	  in	  babies	  born	  from	  teenage	  
girls	  that	  had	  been	  treated	  for	  cystic	  acne	  with	  a	  daily	  dose	  of	  40mg	  isotretinoin	  (13-­‐cis	  
RA)	   during	   their	   pregnancy	   (Lott	   et	   al.,	   1984).	   A	   detailed	   analysis	   of	   RA-­‐induced	  
embryopathy	   of	   the	   mouse	   inner	   ear	   (Frenz	   et	   al.,	   1996)	   reports	   a	   number	   of	  
anomalies,	   such	   as	   the	   absence	   of	   the	   endolymphatic	   duct	   and	   vestibulo-­‐accoustic	  
ganglion	  at	  11.5dpc;	  as	  well	  as	  an	  uncoiled	  cochlear	  duct,	  abnormal	  capsule	  formation	  
and	   incomplete	   semicircular	   duct	   formation	   at	   13.5dpc.	  Defective	   semicircular	   canal	  
formation	  was	  also	  shown	  in	  chick	  following	   in	  ovo	   implantation	  of	  RA-­‐soaked	  beads	  
(Choo	   et	   al.,	   1998).	   Interestingly	   RA	   also	   affects	   cell	   differentiation	   in	   the	   organ	   of	  
Corti,	  with	  exogenous	  RA	  addition	  resulting	  in	  an	  increase	  in	  the	  number	  of	  hair	  cells	  
and	  supporting	  cells	  (Kelley	  et	  al.,	  1993).	  The	  next	  step	  in	  understanding	  the	  role	  of	  RA	  
in	   inner	   ear	   development	   is	   to	   identify	   the	   molecular	   mechanisms	   underlying	   RA-­‐
induced	  inner	  phenotypes.	  Interestingly,	  mutational	  analysis	  of	  Fgf10	  and	  Fgf3	  report	  
defects	   similar	   to	   the	   one	   induced	   by	   excess	   RA,	   such	   as	   abnormal	   semicircular	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formation	  and	  innervation	  was	  reported	  in	  Fgf10	  null	  mice	  (Pauley,	  2003)	  and	  failure	  
to	  form	  the	  endolymphatic	  duct	  and	  reduced	  cochlear	  coiling	  in	  Fgf3	  mice	  (Wright	  and	  
Mansour.,	   2003).	   Furthermore	   in	   silico	   analysis	   of	   the	   Fgf3	   enhancer	   reveals	   the	  
presence	   of	   7	   putative	   RA	   responsive	   elements	   (RAREs).	   In	   this	   chapter,	   the	  
spatiotemporal	   effects	   of	   RA	   on	   Fgf3	   expression	   are	   investigated	   in	   detail	   using	   an	  
Fgf3-­‐lacZ	  reporter	  mouse	  line.	  Moreover,	  a	  new	  non-­‐invasive	  method	  for	  RA	  delivery	  
to	  pregnant	  mice	  is	  designed	  as	  an	  alternative	  to	  gavage	  feeding.	  
	  
3.1	   Development	   of	   an	   improved	   non-­‐invasive	   method	   for	  
retinoic	  acid	  administration	  
Whilst	   the	   demonstration	   had	   been	   done	   that	   mice	   would	   self-­‐administer	   RA	   via	  
chocolate	  pellets,	  only	  50%	  of	  mice	  ate	  such	  treats.	  Furthermore,	  the	  time	  required	  for	  
the	  mice	   to	  eat	   the	   treat	   ranged	   from	  1	   to	  4hrs,	   indicating	   that	   improvements	  were	  
still	   required	   for	   this	   to	   represent	   a	   routine	   method	   of	   RA	   application.	   In	   order	   to	  
refine	  the	  recipe,	  pellets	  of	  various	  sizes	  and	  of	  various	  coating	  (freshly	  made	  RA-­‐free	  
paste	  or	   icing	   sugar)	  were	  experimented.	   These	   trials	   revealed	   that	   the	  pellets	  were	  
more	   easily	   ingested	   when	   their	   size	   was	   around	   70mg.	   	   Furthermore,	   icing	   sugar	  
coating	  also	   increased	   intake.	   	   It	  became	  clear	  that	  the	  presence	  of	  sugar	  seemed	  to	  
positively	   influence	   the	   efficiency	   of	   intake,	   and	   therefore	   I	   decided	   to	   try	   making	  
sugar	  pellets	  rather	  than	  chocolate	  pellets.	  	  Pellets	  were	  prepared	  using	  commercially	  
available	  writing	   icing	   sugar	  and,	  as	   suspected,	  drastically	   increased	   the	  efficiency	  of	  




3.2	  Validation	  of	   the	  new	  protocol	   for	   administering	  RA	  using	  
sugar/chocolate	  pellets	  
After	   improving	   the	   efficiency	   of	   the	   self-­‐administration	   of	   pellets	   above,	   next	   the	  
reliability,	   reproducibility	   and	   harmlessness	   of	   the	   vehicle	   alone	  were	   tested.	   In	   the	  
pilot	  experiments	  carried	  out	  during	  my	  MSc	  project,	  the	  couple	  of	  different	  RA	  doses	  
used	   seemed	   to	  give	  different	  phenotypes	  but	  only	  one	   litter	  was	  analysed	   for	  each	  
dose.	  	  Thus	  to	  explore	  any	  reproducible	  dose-­‐dependent	  relationship,	  a	  wider	  range	  of	  
RA	   dosing	   levels	   was	   also	   tested	   in	   multiple	   litters.	   	   Firstly,	   a	   literature	   search	   was	  
carried	  out	  to	  review	  the	  range	  of	  RA	  doses	  used	  by	  researchers	  (Table	  3.1,	  Appendix	  
Table	  S1,	  note	  that	  references	  for	  both	  tables	  are	  in	  the	  Appendix),	  which	  revealed	  a	  
very	  broad	  range	  of	  RA	  has	  been	  used	  in	  different	  contexts.	  	  
	  




Initially,	  mice	  were	  exposed	  to	  what	  seems	  to	  be	  one	  of	  the	  most	  common	  doses	  used	  
in	   previous	   teratogenic	   studies	   of	   the	   hindbrain	   (10mg/kg).	   Excess	   RA	   was	  
administered	  using	  either	  gavage	  or	  pellet.	  
	  
Analysis	   of	   embryos	   at	   9.5dpc	   revealed	   that	   regardless	   of	   the	   delivery	   method,	   a	  
variety	  of	  developmental	  abnormalities	  similar	   to	  what	  has	  previously	  been	  reported	  
in	  the	  literature	  were	  generated	  (Figure	  3.1).	  	  Malformations	  include	  smaller	  embryos,	  
general	   truncation	   of	   the	   anterior	   CNS	   in	   85%	   (n=13)	   of	   the	   embryos	   (Figure	  
3.1A,C,O,N),	   	  profound	  delay	   in	  the	  closure	  of	  the	  anterior	  neural	  tube	   in	  54%	  of	  the	  
embryos	   (arrows,	   Figure	   3.1A-­‐D,M-­‐O)	   and	   a	   wavy/crenulated	   neural	   tube	   more	  
posteriorly	   (asterisks,	   Figure	   3.1B,D,N,P).	   This	   demonstrated	   that	   similar	   teratogenic	  
phenotypes	   could	   be	   generated	   through	   both	   conventional	   gavage	   feeding	   and	   this	  
new	   system	   for	   delivery	   of	   RA.	   	  Moreover	   the	   phenotypes	   are	   generated	   at	   similar	  
doses	  through	  both	  delivery	  methods.	  
	  
Developmental	  delay	  and	  severity	  of	  malformations	   in	  embryos	  exposed	   to	  10mg/kg	  
prompted	   an	   analysis	   of	   RA	   teratogenicity	   at	   lower	   doses.	   A	   dose	   of	   7mg/kg	   still	  
resulted	  in	  craniofacial	  malformations	  with	  in	  particular	  a	  delay	  in	  anterior	  neural	  tube	  
closure	   in	  90%	  	  (n=31)	  of	  the	  embryos	  (arrows,	  Figure	  3.1E,F,H).	  However,	  the	  dorsal	  
margin	   of	   the	   neural	   tube	   were	   not	   wavy	   as	   in	   embryo	   fed	   with	   10mg/kg	   of	   RA	  
(asterisks,	  Figure	  3.1B,D,N,P)	  but	   instead	  appeared	  smooth	  as	   in	  the	  control	  embryo.	  
Strikingly,	  embryo	  size	  was	  also	  similar	  to	  control	  embryos	  (Figure	  3.1E,H).	  	  
	  
	  
Figure	   3.1	   Dose-­‐dependant	   embryo	   malforma9ons	   following	   RA	   administra9on	   via	   sugar	  
pellets.	  Pregnant	  mice	  were	  fed	  with	  RA-­‐laced	  sugar	  pellets	  at	  7.75dpc	  and	  their	  li:ers	  analyzed	  
at	  9.5dpc.	  Doses	  were	  as	  indicated	  on	  the	  ﬁgure	  :	  (A-­‐D)	  10mg/kg,	  (E-­‐H)	  7mg/kg,	  (I-­‐L)	  4.5mg/kg.	  
Gavage	  administraPon	  was	  also	  performed	  as	  a	  control	  using	  10mg/kg	  (M-­‐P).	  Increasing	  RA	  dose	  
led	   to	   an	   increase	   in	   embryo	   malformaPons	   that	   includes	   open	   neural	   tubes	   (indicated	   with	  
arrows),	   shortened	   prosencephalon	   (indicated	   by	   arrowheads)	   and	   wavy	   neural	   tube	   borders	  
(Indicated	   by	   asterisks).	   Embryos	   exposed	   to	   high	   doses	   of	   RA	  were	   also	   smaller	   than	   normal	  
suggesPng	  a	  developmental	  delay	  or	  growth	  reducPon.	  Comparison	  of	  embryos	  exposed	  to	  RA	  
via	   sugar	   pellets	   or	   gavage	   shows	   that	   the	   exact	   same	   phenotypes	   are	   inducted.	   Scale	   bar	   =	  
500μm.	  Adapted	  from	  (Cadot	  et	  al.,	  2012)	  Copyright	  ©	  2012	  Wiley	  Periodicals.	  Inc	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Furthermore,	  the	  anterior	  truncation	  only	  occurred	  in	  19%	  	  (n=31)	  of	  the	  embryos	  with	  
the	  remaining	  81%	  of	  embryos	  displaying	  a	   less	  severe	  phenotype	  characterized	  by	  a	  
foreshortening	  of	  the	  prosencephalon	  (arrowheads,	  Figure	  3.1E,G,H).	  Surprisingly,	  the	  
incidence	  of	  open	  neural	  tubes	  in	  embryo	  exposed	  to	  7mg/kg	  of	  RA	  was	  higher	  than	  in	  
embryos	  exposed	  to	  10mg/kg.	  However	  this	  does	  not	  imply	  neural	  tube	  formation	  was	  
more	   affected	   by	   7mg/kg	   of	   RA	   as	   evidence	   by	   the	   sharp	   decrease	   in	   anterior	  
truncation	  in	  embryo	  exposed	  to	  this	  lower	  dose	  of	  exogenous	  RA	  (Table	  3.2a).	  Next,	  
an	  even	  lower	  dose	  of	  4.5mg/kg	  of	  RA	  was	  trialled	  (Figure	  3.1I-­‐L).	  Only	  43%	  (n=14)	  of	  
embryos	  exposed	  to	  this	  dose	  presented	  a	  delay	  in	  anterior	  neural	  tube	  closure	  (Figure	  
3.1K),	   none	   displayed	   any	   obvious	   anterior	   truncation	   and	   57%	   of	   the	   embryos	  
displaying	   a	   normal	   phenotype	   (Figure	   2.1I,J).	   Numbers	   of	   embryos	   displaying	   the	  
different	  phenotypes	  are	  summarised	  in	  table	  3.2a.	  
	  
Table	  3.2	  Incidence	  of	  phenotypes	  and	  changes	  in	  Fgf3	  expression	  with	  increasing	  RA	  dose	  
Table	  3.2a	  RA	  administration	  at	  7.75dpc	  
Ra	  dose	  	  (/kg)	   4.5mg	   6mg	   7mg	   8mg	   10mg	  
Number	  of	  embryos	  analysed	   14	   23	   31	   23	   13	  
Anterior	  truncations	   0%	   13%	  (3)	   19%	  (6)	   65%	  (15)	   85%	  (11)	  
Open	  neural	  tube	   43%	  (6)	   78%	  (18)	   90%	  (28)	   91%	  (21)	   54%	  (7)	  
Number	  of	  embryos	  analysed	   7	   23	   22	   29	   7	  
Altered	  Fgf3	  spinal	  cord	  expression	   0%	   0%	   0%	   24%	  (7)	   100%	  
Altered	  Fgf3	  rhombomere	  boundary	  	   28%	  (2)	   74%	  (17)	   90%	  (20)	   100%	   100%	  
Altered	  Fgf3	  otic	  expression	   28%	  (2)	   79%	  (19)	   90%	  (20)	   100%	   ND	  
Table3.2b	  RA	  administration	  at	  8.5dpc	  
RA	  dose	  (/kg)	   4.5mg	   8-­‐10mg	   25mg	   25mg	  gavage	   2x25mg	  gavage	  
Number	  of	  embryos	  analysed	   10	   20	   15	   16	   8	  
Altered	  Fgf3	  otic	  expression	   0%	   90%	  (18)	   93%	  (14)	   88%	  (14)	   100%	  (8)	  
*Numbers	  in	  parentheses	  corresponds	  to	  number	  of	  embryos	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In	  order	  to	  confirm	  that	  the	  chocolate/sugar	  vehicle	  alone	  was	  not	  responsible	  for	  the	  
phenotypes	  observed,	  control	  mice	  were	  fed	  with	  pellets	  of	  1x,	  3x	  and	  5x	  the	  amount	  
of	  unsupplemented	  vehicle	  used	  for	  RA	  administration	  (see	  Figure	  3.2).	  Since	  the	  next	  
experiments	  would	  look	  at	  the	  expression	  of	  Fgf3-­‐lacZ,	  control	  embryos	  presented	  are	  
expressing	   this	   transgene.	   None	   of	   these	   doses	   generated	   any	   of	   the	   abnormalities	  
reported	  with	  excess	  RA,	  confirming	  that	  the	  teratogenicity	  presented	  was	  due	  to	  RA	  
itself	   and	   not	   constituents	   present	   in	   the	   chocolate	   paste	   or	   writing	   icing	   sugar.	   In	  
addition	  Fgf3-­‐lacZ	  expression	  was	  unaltered.	  
	  
Taken	  together,	  this	  new	  method	  of	  RA	  self-­‐administration	  using	  sugar	  pellets	  seems	  
to	   be	   an	   effective	   alternative	   to	   gavage,	   with	   the	   advantages	   of	   not	   involving	   any	  
invasive	  procedures	  or	  requiring	  any	  animal	  restraint.	   In	  addition,	  these	  data	  showed	  
that	  the	  incidence	  and	  severity	  of	  RA-­‐induced	  phenotypes	  is	  dose-­‐dependent.	  	  
	  
	  
3.3	   Fgf3-­‐expression	   in	   embryos	   exposed	   to	   RA	   prior	   to	  
hindbrain	  patterning	  (at	  7.75dpc)	  
In	  order	  to	  address	  the	  spatiotemporal	  relationship	  between	  RA	  and	  Fgf3	  expression	  in	  
the	   whole	   embryo,	   the	   response	   of	   the	   Fgf3-­‐lacZ	   reporter	   line	   to	   increasing	   RA	  
concentrations	  was	   studied.	   	   The	   data	   is	   presented	   in	   sections	   focused	   on	   different	  
developing	  domains:	  	  the	  spinal	  cord,	  hindbrain	  and	  midbrain,	  and	  the	  otic	  vesicle.	  	  	  
	  
	  
Figure	  3.2	  (con%nues)	  	  
Figure	  3.2	  Analysis	  of	  Fgf3-­‐lacZ	  expression	  pa5ern	  in	  9.5dpc	  embryos	  following	  administra>on	  
of	  increasing	  RA	  doses	  at	  7.75dpc.	  Lateral	  and	  dorsal	  views	  of	  untreated,	  RA	  treated	  and	  control	  
embryos	  are	  shown	  in	  consecu>ve	  panels.	  (A.B)	  Untreated	  embryos;	  (C,D)	  4.5mg/kg;	  (E,F)	  6mg/
kg;	  (G,H)	  7mg/kg;	  (I,J)	  8mg/kg;	  (K,L)	  10mg/kg.	  Hindbrain	  Fgf3	  expression	  is	  altered	  from	  6mg/kg	  
(F),	   star>ng	  with	   a	   loss	  of	   rhombomere	  boundary	  expression	  domains.	   Increasing	  doses	  of	  RA	  
leads	   to	   increasing	   altera>on	   of	   Fgf3	   expression	   in	   the	   hindbrain,	   with	   a	   complete	   loss	   of	  
expression	  in	  embryos	  exposed	  to	  10mg/kg	  of	  RA(K,L).	  Fgf3	  expression	  in	  the	  spinal	  cord	  starts	  
becoming	  weaker	  and	  patchy	  with	  doses	  of	  8mg/kg	   (arrows	   in	   J)	  and	  10mg/kg	   (arrows	   in	  K,L).	  
Control	  embryos	  were	  treated	  with	  1x	  sugar	  (M,N),	  3x	  sugar	  (O,P),	  and	  3x	  chocolate	  (Q,R).	  None	  
of	   these	   doses	   lead	   to	   any	   developmental	   abnormali>es	   or	   altera>on	   of	   Fgf3-­‐lacZ	   expression	  
either	  in	  the	  o>c	  vesicle	  (arrowheads	  in	  M,O,Q)	  or	  in	  the	  hindbrain	  (arrows	  in	  N,P,R)	  .	  Scale	  bar	  =	  
500	  μm.	  Adapted	  from	  (Cadot	  et	  al.,	  2012)	  Copyright	  ©	  2012	  Wiley	  Periodicals.	  Inc	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3.3.1	  Spinal	  cord	  	  
Fgf3	  expression	  in	  the	  spinal	  cord	  normally	  consists	  of	  two	  domains.	  The	  first	  domain	  is	  
restricted	  to	  a	  small	  area	  of	  dorsal	  neural	  tube	  expression	  located	  just	  anteriorly	  to	  the	  
forelimb	  bud	  (Figure	  3.2	  Ai).	  The	  second	  domain	  is	  more	  extensive,	  starting	  at	  the	  level	  
of	   the	   forelimb	   and	   spreading	   posteriorly,	   approximately	   until	   the	   future	   hindlimb	  
region	  (Figure	  3.2Aii).	  Fgf3	  expression	  in	  these	  domains	  appears	  unaffected	  in	  embryo	  
treated	   with	   4.5mg,	   6mg	   and	   7mg/kg	   of	   RA	   (Figure	   3.2C,E,G).	   A	   dose-­‐dependent	  
downregulation	  of	  Fgf3	  was	  however	  observed	  with	  RA	  dose	  of	  8mg/kg	   (Figure	  3.2I)	  
and	   10mg/kg	   (Figure	   3.2K)	   of	   RA.	   At	   these	   higher	   doses	   Fgf3	   expression	   appeared	  
patchy	  in	  24%	  	  (n=29)	  of	  the	  embryos	  exposed	  to	  8mg/kg	  of	  RA	  and	  100%	  of	  embryos	  
exposed	  to	  10mg	  of	  RA	  (see	  table	  3.2a).	  It	  was	  however	  spatially	  restricted	  to	  the	  same	  
area	  as	  in	  control	  embryos.	  	  
	  
3.3.2	  Hindbrain	  and	  midbrain	  
The	  minimal	  Fgf3	  enhancer	  used	  in	  this	  study	  lacks	  the	  regulator	  elements	  required	  to	  
drive	   endogenous	  Fgf3	   expression	   in	   rhombomeres	  5	   and	  6.	  However,	   the	  Fgf3-­‐lacZ	  
reporter	   recapitulates	  endogenous	  expression	  throughout	   rhombomeres	  1	  as	  well	  as	  
at	   rhombomere	   boundaries	   r2/3,	   r3/4	   and	   r4/5	   at	   9.5dpc	   (Figure	   3.2B).	   Fgf3	  
expression	   in	   one	   or	   more	   of	   these	   rhombomere	   boundaries	   was	   lost	   when	   using	  
doses	  of	  6	  to	  8mg/kg	  and	  a	  complete	  abolition	  of	  boundary	  expression	  was	  observed	  
with	  10mg/kg	  (Figure	  3.2L).	  On	  the	  other	  hand,	  expression	  of	  Fgf3-­‐lacZ	  in	  rhombomere	  
1	   persists	   and	   actually	   appears	  more	   extensive	   than	   in	   the	   control	   (compare	   Figure	  
3.2B	  to	  3.2F,H,J)	  apart	  from	  a	  dose	  of	  10mg/kg	  where	  expression	  in	  all	  rhombomeres	  
and	   rhombomere	   boundaries	   has	   disappeared.	   This	   is	  most	   likely	   due	   to	   the	   severe	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truncation	  of	  the	  anterior	  neural	  tube.	  Alteration	  of	  Fgf3	  expression	  at	  rhombomeric	  
boundaries	   was	   also	   found	   to	   be	   dose-­‐dependent,	   with	   only	   28%	   of	   embryos	   with	  
altered	   rhombomeres	   boundary	   expression	   for	   a	   dose	   of	   4.5mg/kg	   (n=7);	   74%	   for	  
6mg/kg	   (n=23);	  90%	   for	  7mg/kjg	   (n=22)	  and	  100%	   for	  8-­‐10mg/kg	   (n=36).	  Results	  are	  
summarised	  in	  table	  3.2a.	  
	  
3.3.3	  The	  developing	  inner	  ear/otic	  vesicle	  
The	  particular	  focus	  of	  this	  project	  is	  the	  developing	  inner	  ear,	  therefore	  the	  detailed	  
effects	   of	   RA	   on	   Fgf3	   expression	   in	   the	   developing	   inner	   ear	   were	   also	   analyzed	  
through	  both	  wholemount	  analysis	  and	  sections.	  Figure	  3.3	  illustrates	  sections	  taken	  at	  
dorsal,	  mid	  and	  ventral	  planes	  through	  the	  otocyst,	  along	  the	  horizontal	  axis,	  with	  the	  
exception	  of	  the	  embryo	  for	  10mg/kg.	  Fgf3	  is	  normally	  expressed	  in	  the	  antero-­‐ventral	  
wall	  of	  the	  otic	  vesicle,	  extending	  in	  the	  lateral	  and	  dorsal	  domains	  (Figure	  3.3A-­‐Aiii).	  In	  
embryo	  treated	  with	  4.5mg/kg	  of	  RA	  this	  expression	  was	  unchanged	  (Figure	  3.3B-­‐Biii).	  
However	  with	  doses	  of	  6mg/kg	  and	  7mg/kg	  it	  begins	  to	  be	  lost	  in	  the	  dorsal	  domain	  of	  
the	   otic	   vesicle	   (Figure	   3.3C,D).	   A	   few	   Fgf3-­‐expressing	   cells	   are	   highlighted	   by	  
arrowhead	  in	  Ci	  and	  Di).	  At	  highest	  RA	  doses	  (8-­‐10mg/kg)	  Fgf3	  expression	  was	  totally	  
lost	  from	  the	  dorsal	  otic	  domain	  (Figure	  3.3Ei,Fi).	  The	  ventral	  patch	  of	  expression	  is	  the	  
most	  persistent	  and	  although	  downregulated	   for	  doses	  of	  6	   to	  8mg/kg,	   it	  was	  never	  
abolished	   in	   the	   embryos	   presented	   here	   (Figure	   2.4C,D,Cii,Dii,Ciii,Diii).	   As	   noted	   for	  
the	   spinal	   cord	   and	   hindbrain,	   downregulation	   of	  Fgf3	   expression	   in	   the	   otic	   vesicle	  
was	  dose-­‐dependant:	  28%	  of	  the	  embryos	  exposed	  to	  4.5mg/kg	  showed	  an	  alteration	  
of	   otic	   Fgf3	   expression	   (n=7);	   this	   number	   increases	   to	   74%	  with	   a	   6mg/kg	   RA	  dose	  
(n=23),	  90%	  with	  7mg/kg	  and	  100%	  with	  8mg/kg	  (n=29)	  (see	  table	  3.2a).	  
Figure	   3.3	   Eﬀects	   of	   RA	   on	   o4c	   Fgf3	   expression	   following	   administra4on	   at	   7.75dpc.	   Lateral	  
views	  	  (A-­‐F)	  and	  horizontal	  sec7ons	  of	  control	  and	  RA-­‐treated	  embryos	  are	  shown	  in	  consecu7ve	  
panels.	   	   (A-­‐Aiii)	   untreated	   embryos;	   (B-­‐Biiii)	   4.5mg/kg;	   (C-­‐Ciii)	   6mg/kg;	   (D-­‐Diii)	   7mg/kg;	   (E-­‐Eiii)	  
8mg/kg;	   (F-­‐Fiii)	   10mg/kg.	   Sec7ons	   in	   Fi-­‐Fiii	   are	   in	   the	   anterior-­‐posterior	   direc7on.	   In	   control	  
embryos,	  Fgf3	  expression	  in	  dorsal	  sec7ons	  is	  ﬁrst	  seen	  as	  a	  small	  	  anterior	  patch	  (A,	  Ai).	  In	  mid-­‐
o7c	  sec7ons,	  this	  patch	  extends	  laterally	  (Aii).	  Higher	  magniﬁca7on	  of	  the	  o7c	  vesicle	  are	  shown	  
in	   insets,	  with	   the	  magniﬁed	  o7c	   vesicle	   iden7ﬁed	  by	   an	   arrowhead.	   In	   embryos	   treated	  with	  
4.5mg/kg	  of	  RA	  this	  paUern	  of	  expression	  appeared	  unaﬀected.	  However	  with	  doses	  of	  	  6mg/kg	  
and	  above	  there	  is	  an	  increasing	  altera7on	  of	  o7c	  Fgf3	  expression	  domain,	  where	  expression	  is	  
lost	  in	  dorsal	  sec7ons	  (Ci,Di,Ei);	  and	  becomes	  restricted	  to	  a	  smaller	  and	  smaller	  lateral	  patch	  on	  
mid-­‐o7c	   sec7ons	   (Cii,Dii,Eii),	   thus	   appearing	   as	   lateralized.	   Fgf3	   expression	   in	   the	   ventral	   o7c	  
vesicle	   is	   the	   most	   resistant	   to	   changes	   with	   a	   slight	   downregula7on	   and	   lateraliza7on	   only	  
visible	  in	  embryo	  treated	  with	  8mg/kg	  (Eiii).	  Ov,	  otocyst;	  ba,	  branchial	  arches;	  tel,	  telencephalon.	  
Scale	  bar	  =	  500	  μm.	  Adapted	  from	  (Cadot	  et	  al.,	  2012)	  Copyright	  ©	  2012	  Wiley	  Periodicals.	  Inc	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Interestingly,	   Fgf3	   expression	   also	   appeared	   to	   become	   more	   and	   more	   restricted	  
laterally	  with	   increasing	   RA	   dose,	  making	   the	   domain	   of	   Fgf3	   expression	   in	   the	   otic	  
vesicle	   looks	   like	   if	   it	   was	   shifted	   posteriorly.	   Whereas	   in	   untreated	   embryos	   Fgf3	  
expression	  extends	   laterally	   from	  the	  mid-­‐anterior	   region	  of	   the	  otic	  vesicle	   (inset	   in	  
Figure	   3.3Aii),	   it	   was	   restricted	   to	   a	   small	   lateral	   region	   in	   embryos	   exposed	   to	   RA	  
(insets	  in	  Figure	  3.3Cii,	  Dii,	  Eii)	  
	  
The	   only	   apparent	   discrepancy	   in	   the	   results	   came	   from	   embryos	   exposed	   to	   the	  
highest	   RA	   dose	   tested	   in	   this	   experiment	   (10mg/kg).	   Here	   Fgf3	   expression	   did	   not	  
seem	  to	  be	  downregulated	  but	  instead	  more	  strongly	  expressed	  than	  in	  control.	  Since	  
the	   embryos	   are	   much	   smaller	   in	   size	   and	   present	   characteristics	   of	   earlier	   stages	  
embryos,	  I	  hypothesized	  that	  the	  Fgf3	  expression	  pattern	  in	  the	  otocyst	  represents	  the	  
pattern	  expected	  at	  an	  earlier	  stage.	  	  
	  
In	  order	   to	  compare	  expression	  directly	   to	  my	  own	  results,	  a	  brief	   time	  course	  using	  
the	   exact	   same	   experimental	   conditions	   and	   reagents	   used	   for	   the	   RA	   studies	   (See	  
Figure	   3.4)	   was	   carried	   out.	   	   During	   development,	   a	   progressive	   restriction	   of	   Fgf3	  
expression	   between	   8.5dpc	   and	   10dpc	   is	   observed.	   At	   first	   Fgf3	   expression	  
encompasses	  a	   large	  band	  of	   surface	  ectoderm	  stretching	   from	   the	   invaginating	  otic	  
cup	  to	  the	  2nd	  branchial	  arch	  (Figure	  3.4A).	  Then	  this	  expression	  starts	  dividing	  into	  two	  
territories	   (Figure	   3.4D)	   and	   becomes	   clearly	   separated	   and	   restricted	   to	   smaller	  
regions	   (Figure	   3.4E,F).	   Comparing	   the	   embryo	   exposed	   to	   10mg/kg	   of	   RA	   in	   Figure	  
3.3F	  and	  the	  untreated	  embryo	   in	  Figure	  3.4A,	   the	  pattern	  of	  Fgf3-­‐lacZ	  expression	   is	  
similar	  but	  the	  otic	  vesicle	  size	  is	  much	  larger	  in	  the	  embryo	  treated	  with	  RA.	  	  
Figure	  3.4	  Early-­‐0me	  course	  of	  Fgf3-­‐lacZ	  expression.	  Lateral	  and	  dorsal	   views	  of	  embryos	  are	  
presented	   in	   consecu6ve	   panels	   at	   the	   following	   stages	   :	   (A-­‐Ai)	   8.75dpc;	   (B-­‐Bi)	   9.0dpc;	   (C-­‐Ci)	  
9.25dpc;	   (D-­‐Di)	   9.5dpc;	   (E-­‐Ei)	   10.5dpc;	   (F-­‐Fi)	   11.5dpc.	   At	   early	   stages,	   Fgf3	   expression	  
encompasses	  a	  large	  band	  of	  surface	  ectoderm,	  stretching	  from	  the	  invagina6ng	  o6c	  cup	  to	  the	  
2nd	  branchial	  arch	  (A).	  This	  band	  gets	  thinner	  as	  the	  embryo	  develops	  (B,C)	  and	  eventually	  starts	  
forming	  two	  territories	   (D).	  At	  10.5dpc	  and	  11.5dpc	  these	  two	  domains	  of	  expression	  are	  now	  
clearly	  separated	  (E,F).	  Adapted	  from	  (Cadot	  et	  al.,	  2012)	  Copyright	  ©	  2012	  Wiley	  Periodicals.	  Inc	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Thus	   the	   expression	   with	   this	   dose	   of	   RA	   did	   indeed	   appear	   to	   be	   similar	   to	   that	  
expected	  at	  earlier	  time	  points,	  supporting	  the	  notion	  of	  developmental	  delay	  of	  Fgf3	  
at	  high	  RA	  doses.	  	  	  
	  
If	   embryos	   are	   delayed	   then	   perhaps	   analysis	   after	   an	   additional	   day	   of	   utero	  
development	  (10.5dpc)	  should	  allow	  us	  to	  see	  Fgf3	  expression	  similar	  to	  that	  of	  9.5dpc	  
profile.	   Therefore	   embryos	   exposed	   to	   the	   highest	   RA	   dose	   (10mg/kg)	   at	   10.5dpc;	  
along	  with	   embryos	   exposed	   to	   4.5;	   7	   and	   8mg/kg	  were	   analysed	   at	   this	   later	   time	  
point.	  	  	  
	  
	  
3.4	   RA-­‐induced	   downregulation	   of	   Fgf3	   expression	   is	  
maintained	  at	  10.5dpc	  
Analysis	   of	   the	   effects	   of	   RA	   at	   10.5dpc	   (Figure	   3.5)	   was	   consistent	   with	   the	   dose-­‐
dependent	   alteration	   of	   Fgf3	   expression	   reported	   at	   9.5dpc	   (Figure	   3.5).	   Thus,	   Fgf3	  
expression	   in	   the	   spinal	   cord	   was	   unaffected	   with	   RA	   doses	   up	   to	   7mg/kg	   (Figure	  
3.5C,E)	   but	   was	   strongly	   downregulated	   (Figure	   3.5I)	   or	   even	   lost	   in	   some	   embryos	  
(Figure	  3.5G)	  with	  higher	  doses.	  At	  this	  later	  stage	  of	  development,	  additional	  domains	  
of	  Fgf3	  expression	  are	  now	  visible	   in	  the	  geniculate	  and	  superior	  cervical	  nerves	   (gn,	  
scn,	  Figure	  3.5B).	  These	  were	  unaffected	  by	  doses	  of	  up	  to	  10mg/kg	  of	  RA	  (compare	  
Figure	  3.5B,D,F	  with	  G,H,J).	   	  While	  the	  inner	  ear	  develops,	  Fgf3	  domain	  of	  expression	  
becomes	  restricted	  to	  the	  ventral	  regions	  of	  the	  otic	  vesicle,	  to	  eventually	  appear	  as	  a	  


































































































































































































































































































































With	  RA	  doses	  of	  up	  to	  7mg/kg,	  this	  patch	  of	  expression	  was	  unchanged	  spatially	  but	  it	  
appeared	  smaller	   than	   in	  control	   (compare	  arrowheads	   in	  3.5B	  with	  D,H).	   In	  embryo	  
treated	   with	   a	   higher	   RA	   dose	   of	   8mg/kg,	   otic	   Fgf3	   expression	   was	   strongly	  
downregulated	   (arrowead,	   Figure	  3.5H)	  or	  even	  completely	   lost	   in	  4	  embryos	   (n=14;	  
Figure	   3.5G).	   Administration	   of	   10mg/kg	   of	   RA	   then	   gave	   rise	   to	   embryos	   exhibiting	  
strong	   developmental	   abnormalities	   and	   developmental	   delay	   (Figure	   3.5I,J).	   Some	  
Fgf3	   expression	   was	   still	   detectable	   but	   strongly	   downregulated	   (Figure	   3.5J)	   or	  
impossible	  to	  attribute	  to	  any	  particular	  structure	  (Figure	  3.5I).	  This	  is	  consistent	  with	  
otic	   Fgf3	   expression	   being	   downregulated	   with	   a	   10mg/kg	   dose	   of	   RA,	   although	   it	  
could	  not	  be	  observed	  at	  9.5dpc	  due	  to	  the	  developmental	  delay.	  	  	  	  
	  
	  
3.5	   Semi-­‐quantitative	   analysis	   of	   the	   dose-­‐dependent	  
downregulation	  of	  otocyst	  expression	  
Representative	   embryos	   selected	   after	   thorough	   analysis	   of	   the	   data	   for	   each	   dose,	  
and	   presented	   in	   the	   previous	   figures,	   suggested	   a	   dose-­‐dependency	   of	   Fgf3	  
downregulation	  with	   increasing	  RA	  dose.	   In	  order	   to	  give	  more	  weight	   to	   this	   so	   far	  
only	  descriptive	  demonstration	  of	  Fgf3	  dose-­‐dependent	  downregulation	  by	  exogenous	  
RA,	  a	   semi-­‐quantitative	  analysis	  was	  performed	  using	   the	   ImageJ	  software	   (Rasband,	  
1997).	  The	  otic	  vesicles	  were	  first	  digitally	  dissected.	  To	  do	  so,	  they	  were	  observed	  at	  
high	  magnification	  in	  ImageJ	  and	  their	  areas	  thoroughly	  delimited	  using	  a	  tracing	  tool.	  
Then	   the	   area	   of	   Fgf3	   expression	   was	   delimited	   using	   a	   colour	   detection	   tool.	   The	  
amount	  of	  pixels	  in	  the	  total	  area	  versus	  area	  with	  Fgf3	  expression	  was	  determined.	  	  	  	  
Figure	  3.6	   Image	  analysis	  of	  Fgf3	   expression	   in	   the	  9.5dpc	  o<c	  vesicle	  exposed	   to	   increasing	  
dose	  of	  RA	  at	  7.75dpc.	  A)	  Representa,ve	  array	  of	  digitally	  dissected	  o,c	  vesicle	  from	  control	  and	  
RA-­‐treated	   embryos.	   The	   rela,ve	   area	   of	   Fgf3	   expression	   was	   determined	   using	   the	   ImageJ	  
soAware	  and	   is	   shown	   in	   subscript	   as	   a	  percentage	  of	   the	  area	  of	   the	  whole	  o,c	  vesicle.	  O,c	  
vesicles	   are	  not	  drawn	   to	   scale	   and	  are	   all	   oriented	  with	   their	   anterior	   pole	   toward	   the	   right.	  	  
This	   analysis	   also	   illustrate	   the	   dose-­‐dependent	   lateraliza,on	   of	   Fgf3	   expression.	   B)	   Rela,ve	  
areas	  of	  Fgf3	  expression	   in	  the	  analyzed	  o,c	  vesicles	  were	  ploEed	  as	  a	  histogram	  and	  conﬁrm	  
the	   dose	   dependent	   decrease	   in	   Fgf3	   expression	   with	   increasing	   RA	   dose.	   Plots	   of	   o,c	   Fgf3	  
expression	  area	  for	  embryos	  exposed	  to	  1x	  sugar	  (1xSu);	  3x	  sugar	  (3xSu)	  and	  3x	  chocolate	  (3xCh)	  
conﬁrm	   the	   speciﬁcity	   of	   the	   response	   to	   RA.	   Numbers	   used	   in	   a	   analysis:	   untreated	   n=13;	  
1xsugar	   n=4,	   3xsugar	   n=4,	   3xchocolate	   n=6;	   and	  RA	   :	   4.5mg/kg	  n=	   10;	   6mg/kg	  n=	   13;	   7mg/kg	  








The	  area	  of	  Fgf3	  expression	  on	  these	  2D	  images	  was	  then	  calculated	  as	  a	  percentage	  of	  
the	  overall	  otocyst	  area	  (see	  Figure	  3.6A	  for	  an	  array	  of	  some	  of	  the	  otic	  vesicles	  used	  
for	  analysis).	  Since	  in	  the	  embryos,	  the	  Fgf3	  domain	  of	  expression	  is	   in	  3D	  and	  not	  in	  
2D,	   this	   analysis	   cannot	   be	   viewed	   as	   a	   true	  quantitative	   assay.	   The	  use	  of	   confocal	  
microscopy	   to	   obtain	   real	   3D	   estimates	   was	   also	   explored,	   but	   it	   would	   have	   been	  
extremely	   time	   consuming	   to	   obtain	   the	   data	   for	   just	   one	   otic	   vesicle,	   and	   thus	  
impossible	  at	  the	  scale	  of	  the	  179	  otic	  vesicles	  analysed	  in	  the	  timeframe	  of	  this	  study.	  
This	  2D	  analysis	  is	  nevertheless	  useful,	  as	  it	  allows	  comparing	  a	  large	  number	  of	  9.5dpc	  
embryos	   exposed	   to	   RA	   with	   similar	   and	   different	   doses,	   as	   opposed	   to	   relying	  
exclusively	  on	  1	  or	  2	  representative	  pictures	  of	  embryos	  for	  each	  RA	  doses	  to	  support	  
the	  results.	  
	  
This	   image	   analysis	   first	   revealed	   that	   despite	   variations	   in	   the	   otic	   domain	   of	   Fgf3	  
expression	   using	   a	   same	  dose	   of	   RA,	   there	  was	   a	   clear	   dose-­‐dependent	   decrease	   of	  
Fgf3	   expression	   with	   increasing	   RA	   doses	   (Figure	   3.6A)	   The	   extent	   of	   this	   dose-­‐
dependant	   downregulation	   is	   particularly	   clear	  when	   plotted	   as	   a	   histogram	   (Figure	  
3.6B).	   In	   addition,	   this	   analysis	   confirms	   that	   the	   domain	   of	   Fgf3	   otic	   expression	  
becomes	  lateralized	  with	  increasing	  doses	  of	  RA,	  thus	  appearing	  posteriorly	  shifted	  in	  








3.6	  Fgf3-­‐expression	   in	  embryos	  exposed	   to	  RA	  after	  hindbrain	  
patterning	  (at	  8.5dpc)	  
The	  timing	  of	  exposure	  to	  exogenous	  RA	  has	  been	  shown	  to	  play	  a	  crucial	  role	  in	  the	  
induction	   of	   specific	   phenotypes.	   Exposure	   to	   RA	   prior	   to	   the	   onset	   of	   somatic	  
segmentation	   (7.75-­‐8.25dpc)	   results	   in	   dramatic	   alterations	   of	   hindbrain	   patterning,	  
where	  the	  shortened	  hindbrain	   is	  converted	  to	  a	  more	  posterior	   identity	  as	  evidence	  
by	   the	  changes	   in	  Hox	  genes	  pattern	  of	  expression	   	   (Figure	  1.10;	  Wood	  et	  al.,	   1994;	  
Glover	  et	  al.,	  2006).	  Since	  the	  hindbrain	  plays	  a	  crucial	  role	  in	  inner	  ear	  induction	  and	  
later	   in	   the	   dorso-­‐ventral	   patterning	   of	   the	   otic	   vesicle,	   this	   suggested	   that	   the	  
downregulation	  of	  otic	  Fgf3	  expression	  reported	  in	  embryos	  exposed	  to	  RA	  at	  7.75dpc	  
could	  merely	  be	  due	  to	  secondary	  effects	  of	  altered	  hindbrain	  patterning.	  	  
	  
In	  order	  to	  determine	  if	  excess	  RA	  could	  still	  downregulate	  Fgf3	  expression	  in	  the	  otic	  
vesicle	  independently	  of	  hindbrain	  re-­‐patterning,	  Fgf3	  expression	  was	  also	  analysed	  in	  
embryos	   exposed	   to	   RA	   at	   early	   somite	   stage	   (8.5dpc),	   a	   stage	   where	   the	  
administration	  of	  RA	  does	  not	  alter	  the	  posterior	  hindbrain	  identity	  (Wood	  et	  al.,	  1994;	  
Glover	  et	  al.,	  2006;	  Morriss-­‐Kay	  et	  al.,	  1991).	  Embryos	  examined	  at	  9.5dpc	  (Figure	  3.7)	  
presented	  an	  increasing	  downregulation	  of	  otic	  Fgf3	  expression	  with	  increasing	  doses	  
of	   RA	   (Table	   3.2b),	   thus	   showing	   similarities	   to	   what	   has	   been	   seen	   in	   embryos	  




Figure	  3.7	  Eﬀects	  of	  RA	  administra8on	  a9er	  hindbrain	  pa=erning.	  Lateral	  and	  dorsal	  views	  of	  
control	  and	  RA-­‐treated	  embryos	  at	  9.5dpc	  (A-­‐L)	  and	  10.5dpc	   	  (N-­‐P).	  Fgf3	  expression	  in	  the	  CNS	  
was	   unaltered	   by	   RA	   doses	   inferior	   to	   25mg/kg,	   and	   even	   then	   there	   was	   only	   a	   slight	  
downregulaKon	   (G,H,P).	   In	   the	   oKc	   vesicle	   Fgf3	   expression	   was	   downregulated	   with	   dose	   of	  
8-­‐10mg/kg	   (E)	   and	  even	  almost	   completely	  exKnguished	  with	  RA	  dose	  of	  25mg/kg	   (G).	   Similar	  
downregulaKon	   of	   oKc	   Fgf3	   expression	   was	   observed	   in	   9.5dpc	   embryos	   following	   gavage	  
administraKon	  (I-­‐K).	  Hb,	  hindbrain;	  ov,	  oKc	  vesicle;	  nt,	  dorsal	  neural	   tube.	  Scale	  bar	  =	  500	  μm.	  
Adapted	  from	  (Cadot	  et	  al.,	  2012)	  Copyright	  ©	  2012	  Wiley	  Periodicals.	  Inc	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First	   of	   all,	   alteration	   of	   Fgf3	   expression	   required	   higher	   doses	   of	   RA,	   where	   Fgf3	  
expression	   in	   the	   spinal	   cord	   and	   hindbrain	  was	   unaffected	   by	   doses	   of	   8-­‐10mg/kg,	  
while	  Fgf3	  expression	  in	  the	  otic	  vesicle	  was	  downregulated	  (Figure	  3.7E,F)	  but	  with	  a	  
lower	  incidence	  compared	  to	  embryos	  exposed	  to	  a	  similar	  dose	  at	  7.75dpc.	  Even	  with	  
a	  dose	  of	  25mg/kg	  of	  RA,	  more	   than	  3	   times	   the	  dose	   required	   to	   totally	  extinguish	  
Fgf3	   otic	   expression	   in	   embryo	   exposed	   at	   early	   somites	   stages,	   a	   couple	   of	   Fgf3-­‐
expressing	  cell	  were	  still	  visible	  in	  the	  otic	  vesicle	  of	  all	  but	  one	  embryos.	  Interestingly,	  
in	   embryos	   exposed	   to	   10mg/kg	   of	   RA	   the	   downregulation	   of	   Fgf3	   expression	   was	  
restricted	   to	   the	   otic	   vesicle,	   whereas	   in	   embryo	   exposed	   to	   25mg/kg	   of	   RA	   Fgf3	  
expression	  was	   also	   lost	   in	   the	   branchial	   arches,	   as	  well	   as	   in	   the	   surface	   ectoderm	  
between	  the	  OV	  and	  the	  branchial	  arches	  (compare	  Figure	  3.7E	  and	  G).	  
	  
A	  dose	  of	  25mg/kg	  of	  RA	  also	  seemed	  to	  lead	  to	  a	  slight	  downregulation	  of	  Fgf3	  in	  the	  
hindbrain	   and	   spinal	   cord.	   Fgf3	   expression	   appeared	   unaltered	   in	   all	   area	   of	  
endogenous	   expression	  with	   a	   dose	   of	   4.5mg/kg	   (Figure	   3.7C,D),	   despite	   the	   image	  
analysis	  suggesting	  a	  slight	  downregulation	  (Figure	  3.8).	  In	  addition,	  Fgf3	  seemed	  to	  be	  
evenly	  downregulated	  throughout	  the	  otic	  domain,	  rather	  than	  predominantly	  lost	   in	  
the	  antero-­‐dorsal	  region	  of	  the	  otic	  vesicle,	  and	  thus	  no	  phenomenon	  of	  lateralization	  
of	  Fgf3	  expression	  was	  observed	  at	  this	  stage.	  
	  
In	  order	  to	  further	  prove	  that	  the	  novel	  method	  of	  RA	  administration	  presented	  here	  
has	   no	   influence	   on	   the	   phenotype,	   a	   couple	   of	   gavage	   experiments	   were	   also	  
performed	   using	   RA	   doses	   of	   25mg/kg	   and	   2x25mg/kg	   (Figure	   3.7I-­‐L).	   A	   dose	   of	  
25mg/kg	  gave	   results	   similar	   to	  what	  had	  been	  observed	  when	  using	  RA-­‐laced	  sugar	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pellets,	   where	   Fgf3	   expression	   is	   lost	   both	   in	   the	   otic	   vesicle	   and	   in	   the	   adjacent	  
surface	  ectoderm,	  as	  well	  as	  downregulated	   in	   the	  hindbrain	  and	  spinal	   cord	   (Figure	  
3.7I,J).	  Administration	  of	  2	  doses	  of	  25mg/kg	  of	  RA	  gave	  rise	  to	  similar	  phenotypes	  but	  
with	  an	  increasing	  number	  of	  embryos	  showing	  complete	  loss	  of	  Fgf3	  expression	  in	  the	  
OV	   (Figure	   3.7K,L).	   Expression	   in	   the	   hindbrain	   and	   spinal	   cord	   were	   also	   more	  
downregulated	  than	  with	  a	  single	  shot	  of	  25mg/kg	  of	  RA.	  	  
	  
An	   image	   analysis	   of	   the	   otic	   vesicle	   of	   RA-­‐treated	   embryo	   using	   either	   self-­‐
administration	  of	   sugar	  pellets	   or	   gavage	  was	   also	  performed	  at	   this	   stage	   and	  data	  
plotted	   as	   a	   histogram	   (Figure	   3.8).	   A	   dose	   dependant	   downregulation	   of	   Fgf3-­‐
expression	   in	   the	   otic	   vesicle	   could	   be	   observed,	   independently	   of	   the	   delivery	  
technique.	   The	   incidence	   of	   embryos	   with	   altered	   otic	   expression	   of	   Fgf3	   following	  
administration	  to	  RA	  at	  8.5dpc	  is	  presented	  in	  Table	  3.2b.	  
	  
The	  effects	  of	  RA	  administration	  at	  early	  somitic	  stage	  were	  also	  analysed	  at	  10.5dpc.	  
Following	   administration	   of	   up	   to	   25mg/kg	   of	   RA	   (Figure	   3.7O,P)	   embryo	   appeared	  
morphologically	  similar	  to	  control	  embryos	  (Figure	  3.7N)	  but	  Fgf3	  expression	  started	  to	  
be	  downregulated	  in	  the	  otic	  vesicle	  of	  embryos	  exposed	  to	  RA	  doses10mg/kg	  (Figure	  
3.7O)	   and	   was	   even	  more	   downregulated	   with	   a	   dose	   of	   25mg/kg	   (Figure	   3.7P).	   In	  
addition	  Fgf3	  expression	  was	  lost	  in	  the	  surface	  ectoderm	  adjacent	  to	  the	  otic	  vesicle	  
(Figure	  3.7P)	  as	  previously	  reported	  at	  9.5dpc	  (Figure	  3.7G).	  
	  
Together	  these	  data	  demonstrate	  that	  Fgf3	  expression	  has	  a	  different	  sensitivity	  to	  RA	  



















Figure	  3.8	   image	  analysis	  of	  Fgf3	   expression	   in	   the	  9.5dpc	  o8c	  vesicle	  exposed	   to	   increasing	  
dose	  of	  RA	  at	  8.5dpc.	  A)	  RepresentaKve	  array	  of	  digitally	  dissected	  oKc	  vesicle	  from	  control	  and	  
RA	   treated	   embryos.	   The	   relaKve	   area	   of	   Fgf3	   expression	   was	   determined	   using	   the	   ImageJ	  
so\ware	  and	   is	   shown	   in	   subscript	   as	   a	  percentage	  of	   the	  area	  of	   the	  whole	  oKc	  vesicle.	   This	  
analysis	   illustrates	   the	   diﬀerence	   in	   the	   alteraKon	   of	   Fgf3	   expression	   following	   exposure	   at	  
8.5dpc	   instead	  of	  7.75dpc,	  with	  Fgf3	  being	  downregulated	  throughout	  the	  oKc	  vesicle	  and	  not	  
lateralized.	   B)	   OKc	   image	   analysis	   plobed	   as	   a	   histogram	   conﬁrms	   dose-­‐dependent	  
downregulaKon	  of	  oKc	  Fgf3	  expression	   following	  RA	  administraKon	  a\er	  hindbrain	  paberning.	  
Error	  bars	  represent	  standard	  error	  to	  the	  mean.	  Numbers	  used	  in	  a	  analysis:	  untreated	  n=13;	  RA	  
via	  sugar	  pellet:	  4.5mg/kg	  n=	  18;	  8-­‐10mg/kg	  n=	  21;	  25mg/kg	  n=27;	  and	  RA	  via	  gavage:	  25mg/kg	  









Fgf3	  requires	  higher	  dose	  of	  RA	  to	  be	  clearly	  downregulated	  in	  a	   large	  percentage	  of	  
embryos:	   	  25mg/kg	   in	  early	  somitic	  embryos	  vs.	  8mg/kg	   in	  presomitic	  embryos.	  Fgf3	  
expression	   is	   also	   downregulated	   in	   the	   otic	   vesicle	   whereas	   other	   domain	   of	  
endogenous	  expression	  (CNS)	  remains	  unaltered.	  This	  contrasts	  from	  the	  concomitant	  
downregulation	   of	   Fgf3	   in	   both	   the	   OV	   and	   the	   CNS	   in	   presomitic	   embryos.	  
Importantly,	  there	  was	  a	  dose-­‐dependent	  dowregulation	  of	  Fgf3	  expression	  in	  the	  otic	  
vesicle	   following	   administration	  of	   RA	   at	   the	   early	   somatic	   stage,	   a	   stage	  where	   the	  
posterior	  identity	  of	  the	  hindbrain	  is	  unchanged	  by	  RA.	  Thus	  the	  alteration	  in	  Fgf3	  otic	  
pattern	   of	   expression	   is	   unlikely	   to	   be	   due	   to	   secondary	   effects	   from	   the	   hindbrain.	  
This	  supports	  the	  hypothesis	  of	  a	  direct	  regulation	  of	  Fgf3	  by	  RA.	  
	  
	  
3.7	  Generation	  of	  RA	  phenotypes	  in	  other	  organ	  systems	  
A	  brief	  survey	  of	  the	  literature	  has	  revealed	  that	  RA	  was	  playing	  a	  crucial	  role	  in	  lots	  of	  
different	  organs	  and	  tissues	  of	  the	  developing	  embryo	  (Table	  3.1	  and	  Appendix	  Table	  
S1).	  In	  order	  to	  assess	  whether	  the	  novel	  RA	  delivery	  procedure	  could	  be	  used	  for	  RA	  
studies	  in	  other	  organ	  or	  tissues,	  the	  effects	  of	  RA	  administration	  via	  sugar	  pellets	  and	  
gavage	  were	  compared	  in	  3	  other	  organs	  systems:	  the	  limb,	  the	  palate	  and	  the	  heart.	  
	  
Limb	   abnormalities	   were	   previously	   reported	   in	   100%	   of	   the	   embryos	   exposed	   to	  
100mg/kg	  of	  RA	  at	  11.5dpc	  (Alles	  and	  Sulik,	  1989).	  Administration	  of	  100mg/kg	  of	  RA	  
either	   via	   gavage	   (n=7)	   or	   sugar	   pellets	   (n=10)	   both	   led	   to	   a	   similar	   shortening	   of	  
hindlimbs	  and	  forelimbs	  in	  all	  embryos	  examined	  (Figure	  3.9B,C,	  compare	  to	  untreated	  
3.9A)	  
Figure	  3.9	  Genera.on	  of	   iden.cal	  RA	  phenotypes	   in	  other	  organ	  systems	  using	  sugar	  pellets.	  
Administra*on	   of	   100mg/kg	   of	   RA	   at	   11.5dpc	   results	   in	   similar	   limb	   reduc*on	   anomalies	  
regardless	  whether	   pellets	   or	   gavage	  was	  used	   as	   highlighted	  by	  white	   arrows	   (C,D).	   Iden*cal	  
cleF	  palate	  phenotypes	  at	  18.5dpc	  were	  also	  generated	  using	  pellet	  or	  gavage	  (black	  arrows	  in	  
E,F).	  Eventually,	   similar	  paJerning	  defects	  of	   the	  heart	  vesicles	  were	  also	  obtained	  with	  pellet	  
(H)	  and	  gavage	  (I).	  Untreated	  embryos	  (A,D,G).	  Scale	  bar	  :	  (A-­‐F)=	  5mm;	  (G-­‐I)	  =	  500	  μm.	  Adapted	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The	   palate	  was	   the	   next	   organ	   to	   be	   trialled.	   Exposure	   to	   excess	   RA	   at	   11.5dpc	   has	  
been	   shown	   to	   interfere	   with	   the	   fusion	   of	   the	   palatal	   shelves,	   resulting	   in	   the	  
development	  of	  cleft	  palate.	  An	  RA	  dose	  of	  100mg/kg	  has	  been	  shown	  to	  induce	  a	  cleft	  
palate	   phenotype	   in	   65-­‐82%	  of	   embryos	   (Abbott	   et	   al.,	   2005;	   Campbell	   et	   al.,	   2004;	  
Kochhar	  et	  al.,	  1984).	  Administration	  of	  100mg/kg	  of	  RA	  using	  either	  gavage	  (n=4)	  or	  
sugar	   pellets	   (n=5)	   resulted	   in	   cleft	   palate	   phenotypes	   of	   similar	   severity	   in	   all	   the	  
embryos	  examined	  (Figure	  3.9E,F	  compare	  with	  3.9D).	  
	  
Finally,	  heart	  defects	  have	  been	  reported	  following	  RA	  administration,	  where	  the	  heart	  
presents	  an	  aberrant	  looping	  with	  the	  heart	  vesicles	  being	  arranged	  as	  an	  anterior	  and	  
a	  posterior	  chamber	  instead	  of	  a	  left	  and	  a	  right	  chamber	  (Wasiak	  and	  Lohnes,	  1999).	  
Administration	  of	  10mg/kg	  of	  RA	  at	  7.75dpc	  resulted	  in	  such	  an	  aberrant	  heart	  vesicles	  
arrangement	   (Figure	  3.8H,I)	   regardless	  of	   the	  delivery	  method	  being	  gavage	   (n=5)	  or	  
sugar	  pellets	  (n=13)	  
	  
All	   together	   this	   shows	   that	   RA	   administration	   using	   sugar	   pellets	   can	   be	   applied	   to	  
other	  organ	  systems	  than	  the	  inner	  ear.	  	  
	  
	  
3.8	  Fgf3/Fgf10	  cross-­‐regulation	  
Fgfs	  cross-­‐regulation	  has	  been	  reported	  for	  other	  Fgfs	  during	  inner	  ear	  induction,	  with	  
misexpression	   of	   Fgf10	   expression	   in	   the	   hindbrain	   that	   results	   in	   ectopic	   Fgf8	  
expression;	  and	  double	  knock-­‐out	  of	  Fgf3	  and	  Fgf8	  that	  leads	  to	  a	  downregulation	  of	  
Fgf10	  expression	  (Zelarayan	  et	  al.,	  2007).	  Interestingly	  Fgf10	  expression	  was	  reported	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as	  shifted	  dorso-­‐medially,	  along	  with	  the	  vestibulo-­‐accoustic	  ganglion	  in	  Fgf3	  null	  mice	  
(Hatch	  et	  al.,	  2007).	  Furthermore,	  Fgf3,	  Fgf8,	  and	  Fgf10	  signalling	  from	  the	  hindbrain,	  
endoderm	  and	  mesoderm	  are	  thought	  to	  be	  able	  to	  compensate	  for	  each	  other	  during	  
inner	   induction	   since	   targeted	  mutation	  of	  Fgf3	   or	  Fgf10	   alone	  only	   lead	   to	   variable	  
defects	  of	  mouse	  inner	  ear	  morphogenesis,	  whereas	  Fgf3/Fgf10	  and	  Fgf3/Fgf8	  double	  
mutants	  fail	  to	  develop	  otic	  vesicles.	  Interestingly	  Fgf10	  and	  Fgf3	  are	  also	  expressed	  in	  
the	  developing	   inner	  ear	   itself,	  where	  their	  expressions	  overlap	   in	  the	  antero-­‐ventral	  
wall	  of	  the	  otocyst	  (Hatch	  et	  al.,	  2007;	  Pirvola	  et	  al.,	  2000),	  suggesting	  that	  Fgf3	  could	  
also	  compensate	   for	  Fgf10	  deficiency	  during	   later	   stages	  of	  development.	  Functional	  
redundancy	   could	   also	   reflect	   similar	   regulatory	   mechanisms	   and	   analysis	   of	   this	  
mechanism	  could	  improve	  our	  understanding	  of	  both	  Fgf3	  and	  Fgf10	  regulation	  both	  
individually	   and	   together.	   As	   it	   is	   not	   clear	   which	   mechanisms	   lead	   to	   such	  
compensation,	   Fgf3	   reporter	   expression	   was	   analysed	   in	   an	   Fgf10	   null	   mutant	  
background	  between	  7.75dpc	  and	  11.5dpc.	  	  
	  
Analysis	   of	  wholemount	   Fgf3-­‐lacZ	   embryos	   null	   for	   Fgf10	   revealed	   a	   delay	   and/or	   a	  
downregulation	  of	   Fgf3-­‐lacZ	   expression	   in	   the	  hindbrain	   of	  Fgf10	   knockout	   embryos	  
(Figure	   3.10B)	   compared	   to	   control	   embryos	   at	   the	   same	   stage	   (Figure	   3.10A).	   Fgf3	  
expression	  was	  also	  weaker	  in	  the	  hindbrain	  and	  midbrain	  of	  9.0	  and	  9.5dpc	  Fgf10	  KO	  
embryos	   (Figure	   3.10G,H).	   However	   Fgf3-­‐lacZ	   expression	   appears	   unaltered	   at	   the	  
level	  of	  the	  otic	  vesicle	  (Figure	  3.10G-­‐K).	  At	  10.5dpc,	  level	  of	  reporter	  expression	  in	  the	  
brain	  of	  mutant	  embryos	  (Figure	  3.10I)	  is	  similar	  to	  the	  control	  (Figure	  3.10D)	  and	  the	  
Fgf3-­‐lacZ	  expression	  pattern	  in	  the	  developing	  inner	  ear	  is	  also	  conserved;	  both	  at	  this	  
stage	  and	  at	  11.5dpc	  (Figure	  3.10K).	  
Figure	   3.10	  Wholemount	   analysis	   of	   early	   Fgf3-­‐lacZ	   expression	   in	   a	   Fgf10	   null	   background.	  
Lateral	   and	  dorsal	   views	  are	  presented	   in	   consecu2ve	  panels.	   Embryonic	   stages	   are	   as	   follow:	  
(A,F)	   7.75dpc;	   (B,G)	   9.0dpc;	   (C,H)	   9.5dpc;	   (D,I)	   10.5dpc;	   (E,K)	   11.5dpc.	   At	   7.75dpc,	   Fgf3	  
expression	  was	  absent	  from	  the	  brain	  of	  Fgf10	  null	  embryos	  (F)	  and	  also	  seemed	  downregulated	  
compared	   to	   control	   up	   to	   9.5dpc	   (G,H).	   Hindbrain	   expression	   in	   Fgf10	   null	   embryos	   was	  
however	  similar	  to	  control	  at	  10.5dpc	  (I).	  O2c	  expression	  seems	  unaltered	  between	  9.0dpc	  and	  	  
11.5dpc.	  	  
Figure	   3.11	   Analysis	   of	   early	   Fgf3-­‐lacZ	   expression	   on	   sec>on	   in	   a	   Fgf10	   null	   background.	  
Transverse	  sec2on	  at	  the	  following	  embryonic	  stages:	  (A,E)	  9.5dpc;	  (B,F)	  10.5dpc;	  (C,G)	  10.5dpc;	  
(D,H)	  11.5dpc.	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Fgf3-­‐lacZ	  expression	  was	  also	  analyzed	  on	  sections	  at	  the	   level	  of	   the	  otic	  vesicle.	  At	  
8.5dpc	  Fgf3-­‐lacZ	  expression	  extends	  from	  the	  middle	  of	  the	  ventral	  wall	  of	  the	  otic	  pit	  
and	  along	  the	  surface	  ectoderm	  spreading	  from	  the	  otocyst	  to	  the	  2nd	  branchial	  arches	  
in	  control	  embryo	  (Figure	  3.11A).	  This	  pattern	  of	  expression	  was	  unchanged	  in	  mutant	  
embryos	  (Figure	  3.11E).	  At	  9.5dpc	  Fgf3	  was	  expressed	  in	  the	  anteroventral	  wall	  of	  the	  
otocyst	  both	  in	  control	  and	  Fgf10	  KO	  embryos	  (Figure	  3.11B,F).	  	  
	  
At	  10.5dpc,	  Fgf3	  expression	  is	  restricted	  to	  a	  small	  anteroventral	  patch	  (Figure	  3.11C);	  
this	   expression	   domain	   was	   unaltered	   in	   Fgf10	   KO	   embryos	   despite	   some	  
morphogenetic	   anomalies	   (Figure	   3.11G).	   At	   11.5dpc	   development	   of	   the	   inner	   ear	  
was	   clearly	   abnormal	   in	   Fgf10	   mutant	   embryos	   (Figure	   3.11H)	   compared	   to	   control	  
embryo	   (Figure	   3.11D).	   However,	   there	   were	   still	   no	   significant	   differences	   in	   Fgf3	  
expression	  spatial	  domains	  of	  expression	  and	  thus	  Fgf3	  expression	  is	  unaltered	  in	  the	  
Fgf10	  KO	  mutant.	  
	  
In	   summary,	  maintenance	  of	  Fgf3-­‐lacZ	   expression	   in	  Fgf10	   KO	  mice	   shows	   that	  Fgf3	  
could	   also	   compensate	   for	   the	   lack	   of	   Fgf10	   expression	   at	   later	   stages	   of	   inner	   ear	  
development.	  This	  compensation	  could	  happen	  in	  several	  different	  ways.	  For	  instance,	  
Fgf3	  could	  be	  overexpressed,	  resulting	  in	  more	  FGF3	  protein	  produced	  to	  interact	  with	  
FGFR-­‐2(IIIb).	  Alternatively,	  more	  FGF3	  protein	  could	  also	  be	  produced	  by	  upregulation	  
at	  the	  translation	  level.	  	  The	  results	  presented	  here	  allow	  ruling	  out	  the	  first	  hypothesis	  
since	   there	   was	   no	   significant	   upregulation	   of	   Fgf3-­‐lacZ	   expression	   in	   any	   of	   the	  
embryos	   analysed.	   Therefore	   compensation	   should	   happen	   at	   the	   FGF3	   ligand	   level,	  




INVESTIGATING	  MECHANISMS	  OF	  
FGF10	  TRANSCRIPTIONAL	  REGULATION	  
	  
In	  the	  previous	  chapter,	  the	  regulatory	  importance	  of	  RA	  in	  controlling	  Fgf3	  expression	  
was	   presented.	   	   However,	   this	   regulation	  may	   be	   through	   either	   direct	  mechanisms	  
involving	  one	  or	  more	  of	  a	  number	  of	  RA	  response	  elements,	  or	  indirect	  mechanisms.	  
In	  addition,	  the	  redundant	  requirements	  for	  Fgf3	  and	  Fgf10	  in	  inner	  ear	  induction	  and	  
their	  overlapping	  expression	  in	  the	  otic	  epithelium	  itself	  was	  also	  discussed,	  and	  it	  is	  of	  
interest	   that	  Fgf3	   expression	  was	   never	   lost	   nor	   upregulated	   in	  Fgf10	   null	   embryos.	  
This	  raises	  the	  question	  as	  to	  whether	  these	  genes	  share	  any	  conserved	  mechanisms	  
underlying	   their	   normal	   regulation.	   In	   order	   to	   begin	   an	   Fgf10	   regulatory	   analysis,	  
enhancer	  elements	  responsible	  for	  controlling	  normal	  Fgf10	  expression	  had	  first	  to	  be	  
identified	  and	  cloned.	  
	  
4.1	  Investigation	  of	  the	  endogenous	  Fgf10	  expression	  pattern	  
The	  Fgf10	  mRNA	  expression	  pattern	  was	   first	  analysed	  using	   in	  situ	  hybridization.	  As	  
well	   as	  providing	  detailed	  comparative	  expression	  data	   for	   comparison	   to	  Fgf3,	   such	  
expression	  data	  is	  also	  essential	  to	  evaluate	  expression	  of	  Fgf10-­‐reporter	  constructs,	  in	  
order	  to	  determine	  whether	  or	  not	  a	  given	  construct	  recapitulates	  all	  or	  only	  part	  of	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the	  endogenous	  Fgf10	  expression	  pattern.	  A	  500bp	  fragment	  from	  the	  5’	  region	  of	  a	  
Fgf10	  cDNA	  clone	  was	  used	  to	  synthesize	  antisense	  and	  sense	  Fgf10	  riboprobes.	  	  
	  
Inner	   ear	   Fgf10	   expression	   was	   first	   detected	   around	   8.75dpc	   in	   the	   mouse	   otic	  
placode	   as	   a	   weak	   anterior	   patch	   of	   staining	   (Figure	   4.1A).	   This	   anterior	   patch	   of	  
expression	  becomes	  more	  pronounced	  at	   the	  otic	  cup	  stage	   (Figure	  4.1B).	  The	  Fgf10	  
mRNA	  pattern	  then	  starts	  to	  slightly	  change	  as	  the	  otic	  cup	  begins	  to	  approach	  closure	  
around	   9.5dpc,	   with	   Fgf10	   expression	   now	   extending	   more	   ventrally	   (Figure	   4.1C).	  
Horizontal	   sections	   of	   wholemount	   embryos	   hybridized	   with	   Fgf10	   antisense	  
riboprobes	   reveals	   that	   this	   strong	   antero-­‐ventral	   patch	   of	   expression	   is	   located	  
medially,	  close	  to	  the	  neural	   tube	  (Figure	  4.1F).	  0.25dpc	   later,	  additional	   low	  level	  of	  
Fgf10	  expression	  can	  be	  seen	  throughout	  the	  otic	  vesicle	  epithelium	  in	  addition	  to	  the	  
strong	  patch	  of	  anterior	  expression	  (Figure	  4.1D).	  Fgf10	  expression	  is	  also	  visible	  in	  the	  
vestibulo-­‐acoustic	   and	   trigeminal	   ganglia	   (see	   arrows	   in	   Figure	   4.1E)	   as	   well	   as	  
throughout	  the	  developing	  limb	  (arrows,	  Figure	  4.1D).	  At	  10.0dpc	  of	  development,	  the	  
extrusion	  of	  the	  endolymphatic	  duct	  from	  the	  dorso-­‐medial	  region	  of	  the	  otic	  vesicle	  is	  
the	  first	  visible	  sign	  of	  inner	  ear	  morphogenesis,	  in	  combination	  with	  the	  elongation	  of	  
the	   otic	   vesicle	   along	   its	   dorso-­‐ventral	   axis	   (Figure	   4.1E).	   Fgf10	   expression	   remains	  
prominent	  in	  the	  anterior	  part	  of	  the	  developing	  inner	  ear	  but	  is	  also	  evident	  as	  a	  small	  





Figure	   4.1	   Early	  Fgf10	  mRNA	  expression	   in	   the	  developing	  mouse	   embryo.	   At	   8.75dpc	  Fgf10	  
expression	   is	   ini2ated	   in	   the	  anterior	  part	  of	   the	  o2c	  placode	   (A).	  Expression	   is	  upregulated	  at	  
the	  o2c	  cup	  stage	   	   (B)	  and	  start	  extending	  ventrally	  at	  9.0dpc	  (C).	  At	  9.5dpc	  expression	   is	  now	  
visible	   throughout	   the	   epithelium	   of	   the	   closed	   o2c	   vesicle	   (D),	   although	   s2ll	   stronger	   in	   the	  
antero-­‐ventral	  region.	  Fgf10	  is	  now	  also	  expressed	  in	  the	  developing	  limb	  (arrow,	  D).	  At	  10.0dpc	  
Fgf10	   o2c	   expression	   appears	   as	   a	   strong	   the	   anterior	   patch	   and	   a	   smaller	   dorsal	   patch	  
(arrowheads,	   E).	   In	   addi2on	   expression	   is	   now	   visible	   in	   the	   developing	   ves2bulo-­‐acous2c	  	  	  
ganglion	   (thin	   arrow,	   E)	   and	   the	   trigeminal	   ganglion	   (wide	   arrow,	   E).	   Coronal	   sec2on	   through	  
wholemount	  embryos	  hybridized	  at	  9.5dpc	  shows	  localiza2on	  of	  Fgf10	  expression	  in	  the	  antero-­‐
medial	  wall	   of	   the	  o2c	   vesicle.	  Oc,	  o2c	   cup;	  ov,	  o2c	   vesicle.	   Scale	  bar	  500μm.	  This	  ﬁgure	  also	  
appears	  in	  (Economou	  et	  al.,	  2013).	  Copyright	  ©	  2012	  Elsevier	  B.V.	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4.2	  Generation	  of	  Fgf10-­‐reporter	  constructs	  for	  analysis	  in	  mice	  
Contrary	  to	  Fgf3,	  an	  Fgf10	  reporter	  transgenic	  line	  was	  not	  available,	  so	  the	  first	  step	  
was	   to	   identify	   and	   clone	   a	   cis-­‐acting	   DNA	   sequence	   able	   to	   recapitulate	   Fgf10	  
expression	   in	   vivo.	   An	   Fgf10	   enhancer	   with	   inner	   ear	   expression	   activity	   had	   been	  
previously	  described	  in	  (Ohuchi	  et	  al.,	  2005)	  where	  a	  6.6kb	  enhancer	  region	  upstream	  
Fgf10	  was	  able	  to	  drive	  LacZ	  reporter	  expression	  in	  all	  endogenous	  areas	  of	  the	  inner	  
ear	  (construct	  F,	  Figure	  4.2).	  Interestingly,	  these	  authors	  had	  also	  shown	  that	  a	  smaller	  
800bp	   fragment	   within	   this	   6.6kb	   region	   (construct	   3-­‐1,	   Figure	   4.2)	   drives	   LacZ	  
expression	  in	  more	  restricted	  area	  of	  the	  inner	  ear	  and	  also	  only	  from	  a	  later	  stage	  of	  
development	   than	   normal	   endogenous	   expression.	   The	   modularity	   of	   cis-­‐regulatory	  
control	  units	  has	  been	  demonstrated	  in	  a	  large	  number	  of	  genes	  such	  Fgf4	  (Iwahori	  et	  
al.,	  2004),	  Ngn1	  (Nakada	  et	  al.,	  2004),	  Pax2	  (Pfeffer	  et	  al.,	  2002),	  Dlx	  (Park	  et	  al.,	  2004)	  
and	  Hox	   genes	   (Tumpel	   et	   al.,	   2002).	   As	  well	   as	   looking	   to	   explore	   the	  mechanisms	  
underlying	   normal	   Fgf10	   regulation,	   this	   project	   also	   looked	   to	   pursue	   further	   the	  
potential	   for	   other	   regulatory	   modules	   involved	   in	   controlling	   Fgf10	   inner	   ear	  
expression.	   Identification	  of	   such	   regulatory	  modules	   controlling	  Fgf10	   expression	   in	  
different	  areas	  of	  the	  inner	  ear	  would	  increase	  our	  understanding	  of	  Fgf10	  role	  in	  the	  
development	  of	   each	  of	   these	   regions.	  Unfortunately,	   neither	  Ohuchi’s	   reporter	   line	  






Figure	  4.2	  Schema0c	  of	  the	  Fgf10	  upstream	  region	  and	  constructs	  generated.	  Loca%on	  of	   the	  
Fgf10	   enhancer	   fragments	   previously	   tested	   in	   (Ohuchi	   et	   al.,	   2005)	   are	   indicated	   and	  
highlighted	  with	  asterisks	  (construct	  F	  and	  3-­‐1).	  Dark	  boxes	  a,b,c	  and	  d	  are	  conserved	  element,	  
with	  these	  4	  regions	  being	  highly	  homologous	  in	  mouse,	  chick	  and	  human.	  The	  6.6kb	  construct	  F	  
was	  shown	  to	  recapitulate	  Fgf10	  expression	  in	  all	  endogenous	  area	  of	  expression.	  The	  0.8kb	  3-­‐1	  
construct	  was	   shown	   to	   drive	   expression	   in	   restricted	   are	   of	   the	   inner	   ear	   only.	  White	   boxes	  
represents	  enhancer	  fragment	  cloned	  prior	  to	  the	  start	  of	  this	  PhD	  (P.DaNa).	  They	  were	  designed	  
based	  on	  the	  loca%on	  of	  puta%ve	  Gata3	  binding	  sites	  (symbolized	  as	  plain	  red	  circles).	  The	  1.4kb	  
3F3R	   fragment	   includes	   the	   limited	   ear	   800bp	   enhancer	   3-­‐1	   and	   and	   7F3R	   and	   3F7R	   were	  
designed	   to	   encompass	   the	   en%re	   enhancer	   region	   required	   for	   full	   Fgf10	   endogenous	  
expression.	  Grey	  boxes	  are	   the	   constructs	   generated	   in	   this	  project.	   The	  5.6kb	  7F7R	  enhancer	  
was	  reconstructed	  using	  the	  7F3R	  and	  3F7R	  fragments	  previously	  obtained	  by	  high-­‐ﬁdelity	  PCR	  
ampliﬁca%on.	  The	  7F3F-­‐3R7R	  enhancer	  correspond	  to	  7F7R	  from	  which	  was	  speciﬁcally	  deleted	  
3F3R.	   It	  was	  generated	   in	  order	   to	  determine	  whether	  poten%al	  ear	   regulatory	  elements	   lying	  
outside	  3F3R	  could	  be	  separated	  as	  dis%nct	  regulatory	  modules	  controlling	  Fgf10	  expression	  in	  
diﬀerent	  loca%on/%me	  than	  3F3R.	  7F3F	  and	  3R7R	  were	  also	  cloned	  independently	  for	  the	  same	  
purpose.	  Four	  more	  constructs	   termed	  Neuro1.1,	  Neuro2.5,	  3F-­‐Neuro	  and	  7F-­‐Neuro	  were	  also	  
generated	   following	   bioinforma%cs	   analysis	   of	   the	   Fgf10	   enhancer	   with	   an	   updated	   database	  
that	   revealed	   the	  presence	  of	   puta%ve	  binding	   sites	   for	  members	   of	   the	  Neurogenin	   pathway	  
(NGN1,	   NEUROD	   and	   NSCL1,	   symbolized	   as	   plain	   green	   circles).	   Two	   diﬀerent	   reporter	   genes	  
were	  used,	  ZsGreen	   and	  DsRed,	   in	  order	   to	   later	  allow	   for	  compara%ve	  analysis	  of	   the	  speciﬁc	  
expression	   paNern	   generated	   by	   the	   diﬀerent	   enhancer	   in	   a	   same	   embryo	   -­‐	   the	   use	   of	   two	  
diﬀerently	  colored	  ﬂuorescent	  molecules	  will	  allow	  determining	  area	  of	  overlapping	  expression	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4.2.1	  Reconstruction	  of	  the	  full	  Fgf10	  enhancer	  
Based	  on	  the	  results	  described	  by	  Ohuchi	  et	  al.	  (2005),	  a	  larger	  fragment	  was	  cloned	  as	  
part	   of	   an	   MSc	   project	   in	   the	   laboratory	   (P.Datta).	   This	   1.4kb	   enhancer	   (hereafter	  
referred	  to	  as	  3F3R)	  that	   incorporates	  the	  limited	  800bp	  3-­‐1	  enhancer	  (Ohuchi	  et	  al.,	  
2005)	   and	  additional	   5’	   and	  3’	   sequences	  was	   cloned	  upstream	  of	   green	   fluorescent	  
reporter	  gene	  called	  ZsGreen	  (Figure	  4.2).	  In	  addition	  two	  larger	  overlapping	  genomic	  
regions	  had	  been	  amplified	  (3F7R	  and	  7F3R,	  Figure	  4.2)	  that	  together	  included	  all	  the	  
putative	  GATA3	  binding	  sites	  thought	  to	  be	  important	  for	  Fgf10	  regulation	  in	  the	  inner	  
ear,	   and	   were	   thus	   predicted	   to	   encompass	   the	   full	   Fgf10	   enhancer.	   In	   order	   to	  
recreate	  a	  fully	  functional	  inner	  ear	  enhancer,	  I	  first	  looked	  to	  recreate	  the	  5.6kb	  7F7R	  
genomic	  region	  (Figure	  4.3)	  by	   ligating	  together	  these	  two	  7F3R	  and	  3R7R	  fragments	  
that	  had	  been	  previously	  amplified	  by	  high	  fidelity	  PCR.	  	  
Figure	  4.3	  The	  7F7R-­‐DsRed	  reporter	  construct.	  The	  5.9kb	  7F7R	  fragment	  is	  indicated	  in	  grey.	  Above	  it,	  
the	   7kb	   upstream	   Fgf10	   are	   represented,	   along	   with	   putative	   binding	   sites	   for	   GATA3	   (in	   red),	  
NEUROD/NSCL1/NGN1	  (in	  green),	  and	  retinoic	  acid	  (in	  blue).	  Enhancer	   fragments	  previously	  tested	  by	  
Ohuchi	  (2005)	  are	  indicated	  with	  asterisks	  (construct	  F	  and	  3-­‐1).	  Dark	  boxes	  a,	  b,	  c	  and	  d	  are	  conserved	  
elements,	  with	  these	  4	  regions	  being	  highly	  homologous	  in	  mouse,	  chick	  and	  human.	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Using	   the	   strategy	   outlined	   in	   Figure	   4.4a,	   a	   HindII-­‐XbaI	   fragment	   from	   3F7R	   was	  
ligated	  downstream	  and	  contiguous	  to	  the	  endogenous	  HindII	  site	  using	  a	  HindIII-­‐HincII	  
fragment	   of	   7F3R.	   Successful	   cloning	   was	   confirmed	   by	   restriction	   analysis	   using	   (i)	  
digestion	  with	  AflII	  that	  was	  predicted	  to	  linearise	  the	  8.6kb	  clone	  and	  (ii)	  a	  SpeI	  digest	  
that	   releases	   the	   5.7kb	   enhancer	   from	   the	   2.9kb	   pSK-­‐bluescript	   backbone	   (Figure	  
4.4b).	  
	  
A	   reporter	   system	  was	   then	   chosen.	   Previously	   3F3R	   had	   been	   cloned	   in	   a	   ZsGreen	  
reporter	  construct	  including	  a	  minimal	  ßglobin	  promoter,	  which	  is	  on	  its	  own	  unable	  to	  
support	  expression.	  	  Fluorescent	  expression	  in	  the	  inner	  ear	  was	  detected	  using	  such	  a	  
3f3r-­‐ZsGreen	   construct	   in	   transgenic	  embryos	   (Economou	  et	   al.,	   2012).	   This	   reporter	  
could	  have	  been	  used	  for	  7F7R	  too,	  but	  since	  the	  aim	  of	  this	  project	  was	  to	  identify	  any	  
modular	  components	  underlying	   regulation,	   for	  example	  by	  comparing	   the	  3F3R	  and	  
7F7R	  reporter	  patterns,	  a	  second	  fluorescent	  reporter	  (DsRed)	  was	  selected.	  	  Thus	  the	  
experimental	   design	   was	   to	   enable	   easy	   comparison	   of	   the	   patterns	   of	   expression	  









Figure	   4.4	   Reconstruc0on	   of	  
the	   7F7R	   enhancer.	   a)	  
Overview	   of	   the	   cloning	  
strategy	   used	   to	   reconstruct	  
7F7R.	   B)	   Restric%on	   analysis	  
conﬁrms	  cloning	  of	  7F7R	  in	  SK	  :	  
AﬂII	   linearises	   the	   8.5kb	   clone	  
and	   SpeI	   releases	   the	   5.6kb	  
enhancer	   from	   the	   2.9kb	  




A	   pDsRed	   expression	   vector	   was	   purchased	   (Clontech).	   This	   clone	   however	   did	   not	  
contain	   any	   promoter	   so	   first	   it	   had	   to	   be	   modified.	   A	   human	   ßglobin	   minimal	  
promoter	   had	   previously	   been	   inserted	   in	   front	   of	   the	   promoterless	   pZsgreen	   clone	  
and	   shown	   to	   successfully	  drive	   reporter	  expression	   in	  mice	  when	   in	  presence	  of	  an	  
enhancer	  (M.Maconochie,	  personal	  communication;	  Economou	  et	  al.,	  2012)	  and	  thus	  
the	  same	  strategy	  was	  adopted.	  
	  
The	  114bp	  ßglobin	  minimal	  promoter	  was	  digested	  from	  a	  ZsGreen	  reporter	  construct	  
and	  cloned	  as	  a	  BamHI	  fragment	  upstream	  the	  DsRed	  reporter	  gene.	  In	  addition,	  a	  new	  
SpeI	  restriction	  site	  was	  also	  incorporated	  by	  the	  insertion	  of	  SpeI	  linkers	  upstream	  of	  
the	   promoter	   to	   facilitate	   future	   cloning	   (Figure	   4.5a).	   Successful	   insertion	   of	   the	  
ßglobin	   promoter	   was	   confirmed	   by	   digestion	   with	   BamHI	   to	   release	   the	   114bp	  
promoter	   from	   4.1kb	   pDsRed	   vector	   backbone	   (Figure	   4.5b).	   In	   addition,	   the	  
generation	   of	   the	   SpeI	   restriction	   was	   confirmed	   by	   successful	   linearization	   of	   the	  












Figure	  4.5	  Modiﬁca0on	  of	  the	  pDsRed-­‐Express2-­‐1	  reporter	  vector.	  a)	  Schema%c	  of	  the	  pDsRed	  
expression	   vector	   (Clonetech)	   and	   loca%on	   of	   SpeI	   linkers	   and	   βglobin	   promoter	   inser%on.	   b)	  
Restric%on	  analysis	   of	   two	  βglobin-­‐DsRed	  posi%ve	   clones	   (1	   and	  2).	  BamHI	  digest	   releases	   the	  
114bp	   promoter.	   1.5%	   agarose	   gel.	   c)	   The	   genera%on	   of	   a	   novel	   SpeI	   restric%on	   sites	   is	  
conﬁrmed	  by	   the	   linearisa%on	  of	   the	   clones.	   Clone	   1	   is	   of	   the	   expected	   4.2kb	   size,	   Clone	   2	   is	  
0.2kb	  bigger.	  Sequencing	  results	  showed	  clone	  2	  contains	  3	  repeat	  of	  the	  βglobin	  enhancer,	  as	  






BamHI digest SpeI digest 
1	   1	  2	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4.2.2	  Can	  ‘early’	  and	  ‘late’	  patterns	  of	  Fgf10	  expression	  be	  separated?	  
According	  to	  Ohuchi	  et	  al.	  (2005),	  the	  full	  6.6kb	  enhancer	  was	  able	  to	  recapitulate	  the	  
full	   endogenous	   pattern	   of	   Fgf10	   expression	   from	   8.75dpc	   onwards	   whereas	   the	  
smaller	   ~800bp	  enhancer	   could	  only	  drive	  Fgf10	   expression	   in	   restricted	  area	  of	   the	  
inner	  ear	   and	   from	   later	  developmental	   stages	   (around	  10.5dpc),	   the	   “late”	  pattern.	  	  
The	   constructs	   here	   7F7R	   (5.6kb)	   and	   3F3R	   (1.4kb)	   were	   predicted	   to	   mirror	   these	  
activities.	  	  
	  
The	  7F3F-­‐3R7R	  construct	  
In	   order	   to	   determine	   if	   ‘early’	   and	   ‘late’	   patterns	   can	   be	   separated	   into	   distinct	  
control	  elements,	  a	  2nd	  reporter	  construct	  encompassing	  the	  5.6kb	  region	  but	  lacking	  
the	  1.4kb	  (3F3R)	  late	  element	  was	  generated	  (7F3F-­‐3R7R;	  Figure	  4.6).	  	  
	  
Figure	   4.6	   The	   7F3F-­‐3R7R-­‐ZsGreen	   reporter	   construct.	   The	   7F3F-­‐3R7R	   enhancer	   is	   indicated	   in	   grey.	  
Above	  it	  the	  7kb	  upstream	  Fgf10	  are	  represented,	  along	  with	  putative	  binding	  sites	  for	  GATA3	  (in	  red),	  
NEUROD/NSCL1/NGN1	   (in	   green),	   and	   RA	   (in	   blue).	   Enhancer	   fragments	   previously	   tested	   by	   Ohuchi	  
(2005)	   are	   indicated	   with	   asterisks	   (construct	   F	   and	   3-­‐1).	   Dark	   boxes	   a,	   b,	   c	   and	   d	   are	   conserved	  
elements,	  with	  these	  4	  regions	  being	  highly	  homologous	  in	  mouse,	  chick	  and	  human.	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To	  do	  so,	  a	  set	  of	  PCR	  primers	  were	  designed	  to	  amplify	  7F3F	  and	  3R7R,	  while	  adding	  a	  
unique	  NdeI	  restriction	  site	  to	  the	  3’	  end	  of	  the	  7F3F	  fragment,	  and	  to	  the	  5’	  end	  of	  the	  
3R7R	   fragment.	   This	   allowed	   ligating	   the	   two	   fragments	   together	   while	   specifically	  
excluding	  the	  3F3R	  enhancer	  region	  (Figure	  4.7a).	  SpeI	  sites	  were	  also	  added	  by	  PCR	  in	  
5’	  of	  7F3F	  and	  3’	  of	  3R7R	  to	   facilitate	  cloning.	  An	  overview	  of	   the	  cloning	  strategy	   is	  
given	   in	   Figure	   4.7b.	   Successful	   insertion	   of	   7F3F	   in	   3R7R-­‐SK	   was	   confirmed	   by	  
restriction	  analysis	  with	  BglII	  that	  linearises	  the	  7.2kb	  7F3R-­‐3R7R-­‐SK	  plasmid	  by	  cutting	  
once	  into	  7F3F,	  and	  using	  the	  introduced	  NdeI	  site	  that	  cuts	  at	  the	  junction	  between	  
7F3R	  and	  3R7R	  (Figure	  4.7c).	  The	  7F3R-­‐3R7R	  enhancer	  was	   then	  subcloned	  as	  a	  SpeI	  
fragment	   in	  the	  pZsGreen	  reporter	   (Figure	  4.7e)	  and	  cloning	  confirmed	  by	  restriction	  
analysis	  with	  NdeI	   that	   linearises	  the	  8.4kb	  construct,	  and	  HindII	  NdeI	   that	  generates	  















Figure	  4.7	  Genera0on	  of	  a	  7F7R	  enhancer	  speciﬁcally	  deleted	  from	  3F3R.	  a)	  Schema%c	  of	  the	  
primers	  used	   to	   insert	  SpeI	   and	  NdeI	  by	  high-­‐ﬁdelity	  PCR.	  b)	  Overview	  of	   the	   strategy	  used	   to	  
reconstruct	  7F3F-­‐3R7R.	  c)	  Restric%on	  analysis	  of	  7F3F-­‐3R7R-­‐SK:	  BglII	  and	  NdeI	  both	  linearises	  the	  
7.2kb	   construct.	   d)	   Restric%on	   analysis	   of	   7F3F-­‐3R7R-­‐ZsGreen	   :	   NdeI	   linearises	   the	   8.4kb	  
construct,	  and	  NdeI/HindIII	  double	  digest	  geneartes	  two	  fragments	  of	  5.4	  and	  3kb	  as	  expected.	  




















Figure	  4.7	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7F3F	  and	  3R7R	  constructs	  
7F3F-­‐DsRed	   and	   3R7R-­‐DsRed	   constructs	   (Figure	   4.8)	   were	   also	   prepared	   in	   order	   to	  
test	  whether	  the	  region	  that	  contains	  the	  early	  pattern	  of	  expression	  can	  be	  separated	  
into	  two	  distinct	  regulatory	  modules.	  Briefly,	  7F3F	  (Figure	  4.9)	  and	  3R7R	  (Figure	  4.10)	  
were	  cloned	  as	  SpeI-­‐HindIII	  fragment	  in	  the	  βglobin-­‐DsRed	  reporter.	  7F3F	  cloning	  was	  
confirmed,	   with	   restriction	   analysis	   with	   HindII	   that	   linearises	   the	   7.2kb	   clone	   and	  
digestion	  with	   BglI	   that	   generates	   two	   fragments	   of	   7.2kb	   and	   5kb	   by	   cutting	   once	  
within	   DsRed	   and	   once	   within	   7F3F	   (Figure	   4.9b).	   3R7R	   cloning	   was	   confirmed	   by	  
restriction	   analysis	   with	   BglI	   that	   linearised	   the	   5.4kb	   clone	   and	   BglI/PvuII	   double	  
digest	  that	  generates	  two	  fragments	  of	  3.1kb	  and	  2.3kb	  (Figure	  4.10b).	  	  
	  
Figure	  4.8	  The	  7F3F	  and	  3R7R-­‐DsRed	  reporter	  constructs.	  The	  7F3F	  and	  3R7R	  regions	  are	  indicated	  in	  
grey.	  Above	  it	  the	  7kb	  upstream	  Fgf10	  are	  represented,	  along	  with	  putative	  binding	  sites	  for	  GATA3	  (in	  
red),	  NEUROD/NSCL1/NGN1	  (in	  green),	  and	  retinoic	  acid	  (in	  blue).	  Enhancer	  fragments	  previously	  tested	  
by	   Ohuchi	   (2005)	   are	   indicated	   with	   asterisks	   (construct	   F	   and	   3-­‐1).	   Dark	   boxes	   a,	   b,	   c	   and	   d	   are	  





Figure	   4.9	   Genera0on	   of	  
the	   7F3F-­‐DsRed	   construct.	  
a)	   Overview	   of	   the	   cloning	  
strategy	  used	  to	  reconstruct	  
7F3F.	  b)	  Restric%on	  analysis	  
conﬁrms	   cloning	   of	   7F3F	   in	  
pDSRed	   :	   HindIII	   linearises	  
the	   7.2kb	   clone	   and	   BglII	  
generates	  two	  fragments	  of	  
5kb	  and	  2.2kb	  as	  expected.	  
a) 
b) 
Figure	   4.10	   Genera0on	   of	  
the	   3R7R-­‐DsRed	   construct.	  
a)	   Overview	   of	   the	   cloning	  
strategy	  used	  to	  reconstruct	  
3R7R.	  b)	  Restric%on	  analysis	  
conﬁrms	   cloning	  of	   3R7R	   in	  
pDSRed	   :	   BglI	   linerises	   the	  
5.4kb	   clone	   and	   BglI/PvuI	  
double	   digest	   generates	  
two	   fragments	   of	   3.1	   and	  
2.3kb	  as	  expected.	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4.3	  Candidate	  upstream	  regulators	  of	  Fgf10	  expression	  	  
One	   of	   the	  main	   objectives	   of	   this	   project	   was	   to	   use	   an	   Fgf10-­‐reporter	   transgenic	  
mouse	   to	   investigate	   whether	   Fgf10	   is,	   like	   Fgf3,	   also	   subject	   to	   control	   by	   RA.	   	   In	  
addition,	   bioinformatic	   analysis	   of	   the	   enhancer	   by	  Ohuchi	   (2006)	   and	   P.Datta	   (Msc	  
Thesis	  2007,	  University	  of	  Sussex)	  had	  also	  revealed	  the	  presence	  of	  binding	  sites	  for	  
other	  putative	  upstream	  regulators	  of	  Fgf10,	  expression	  such	  as	  binding	  sites	   for	  the	  
transcription	   factor	   GATA3.	   In	   particular,	   the	   ‘late’	   3F3R	   enhancer	   contains	   three	  
GATA3	  binding	  sites	  (Figure	  4.2),	  and	  two	  of	  which	  are	  highly	  conserved	  across	  Mouse,	  
Human	   and	   Chick	   species.	   	   This	   was	   of	   particular	   interest	   because	   a	   relationship	  
between	  Gata3	  and	  Fgf10	  had	  already	  been	  suggested	  in	  the	  developing	  inner	  ear.	  	  
	  
Fgf10	  expression	  appeared	  to	  be	  either	  strongly	  downregulated	  or	  not	  upregulated	  in	  
the	  inner	  ear	  in	  Gata3	  mouse	  mutants	  (Lillevali	  et	  al.,	  2006).	  Moreover	  Fgf10	  appeared	  
to	  be	  transactivated	  by	  GATA3	  in	  vitro	  in	  an	  NIH3T3	  fibroblast	  cell	  line	  (Lillevali	  et	  al.,	  
2006).	  However,	  evidence	  for	  direct	  regulatory	  control	  of	  Fgf10	  by	  GATA3	  in	  vivo	  were	  
lacking,	   and	   Gata3	   could	   instead	   exert	   its	   regulatory	   control	   through	   initiating	   a	  
cascade	   of	   gene	   transcription	   prior	   to	   an	   effect	   on	   cis-­‐acting	   regulatory	   regions	   of	  
Fgf10	   through	   unknown	   intermediate(s).	   In	   order	   to	   investigate	   whether	   Gata3	  
represented	  a	  good	  candidate	  for	  a	  direct	  regulator	  of	  Fgf10,	   I	   looked	  to	  analyse	  the	  







4.3.1	   Is	   Gata3	   expressed	   at	   the	   right	   time	   and	   place	   to	   regulate	   Fgf10	  
expression	  in	  the	  inner	  ear?	  
In	   order	   to	   confirm	   that	  Gata3	   and	  Fgf10	   are	   expressed	   in	   overlapping	   areas	   of	   the	  
inner	   ear	   during	   early	   stages	   of	   development,	   comparative	   Fgf10	   and	   Gata3	  
expression	  was	  analysed	  via	  non-­‐radioactive	  in	  situ	  hybridization.	  	  
	  
Generation	  of	  Gata3	  riboprobes	  
Firstly,	  Gata3	  riboprobes	  were	  generated.	  A	  full-­‐length	  Gata3	  cDNA	  including	  3’	  and	  5’	  
UTRs	   was	   ordered	   from	   (Geneservices).	   	   Bioinformatics	   was	   next	   used	   to	   try	   and	  
determine	  which	  region(s)	  would	  be	  suitable	  to	  make	  riboprobes.	  Blast	  analysis	  of	  the	  
full	   length	  Gata3	  cDNA	  clone	  sequence	  against	  the	  mouse	  genome	  revealed	  a	  500bp	  
central	  region	  highly	  conserved	  amongst	  members	  of	  the	  Gata3	   family	  (Figure	  4.11a)	  
that	   could	   potentially	   hybridise	   against	   other	   GATA	   family	   members.	   	   This	   highly	  
conserved	  region	  is	  located	  between	  1.3kb	  and	  1.7kb	  of	  the	  Gata3	  cDNA.	  
	  
Therefore	  restriction	  enzymes	  were	  carefully	  chosen	  to	  exclude	  this	  conserved	  region	  
from	   the	   region	  used	   for	   generating	   riboprobes.	   Two	  different	  DNA	   fragments	  were	  
chosen	  for	  further	  testing,	  750bp	  in	  5’	  and	  450bp	  in3’	  (Figure	  4.11a).	  Successful	  cloning	  
of	  the	  450bp	  cDNA	  fragment	  in	  pbluescript	  was	  confirmed	  by	  restriction	  analysis	  with	  
SacI/NotI	   double	   digest	   releasing	   the	   450bp	   riboprobe	   (Figure	   4.11b).	   Restriction	  
analysis	   also	   confirmed	   the	   cloning	   of	   the	   750bp	   fragment	   in	   pbluescript	  with	  EcoRI	  




Figure	   4.11	   Genera>on	   and	   trial	   of	   Gata3	   riboprobes.	   a)	   Schema2c	   of	   the	   Gata3	   cDNA	  	  
highligh2ng	   a	   central	   region	   highly	   conserved	   among	   Gata3	   members.	   Two	   cDNA	   fragments	  
excluding	  this	  region	  of	  homology	  were	  selected	  for	  subcloning	  in	  SK:	  750bp	  in	  5’	  and	  450bp	  in	  
3’.	  b)	  Restric2on	  analysis	  conﬁrms	  cloning	  of	  the	  3’	  450bp	  fragment,	  with	  the	  genera2on	  of	  two	  
fragments	   of	   3kb	   and	   450bp.	   c)	   Restric2on	   analysis	   conﬁrm	   cloning	   of	   the	   5’	   750bp	   cDNA	  
fragment,	   with	   EcoRI	   linearising	   the	   3.7kb	   fragment	   and	   EcoRI/BamHI	   releasing	   the	   750bp	  
riboprobe.	   d)	   In	   situ	  hybridiza2on	  of	  wholemount	   embryos	   at	   9.0dpc	  with	  Gata3	   sens	   control	  
probes	   (A)	   or	   an2sens	   riboprobes	   (B,C)	  Gata3	   expression	   in	   the	   o2c	   epithelium	   is	   prominent	  
dorsally	  and	  extends	  posteriorly,	  anteriorly	  and	  laterally.	  A	  dorsal	  view	  of	  the	  embryos	  shows	  the	  
strong	  dorsal	  expression	  in	  the	  o2c	  cup.	  Scale	  bar	  =	  500μm	  
 Gata3 cDNA clone 









The	  450bp	  3’riboprobe	  was	   first	   tested	   in	  mice	  wholemount	   in	   situ.	   Both	   sense	   and	  
antisense	   probes	   were	   prepared	   and	   hybridized	   against	   9-­‐9.5dpc	   embryos.	   Gata3	  
expression	   was	   not	   detected	   in	   any	   of	   the	   embryo	   analysed	   (data	   not	   shown).	   The	  
750bp	  5’riboprobe	  was	  also	  tested	  and	  strong	  expression	  in	  the	  developing	  otic	  vesicle	  
was	  evident	   (B,	  C	   in	  Figure	  4.11d),	  with	   the	   sense	  control	  not	  giving	  any	   signal	   (A	   in	  
Figure	  4.11d).	   	   This	   probe	  was	   thus	  used	   to	   investigate	  early	   expression	  of	  Gata3	   in	  
wholemount	  embryos.	  	  
	  
Analysis	  of	  the	  early	  pattern	  of	  Gata3	  expression	  
Gata3	  expression	  is	  first	  visible	  throughout	  the	  anterior	  most	  part	  of	  the	  otic	  placode	  
at	  8.75-­‐9dpc	  (Figure	  4.12A);	  and	  continues	  to	  be	  expressed	  here	  later	  as	  placode	  starts	  
invaginating	  to	  form	  the	  otic	  cup	  (Figure	  4.12B).	  Dorsal	  view	  confirms	  the	  lack	  of	  Gata3	  
expression	  in	  the	  latero-­‐medial	  wall	  of	  the	  otic	  vesicle	  (Figure	  4.12C).	  Gata3	  expression	  
can	  also	  be	   seen	   throughout	   the	  otic	  epithelium	  as	  otic	   cup	   closes	  but	  expression	   is	  
now	  considerably	  weaker	  in	  the	  ventral	  wall	  (Figure	  4.12D).	  Gata3	  expression	  was	  also	  
detected	   in	   the	   developing	   vestibulo-­‐acoustic	   and	   trigeminal	   ganglion	   at	   9.5dpc	  
(arrows,	   Figure	   4.12E)	   and	   10.5dpc	   (Figure	   12F).	   These	   results	   compared	   favourably	  
with	   the	  pattern	  of	  GATA3	  expression	  previously	   reported	   in	   the	   inner	  ear	   (Lawoko-­‐





Figure	  4.12	  Early	  paAern	  of	  Gata3	  expression	  in	  the	  developing	  inner	  ear.	  Gata3	  expression	  is	  
visible	  throughout	  the	  o2c	  placode	  at	  8.75dpc	  (A).	  As	  the	  placode	  starts	  to	  invaginate,	  expression	  
is	  upregulated	  (B).	  Dorsal	  views	  of	  the	  o2c	  cup	  conﬁrms	  the	  pa_ern	  of	  expression	  noted	  in	  Figure	  
4.8D,	  with	  a	  lack	  of	  expression	  in	  the	  lateral	  wall	  (C).	  Strong	  Gata3	  expression	  in	  the	  developing	  
inner	  ear	  with	  the	  excep2on	  of	  the	  latero-­‐medial	  domain	  is	  also	  seen	  as	  the	  o2c	  is	  almost	  closed	  
(D).	   Gata3	   is	   s2ll	   expressed	   throughout	   the	   o2c	   vesicle	   at	   9.5dpc	   (E).	   At	   10.5dpc	   Gata3	  
expression	  appears	  to	  be	  restricted	  to	  the	  anterior	  o2c	  epithelium	  and	  developing	  ganglion	  (F).	  
Coronal	  sec2ons	  of	  a	  wholemount	  embryo	  hybridized	  at	  9.5dpc	  conﬁrm	  expression	  throughout	  
the	   o2c	   epithelium.	   Scale	   bar	   =	   500μm.	   This	   ﬁgure	   also	   appears	   in	   (Economou	   et	   al.,	   2013).	  





Comparison	  of	  Fgf10	  and	  Gata3	  pattern	  of	  expression	  
At	  the	  time	  of	  Fgf10	  onset	  of	  expression,	  Gata3	   is	  already	  expressed	  throughout	  the	  
otic	   placode	   and	   overlaps	   with	   Fgf10	   in	   the	   anterior	   region	   of	   the	   otic	   placode	  
(compare	  Figure	  4.1A	  and	  4.12A).	  As	  the	  otic	  cup	  starts	  to	  invaginate,	  both	  Gata3	  and	  
Fgf10	  are	  upregulated	  in	  the	  anterior	  otic	  epithelium	  (compare	  Figure	  4.1B	  and	  4.12B),	  
Both	  Gata3	  and	  Fgf10	  are	  preferentially	  expressed	  in	  the	  antero-­‐medial	  wall	  of	  the	  otic	  
vesicle	  (compare	  Fig	  4.1F	  and	  4.12D)	  with	  weaker	  expression	  in	  the	  lateral	  domain.	  At	  
10dpc,	   Fgf10	   and	  Gata3	   are	   both	   expressed	   in	   the	   anterior	   wall	   of	   the	   developing	  
inner	  ear	  as	  well	   as	   in	   the	   trigeminal	  and	  vestibulo-­‐acoustic	  ganglia	   (compare	  Figure	  
4.1E)	  and	  4.12E).	  Thus,	  Gata3	  expression	  overlaps	  Fgf10	  expression	  throughout	  early	  
inner	  ear	  development.	  	  	  	  
	  
4.3.2	   Are	  members	   of	   the	   Neurogenin	   pathway	   expressed	   at	   the	   right	  
time	  and	  place	  to	  regulate	  Fgf10	  expression	  in	  the	  inner	  ear?	  
I	   was	   also	   interested	   to	   identify	   whether	   there	   were	   additional	   putative	   Fgf10	  
upstream	  regulators	  in	  addition	  to	  Gata3.	  Therefore	  an	  updated	  in	  silico	  analysis	  of	  the	  
10kb	   region	   upstream	   of	   Fgf10	   was	   performed	   using	   the	   Genomatix	   software	  
(www.genomatix.de)	  using	  the	  updated	  databases	   (2010);	  and	  using	  MatInspector	  to	  
identify	  putative	  transcription	  factor	  binding	  sites.	  This	  analysis	  revealed	  the	  presence	  
of	   a	   cluster	   of	   binding	   sites	   for	   members	   of	   the	   Neurogenin	   pathway	   (NEUROD1,	  
NSCL1	  and	  NGN1)	  close	  to	  the	  endogenous	  Fgf10	  promoter,	  with	  some	  of	  these	  sites	  




Figure	   4.13	   Presence	   of	   conserved	   puta>ve	   binding	   sites	   for	   neurogenic	   factors	  
upstream	   Fgf10.	   Bioinforma2c	   analysis	   of	   the	   region	   upstream	   Fgf10	   revealed	   a	  
cluster	  of	  binding	  sites	  for	  member	  of	  the	  Neurogenin	  pathway	  (indicated	  as	  green	  
dots	   on	   the	   ﬁgure).	   Alignment	   with	   the	   upstream	   regions	   of	   human	   and	   chicken	  
Fgf10	  reveals	  that	  some	  of	  these	  sites	  are	  conserved.	  
Figure	  4.14	  Compara>ve	  analysis	  of	  NeuroD	  and	  Fgf10	  expression	  in	  wholemont	  in	  
situ	  mouse	  embryo	  at	  9.5	  and	  10.5dpc.	  NeuroD	  is	  stronlgy	  expressed	  in	  the	  antero-­‐
ventral	   wall	   of	   the	   o2c	   vesicle	   and	   the	   forming	   ves2bulo-­‐acous2c	   (gVIII)	   and	  
trigeminal	   (gIII)	   ganglia	   at	   9.5dpc	   (A).	   At	   this	   stage,	   Fgf10	   is	   also	   expressed	   in	   the	  
anterior	  wall	  of	  the	  o2c	  vesicle,	  as	  well	  as	  in	  developing	  gVIII	   	  and	  trigeminal	  ganglia	  
(arrows,	  B).	  This	  pa_ern	  of	  expression	  is	  conserved	  at	  10.5dpc.	  Scale	  bar	  =	  500μm	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Clustering	   of	   these	   sites,	   together	   with	   expression	   of	   Fgf10	   in	   inner	   ear	   neurons	  
(Fritzsch	   et	   al.,	   2010)	   suggest	   Fgf10	   might	   be	   a	   direct	   downstream	   target	   of	   the	  
Neurogenin	   pathway.	   In	   order	   to	   confirm	   that	  members	  of	   the	  Neurogenin	   pathway	  
and	  Fgf10	  are	  expressed	  in	  overlapping	  areas	  of	  the	  developing	  inner	  ear,	  one	  member	  
of	  this	  pathway,	  NeuroD	  was	  chosen	  for	  comparative	  in	  situ	  analysis	  with	  Fgf10.	  	  
	  
Comparative	  analysis	  of	  NeuroD	  and	  Fgf10	  expression	  
Previously	  I	  had	  isolated	  and	  cloned	  a	  500bp	  NeuroD	  cDNA	  fragment	  and	  shown	  that	  
probes	   synthesised	   from	   this	   fragment	   could	   successfully	  detect	   the	  early	  pattern	  of	  
NeuroD	  expression	  in	  mice	  at	  9.5dpc	  (S.	  Cadot,	  Msc	  Report	  2008,	  University	  of	  Sussex).	  
Here	  wholemount	  in	  situ	  hybridization	  was	  carried	  out	  using	  this	  NeuroD	  riboprobe	  at	  
9.5dpc	  and	  10.5dpc.	  At	  9.5dpc,	  NeuroD	  is	  strongly	  expressed	  in	  the	  antero-­‐ventral	  wall	  
of	  the	  otic	  vesicle	  as	  well	  as	  in	  the	  delaminating	  neuroblasts	  populating	  the	  vestibulo-­‐
acoustic	   ganglion,	   as	   well	   as	   the	   trigeminal	   ganglion	   (Figure	   4.14A).	   Fgf10	   is	   also	  
express	  in	  the	  anterior	  wall	  of	  the	  otic	  vesicle	  and	  in	  the	  developing	  vestibulo-­‐acoustic	  
and	   trigeminal	   ganglia	   (Figure	   4.14B).	   This	   pattern	   of	   expression	   was	   conserved	   at	  
10.5dpc	  both	  for	  NeuroD	  (Figure	  4.14C)	  and	  Fgf10	  (Figure	  4.14D).	  Thus	  at	  these	  early	  
stages	   of	   inner	   ear	   development,	  NeuroD	   is	   expressed	   in	   the	   right	   area	   to	   act	   as	   a	  








4.4	  Reporter	   constructs	   to	   investigate	  Fgf10	   regulation	  by	   the	  
Neurogenin	  pathway	  	  
The	  7F7R	  enhancer	  cloned	  above	  (section	  4.2.1)	  to	  reconstruct	  the	  “full”	  Fgf10	   inner	  
ear	  domain	  excludes	  a	  1.1kb	  region	  proximal	  to	  the	  endogenous	  promoter	  (Figure	  4.2).	  
The	  clusters	  of	  neurogenic	  binding	  sites	  identified	  above	  are	  localized	  within	  this	  1.1kb	  
region.	   	  Thus,	   in	  order	   to	   test	   the	   regulatory	  activity	  of	   these	  sites	  and	   the	  potential	  
role	  of	  the	  Neurogenin	  pathway	  in	  controlling	  Fgf10	  expression,	  additional	  enhancer-­‐
reporter	  constructs	  were	  generated.	  	  
	  
Neuro2.5	  construct	  
Firstly,	   a	   2.5kb	   enhancer	   fragment	   that	   includes	   all	   the	   putative	   binding	   sites	   for	  
member	  of	  the	  Neurogenin	  family	  was	  cloned	  (Figure	  4.15).	  	  
	  
Figure	  4.15	  The	  Neuro2,5-­‐DsRed	   reporter	   construct.	  The	  Neuro2,5	  enhancer	   fragment	   is	   indicated	   in	  
grey.	  Above	  it,	  the	  7kb	  upstream	  Fgf10	  are	  represented,	  along	  with	  putative	  binding	  sites	  for	  GATA3	  (in	  
red),	   NEUROD/NSCL1/NGN1	   (in	   green),	   and	   RA	   (in	   blue).	   Enhancer	   fragments	   previously	   tested	   by	  
Ohuchi	  (2005)	  are	  indicated	  with	  asterisks	  (construct	  F	  and	  3-­‐1).	  Dark	  boxes	  a,	  b,	  c	  and	  d	  are	  conserved	  
elements,	  with	  these	  4	  regions	  being	  highly	  homologous	  in	  mouse,	  chick	  and	  human.	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Initial	  and	  multiple	  attempts	  to	  amplify	  a	  2.5kb	  fragment	  from	  mouse	  genomic	  DNA,	  a	  
fragment	   overlapping	   the	   7F7R	   enhancer,	   containing	   all	   the	   putative	   neurogenic	  
binding	   sites,	   and	   extending	   just	   in	   front	   of	   the	   promoter,	   were	   unsuccessful.	  
Sequence	  analysis	  of	  this	  region	  revealed	  a	  high	  GC	  content	  of	  this	  region	  that	  might	  
explain	  a	  failure	  to	  amplify	  in	  such	  a	  complex	  template	  (genomic	  DNA).	  Thus	  instead	  an	  
Fgf10	   BAC	   clone	   was	   therefore	   ordered	   (Geneservices)	   in	   order	   to	   provide	   a	   more	  
specific	   template	   for	   PCR	   amplification.	   Using	   a	   high-­‐fidelity	   DNA	   polymerase	   and	   a	  
buffer	  special	  for	  region	  riche	  in	  GC,	  this	  template	  permitted	  amplification	  of	  a	  2.9kb	  
fragment	  (Figure	  4.16a).	  This	  Neuro2.5	  fragment	  amplified	  by	  PCR	  happened	  to	  have	  
naturally	   occurring	   restriction	   sites	   at	   both	   ends:	   EcoRI	   in	   5’	   and	   SacI	   in	   3’	   that	  
permitted	  directional	  cloning	  in	  SK	  (Figure	  4.16a).	  Successful	  cloning	  was	  confirmed	  by	  
restriction	   analysis	   (Figure	   4.16b).	   AflII	   linearised	   the	   5.5kb	   Neuro2.5-­‐SK	   clone	   by	  
cutting	  at	  a	  single	  site	  within	  the	  Fgf10	  enhancer	  fragment.	  An	  AflII/SacI	  double	  digest	  
cuts	   in	  both	   the	   insert	  and	   the	  pBluescript	  vector,	  generating	   two	  DNA	  fragments	  of	  
3.7kb	  and	  1.8kb	  (Figure	  4.16b).	  	  
	  
Neuro2.5	   was	   then	   sub-­‐cloned	   in	   reverse	   orientation	   in	   pDsRed	   as	   an	   EcoRI-­‐SacI	  
fragment	  (Figure	  4.16d).	  Cloning	  was	  confirmed	  by	  restriction	  analysis	  with	  EcoRI,	  that	  
linearizes	   the	   6.7kb	   construct,	   and	  AflII	   that	   generates	   two	   fragments	   of	   4.9kb	   and	  
1.8kb	  by	   cutting	  both	   in	  Neuro2.5	  and	   in	  pDsRed	   (Figure	  4.16c).	  Reverse	  orientation	  
was	  chosen	  because	  this	  fragments	  lies	  really	  close	  to	  the	  promoter	  and	  could	  possibly	  
contain	  part	  of	  the	  Fgf10	  promoter,	  which	  could	  drive	  reporter	  gene	  expression	  in	  the	  
absence	  of	  suitable	  enhancer	  thus	  compromising	  the	  regulatory	  analysis	  of	  Fgf10.	  
	  
a) 
Figure	   4.16	   Genera0on	   of	   a	   Neuro2.5-­‐DsRed	   reporter	   construct.	   a)	   Overview	   of	   the	   cloning	  
strategy	  used.	  Neuro2.5	  was	  ampliﬁed	  by	  high-­‐ﬁdelity	  PCR	  with	  the	  primers	  and	  PCR	  condi%ons	  
as	  indicated	  in	  sec%on	  2.7.2.	  Neuro2.5	  naturally	  contained	  an	  EcoRI	  site	  in	  5’	  and	  SacI	  site	  in	  3’	  
that	  were	  used	  for	  cloning	  in	  SK.	  b)	  Restric%on	  analysis	  	  conﬁrms	  cloning	  of	  Neuro2.5	  in	  SK,	  with	  
AﬂII	   that	   generates	   one	   5.5kb	   fragment	   and	   AﬂII/SacI	   double	   digest	   that	   generates	   two	  
fragments	  of	  3.7kb	  and	  1.8kb.	  c)	  Neuro2.5	  was	  then	  sub-­‐cloned	  in	  reverse	  orienta%on	  in	  pDsRed	  
and	   cloning	   conﬁrmed	   by	   restric%on	   analysis	   with	   EcoRI	   that	   linearises	   the	   construct	   and	  
generate	   a	   fragment	   of	   	   6.7kb;	   and	   AﬂII	   that	   generates	   two	   fragment	   of	   4.9	   and	   1.8kb.	   d)	  











In	  order	  to	  determine	  whether	  the	  cluster	  of	  neurogenic	  binding	  sites	  on	  its	  own	  could	  
drive	  Fgf10	  expression,	  a	  second	  fragment	  (Neuro1.1),	  which	  contains	  only	  the	  cluster	  
of	   neurogenic	   binding	   sites	   close	   to	   the	   promoter,	   was	   cloned	   (Figure	   4.17).	   As	   for	  
Neuro2.5,	  Neuro1.1	  was	  first	  amplified	  by	  PCR	  using	  again	  a	  Fgf10	  Bac	  as	  a	  template.	  
Since	  the	  Phusion	  High-­‐fidelity	  polymerase	  used	  for	  amplification	  generates	  blunt-­‐end	  
and	   the	   Neuro1.1	   PCR	   fragment	   contains	   a	   SacI	   restriction	   site	   in	   3’	   (Figure	   4.18a),	  
Neuro1.1	   could	   then	   be	   cloned	   directionally	   in	   pSK.	   Restriction	   analysis	   confirmed	  
cloning,	  with	  SmaI	   that	   linearizes	  the	  4kb	  fragment	  and	  SacI/HindIII	   that	  releases	  the	  
1.1kb	  enhancer	  (Figure	  4.18b).	  
	  
Figure	  4.17	  The	  Neuro1,1-­‐DsRed	  reporter	  construct.	  The	  Neuro1,1	  enhance	  is	  indicated	  in	  grey.	  Above	  
it	   the	   7kb	   upstream	   Fgf10	   are	   represented,	   along	   with	   putative	   binding	   sites	   for	   GATA3	   (in	   red),	  
NEUROD/NSCL1/NGN1	  (in	  green),	  and	  retinoic	  acid	  (in	  blue).	  Enhancer	   fragments	  previously	  tested	  by	  
Ohuchi	  (2005)	  are	  indicated	  with	  asterisks	  (construct	  F	  and	  3-­‐1).	  Dark	  boxes	  a,	  b,	  c	  and	  d	  are	  conserved	  
elements,	  with	  these	  4	  regions	  being	  highly	  homologous	  in	  mouse,	  chick	  and	  human.	  
	  
a) 
Figure	   4.18	   Genera0on	   of	   a	   Neuro1.1-­‐DsRed	   reporter	   construct.	   a)	   Overview	   of	   the	   cloning	  
strategy	   used.	   Neuro1.1	   was	   ampliﬁed	   by	   high-­‐ﬁdelity	   PCR	   with	   Phusion.	   Phusion	   generates	  
blunt	  end	  and	  thus	  the	  1.1kb	  fragment	  was	  cloned	  as	  a	  SacI/blunt	  fragment	  into	  SK	  digested	  with	  
SacI	  and	  EcoRV.	  b)	  Cloning	  was	  conﬁrmed	  by	   restric%on	  analysis,	  with	  SmaI	   that	   linearises	   the	  
4kb	  Neuro1.1-­‐SK	  clone	  and	  SacI/HindIII	  double	  digest	  that	  releases	  the	  1.1kb	  neuroenhancer.	  c)	  
Neuro1.1	  was	   then	   subcloned	   in	   pDsRed	   in	   reverse	   orienta%on	   as	   a	   SacI-­‐HincII	   fragment	   and	  
cloning	   conﬁrmed	   by	   restric%on	   analysis	   with	   both	   SmaI	   digest	   and	   SacI/SacII	   digest,	   both	  





Figure	  4.18	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Neuro1.1	   was	   then	   subcloned	   in	   pDsRed	   in	   reverse	   orientation	   as	   a	   SacI-­‐HincII	  
fragment	   (Figure	   4.18d)	   and	   cloning	   confirmed	   by	   restriction	   analysis.	   SmaI	   and	  
SacI/SacII	  double	  digest	  both	  resulted	  in	  the	  generation	  of	  two	  fragments	  of	  4.2kb	  and	  
1.1kb	  (Figure	  4.18c),	  as	  expected	  from	  the	  clone	  restriction	  map	  (Figure	  4.18d)	  
	  
3F-­‐Neuro	  construct	  
The	  discovery	  of	  potential	  Fgf10	  regulatory	  region	  not	  included	  in	  the	  7F7R	  enhancer	  
also	   prompted	   a	   new	   detailed	   comparison	   with	   the	   full	   Fgf10	   enhancer	   previously	  
delimited	   by	   Ohuchi	   et	   al.	   (2005).	   This	   revealed	   that	   two	   out	   of	   four	   conserved	  
elements	   upstream	   Fgf10	   were	   not	   included	   in	   7F7R:	   elements	   c	   and	   d	   are	   lacking	  
(Figure	   4.2).	   Conserved	   elements	   b,	   c	   and	   d	   are	   thought	   to	   be	   involved	   in	   Fgf10	  
regulation	   in	   the	   developing	   limb	   (Sasaki	   et	   al.,	   2002),	   and	   thus	   are	   less	   likely	   to	  
contain	   ear	   regulatory	   elements	   if	   we	   assume	   that	   regulatory	  modules	   are	   discrete	  
entities	   that	   do	   not	   overlaps	   (Davidson,	   2006).	   However,	   these	   results	   were	  mostly	  
based	  on	  transient	  mouse	  embryos,	  that	  is	  to	  say	  embryos	  resulting	  from	  injected	  eggs	  
that	   are	   harvested	   at	   specific	   developmental	   stage	   following	   implantation	   in	   a	  
pseudopregnant	  mother.	  This	  does	  not	  allow	  an	  analysis	  as	  detailed	  as	  with	  a	  stable	  
transgenic	   line,	   where	   the	   embryos	   are	   instead	   brought	   to	   term	   and	   then	   used	   to	  
generate	   as	  many	   litters	   as	   necessary	   for	   a	   full	   analysis	   of	   the	   transgene	   pattern	   in	  
several	   embryos	   for	   each	   founder.	   Furthermore,	   the	   position	   of	   these	   conserved	  
elements	  suggests	  3F-­‐Neuro	  rather	  than	  7F7R	  contains	  all	  the	  elements	  to	  recapitulate	  
Fgf10	   expression	   (Figure	   4.19).	   The	   generation	   of	  Fgf10-­‐reporter	  mouse	   line	   able	   to	  
recapitulate	  Fgf10	  pattern	  of	  expression	  in	  all	  endogenous	  areas	  being	  one	  of	  the	  aims	  
of	  this	  project,	  3F-­‐Neuro	  was	  cloned.	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Figure	  4.19	  The	  3F-­‐Neuro-­‐DsRed	  reporter	  construct.	  The	  3F-­‐Neuro	  enhancer	  is	  indicated	  in	  grey.	  Above	  
it	   the	   7kb	   upstream	   Fgf10	   are	   represented,	   along	   with	   putative	   binding	   sites	   for	   GATA3	   (in	   red),	  
NEUROD/NSCL1/NGN1	  (in	  green),	  and	  retinoic	  acid	  (in	  blue).	  Enhancer	   fragments	  previously	  tested	  by	  
Ohuchi	  (2005)	  are	  indicated	  with	  asterisks	  (construct	  F	  and	  3-­‐1).	  Dark	  boxes	  a,	  b,	  c	  and	  d	  are	  conserved	  
elements,	  with	  these	  4	  regions	  being	  highly	  homologous	  in	  mouse,	  chick	  and	  human.	  
	  
In	  order	  to	  generate	  a	  3F-­‐Neuro-­‐DsRed	  construct;	  3F7R	  and	  Neuro2.5	  were	  first	  ligated	  
together.	  Briefly,	  3F7R	  and	  Neuro2.5	  overlaps	  (Figure	  4.2)	  and	  a	  single	  AflII	  restriction	  
site	   is	   located	   in	   the	   overlapping	   region	   between	   the	   two	   fragments	   (Figure	   4.20a)	  
Neuro2.5	  was	   digested	  with	  AfllI	   and	  SacI	   and	   cloned	   into	   a	   3F7R-­‐SK	   clone	  digested	  
with	   the	   same	   enzyme,	   thus	   recreating	   the	   full	   length	   3F-­‐neuro	   (Figure	   4.20a).	  
Restriction	  analysis	  confirmed	  the	  cloning	  had	  been	  successful,	  with	  EcoRI	  giving	  rise	  to	  
two	  DNA	  fragments	  of	  5.4kb	  and	  1.2kb	  and	  EcoRI/SacI	  to	  three	  fragments	  of	  3kb,	  2.5kb	  
and	   1.2kb	   (Figure	   4.20b).	   3F-­‐Neuro	   was	   then	   subcloned	   into	   pDsRed	   in	   reverse	  
orientation	   as	   a	   SacI-­‐SpeI	   fragment	   (Figure	   4.20d).	   Cloning	   was	   confirmed	   by	  
restriction	  analysis	  with	  BglI	  that	  linearizes	  the	  7.9kb	  clone	  and	  BglI/PvuI	  double	  digest	  
that	  generates	  two	  fragments	  of	  4.3kb	  and	  3.6kb	  (Figure	  4.20c)	  
	  
a) 
Figure	   4.20	   Genera0on	   of	   a	   3F-­‐Neuro-­‐DsRed	   reporter	   construct.	   a)	   Overview	   of	   the	   cloning	  
strategy	   used.	   3F-­‐neuro	   was	   reconstructed	   by	   direc%onal	   cloning	   of	   Neuro2.5	   as	   a	   AﬂII-­‐SacI	  
fragment	   into	   the	   3F7R-­‐SK	   clone.	   b)	   Restric%on	   analysis	   was	   performed	   using	   EcoRI	   that	  
generates	   two	   fragments	  of	  5.4kb	  and	  1.2kb	  and	  EcoRI/SalI	   that	  generates	   three	   fragments	  of	  
3kb,	  2.5kb	  and	  1.2kb.	  c)	  3F-­‐neuro	  was	  then	  subcloned	  in	  reverse	  orienta%on	  in	  pDsRed	  as	  a	  SacI-­‐
SpeI	   fragment.	  Restric%on	  analysis	   conﬁrmed	   cloning	  with	  BglII	   that	   linearizes	   the	  7.9kb	   clone	  









Eventually,	  a	  construct	  including	  both	  7F7R	  and	  the	  potential	  neuroenhancer,	  and	  and	  
hereafter	  7F-­‐Neuro	  (Figure	  4.21)	  was	  also	  generated.	  7F-­‐Neuro	  was	  reconstructed	  by	  
directional	  cloning	  of	  7F7R	  in	  the	  Neuro2.5-­‐DsRed	  clone	  as	  a	  SpeI-­‐EcoRI	  digest	  (Figure	  
4.22a).	  Restriction	  analysis	  confirms	  cloning	  with	  AflII	  generating	  two	  fragments	  of	  6kb	  
and	  4.9kb,	  BglII	   two	  fragments	  of	  5-­‐5.kb	  and	  HindIII	  generating	  one	  10.9kb	  fragment	  




Figure	  4.21	  The	  7F-­‐Neuro-­‐DsRed	  reporter	  construct.	  The	  7F-­‐Neuro	  enhancer	  is	  indicated	  in	  grey.	  Above	  
it	   the	   7kb	   upstream	   Fgf10	   are	   represented,	   along	   with	   putative	   binding	   sites	   for	   GATA3	   (in	   red),	  
NEUROD/NSCL1/NGN1	  (in	  green),	  and	  retinoic	  acid	  (in	  blue).	  Enhancer	   fragments	  previously	  tested	  by	  
Ohuchi	  (2005)	  are	  indicated	  with	  asterisks	  (construct	  F	  and	  3-­‐1).	  Dark	  boxes	  a,	  b,	  c	  and	  d	  are	  conserved	  






Figure	   4.22	   Genera0on	   of	   7F-­‐Neuro-­‐DsRed	   reporter	   construct.	   a)	   Overview	   of	   the	   cloning	  
strategy	  used.	  7F-­‐neuro	  was	  reconstructed	  by	  direc%onal	  cloning	  of	  7F7R	  in	  the	  Neuro2.5-­‐DsRed	  
clone	   as	   a	   SpeI-­‐EcoRI	   digest.	   Restric%on	   analysis	   conﬁrm	   cloning	   with	   AﬂII	   genera%ng	   two	  
fragments	  of	  6kb	  and	  4.9kb,	  BglII	  two	  fragment	  of	  5-­‐5.9kb	  (appears	  as	  a	  single	  band	  on	  gel)	  and	  
HindIII	  linearises	  the	  construct	  genera%ng	  one	  10.9kb	  fragment.	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4.5	  Generation	  and	  analysis	  of	  transgenic	  mouse	  lines	  
In	   vivo	   analysis	   of	   Fgf10	   regulation	   in	   the	   mouse	   was	   started	   with	   the	   injection	   of	  
7F7R-­‐DsRed,	   the	   large	   enhancer	   fragment	   expected	   to	   recapitulate	   the	   full	   Fgf10	  
endogenous	  inner	  ear	  pattern.	  Two	  independent	  transgenic	  lines	  containing	  the	  7F7R-­‐
DsRed	   constructs	   were	   generated.	   	   Mice	   that	   had	   integrated	   the	   transgene	   were	  
identified	  by	  PCR	  (Figure	  4.23a)	  and	  selected	  for	  further	  breeding.	  For	  instance,	  one	  of	  
the	  injection	  sessions	  leads	  to	  the	  generation	  of	  a	  female	  founder	  (2084;	  Figure	  4.23b).	  	  
This	  founder	  was	  then	  crossed	  with	  wild-­‐type	  males	  to	  increase	  the	  colony.	   	  The	  first	  
litter	  consisted	  of	  6	  pups,	  and	  included	  1	  male	  and	  2	  female	  carrying	  the	  7F7R-­‐DsRed	  
transgene	  (Figure	  4.23b).	  This	  2nd	  generation	  of	  transgenics	  were	  crossed	  either	  with	  
wild-­‐type	  mice	  or	  with	  other	  7F7R	  transgenics,	  and	  embryos	  were	  harvested	  at	  9.5dpc.	  	  
PCR	   analysis	   for	   detection	   of	   the	   transgene	   in	   embryos	  was	   carried	   out	   on	   yolk	   sac	  
DNA	  to	   identify	  embryos	  carrying	   the	   transgene,	  and	  embryos	  positive	   for	   the	  7F7R-­‐
DsRed	   transgene	  were	  analysed	   for	   fluorescence.	  However	  no	   fluorescence	  could	  be	  
detected	  in	  any	  of	  the	  embryos	  analysed	  (n=6;	  data	  not	  shown).	  	  
	  
In	  the	  experiments	  described	  by	  Ohuchi	  et	  al.	   (2005),	   the	  smaller	  enhancer	   (~800bp)	  
only	  drove	  expression	  of	  Fgf10	  from	  11.5dpc	  onwards.	  In	  order	  to	  determine	  if	  Fgf10	  
expression	  was	  maybe	  just	  delayed	  with	  the	  7F7R	  transgene,	  with	  essential	  elements	  
missing	  for	  earlier	  expression,	  embryos	  were	  also	  analysed	  at	  later	  stages,	  at	  10.5dpc	  
and	  11.5dpc.	   	  Unfortunately,	  here	  again,	  Dsred	   fluorescence	  was	  not	  detected	  in	  any	  




















































































































































































This	  lack	  of	  fluorescence	  from	  the	  reporter	  could	  be	  explained	  in	  several	  ways:	  
1) The	  reporter	  gene	  may	  not	  be	  expressed.	  This	  could	  be	  due	  to	  a	  technical	  issue	  in	  
generating	   the	   construct,	   such	   as	   inadvertently	   picking	   up	   a	   mutation	   in	   the	  
promoter,	  or	  in	  crucial	  binding	  sites	  in	  the	  enhancer	  that	  would	  prevent	  or	  at	  least	  
drastically	  reduce	  reporter	  gene	  expression	  
2) A	  mutation	   could	   have	   been	   introduced	   in	   the	   reporter	   gene	   itself	   leading	   to	   a	  
non-­‐functional	  DSRED	  protein	  and	  thus	  no	  fluorescence	  	  
3) The	  reporter	   transgene	  may	  have	   integrated	   into	   the	  genome	   in	  a	   region	   that	   is	  
quiescent	  and	  refractory	  to	  expression.	  	  
4) The	   level	   of	   fluorescence	  may	   be	   too	   low	   and	   not	   be	   suitable	   for	   direct	   in	   vivo	  
imaging	  at	  this	  stage	  in	  the	  mouse.	  	  	  Thus	  the	  signal	  may	  need	  to	  be	  amplified	  to	  
be	  visible.	  	  
	  
A	   sample	  of	   the	  purified	  7F7R-­‐DsRed	   construct	   that	   had	  been	  used	   for	   the	   injection	  
was	   sent	   for	   sequencing	   to	   check	   the	   sequence	   integrity	   of	   the	   fragment	   used,	   to	  
confirm	   the	   presence	   of	   the	   promoter	   in	   the	   right	   orientation	   and	   the	   absence	   of	  
mutations	  in	  the	  promoter/DsRed	  reporter	  gene.	  	  
	  
Sequence	  data	  from	  different	  reads	  using	  different	  primers	  were	  compared	  not	  only	  to	  
mouse	  genome	  database	  (www.ensembl.org/mus_musculus),	  but	  also	  blasted	  against	  
sequence	   data	   from	   other	   constructs	   generated	   in	   this	   lab	   that	   had	   been	   shown	   to	  
drive	  expression	  in	  vivo.	  For	  instance	  the	  ßglobin	  promoter	  from	  the	  DsRed	  construct	  
was	  found	  to	  be	  perfectly	  aligned	  with	  the	  ßglobin	  sequence	  from	  a	  functional	  ßglobin-­‐
ZsGreen	   transgene.	   DsRed	   coding	   sequence	   was	   also	   perfectly	   aligned	   with	   the	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sequence	   of	   a	   different	   but	   functional	   reporter	   in	   a	   CMV-­‐DsRed	   plasmid.	   Sequence	  
analysis	  confirmed	  the	  ßglobin	  promoter	  was	  in	  the	  correct	  orientation	  and	  free	  from	  
mutations.	  No	  mutations	  were	  detected	  from	  the	  sequence	  expected	  in	  DsRed	  either.	  
The	   part	   of	   the	   enhancer	   sequenced	   corresponding	   to	   7F7R	   did	   not	   reveal	   the	  
presence	  of	  any	  mutations	  either.	  Although	  the	  entire	  5.7kb	  of	  the	  enhancer	  was	  not	  
sequenced,	   it	   is	   unlikely	   that	   even	   a	   few	   spontaneous	  mutations	  would	   totally	   shut	  
down	   enhancer	   activity,	   as	   these	   would	   have	   to	   occur	   inadvertently	   in	   essential	  
binding	  sites,	  and	  that	  DsRed	  expression	  in	  all	  endogenous	  areas	  of	  expression	  in	  vivo	  
would	   have	   to	   be	   affected.	   These	   data	   suggested	   that	   the	   construct	   should	   be	  
functional	  on	  the	  basis	  of	  the	  sequences	  analysed.	  	  
	  
A	   second	   testable	   hypothesis	   was	   that	   the	   transgene	   was	   functional	   and	   DsRed	   is	  
expressed,	  but	  at	  a	  level	  too	  low	  to	  be	  detected	  without	  amplification.	  In	  order	  to	  test	  
this,	   two	   different	   DSRED	   antibodies	   were	   used	   in	   immunolabelling	   experiments.	  
Following	  immunolabelling	  against	  whole	  transgenic	  embryos	  (9.5dpc	  and	  10dpc)	  both	  
wholemount	   and	   flatmounts	   were	   analysed	   using	   fluorescent	   microscopy.	   Again	  
expression	  was	  not	  detected	  (Figure	  4.23c).	  Thus	  in	  the	  absence	  of	  reporter	  detection,	  
none	  of	  the	  two	  lines	  generated	  could	  be	  used	  for	  further	  regulatory	  studies	  of	  Fgf10.	  	  
	  
Another	  hypothesis	   is	   that	  7F7R	  does	  not	  contain	  some	  of	   the	  elements	   requires	   for	  
Fgf10	  expression	  and/or	  contains	  negative	  regulatory	  elements.	  Comparison	  with	  the	  
enhancer	  used	  by	  Ohuchi	   indeed	  revealed	  the	  presence	  of	  additional	  sequences	  in	  5’	  
of	   the	   7F7R	   enhancer.	   These	   sequences	   might	   contain	   binding	   sites	   for	   negative	  
regulators	   of	   Fgf10.	   In	   addition,	   as	   discussed	   in	   the	   previous	   subchapter	   the	   7F7R	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enhancer	   lacks	   2	   conserved	   elements.	   However,	   the	   3F3R	   fragment	   was	   shown	   to	  
drive	  the	  early	  and	   late	  patterns	  of	  expression	  (Economou	  et	  al.,	  2012).	   	  Thus,	  whilst	  
additional	  neural	  domains	   that	  have	  never	  been	   intensively	   studied	   for	   any	  of	   these	  
reporters	  could	  be	  present	  in	  these	  missing	  domains,	  the	  ability	  of	  3F3R	  to	  drive	  early	  
inner	  ear	  expression	  suggests	  that	  7F7R	  transgene	  should	  have	  worked	  and	  this	  will	  be	  
discussed	  later.	  
	  
4.6	   Investigation	   of	  mouse	  Fgf10	   regulation	   in	   the	   developing	  
chicken	  inner	  ear	  
The	  time	  required	  to	  generate	  further	  stable	  lines	  of	  transgenic	  mice	  did	  not	  allow	  for	  
the	  testing	  of	   the	  additional	  Fgf10-­‐reporter	  constructs	  generated	   in	  mice.	   	  Therefore	  
an	  alternative	  animal	  model,	  the	  chicken	  embryo,	  was	  chosen	  to	  assess	  the	  regulatory	  
activity	  of	  the	  mouse	  Fgf10	  enhancer	  constructs.	  The	  chicken	  embryo	  has	  been	  shown	  
to	   be	   a	   really	   useful	   model	   to	   quickly	   identify	   and	   at	   low	   cost,	   mouse	   regulatory	  
regions	   (Timmer	  et	   al.,	   2001).	   In	   addition,	   experiments	   in	   this	   laboratory	  had	   shown	  
that	   3F3R	   could	   drive	   expression	   of	   ZsGreen	   in	   the	   chicken	   inner	   ear	   following	   otic	  
placode	   electroporation	   (A.Economou,	   personal	   communication).	   However,	   the	  
ßglobin	   minimal	   promoter	   used	   in	   the	   mouse	   reporter	   constructs	   unfortunately	  
appeared	   to	   drive	   constitutive	   reporter	   expression	   in	   chick	   i.e.	   in	   the	   absence	   of	  
enhancer	   elements	   (A.	   Economou,	   personal	   communication).	   Therefore	   a	   different	  
reporter	  system	  was	  required	  for	  the	  regulatory	  analysis	  of	  test	  enhancers	  from	  mouse	  




An	  independent	  project	  in	  the	  lab	  had	  led	  to	  the	  generation	  of	  a	  new	  ßglobin	  minimal	  
promoter,	   where	   sequences	   driving	   constitutive	   expression	   were	   removed	   but	   still	  
able	   to	   drive	   reporter	   expression	   in	   presence	   of	   functional	   enhancer	   elements.	   This	  
newly	  engineered	  minimal	  promoter	   is	   termed	   the	  “miniglobin”	  promoter.	   	  This	  was	  
used	  to	  generate	  two	  different	  base	  reporter	  vectors,	  one	  solely	  composed	  of	  the	  new	  
miniglobin	   promoter	   and	   the	   ZsGreen	   reporter	   gene	   (MiniglobinZsGreen,	   see	   Figure	  
4.17a),	   and	  a	   second	  vector	  also	  harbouring	  an	   internal	  CMV-­‐DsRed	   control	   cassette	  
(MiniZsGreen-­‐DsRed,	  see	  Figure	  4.24b).	  This	  dual	  reporter	  vector	  should	  allow	  for	  the	  
detection	  of	  both	  red	  fluorescence	  as	  a	  transfection	  control	  and	  green	  fluorescence	  for	  
testing	  enhancer	  activity	  in	  the	  same	  cells.	  	  This	  is	  different	  from	  a	  co-­‐electroporation	  
system	   where	   experimental	   and	   control	   reporters	   cassettes	   are	   introduced	   via	   two	  
different	  vectors	  and	  there	   is	   thus	  no	  assurance	  that	   the	  cells	  expressing	  the	  control	  
also	   contain	   the	   enhancer-­‐reporter	   vector	   and	   vice	   versa.	   A	   similar	   dual	   construct	  
system	   had	   been	   successfully	   used	   for	   chick	   electroporation	   in	   another	   laboratory	  
(Jung	  et	  al.,	  2009).	  
	  
Regulatory	  analysis	  of	  Fgf10	  using	  the	  dual	  reporter	  system	  
The	  dual	   reporter	   system	  was	   first	   used	   to	   test	   the	   regulatory	   activity	   of	   four	  Fgf10	  
enhancer	   fragments:	   7F7R,	   7F3F-­‐3R7R,	   3F-­‐Neuro	   and	   3F3R	   (Figure	   4.2).	   3F3R	   has	  
already	  been	  shown	  to	  drive	  reporter	  expression	  when	  cloned	  in	  miniglobin-­‐ZsGreen.	  
Therefore,	  it	  was	  used	  as	  a	  positive	  control	  for	  the	  dual	  reporter	  system.	  All	  fragments	  
were	  cloned	  as	  XhoI-­‐EcoRV	  fragments,	  3F3R	  and	  7F7R	  in	  a	  forward	  orientation	  and	  3F-­‐
Neuro	  in	  the	  reverse	  orientation	  since	  it	  might	  contain	  part	  of	  the	  Fgf10	  promoter.	  	  
a) 
b) 
Figure	   4.24	   Miniβglobin-­‐ZsGreen	   and	   MiniZsGreen-­‐DsRed	   reporter	   vectors.	   Map	   of	   the	  
Miniβglobin-­‐ZsGreen	   reporter	   (a)	   and	   MiniZsGreen-­‐DsRed	   dual	   reporter	   are	   (b).	   The	   dual	  
reporter	   consists	   in	   the	   Miniβglobin-­‐ZsGreen	   construct	   cloned	   into	   a	   CMV-­‐DsRed	   control	  
plasmid.	  Clone	  maps	  were	  taken	  from	  Shravani	  disserta%on	  (Msc,	  2011)	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Analysis	   of	   embryos	   electroporated	   with	   the	   7F7R-­‐dual	   reporter	   did	   not	   reveal	   any	  
fluorescence	   for	  DsRed	   or	   ZsGreen	   in	   any	   of	   the	   embryos	   examined	   (n=9,	   data	   not	  
shown).	  With	  other	  constructs,	  CMV-­‐DsRed	  expression	  was	  detected	  in	  3F3R	  (n=8/14;	  
Figure	   4.25B),	   3F-­‐Neuro	   (n=2/4;	   Figure	   4.25C)	   and	   7F3F-­‐3R7R	   (n=3/6;	   Figure	   4.25H)	  
embryos.	   Interestingly,	   there	   was	   apparently	   no	   decrease	   in	   the	   number	   of	   DSRED	  
positives	  cells	  from	  one	  construct	  to	  another	  despite	  their	  increasing	  size:	  3F3R-­‐dual	  is	  
8.3kb,	   3F-­‐Neuro	   is	   9.4kb	   and	   7F3F-­‐3R7R	   is	   11.1kb	   (compare	   Figure	   4.25B,E,H).	  
However,	   despite	   this	   good	   electroporation	   efficiency,	   ZsGreen	   expression	   was	   not	  
seen	  in	  any	  of	  the	  cells	  that	  had	  successfully	  taken	  the	  reporter	  construct,	  with	  all	  the	  
constructs	   tested	   (Figure	   4.25C,F).	   Since	   in	   3F3R-­‐ZsGreen	   mice	   reporter	   gene	  
expression	   is	   restricted	   to	   the	   inner	   ear	   (Economou,	   2012),	   the	   lack	   of	   ZsGreen	  
expression	   in	   chick	   embryos,	   electroporated	   with	   3F3R-­‐dual	   reporter,	   could	   be	  
explained	  by	  the	  CMV-­‐DsRed	  positive	  cells	  being	  all	  outside	  the	  otic	  vesicle	  (as	  seen	  in	  
Figure	   4.25B).	   However,	   the	   lack	   of	   expression	   reported	   with	   the	   larger	   3F-­‐Neuro	  
fragments,	   despite	  CMV-­‐DsRed	   being	  expressed	   in	   the	  anterior	  otic	   vesicle,	   suggests	  
they	  may	  be	  a	  technical	  issue	  with	  the	  minißglobin-­‐ZsGreen	  part	  of	  the	  construct.	  
	  
DNA	  samples	  from	  the	  plasmids	  used	  for	  electroporation	  were	  sent	  for	  sequencing	  to	  
check	  that	  the	  three	  different	  enhancers	  had	  been	  cloned	  successfully	  and	  that	  there	  
wasn’t	  any	  mutation	  in	  the	  ßglobin	  promoter.	  No	  sequence	  anomalies	  were	  detected.	  	  
Perhaps	   the	  use	  of	   a	   strong	  CMV	  promoter	  preferentially	   sequesters	   general	   and/or	  
specific	  transcription	  factors	  and	  cofactors	  and	  thus	  out	  competes	  expression	  from	  the	  
enhancer-­‐reporter	  module	  of	   the	  construct.	  This	  might	   reflect	   the	  close	  proximity	  of	  





















































































































































































































































































































































































































































































































































































































To	   conclude	   the	   dual	   reporter	   system	  did	   not	   seem	   to	   allow	   a	   quick	   analysis	   of	   the	  
Fgf10	   test	   regions,	  and	  would	   require	   further	  experiments	   to	   identify	   the	  underlying	  
problems.	  Unfortunately	   there	  was	   insufficient	   time	   to	   identify	   the	  underlying	   cause	  
for	   these	   reporter	   construct	   inabilities	   to	   drive	   ZsGreen	   expression.	   Interestingly	  
however,	   these	   experiments	   do	   show	   that	   constructs	   up	   to	   11.1kb	   are	   able	   to	  
successfully	  be	  electroporated	  in	  the	  chicken	  embryo.	  This	   is	   larger	  than	  described	  in	  
other	   studies	   that	   reported	   10kb	   as	   being	   the	   upper	   limit	   of	   circular	   plasmid	   length	  
that	  can	  be	  used	  for	  electroporation	  (Uchikawa,	  2008).	  
	  
Regulatory	  analysis	  of	  Fgf10	  using	  co-­‐electroporation	  
Instead,	   a	   co-­‐electroporation	   approach	   was	   next	   attempted.	   	   Fgf10-­‐Mini-­‐ZsGreen	  
reporters	   were	   co-­‐electroporated	   with	   a	   CMV-­‐DsRed	   reporter	   control.	   Co-­‐
electroporations	   were	   performed	   for	   7F7R-­‐MiniZsGreen	   and	   3F3R-­‐MiniZsGreen	   (as	  
positive	   control	   of	   Fgf10	   expression).	   For	   the	   3F3R-­‐MiniZsGreen	   construct,	   co-­‐
electroporations	   appeared	   unsuccessful,	   with	   none	   of	   the	   chick	   embryo	   expressing	  
either	   DsRed	   or	   ZsGreen	   (n=0/8,	   data	   not	   shown).	   For	   7F7R,	   one	   embryo	   was	  
expressing	  weakly	  the	  DsRed	  control	  (n=1/5).	  In	  this	  embryo	  there	  also	  appeared	  to	  be	  
an	   isolated	   cell	   expressing	   ZsGreen	   at	   the	   level	   of	   the	   forebrain	   (data	   not	   shown).	  
Another	   embryo	   not	   positive	   for	  DsRed	   control,	   also	   seemed	   to	   have	   one/few	   cells	  
positives	   for	   ZsGreen	   reporter	   expression,	   and	   moreover	   in	   the	   region	   of	   the	   otic	  
vesicle	   (data	   not	   shown).	   Overall	   the	   number	   of	   cells	   electroporated	  was	   quite	   low	  
compared	   to	   the	   results	   usually	   obtained	   with	   the	   same	   parameters	   in	   the	   lab.	   In	  
addition,	   the	  electroporation	  efficiency	  with	  miniZsGreen	   reporter	   construct	   seemed	  
to	   be	   lower	   than	   when	   using	   the	   large	   dual	   reporter	   construct.	   Eventually,	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electroporations	  were	   also	   repeated	  with	   the	   help	   of	   another	   researcher	   in	   the	   lab	  
(A.Economou),	  who	  electroporated	  the	  constructs	  with	  myself	  carrying	  out	  the	  embryo	  
analysis.	   The	  3F3R-­‐MiniZsGreen,	   3F7R-­‐MiniZsGreen	   and	  7F7R-­‐MiniZsGreen	   constructs	  
were	  all	  co-­‐electroporated	  with	  CMV-­‐DsRed.	  
	  
The	   first	   Fgf10	   enhancer	   fragment	   to	   be	   tested	  was	   3F3R	   (Figure	   4.2).	  Out	   of	   the	   3	  
embryos	   still	   alive	   24	   hours	   after	   electroporation,	   3/7	   survived,	   one	  did	   not	   express	  
either	   DsRed	   or	   ZsGreen	   and	   the	   second	   embryo	   only	   expressed	   DsRed	   (data	   not	  
shown).	   The	   3rd	   embryo	   (Figure	   4.26A,B,C)	   showed	   expression	   of	   the	  DsRed	   control	  
plasmid	  in	  the	  anterior	  part	  of	  the	  otic	  vesicle	  (arrowhead,	  Figure	  4.26B)	  	  as	  well	  as	  in	  a	  
cluster	   of	   cell	   located	   just	   rostrally	   to	   the	   otic	   vesicle.	   A	   few	   cells	   also	   seemed	   to	  
express	   ZsGreen	   within	   this	   rostral	   cluster	   but	   weakly	   (arrowhead,	   Figure	   4.26C,C’).	  
3F3R	  usually	  give	   rise	   to	  a	   stronger	   reporter	  expression,	  where	  ZsGreen	   is	  expressed	  
not	   only	   in	   the	   otic	   vesicle	   but	   also	   throughout	   the	   head	   surface	   ectorderm	  
(A.Economou.	  personal	  communication)	  
	  
The	   second	   enhancer	   fragment	   tested	  was	   3F7R	   (Figure	   4.2).	   Out	   of	   4	   embryos	   still	  
alive	  24	  hours	  after	  electroporation	  (n=4/6),	  three	  embryos	  demonstrated	  expression	  
from	   the	   DsRed	   control	   plasmid	   and	   two	   embryos	   had	   a	   fluorescent	   green	   signal,	  
showing	   the	   enhancer	   is	   able	   to	   drive	   ZsGreen	   reporter	   expression.	   One	   of	   these	  
chicken	   embryos	   showed	   strong	   DsRed	   expression	   in	   the	   otic	   vesicle	   (arrowhead,	  
Figure	  4.26E)	  as	  well	  as	  in	  a	  cluster	  of	  cells	  located	  caudally.	  A	  few	  cells	  could	  also	  be	  
seen	   weakly	   expressing	   ZsGreen	   in	   the	   dorsal	   wall	   of	   the	   otic	   vesicle	   (arrowhead,	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The	  third	  enhancer	  to	  be	  tested	  was	  7F7R	  (Figure	  4.2).	  Out	  of	  6	  embryos	  still	  alive	  24	  
hours	  after	  electroporation	   (n=6/8),	   two	  did	  not	   show	  any	  expression	  and	  4	   showed	  
both	  DsRed	   and	  ZsGreen	   fluorescent	   signals.	  One	  of	   the	  embryos	   strongly	  expressed	  
CMV-­‐DsRed	   in	   the	   hindbrain	   (Figure	   4.26H),	   furthermore	  DsRed	   expression	  was	   also	  
extending	   caudally	   to	   the	   otic	   vesicle	   from	   the	   forebrain	   to	   posterior	   otic	   domains.	  
Expression	   of	   ZsGreen	   was	   also	   strong	   in	   the	   forebrain	   (arrow,	   Figure	   4.26I,I’)	   and	  
there	  was	  a	  small	  patch	  of	  expression	  in	  the	  otic	  vesicle	  (arrowhead,	  Figure	  4.	  26I,I’).	  
	  
These	  results	  showed	  that	  all	  the	  Fgf10	  enhancer	  fragments	  tested	  were	  able	  to	  drive	  
reporter	  expression	   in	  the	  chicken	  otic	  epithelium,	  as	  well	  as	  additional	  ectopic	  cells,	  
with	   the	   7F7R	   region	   apparently	   driving	   stronger	   and	  more	   widespread	   expression.	  	  
However,	  only	  a	  small	  number	  of	  embryos	  were	  examined	  and	  further	  analysis	  would	  
be	   required	   before	   drawing	   any	   conclusions.	   	   Importantly	   these	   experiments	   also	  
demonstrate	  that	  the	  constructs	  I	  generated	  to	  investigate	  the	  regulation	  of	  Fgf10,	  and	  
in	  particular	  7F7R	  are	  functional	  in	  vivo.	  Future	  experiments	  will	  be	  needed	  to	  address	  
why	  they	  do	  not	  work	  in	  the	  mouse.	  	  However	  there	  appear	  to	  be	  species	  differences	  
in	  control	  outside	  the	  inner	  ear,	  including	  the	  regulatory	  input	  of	  Gata3	  (A.Economou,	  
personal	  communication).	  	  Thus,	  this	  cannot	  replace	  the	  use	  of	  transgenic	  mice,	  but	  it	  
can	   be	   use	   to	   test	   constructs	   functionality	   in	   vivo	   and	   maybe,	   in	   conjunction	   with	  







4.7	  Regulation	  of	  Fgf10	  by	  retinoic	  acid	  
Subsequently	   to	   the	   analysis	   of	   my	   series	   of	   Fgf10-­‐reporter	   construct,	   the	   3F3R	  
enhancer	   was	   shown	   to	   contain	   all	   the	   elements	   required	   to	   recapitulate	   the	   full	  
pattern	  of	  Fgf10	  expression	  in	  the	  inner	  ear	  (Economou	  et	  al.,	  2012).	  Thus,	  a	  stable	  line	  
containing	  the	  3F3R	  transgene	  was	  used	  to	  study	  the	  effect	  of	  RA	  on	  Fgf10	   inner	  ear	  
expression.	   	   Frenz	   and	   colleagues	   (Frenz	   et	   al.,	   2010)	   had	   shown	   Fgf3	   and	   Fgf10	  
downregulation	   in	   the	   inner	  ear	   following	  RA	  administration	  at	  8.5dpc	  using	  RT-­‐PCR,	  
but	  these	  results	  lack	  the	  detailed	  cellular	  resolution	  required	  to	  detect	  any	  changes	  in	  
expression	  pattern.	   	   For	  example	   is	   there	  a	  general	  downregulation	  of	  expression	  of	  
Fgf10	  or	   is	  the	  Fgf10	   inner	  ear	  domain	  composed	  of	  RA-­‐dependent	  and	  independent	  
domains	   within	   the	   otic	   vesicle?	   To	   determine	   this,	   an	   in	   vivo	   analysis	   is	   required.	  
Using	   the	  same	  method	  of	   self-­‐ingestion	  of	  RA-­‐laced	  sugar	  pellets	  developed	   for	   the	  
analysis	   of	   Fgf3-­‐regulation	   (section	   3.1)	   and	   the	   3F3R-­‐transgenic	   line,	   a	   preliminary	  
experiment	  was	  performed	  using	  25mg	  of	  RA	  administered	  at	  8.5dpc.	  
	  
In	  half	  of	  the	  embryos	  examined	  (n=2/4),	  the	  pattern	  of	  Fgf10-­‐expression	  was	  similar	  
to	  control	  embryos	  (Figure	  4.27E)	  with	  reporter	  expression	  evident	  throughout	  the	  otic	  
vesicle,	  together	  with	  a	  strong	  patch	  of	  expression	  in	  the	  anterior	  wall	  (Figure	  4.27D).	  
In	   the	  other	   two	  embryos,	   the	  strong	  patch	  of	  Fgf10	   expression	  was	   shifted	  dorsally	  
(Figure	   4.27F,G).	   Interestingly	   these	   two	   embryos	   showed	   brain	   malformation	  
suggesting	   a	   developmental	   delay.	   In	   particular	   one	   of	   the	   embryos	   had	   an	   open	  
neural	  tube	  (Figure	  4.27B),	  a	  phenotype	  characteristic	  of	  embryos	  exposed	  to	  RA	  prior	  
to	  hindbrain	  patterning.	  	  
	  
Figure	   4.27	   Eﬀect	   of	   exogenous	   RA	   administra:on	   on	   Fgf10	   expression	   in	   the	   9.5dpc	   o:c	  
vesicle.	  (A)	  Brigh*ield	  pictures	  of	  control	  embryo.	  (B-­‐D)	  Brigh*ield	  pictures	  of	  embryos	  exposed	  
to	  RA.	  (E-­‐F)	  Enlargements	  of	  the	  oAc	  vesicles	  of	  embryos	  A	  to	  D.	  In	  untreated	  embryos,	  Fgf10	  is	  
expressed	   throughout	   the	   oAc	   vesicle	   with	   a	   stronger	   patch	   of	   expression	   located	   anteriorly	  
(arrowhead,	  E).	  Following	  administraAon	  of	  25mg/kg	  of	  RA	  at	  8.5dpc,	  2	  embryos	  (n=4)	  presented	  
a	   normal	   paMern	   of	   Fgf10	   expression	   (arrowhead,	   H).	   However,	   Fgf10	   was	   strongly	  
downregulated	   in	   the	   two	  other	   embryos,	   as	  well	   as	   shiOed	  dorsally	   (broken	   lines	  delimit	   the	  
new	  area	  of	  	  expression,	  which	  is	  pointed	  out	  with	  an	  arrowhead	  (F,G)).	  Scale	  bar	  500μm.	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This	   suggested	   that	   the	   embryos	  with	   a	   dorsal	   shift	   of	  Fgf10	   expression	  might	   have	  
been	  exposed	  to	  RA	  at	  a	  slightly	  earlier	  stage	  in	  utero	  than	  the	  ones	  with	  an	  unaltered	  
expression.	   This	  might	   suggest	   that	   RA	   only	   affects	   Fgf10	   expression	   if	   embryos	   are	  
exposed	  prior	  to	  hindbrain	  patterning.	  To	  conclude,	  the	  experiments	  here	  suggest	  that	  
Fgf10,	  like	  Fgf3	  are	  under	  the	  regulatory	  control	  of	  RA	  signalling.	  	  Although	  4	  embryos	  
with	   mixed	   phenotypes	   only	   weakly	   support	   this	   conclusion;	   further	   experiments	  
performed	  as	  part	   of	   a	   separate	  project,	   but	  based	  on	  my	  working	  hypothesis,	   later	  
confirmed	  these	  preliminary	  results	  (Ecomomou	  et	  al.,	  2012).	  This	  is	  discussed	  in	  more	  





















In	   this	   report,	   a	  novel,	  non-­‐invasive	  method	  of	   retinoic	  acid	  administration	  via	   sugar	  
pellets	   is	   developed	   and	   shown	   to	   be	   an	   efficient	   and	   reliable	   alternative	   to	   gavage	  
delivery.	   Detailed	   analysis	   of	   Fgf3-­‐lacZ	   embryos	   exposed	   to	   RA	   using	   this	   method	  
shows	  that	   the	  timing	  of	  RA-­‐administration	   is	  critical.	  Administration	  of	  RA	  at	  8.5dpc	  
only	   leads	   to	   a	   dose-­‐dependant	   downregulation	   of	   otic	   Fgf3	   expression,	   whereas	  
administration	  of	  RA	  at	  7.75dpc	   lead	   to	  dowregulation	  of	  Fgf3	   expression	  as	  well	   as	  
lateralization	   of	   Fgf3	   expression	   with	   increasing	   RA	   dose.	   This	   novel	   method	   of	   RA	  
administration	  is	  also	  suitable	  for	  use	  in	  other	  organ	  systems,	  as	  shown	  by	  producing	  
the	   same	   range	   of	   phenotypes	   obtained	   using	   gavage	   administration.	   Using	   this	  
method	   the	   effect	   of	   RA	   on	   Fgf10	   expression	   using	   a	   3f3r-­‐transgenic	   line	   was	   also	  
examined.	  	  Comparison	  of	  Fgf3	  and	  Fgf10	  control	  by	  RA,	  reveals	  both	  similarities	  and	  
differences	  in	  the	  regulation	  of	  these	  two	  genes	  by	  RA.	  	  
	  
5.1	  Regulation	  of	  Fgf3	  by	  Retinoids	  
5.1.1	  An	  alternative	  method	  for	  RA	  delivery	  to	  pregnant	  mice	  
In	  order	   to	  study	  the	  role	  of	   retinoids	   in	  embryonic	  development	   two	  methods	  have	  
traditionally	  been	  used.	  The	  most	  widely	  used	  method	   is	  gavage	   feeding.	  For	  gavage	  
administration,	  RA	  is	  first	  dissolved	  in	  DMSO	  or	  in	  a	  vegetable	  oil	  such	  as	  sesame	  seed	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oil.	   The	   oily	   mix	   is	   then	   directly	   delivered	   to	   the	   oesophagus	   via	   a	   feeding	   needle	  
and/or	   tube.	  This	  generates	  distress	  due	   to	  animal	   restraint	  and	   the	   insertion	  of	   the	  
needle/tube,	   as	   shown	   by	   the	   elevated	   levels	   of	   plasma	   corticosterone	   following	  
gavage	  administration	  in	  rat	  (Brown	  et	  al.,	  2000).	  A	  volume-­‐dependent	  stress	  response	  
was	  also	  reported	  in	  oil-­‐based	  gavage	  (Brown	  et	  al.,	  2000).	  In	  addition	  to	  this	  general	  
distress,	  gavage	  can	  directly	  cause	  damage	  to	  the	  trachea	  or	  worse,	  result	   in	  delivery	  
of	  the	  solution	   into	  the	   lungs	  and	  therefore	  can	  only	  be	  performed	  by	  highly	  trained	  
staff.	   A	   second,	   less	   used	  method	   to	   deliver	   RA,	   is	   via	   intraperitoneal	   (IP)	   injections	  
(see	   references	   in	   Table	   3.1).	   Although	   less	   invasive	   than	   the	   gavage	  method	   it	   still	  
presents	   disadvantages.	   Here	   again,	   there	   is	   the	   general	   distress	   associated	   with	  
mouse	   restraint	   (Hurst	   and	  West,	   2010)	   and	  with	   the	   insertion	   of	   a	   needle	   into	   the	  
abdomen	   (Meijer	   et	   al.,	   2006).	   In	   addition	   the	   exact	   injection	   site	   of	   RA	   cannot	   be	  
exactly	   controlled.	   It	   could	   potentially	   damage	   internal	   organs	   or	   perforate	   the	  
amniotic	   sac,	   leading	   to	   variation	   of	   the	   actual	   dose	   reaching	   the	   embryos	   in	   each	  
separate	  injection.	  Therefore,	  in	  addition	  to	  the	  welfare	  burden	  imposed	  on	  the	  mice,	  
this	  could	  also	  affect	   the	  experimental	  outcome.	  The	  stress	   imposed	  by	  both	  gavage	  
and	   IP	   injection	   is	   another	   factor	   that	   can	   influence	   the	   RA	   effect.	   Indeed	  maternal	  
restraint	  has	  been	  shown	  to	  enhance	  teratogenicity	  in	  mice	  (Rasco	  and	  Hood,	  1995a,	  
b).	  Thus	  reducing	  stress	  is	  likely	  to	  increase	  the	  reproducibility	  of	  RA	  phenotypes.	  	  
	  
Refinement	   of	   the	   gavage	   method	   has	   been	   attempted	   in	   the	   rat,	   where	   gavage	  
needles	  were	  coated	  in	  sucrose,	  and	  this	  appeared	  to	  reduce	  stress-­‐related	  behaviours	  
(Hoggatt	  et	  al.,	  2010).	  Administration	  of	  RA	  via	  food	  has	  also	  been	  carried	  out	  in	  mice	  
with	  self-­‐administration	  of	  food	  containing	  RA	  across	  several	  days	  (Niederreither	  et	  al.,	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2001).	  	  However	  this	  method	  does	  not	  permit	  specific	  dose	  or	  timing	  of	  delivery	  to	  be	  
carefully	  controlled,	  two	  criteria	  that	  dramatically	  impact	  on	  the	  severity	  and	  incidence	  
of	  induced	  phenotypes.	  
	  
This	  project	   looked	  to	   investigate	  and	  develop	  an	  alternative	  non-­‐invasive	  method	  of	  
RA	   administration	   that	   allows	   the	   delivery	   of	   specific	   doses	   of	   RA	   at	   a	   specific	   time	  
during	   embryonic	   development.	   Pregnant	  mice	   were	   first	   trained	   with	   chocolate	   or	  
sugar	  pellets,	  and	   it	  appeared	   that	  mice	  preferred	  sugar	  pellets	   to	  chocolate	  pellets.	  
Chocolate/sugar	  pellets	  were	  then	  laced	  with	  RA	  and	  pregnant	  mice	  were	  found	  to	  still	  
readily	   completely	   ingest	   them	   in	   less	   than	   30min	   on	   average,	   ensuring	   delivery	   of	  
specific	  RA	  doses	  at	  specific	  times.	  The	  sugar	  or	  the	  chocolate	  pellets	  were	  shown	  to	  
not	  have	  teratogenic	  effects	  by	  themselves	  that	  could	  interfere	  with	  the	  presentation	  
of	   the	   RA-­‐induced	   phenotypes.	   This	   was	   an	   important	   parameter	   to	   assess	   since	  
chocolate	  has	  been	  shown	  to	  be	  toxic	  to	  mice,	  with	  exposure	  during	  pregnancy	  leading	  
to	  kidney	  (Patera	  et	  al.,	  2006)	  and	  limb	  (Skopinski	  et	  al.,	  2003)	  defects	  in	  the	  progeny.	  
However	  doses	  used	  in	  these	  studies	  were	  400mg	  daily	  throughout	  pregnancy,	  which	  
is	   500	   times	   the	   amount	   used	   	   (0.8mg	   chocolate/pellet)	   in	   this	   study.	   In	   addition,	  
pregnant	  mice	  were	   exposed	   to	   a	  maximum	   of	   two	   doses	   of	   0.8mg,	   assuming	   they	  
were	   trained	   once	   before	   the	   RA	   administration.	   	   Furthermore,	   the	   excess	   control	  
experiments	   exposed	   to	   chocolate/sugar	   doses	   of	   3x	   to	   5x	   the	   single	   dose,	   and	  
harvested	   24h	   after	   administration,	   did	   not	   show	   any	   abnormal	   phenotype.	   Neither	  
craniofacial	  malformations	  nor	  neural	  tube	  defects	  were	  detected,	  and	  Fgf3	  expression	  
was	  also	  unaltered.	  Altogether	  this	  demonstrates	  that	  chocolate	  and	  sugar	  are	  unlikely	  




The	   incidence	   of	   craniofacial	   malformations	   and	   altered	   Fgf3	   	   expression	   in	   mouse	  
embryos	   at	   9.5dpc	   was	   also	   scored	   in	   this	   study.	   The	   frequency	   of	   craniofacial	  
phenotypes,	   such	   as	   anterior	   truncations	   and	   open	   neural	   tube	   phenotypes	   (Table	  
3.2),	   compares	   favourably	   following	   pellet	   delivery	   of	   RA	   with	   previously	   published	  
data	   (Appendix	   Table	   S1)	   although	   a	   direct	   comparison	   between	   administration	  
methods	  is	  not	  possible	  due	  to	  a	  slight	  difference	  in	  the	  exact	  timing	  of	  exposure.	  	  
	  
The	  pellet	  delivery	  method	  is	  also	  applicable	  to	  studying	  other	  organ	  systems,	  such	  as	  
the	   limb,	  palate	  and	  heart,	  where	  similar	  phenotypes	  were	  obtained	  using	  gavage	  or	  
sugar	  pellet	  administration.	  In	  addition	  the	  incidence	  of	  these	  phenotypes	  were	  similar	  
to	  those	  obtained	  using	  RA	  delivery	  by	  gavage	  (Appendix	  Table	  S1).	  	  
	  
Therefore	   this	  new	  method	   is	  an	  effective	  delivery	   system	  to	  study	   the	  effect	  of	   the	  
exposure	  to	  a	  specific	  dose	  of	  RA	  at	  a	  particular	  developmental	  time	  regardless	  of	  the	  
organ	  system	  under	  investigation,	  while	  providing	  the	  best	  welfare	  outcome.	  
	  
5.1.2 RA	  dosing	  regimes	  
RA	   acts	   as	   a	   morphogen	   during	   development,	   with	   different	   doses	   giving	   rise	   to	  
different	  cell	  fates.	  Due	  to	  this	  morphogenetic	  property,	  RA	  is	  thought	  to	  be	  involved	  
in	  establishing	  pattern	   formation	   in	   the	  developing	  embryo	   in	  a	  number	  of	  contexts.	  
The	   establishment	   of	   pattern	   formation	   in	   the	   hindbrain	   of	   differential	   Hox	   genes	  
induction	   is	  one	  of	   the	  best	  examples	  of	   the	  morphogen	  properties	  of	  RA,	  where	  RA	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from	  the	  paraxial	  mesoderm	  differentially	  induces	  Hox	  genes	  expression	  along	  the	  AP	  
axis	  (White	  et	  al.,	  2007).	  	  
	  
Since	   a	   small	   difference	   in	   the	   RA	   dose	   can	   have	   a	   tremendous	   effect	   on	   the	  
phenotype,	   it	   is	   not	   surprising	   that	   a	   wide	   range	   of	   doses	   have	   been	   used	   in	  
investigating	  the	  role	  of	  RA	  in	  the	  development	  of	  different	  organ	  systems	  such	  as	  the	  
CNS,	  PNS,	  limb,	  palate,	  heart	  and	  eye	  (Table	  3.1	  and	  Appendix	  Table	  S1).	  A	  brief	  survey	  
of	  the	  literature	  reveals	  that	  RA	  doses	  ranging	  from	  0.3-­‐200mg/kg	  have	  been	  used	  in	  
gavage	   experiments	   and	   1-­‐70mg/kg	   in	   experiments	   using	   IP	   injection	   (Table	   3.1).	  
Furthermore,	  due	  to	  the	  morphogenetic	  influence	  of	  RA,	  it	  would	  seem	  appropriate	  to	  
never	   restrict	   the	   analysis	   of	   retinoid	   function	   in	   an	   organ	   system,	   to	   just	   one	  
concentration	  of	  RA.	  
	  
This	  is	  commonly	  and	  easily	  performed	  in	  zebrafish	  studies,	  where	  the	  RA	  can	  be	  easily	  
applied	  at	  different	  concentrations	  to	  the	  environment	  (Hans	  and	  Westerfield,	  2007).	  
RA	  can	  also	  be	  easily	  applied	  at	  specific	  concentration	  to	  chick	  embryos,	  using	  beads	  
loaded	   with	   different	   nanomolar	   quantities	   of	   RA.	   However	   this	   suffers	   from	   the	  
drawback	   of	   establishing	   the	   morphogen	   gradient	   from	   the	   bead	   itself	   rather	   than	  
systemic	  delivery.	  	  In	  addition,	  the	  chick/RA	  bead	  system	  differs	  from	  the	  situation	  in	  
mammals	  where	  in	  utero	  development	  doesn’t	  allow	  direct	  exposure	  to	  RA.	  Delivery	  of	  
RA	  to	  embryo	  indirectly	  via	  maternal	  administration	  means	  we	  can	  be	  less	  sure	  of	  the	  
exact	  dose	  that	  reaches	  the	  target	  tissue/organ	  in	  the	  developing	  embryos.	  Therefore	  
in	  this	  report	  a	  range	  of	  RA	  doses	  were	  applied,	  ranging	  from	  4.5mg	  to	  10mg/kg,	  and	  
leads	   to	   the	   development	   of	   a	   variety	   of	   neural	   tube	   defects	   seen	   following	   gavage	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treatment.	  Increasing	  doses	  lead	  to	  an	  increasing	  incidence	  of	  defects	  and	  an	  increase	  
in	  their	  severity.	  
	  
5.1.3 Effect	  of	  RA	  on	  Fgf3	  expression	  in	  embryos	  
A	   range	   of	   RA	   doses	   and	   their	   effect	   on	   Fgf3	   regulation	  was	   investigated	   using	   the	  
Fgf3-­‐lacZ	  reporter	  line.	  Expression	  of	  Fgf3	  following	  RA	  administration	  at	  7.75dpc,	  was	  
first	  analysed	  in	  the	  developing	  CNS.	  Spinal	  cord	  expression	  is	  unaltered	  when	  exposed	  
to	  doses	  up	  to	  7mg/kg	  of	  RA,	  but	  is	  then	  downregulated	  with	  doses	  of	  8-­‐10mg/kg.	  In	  
the	  hindbrain,	  rather	  than	  a	  straightforward	  dowregulation	  with	  increasing	  dose	  of	  RA,	  
interesting	   changes	   in	   the	   spatial	   expression	   of	   Fgf3	   were	   noted.	   Exposure	   to	  
increasing	   doses	   of	   RA	   first	   led	   to	   an	   expansion	   of	   the	   rhomobomere	   1	   domain	   of	  
reporter	  expression,	  with	  loss	  of	  one	  or	  more	  rhombomeres	  boundaries,	  followed	  by	  a	  
loss	  of	  expression	  at	   the	  highest	  dose.	  This	   is	   in	  agreement	  with	   the	  model	   in	  which	  
the	  hindbrain	   is	  undergoing	  patterning	  at	  7.75dpc,	  and	  excess	  RA	  applied	  during	  this	  
period	   leads	   to	   a	   posteriorisation	   of	   hindbrain	   identity	   (reviewed	   in	   Glover	   et	   al.,	  
2006).	  Comparison	  of	  9.5dpc	  embryos	  exposed	  to	  8mg/kg	  of	  RA	  with	  embryos	  exposed	  
to	   10mg/kg	   of	   RA	   suggest	   the	   loss	   of	   expression	   could	   be	   the	   result	   of	   the	   anterior	  
truncation	   of	   the	   brain	   (and	   increasing	   posteriorisation)	   resulting	   in	   the	   loss	   of	   the	  
rhombomere	  1	  domain.	   Interestingly,	   these	  results	  also	  suggest	   that	  an	   independent	  
RA	   regulatory	   pathway	   governs	   Fgf3	   expression	   in	   rhombomere	   1	   and	   in	   the	  
rhombomeres	  boundaries.	  
	  
Administration	   of	   RA	   at	   8.5dpc	   did	   not	   have	   any	   effect	   on	   Fgf3	   expression	   in	   the	  
hindbrain	   until	   embryos	  were	   exposed	   to	   25mg/kg	   of	   RA,	   and	   resulted	   in	   a	   general	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downregulation	  of	  Fgf3	  expression	  without	  any	  changes	  in	  the	  boundaries	  of	  its	  spatial	  
domain	  of	  expression.	  This	   is	   consistent	  with	   the	  neural	   tube	  having	  now	  completed	  
patterning,	   thus	   preventing	   dramatic	   changes	   in	   rhombomeres	   boundaries/identity,	  
although	  subtle	  modifications	  of	  other	  genes	  expression	  may	  still	  happen	  (Morriss-­‐Kay	  
et	  al.,	  1991).	  	  
	  
5.1.4 Dose-­‐dependent	  effect	  of	  RA	  on	  Fgf3	  expression	  in	  the	  otic	  vesicle	  
The	  dose-­‐dependent	  teratogenicity	  of	  inner	  ear	  phenotypes	  following	  gavage	  delivery	  
of	   RA	   has	   been	   previously	   investigated	   in	   the	   inner	   ear	   (Frenz	   et	   al.,	   1996).	   These	  
authors	  showed	  that	  increasing	  doses	  of	  RA	  leads	  to	  an	  increase	  in	  the	  incidence	  of	  ear	  
phenotypes	  when	  embryos	  are	  exposed	  to	  RA	  at	  8.25-­‐8.5dpc,	  but	  not	  when	  exposed	  at	  
7.25-­‐7.5dpc	  when	  no	  phenotype	  was	  reported.	  
	  
In	   agreement	  with	   this,	   the	   incidence	   of	   otic	   Fgf3	   alteration	   of	   expression	  was	   also	  
found	   to	   be	   dose-­‐dependent.	   However,	   considerably	   lower	   levels	   of	   RA	   than	   those	  
required	   for	   teratogenicity	   are	   able	   to	   affect	   Fgf3	   expression.	   The	   teratogenic	   study	  
looked	   at	   inner	   ear	   phenotypes	   at	   11.5	   and	   13.5dpc	   whereas	   the	   gene	   expression	  
analysis	   presented	   here	   was	   carried	   out	   at	   earlier	   stages	   (9.5	   and	   10.5dpc).	  
Furthermore,	   the	   generation	   of	   an	   inner	   ear	   phenotype	  most	   probably	   requires	   the	  
alteration	  in	  the	  expression	  of	  numerous	  genes	  in	  addition	  to	  Fgf3,	  that	  might	  require	  
increased	  doses	  of	  RA	  and/or	  at	  different	  times.	  An	  alternative	  explanation	  could	  be	  an	  




In	  conclusion	  this	  study	  reveals	  a	  dose-­‐dependent	  effect	  of	  RA	  on	  gene	  expression	  that	  
is	   consistent	   with	   the	   dose-­‐dependent	   otic	   phenotypes	   previously	   reported	   (Frenz,	  
1996).	  This	  likely	  reflects	  a	  dysregulation	  of	  inner	  ear	  patterning	  by	  RA	  excess.	  	  
	  
5.1.5 Patterning	  in	  the	  otic	  vesicle	  
Downregulation	  of	  Fgf3	  expression	  following	  exposure	  to	  increasing	  dose	  of	  RA	  shown	  
here	   is	   consistent	   with	   previous	   RT-­‐PCR	   studies	   (Frenz	   et	   al.,	   2010).	   	   However	   this	  
study	  also	  reveals	  the	  differential	  downregulation	  of	  Fgf3	  expression	  in	  different	  areas	  
of	   the	   inner	  ear.	  Following	  RA	  administration	  at	  7.75dpc,	  Fgf3	   reporter	  expression	   is	  
first	  downregulated	  in	  the	  antero-­‐dorsal	  wall	  of	  the	  otic	  vesicle,	  with	  increasing	  doses	  
of	  RA	  leading	  to	  the	  progressive	  restriction	  of	  Fgf3	  expression	  to	  a	  small	  medio-­‐lateral	  
domain.	  This	  contrasts	  with	  the	  effect	  of	  RA	  administration	  at	  8.5dpc,	  which	  results	  in	  
a	   general	   downregulation	   of	   Fgf3	   expression	   without	   any	   changes	   in	   the	   spatial	  
expression	  of	  Fgf3	  in	  the	  otic	  vesicle.	  	  
	  
These	   time-­‐dependent	  differences	   in	   the	   alteration	  of	  Fgf3	   expression	   are	   similar	   to	  
those	   reported	   in	   the	   hindbrain,	   which	   are	   thought	   to	   reflect	   the	   status	   of	   the	  
patterning	   process	   at	   the	   time	   of	   RA	   administration.	   Interestingly	   RA	   has	   also	   been	  
shown	   to	   be	   involved	   in	   early	   inner	   ear	   patterning	   (Bok	   et	   al.,	   2011;	   Hans	   and	  
Westerfield,	  2007;	  Radosevic	  et	  al.,	  2011;	  Romand	  et	  al.,	  2006).	  Thus,	  the	  lateralization	  
of	   Fgf3	   expression	   following	   presomitic	   RA	   administration	   could	   be	   the	   result	   of	  
reprogramming	   inner	   ear	   re-­‐patterning	   at	   7.75dpc,	   suggesting	   otic	   vesicle	   gene	  
expression	   domains	   are	   still	   in	   the	   process	   of	   being	   established	   at	   this	   stage.	   Then	  
following	   RA	   administration	   at	   8.5dpc,	   the	   downregulated	   but	   otherwise	   unchanged	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domain	  of	  Fgf3	  otic	  expression	  could	  reflect	  that	  otic	  patterning	  is	  now	  too	  advanced	  
to	  allow	  the	  reprogramming	  of	  Fgf3	  spatial	  expression.	  	  
	  
The	   responsiveness	   of	   otic	   tissue	   to	   RA	   has	   been	   previously	   investigated	   using	   a	  
transgenic	  mouse	   line	   in	  which	   LacZ	  was	   placed	   under	   the	   control	   of	   RA	   responsive	  
elements	   (RAREs),	   and	   reveals	   a	   progressive	   withdrawal	   of	   RA	   responsiveness	   first	  
from	   the	  anterior	   region	  and	  moving	  posteriorly	   (Bok	  et	   al.,	   2011).	   In	  particular,	   the	  
anterior	   border	  of	  LacZ	   activity	  was	   located	   rostrally	   to	   the	  otic	   placode	  at	   8.25dpc,	  
whereas	  half	  a	  day	  later,	  at	  8.75dpc,	  only	  the	  posterior	  otic	  domain	  of	  the	  invaginating	  
otic	  vesicle	  was	  still	  positive	  for	  LacZ	  reporter	  activity.	  This	  is	  consistent	  with	  a	  model	  
where	  a	  gradient	  of	  RA	  would	  be	  involved	  in	  the	  patterning	  the	  inner	  ear	  up	  to	  at	  least	  
8.25dpc,	  with	   different	   RA	   doses	   eliciting	   different	   gene	   expression	   responses	   along	  
the	   antero-­‐posterior	   axis	   of	   the	   otic	   vesicle.	   Once	   the	   appropriate	   set	   of	   genes	   had	  
been	   activated	   or	   repressed,	   RA	   responsiveness	   would	   progressively	   diminish	  
reflecting	  that	  the	  otic	  vesicle	  pattern	  had	  been	  established	  in	  this	  structure.	  
	  
Studies	   on	   pattern	   formation	   in	   invertebrates	   such	   as	   Drosophila,	   show	   that	   the	  
organization	   of	   primordial	   larval	   structures	   depend	   on	   positional	   information	   in	   the	  
form	   of	   morphogen	   gradients	   in	   delimiting	   compartments.	   Expression	   of	   intrinsic	  
selector	   genes	   (e.g.	   the	   homeobox	   genes)	   would	   then	   determine	   the	   fate	   of	   cells	  
within	   a	   specific	   compartment,	   as	   well	   as	   instruct	   them	   on	   how	   to	   interact	   with	  
adjacent	  compartments	  (Lawrence	  and	  Struhl,	  1996).	  A	  similar	  compartment-­‐boundary	  
model	  of	  cell	   fate	  specification	  has	  been	  proposed	  to	  explain	  patterning	   in	   the	   inner	  
ear	   (Fekete,	   1996).	   Regional	   expression	   in	   the	   otic	   vesicle	   can	   be	   induced	   and/or	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maintained	  by	  signals	  emanating	  from	  surrounding	  tissues,	  such	  as	  FGFs	  signaling	  from	  
the	  hindbrain,	  and	  RA	   from	  the	  presomitic	  mesoderm,	   resulting	   in	   the	  generation	  of	  
otic	   compartments	   expressing	   different	   sets	   of	   genes	   (Figure	   1.5).	   The	   boundaries	  
between	   these	   compartments	   could	   then	   serve	   as	   sites	   of	   cell-­‐cell	   interaction	   to	  
mediate	  local	  patterning	  and	  cell	  fate	  specification	  in	  the	  inner	  ear	  (Fekete,	  1996).	  
	  
In	   the	   context	   of	   this	   model,	   the	   changes	   in	   the	   spatial	   expression	   domain	   of	   Fgf3	  
could	   be	   interpreted	   as	   a	   disruption	   of	   otic	   boundaries	   by	   excess	   RA.	   This	   is	   in	  
agreement	  with	  a	  recent	  study	   in	  mice	  showing	  a	   loss	  of	  another	  anterior	  domain	  of	  
gene	   expression,	   NeuroD1	   from	   the	   antero-­‐ventral	   region	   of	   the	   otocyst	   following	  
gavage	  administration	  of	  RA	  at	  7.75dpc,	  whereas	  Tbx1	   expression,	  which	   is	  normally	  
only	  expressed	  posteriorly	  was	  detected	  both	  in	  the	  posterior	  and	  the	  anterior	  poles	  of	  
the	   otic	   vesicle	   (Figure	   5.1A;	   Bok	   et	   al.,	   2011).	   Thus	   it	   has	   been	   proposed	   that	   an	  
excess	  of	  RA	  leads	  to	  a	  posteriorization	  of	  the	  otic	  vesicle	  (Bok	  et	  al.,	  2011).	  	  
	  
Inner	   ear	   patterning	   by	   an	   anterior-­‐posterior	   RA	   gradient	   is	   further	   supported	   by	   a	  
series	  of	  experiments	  in	  chick	  embryos,	  where	  the	  effect	  of	  beads	  loaded	  either	  with	  
retinoic	   acid	   or	  with	   citrate	   –	   that	   block	   RA	   signalling	   -­‐	  was	   investigated.	   Increasing	  
rostral	  RA	  signalling	  via	  the	  implantation	  of	  RA	  beads	  anteriorly	  to	  the	  otic	  vesicle	  lead	  
to	   results	   similar	   to	   RA	   administration	   in	   mice	   with	   the	   anterior	   downregulation	   of	  
NeuroD1	  and	  the	  ectopic	  expression	  of	  Tbx1	   in	  the	  anterior	  region	  of	  the	  otic	  vesicle	  
(Figure	  5.1A;	  Bok	  et	  al.,	  2011).	  	  
	  
	  























Figure	   5.1	   Eﬀects	   of	   RA	   and	   FGF	   signalling	   on	   the	   antero-­‐posterior	   paGerning	   of	   the	   o=c	  
vesicle.	   Here	   are	   schema@zed	   some	   signiﬁcant	   results	   from	   the	   analysis	   of	   RA	   and	   FGF	  
signalling	  on	  the	  paBerning	  of	  the	  o@c	  vesicle	  (OV)	  in	  mouse,	  chicken	  and	  zebraﬁsh	  (A-­‐D).	  The	  
paBern	  of	  expression	  of	  Fgf3	  in	  Tbx1	  mutant	  is	  also	  shown	  (E).	  Excess	  of	  RA	  (A),	  and	  blocking	  of	  
FGF	   signalling	   (B),	   both	   lead	   to	   a	   loss/downregula@on	   of	   anterior	   genes	   and	   a	   mirror	  
duplica@on	  of	  posterior	   genes.	   Conversely,	   blocking	  RA	   signalling	   (C),	   or	   overexpressing	  Fgf3	  
(D),	   both	   lead	   to	   a	   mirror	   duplica@on	   of	   anterior	   genes	   and	   a	   downregula@on	   of	   posterior	  
genes.	  Interes@ngly,	  lack	  of	  Tbx1	  also	  lead	  to	  a	  mirror	  duplica@on	  of	  the	  anterior	  gene	  Fgf3	  (E).	  
See	  text	  (sec@on	  5.1.5)	  for	  details	  and	  references.	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Blocking	   caudal	  RA	   signalling	   via	   the	   implantation	  of	   citrate	  beads	  posteriorly	   to	   the	  
otic	  vesicle	  resulted	   in	  ectopic	  expression	  of	  NeuroD1	  expression	  posteriorly,	  with	   its	  
normal	  expression	  in	  the	  antero-­‐ventral	  wall	  of	  the	  otic	  vesicle	  unaltered	  (Figure	  5.1C;	  
Bok	   et	   al.,	   2011).	   In	   addition,	   blocking	   rostral	   RA	   signalling	   via	   the	   implantation	   of	  
citrate	   beads	   rostrally	   to	   the	   otic	   vesicle	   results	   in	   the	   downregulation	   of	  NeuroD1	  
expression.	   All	   together	   this	   shows	   that	   RA	   is	   an	   essential	   determinant	   of	   antero-­‐
posterior	  patterning	  with	  low	  concentrations	  and/or	  shorter	  exposure	  to	  RA	  inducing	  
an	   anterior,	   neurosensory	   (NeuroD+)	   fate,	   whereas	   higher	   concentrations	   and/or	  
longer	   exposure	   to	   RA	   would	   induce	   a	   posterior,	   non-­‐sensory	   fate.	   In	   vivo	   this	   RA	  
gradient	  is	  controlled	  by	  the	  precise	  spatio-­‐temporal	  expression	  of	  RA	  synthetizing	  and	  
catabolising	   enzymes	   (see	   section	   1.4.1).	  Tbx1	   is	   one	   of	   the	   genes	   that	  mediate	   the	  
effects	   of	   RA	   on	   A-­‐P	   patterning,	   with	   an	   absence	   of	   Tbx1	   in	   mice	   resulting	   in	   the	  
posterior	   expansion	   of	   the	   anterior	   neurosensory	   domain,	   and	   duplication	   of	   the	  
vestibulo-­‐cochlear	  ganglion.	   	   In	   contrast,	  Tbx1	   overexpression	   in	  humans	   results	   in	  a	  
reduction	  of	  the	  neurogenic	  domain	  and	  in	  the	  size	  of	  the	  ganglion	  (Raft	  et	  al.,	  2004).	  	  
	  
NeuroD1	  may	   be	   one	   of	   the	   neurosensory	   genes	  mediating	   the	   effect	   of	   RA	   on	   A-­‐P	  
patterning	  in	  the	  anterior	  part	  of	  the	  otic	  vesicle.	  Mice	  lacking	  NeuroD1	  are	  deaf	  and	  
display	   a	   severe	   reduction	   of	   sensory	   neurons	   in	   the	   vestibulo-­‐cochlear	   ganglion,	   a	  
shortened	   and	   widened	   cochlear	   duct,	   and	   defects	   in	   hair	   cell	   organization	   in	   the	  
organ	   of	   Corti,	   with	   duplication	   and	   ectopic	   addition	   of	   inner	   hair	   cells	   and	  




Downregulation	   and	   relocalisation	   of	   Fgf3	   expression	   following	   presomitic	   RA	  
administration	   (Figure	  5.1A)	   suggests	   that	  may	  also	  mediate	   the	  effects	  of	  RA	  on	  AP	  
patterning,	   and	   in	   particular	   play	   a	   major	   role	   in	   the	   development	   of	   structures	  
thought	  to	  emerge	  from	  the	  antero-­‐ventral	  wall	  of	  the	  otic	  vesicle	  such	  as	  the	  sensory	  
hair	  cells	  and	  neurons	  of	  the	  cochlear	  and	  vestibular	  system.	  In	  humans,	  homozygous	  
mutation	   of	   Fgf3	   has	   been	   linked	   to	   deafness,	   suggesting	   a	   role	   in	   cochlear	  
formation/function.	   However	   most	   individuals	   affected	   lack	   the	   entire	   inner	   ear,	  
including	  cochlea,	  and	   the	  vestibule	   (Riazuddin	  et	  al.,	  2011)	   thus	  making	  unclear	   the	  
exact	  role	  of	  Fgf3	   in	  inner	  ear	  patterning.	  Homozygous	  mutation	  of	  Fgf3	   in	  mice	  lead	  
to	  less	  dramatic	  phenotypes,	  such	  as	  reduction	  in	  size	  and	  dorsal	  shift	  of	  the	  vestibulo-­‐
acoustic	  ganglion,	  poor	  cochlear	  coiling	  and	  abnormal	  vestibular	  structures	   (Hatch	  et	  
al.,	   2007).	   In	   another	  Fgf3	  mutant,	   hearing	   and	   vestibular	   function	  was	   found	   to	   be	  
completely	  unimpaired	  (Alvarez	  et	  al.,	  2003).	  	  
	  
Variability	  in	  the	  phenotypes	  observed	  in	  Fgf3	  mutant	  mice	  could	  potentially	  be	  due	  to	  
different	   factors.	   Firstly,	   the	   selection	  of	   strain	   for	  making	   a	   null	  mutant	   can	  have	   a	  
significant	   effect	   on	   the	   phenotype	   (Thyagarajan	   et	   al.,	   2003)	   due	   to	   their	   different	  
genetic	  backgrounds.	  This	  effect	   is	  due	  to	   ‘modifier	  genes’,	  which	  act	   in	  combination	  
with	  the	  causative	  genes	  (Montagutelli,	  2000).	  Some	  genetic	  backgrounds	  may	  include	  
modifier	   genes	   that	   compensate	   for	   the	   missing	   genes,	   whereas	   in	   other	   genetic	  
backgrounds	  there	  may	  be	  additional	  dysfunctional	  genes	  that	  will	   lead	  to	  a	  stronger	  
phenotype.	  Secondly,	  the	  way	  the	  gene	  is	  targeted	  may	  also	  influence	  the	  phenotype.	  
For	  example,	  the	  first	  Fgf3	  null	  mutant	  was	  generated	  by	  insertion	  of	  a	  neomycin	  (neo)	  
resistance	  gene	  under	   the	  control	  of	  a	  phosphoglycerate	  kinase	  1	   (PGK)	  promoter	   in	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the	  first	  exon	  of	  Fgf3	  (Wright	  et	  al,	  2003)	  and	  the	  PGK-­‐neo	  cassette	  has	  been	  reporter	  
to	   influence	  the	  expression	  of	  nearby	  genes,	  resulting	   in	  unusual	  phenotypes	  (Rijli	  et	  
al.,	  1994;	  Wang	  et	  al.,	  1999).	  However	  Hatch	  et	  al.	   (2007)	  used	  two	  transgenic	   lines,	  
one	  with	  a	  neo	  insertion	  in	  the	  exon	  1	  of	  Fgf3	  and	  a	  second	  one	  with	  a	  deletion	  of	  exon	  
2,	  who	  both	  exhibits	  similar	  phenotypes	  so	  we	  can	  here	  rule	  out	  an	  effect	  of	  the	  neo	  
selector	  gene.	  
	  
Interestingly,	   analysis	   of	   otic	   gene	   expression	   in	   Fgf3	   null	   mutants	   revealed	   that	  
expression	  of	   ventral	  otic	   genes	   involved	   in	   cochlear	  development	   such	  as	  Pax2	   and	  
Otx2	  was	  unaffected	  (Hatch	  et	  al.,	  2007)	  whereas	  the	  expression	  of	  dorsally	  expressed	  
genes	  such	  as	  Gbx2,	  Wnt2b,	  Dlx5	  and	  Hmx3	  was	  absent	  or	  shifted.	  This	  is	  in	  agreement	  
with	   a	   compartment/boundary	   model	   where	   formation	   of	   inner	   ear	   structures	  
depends	  on	  signalling	  between	  compartments	  to	  mediate	  local	  patterning	  and	  cell	  fate	  
specification.	  
	  
Homozygous	  mutation	   of	   Tbx1	   also	   leads	   to	   an	   inner	   ear	   phenotype	   showing	   some	  
similarities	  to	  homozygous	  Fgf3	  mutation,	  with	  Tbx1	  mutant	  also	  showing	  hypoplasia,	  
and	  abnormal	  or	  lacking	  vestibular	  and	  cochlear	  structure	  (Arnold	  et	  al.,	  2006a;	  Arnold	  
et	   al.,	   2006b).	   However	   instead	   of	   being	   reduced	   as	   in	   Fgf3	  mutants,	   the	   vestibulo-­‐
acoustic	  ganglion	  domain	  was	  expanded.	  Furthermore,	  Fgf3	  was	  ectopically	  expressed	  
in	   the	   posterior	   otic	   vesicle	   domain	   (Figure	   5.1E).	   This	   is	   consistent	  with	   the	   role	   of	  
Tbx1	   in	  maintaining	   posterior	   non-­‐neurogenic	   otic	   identity	   and	   suggests	   that	   at	   the	  




This	   model	   is	   also	   consistent	   with	   the	   role	   of	   Fgf3	   in	   zebrafish	   where	   it	   has	   been	  
demonstrated	   that	   blocking	   FGF	   signalling	   results	   in	   a	   loss	   of	   anteriorly	   expressed	  
genes	   Pax5	   and	   Hmx2,	   wheareas	   genes	   normally	   expressed	   in	   the	   posterior	  
compartments	   such	  as	  Fst1	   and	  Otx1	   becomes	  ectopically	   expressed	  anteriorly.	   (see	  
schematic	   of	   Fst1	   expression	   in	   Figure	   5.1B;	   Hammond	   and	  Whitfield,	   2011).	   These	  
results	  are	  similar	  to	  what	  can	  be	  observed	  when	  altering	  RA	  signalling.	  As	  mentioned	  
above,	   excess	   of	   RA	   results	   in	   the	   loss	   of	   anteriorly	   expressed	   genes	   such	   as	   Lfng,	  
NeuroD1	   and	   Fgf3	   and	   the	   duplication	   of	   posteriorly	   expressed	   genes	   such	   as	   Tbx1	  
anteriorly	  (see	  schematic	  of	  NeuroD,	  Fgf3	  and	  Tbx1	  expression	   in	  Figure	  5.1A;	  Bok	  et	  
al.,	  2011;	  Cadot	  et	  al.,	  2012).	  Interestingly	  the	  use	  of	  specifically	  localized	  RA	  bead	  and	  
systemic	  RA	  administration	  lead	  to	  similar	  results.	  This	  suggests	  that	  otic	  patterning	  is	  
highly	   sensitive	   to	   difference	   in	   effective	   RA	   concentration,	   regardless	   of	   the	   exact	  
distribution	  of	  exogenous	  RA	  around	  the	  embryo.	  Conversely,	  blocking	  of	  RA	  signalling	  
leads	  to	  a	  duplication	  of	  anterior	  gene	  expression	  domains	  such	  as	  NeuroD1	  that	  then	  
starts	  to	  be	  expressed	  posteriorly	  in	  the	  chick	  otic	  vesicle;	  along	  with	  a	  downregulation	  
of	  Tbx1	  expression	  in	  the	  posterior	  domain	  (Figure	  5.1C;	  Bok	  et	  al.,	  2011).	  
	  
Furthermore,	  when	  observed	  at	  later	  stages,	  the	  otic	  vesicles	  of	  Zebrafish	  in	  which	  FGF	  
signalling	   was	   inhibited	   display	   a	   lack	   of	   anterior	   structures	   and	   a	   duplication	   of	  
posterior	   regions	   (Hammond	   and	   Whitfield,	   2011).	   Mirror	   duplication	   of	   the	   two	  
posterior	   halves	   were	   also	   reported	   in	   chick	   embryo	   in	   which	   RA	   bead	   had	   been	  
implanted	  next	  to	  the	  otic	  cup.	  Conversely,	  overexpression	  of	  Fgf3	  results	  in	  the	  loss	  of	  
posterior	  otic	  structures	  and	  a	  duplication	  of	  anterior	  domains	  in	  Zebrafish	  (Hammond	  
and	  Whitfield,	   2011).	   In	   other	   words,	   inhibiting	   FGF	   signalling	   mimics	   the	   effect	   of	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excess	  RA,	  whereas	  overexpression	  of	  Fgf3	  mimics	  the	  effect	  of	  blocking	  RA	  signalling,	  
suggesting	   Fgf3	  may	   be	   one	   of	   the	   key	   gene	   by	  which	   RA	   regulates	   otic	   patterning.	  
Patterns	  of	  gene	  expressions	  also	  supporting	  this	  hypothesis	  are	  schematised	  in	  Figure	  
5.1.	  
	  
In	  conclusion,	  all	  together	  these	  studies	  suggest	  that	  AP	  otic	  patterning	  depends	  on	  an	  
antero-­‐posterior	  gradient	  of	  RA,	  with	  induction	  of	  Tbx1	  by	  high	  doses	  of	  RA	  playing	  a	  
major	  role	  in	  the	  specification	  of	  the	  posterior	  part	  of	  the	  otic	  vesicle,	  and	  induction	  of	  
Fgf3	  by	  low	  doses	  of	  RA	  playing	  a	  major	  part	  in	  the	  specification	  of	  the	  anterior	  part	  of	  
the	  otic	  vesicle.	  The	  exact	  timing	  of	  axis	  fixation	  have	  not	  yet	  been	  established	  in	  mice,	  
but	  the	  plasticity	  of	  gene	  expression	  such	  as	  Fgf3	  (Cadot	  et	  al.,	  2012),	  as	  well	  as	  Tbx1	  
(Bok	  et	  al.,	  2011)	  following	  RA	  administration	  is	  consistent	  with	  ongoing	  AP	  patterning	  
at	  7.75dpc.	   	  On	  the	  other	  hand,	  Fgf3	  expression	  domains	  are	  not	  spatially	  altered	  by	  
excess	  RA	  at	  8.5dpc	   (Cadot	  et	  al.,	   2012),	   thus	   suggesting	   that	   the	  AP	  axis	   is	   fixed	  by	  
8.5dpc.	  This	  dual	  effect	  of	  RA	  in	  the	  early	  inner	  ear	  is	  discussed	  in	  more	  details	  in	  the	  
following	  section.	  
	  
5.1.6 Interpreting	  the	  dual	  effect	  of	  RA	  in	  the	  early	  inner	  ear	  
The	  downregulation	  of	  Fgf3	  expression	  in	  embryos	  exposed	  to	  RA	  may	  be	  explained	  by	  
direct	   regulation	   of	   Fgf3	   through	   RA-­‐binding	   sites	   located	   in	   the	   enhancer	   region	  
regardless	  of	  the	  stage	  of	  administration.	  However	  the	  lateralization	  of	  Fgf3	  expression	  
that	  is	  only	  observed	  following	  exposure	  to	  RA	  at	  7.75dpc	  requires	  an	  additional	  level	  
of	  regulation.	  One	  possibility	  is	  that	  Fgf3	  is	  negatively	  regulated	  by	  other	  transcription	  
factors	  responding	  to	  higher	  RA	  levels,	  with	  the	  loss	  of	  Fgf3	  expression	  in	  the	  antero-­‐
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dorsal	  part	  of	  the	  otic	  vesicle	  thus	  reflecting	  direct	  and	  indirect	  downregulation	  of	  RA.	  
Another	   possibility	   is	   that	   the	   spatial	   change	   of	   the	   Fgf3	   expression	   domain	   in	   otic	  
vesicle	  could	  be	  linked	  to	  the	  posteriorisation	  of	  the	  hindbrain.	  	  
	  
In	  order	  to	  explain	  why	  Fgf3	  expression	  is	  first	  lateralized	  before	  becoming	  increasingly	  
downregulated	  with	  increasing	  dose	  of	  RA,	  I	  propose	  the	  following	  model	  (Figure	  5.2).	  
A	  major	  source	  of	  RA	   involved	   in	  the	  patterning	  of	  the	  hindbrain	  and	  the	  otic	  vesicle	  
comes	   from	   the	   caudal	   expression	   of	   Raldh2	   in	   the	   somites	   and	   lateral	   plate	  
mesoderm	  (Romand	  et	  al,	  2006;	  Bok	  et	  al.	  2011).	  This	  generates	  a	  RA	  gradient	  along	  
the	  AP	  axis	  that	  is	  accentuated	  across	  the	  otic	  vesicle	  through	  the	  action	  of	  several	  RA	  
catabolyzing	   enzymes,	   in	   particular	   CYP26C1,	   that	   is	   expressed	   rostrally	   to	   the	   otic	  
vesicle	   at	   8dpc.	   This	   RA	   source	   seems	   to	   generate	   a	   posteriorising	   signal	   since	   the	  
expression	   of	   anterior	   neurogenic	   genes	   such	   as	   NeuroD	   is	   lost	   following	  
administration	  of	  50mg/kg	  of	  RA	  (Bok	  et	  al,	  2011).	  	  
	  
However,	   if	  the	  RA	  gradient	  were	  behaving	  like	  a	  simple	  sink	  and	  source	  model,	  with	  
anterior	  genes	  such	  as	  Fgf3	  being	  downregulated	  at	  high	  RA	  concentration,	  we	  would	  
predict	   an	   anterior	   shift	   or	   a	   general	   downregulation	   of	   Fgf3	   otic	   expression	   with	  
increasing	  RA	  administration.	  Instead,	  this	  study	  shows	  that	  the	  expression	  of	  Fgf3	  at	  
the	  boundary	  between	  anterior	  and	  posterior	  compartments	  stay	  unchanged,	  whereas	  
the	  expression	  in	  the	  anterior	  and	  dorsal	  part	  of	  the	  otic	  vesicle	  becomes	  increasingly	  
downregulated	  with	  increasing	  doses	  of	  RA.	  	  
	  
	  
Figure	   5.2	   Model	   of	   exogenous	   re=noic	   acid	   eﬀect	   on	   o=c	   paGerning.	   (A)	   On	   the	   lek,	  
endogenous	   RA	   sources	   are	   represented	   in	   red;	   on	   the	   right,	   the	   red	   arrows	   symbolized	   how	  
these	  sources	  aﬀect	  o@c	  paBerning.	  Endogenous	  sources	  of	  RA	  synthesis	  include	  the	  presomi@c	  
(PSM)/early	   somi@c	   mesoderm,	   located	   caudally	   to	   the	   o@c	   vesicle,	   and	   the	   anterior	   o@c	  
epithelium.	   During	   normal	   embryonic	   development,	   the	   developing	   inner	   ear	   is	   therefore	   in	  
between	  two	  opposing	  gradients.	  I	  suggest	  that	  the	  strict	  localiza@on	  of	  Fgf3	  to	  the	  anterior	  o@c	  
ep@helium	   is	   due	   to	   his	   requirement	   for	   a	   lower	   RA	   threshold	   than	   posterior	   genes	   and	   its	  
downregula@on	   by	   high	   RA	   level	   (from	   the	   PSM)	   ,	   thus	   preven@ng	   Fgf3	   expression	   to	   spread	  
posteriorly.	   (B)	   	   Changes	   in	   RA	   signaling	   strength	   and	   Fgf3	   expression	   following	   RA	   systemic	  
delivery	   of	   exogenous	   RA:	   combina@on	   of	   exogenous	   RA	   with	   endogenous	   RA	   results	   in	   an	  
eleva@on	   of	   the	   two	   opposing	   RA	   gradients.	   The	   increasing	   anterior	   gradient	   would	   then	  
progressively	  downregulate	  Fgf3	  expression,	  star@ng	  by	  the	  anterior	  pole.	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Therefore,	  there	  must	  be	  a	  mechanism	  that	  maintains	  the	  boundary	  between	  anterior	  
and	  posterior	  compartments,	  this	  could	  be	  the	  result	  of	  the	  source	  and	  sink	  interaction	  
described	  by	  Bok	  et	  al.,	   (2001),	  with	  relative	  concentrations	  of	  RA	  specifying	  the	  two	  
poles	   of	   the	   otic	   vesicle.	   Then	   a	   second	   mechanism,	   based	   on	   effective	   RA	  
concentrations,	  would	  specify	  the	  identity	  of	  each	  pole.	  
	  
In	  our	  model,	  we	  believe	  this	  second	  mechanism	  reflects	  the	  presence	  of	  an	  additional	  
RA	  source	  not	  considered	  by	  Bok	  et	  al.	  (2001).	  Retinoid	  synthesizing	  enzymes	  are	  also	  
expressed	  in	  the	  otic	  epithelium	  in	  anterior/dorsal	  regions.	  	  Raldh2	  is	  expressed	  in	  the	  
dorsal	  otic	  epithelium,	  and	  Raldh3	   in	  the	  dorsal	  and	  antero-­‐ventral	  region	  of	  the	  otic	  
epithelium	   (Romand	   et	   al.,	   2006),	   that	   together	   form	   a	   second	  RA	   source	   anteriorly	  
and	  dorsally	   (Figure	  5.2).	   Thus,	  when	   increasing	  doses	  of	   exogenous	  RA	  are	   applied,	  
both	  the	  posterior	  signal	  and	  this	  second	  antero-­‐dorsal	  source	  become	  more	  robust.	  A	  
combination	  of	  raised	  systemic	  RA	  levels	  together	  with	  RA	  generated	  in	  the	  wall	  of	  the	  
otic	  vesicle	  would	  expose	  Fgf3	   to	  abnormally	  high	   level	  of	  RA	  anteriorly	  and	  dorsally	  
and	  therefore	  explain	  the	  gradual	  and	   increasing	  dorsal	  and	  anterior	   loss	  of	   reporter	  
expression.	  	  
	  
This	   model	   is	   complementary	   to	   the	   one	   proposed	   by	   Bok	   et	   al.	   (2001)	   as	   this	  
additional	  source	  of	  RA	  also	  allows	  to	  explain	  the	  ectopic	  expression	  of	  Tbx1	  anteriorly	  
following	   RA	   administration	   at	   7.75dpc.	   It	   would	   be	   interesting	   to	   look	   at	   NeuroD	  
expression	  following	  exposure	  to	  a	  range	  of	  RA	  doses	  to	  see	  whether	  it	  confirms	  this	  




In	   the	   introductory	  paragraph	  of	   this	   section,	   the	  possibility	  of	  an	  additional	   level	  of	  
regulation	   by	   transcription	   factors	   responding	   to	   higher	   level	   of	   RA	   was	   also	  
mentioned.	  Tbx1	  would	  be	  a	  good	  candidate	  since	  it	  starts	  being	  expressed	  where	  Fgf3	  
expression	  is	  lost	  following	  exposure	  to	  RA.	  Furthermore,	  as	  discussed	  in	  section	  5.1.5,	  
Fgf3	  is	  ectopically	  expressed	  posteriorly	  in	  Tbx1	  mutant	  (Figure	  5.1E;	  Raft	  et	  al.,	  2004).	  
All	   together	   these	   results	   suggests	   that	   Tbx1	   represses	   Fgf3	   expression,	   although	  
whether	  this	  regulation	  is	  direct	  or	  indirect	  remains	  to	  be	  determined.	  
	  
Eventually,	   there	   is	   the	  possibility	   that	   the	  altered	  expression	  of	  otic	  genes	   reported	  
does	  not	  reflect	  a	  direct	  regulation	  of	  otic	  patterning	  by	  RA,	  but	  a	  secondary	  effect	  of	  
hindbrain	   posteriorization.	   This	   question	   has	   been	   addressed	   in	   chick	   by	   altering	  
rhombomere	  patterns	  to	  mimic	  the	  effects	  of	  RA	  bead	  implantation	  (Bok	  et	  al.,	  2011).	  
To	  do	   so,	   they	   replaced	   the	   rhombomeres	   normally	   adjacent	   to	   the	   ear	   (r4-­‐r6)	   by	   a	  
block	   of	   caudal	   tissues	   containing	   r7	   and	   the	   spinal	   cord.	   This	   transplantation	  
experiment	  did	  not	  result	  in	  the	  altered	  genes	  expression	  reported	  with	  RA	  (Bok	  et	  al.,	  
2011).	   This	   suggests	   that,	   at	   least	   in	   chick,	   the	   effects	   of	   RA	   on	   otic	   patterning	   are	  
independent	  of	  hindbrain	  signalling.	  	  
	  
In	   summary,	   in	   the	   first	   part	   of	   this	   thesis	   I	   have	   proposed	   and	   developed	   a	   new	  
method	   for	   retinoic	   acid	   administration,	   and	   used	   this	   to	   administer	   RA	   to	   Fgf3-­‐
reporter	   transgenic	  mice.	  This	   revealed	  a	  dose	  dependant	  downregulation	  of	  Fgf3	   in	  
the	   developing	   inner	   ear	   and	   in	   the	   hindbrain.	   Reporter	   expression	   was	   also	  
differentially	   downregulated	   according	   to	   the	   developmental	   stage	   of	   RA	   exposure.	  
Furthermore,	  this	  study	  also	  highlights	  the	  value	  of	  transgenic	  reporter	  lines	  that	  allow	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following	   in	   considerable	   detail	   subtle	   changes	   of	   expression	   that	   for	   many	   genes	  
would	  not	  be	  readily	  detected	  via	  in	  situ	  hybridization	  alone.	  	  
	  
	  
5.2 Regulatory	  analysis	  of	  Fgf10	  	  
5.2.1 Investigating	  Fgf10	  regulation	  in	  mice	  
Hindbrain	   Fgf10	   and	   Fgf3	   have	   been	   shown	   to	   be	   redundantly	   required	   for	   otic	  
placode	   induction	   (Zelarayan	   et	   al.,	   2007),	   and	   mutation	   in	   either	   Fgf3	   or	   Fgf10	   is	  
linked	  to	  deafness	   in	  humans.	   Interestingly	  the	  two	  human	  deafness	  syndromes	  with	  
which	   they	   are	   associated	   are	   phenotypically	   very	   similar.	   Fgf3	   mutations	   underlie	  
LAMM	  syndrome	  (labyrinthine	  aplasia,	  microtia,	  and	  microdontia,	  OMIM	  610706)	  that	  
is	  characterized	  by	  lack	  of	  all	  inner	  ear	  structures	  (aplasya)	  and	  microdontia	  (Riazuddin	  
et	  al.,	  2011).	  Fgf10	  mutations	  lead	  to	  LADD	  syndrome	  (Lacrimo-­‐auriculo-­‐dento-­‐digital,	  
OMIM	   149730)	   that	   is	   characterized	   by	   hearing	   loss	   and	  microdontia	   (Shams	   et	   al.,	  
2007).	   The	   ability	   of	   the	   two	   genes	   to	   compensate	   for	   each	   other	   during	   the	   otic	  
induction	  in	  mice	  (Zelarayan	  et	  al.,	  2007)	  suggests	  they	  can	  trigger	  similar	  downstream	  
pathways	   and	  may	   also	   be	   sharing	   the	   same	   upstream	   regulators	   in	   the	   hindbrain.	  
Furthermore,	   they	   are	   also	   expressed	   in	   the	   developing	   inner	   ear	   itself,	   with	  
expression	   in	   particular,	   overlapping	   in	   the	   antero-­‐ventral	   wall	   of	   the	   otic	   vesicle,	   a	  
region	  that	   is	   thought	  to	  give	  rise	  to	  the	  neurosensory	  components	  of	   the	   inner	  ear.	  
This	   suggests	  Fgf10	   and/or	  Fgf3	  may	   be	   involved	   in	   the	   generation	   of	   neurons,	   hair	  
cells	  or	  even	  both,	  and	  this	  has	  been	  brought	  out	  by	  phenotype	  analysis	  (section	  1.3)	  
making	  them	  potential	  factors	  to	  be	  used	  in	  future	  gene	  therapy	  to	  treat	  deafness.	  In	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agreement	  with	  this,	  Fgf3	  and	  Fgf10	  were	  used	  in	  vitro	  to	  induce	  the	  differentiation	  of	  
hair	   cell-­‐like	   cells	   and	   auditory	   neurons	   (Chen	   et	   al.,	   2012).	   Furthermore,	   these	   otic	  
neuroprogenitors	  were	  shown	  to	  differentiate	  and	  improve	  auditory-­‐evoked	  response	  
in	  gerbil.	  	  
	  
In	  order	  to	  generate	  a	  Fgf10-­‐reporter	  transgenic	  mice	  line,	  I	  first	  attempted	  to	  delimit	  
an	  enhancer	  element	   that	  would	   recapitulate	   the	   full	   pattern	  of	  Fgf10	   expression	   in	  
the	   inner	  ear,	  as	  well	  define	  any	  different	  cis-­‐regulatory	  modules	  or	  units	  controlling	  
Fgf10	  expression	   in	  different	  areas	  of	   the	   inner	  ear	   in	  either	  spatial	  and/or	  temporal	  
terms.	   Previous	   studies	   had	   revealed	   that	   a	   7kb	   region	   upstream	  Fgf10	  was	   able	   to	  
recapitulate	   the	   full	   pattern	   of	   Fgf10	   expression	   whereas	   a	   smaller	   800bp	   region	  
within	   this	   enhancer	   was	   believed	   to	   control	   Fgf10	   expression	   from	   later	   stages	  
(11.5dpc),	  and	  in	  restricted	  areas	  of	  the	  inner	  ear	  only	  (Ohuchi	  et	  al.,	  2005).	  	  
	  
A	  series	  of	  constructs	  were	  prepared	  to	  generate	  an	  Fgf10-­‐reporter	  line	  recapitulating	  
the	   full	   pattern	   of	   Fgf10	   expression	   (7F7R-­‐DsRed)	   and	   a	   variety	   of	   subfragment-­‐
reporter	   constructs	   that	   may	   reveal	   any	   distinct	   modular	   organization	   of	   the	  
regulatory	   region.	   	   In	   addition,	   a	   cluster	   of	   neurogenin-­‐related	   binding	   sites	   was	  
detected	  and	  additional	  constructs	  prepared	  to	  test	  the	  potential	  input	  of	  this	  pathway	  
in	  normal	  Fgf10	  regulation.	  Finally	  these	  would	  be	  compared	  with	  the	  Fgf3	  regulatory	  
data,	  particularly	  the	  RA	  control	  of	  Fgf3.	  
	  
However	   the	   generation	   of	   Fgf10-­‐reporter	  mice	   containing	   a	   large	   upstream	   region	  
proved	   to	   be	   difficult	   and	   delayed	   the	   generation	   of	   stable	   transgenic	   lines.	   Two	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independent	   7F7R-­‐DsRed	   lines	  were	   eventually	   obtained	   but	   founders	  were	   female,	  
and	   following	   breeding	   to	   increase	   the	   colony	   size,	   neither	   was	   found	   to	   exhibit	  
fluorescent	   staining	   in	   the	   developing	   inner	   ear	   (nor	   in	   other	   embryonic	   domains	  
examined	   at	   the	   same	   stages).	   The	   lack	   of	   reporter	   expression	   can	   be	   explained	   in	  
several	  ways.	  First,	  a	  mutation	  may	  have	  been	  introduced	  in	  the	  promoter,	  reporter	  or	  
enhancer.	   Sequencing	   of	   the	   promoter	   and	   reporter	   did	   not	   reveal	   any	   sequence	  
mutations.	   Next,	   functionality	   of	   the	   7F7R	   enhancer	   was	   confirmed	   by	   reporter	  
expression	   in	   the	   chicken	  embryo	   following	  otic	   vesicle	   electroporation.	   Second,	   the	  
transgene	  may	  have	   randomly	   integrated	   in	   a	   part	   of	   the	   genome	   that	   is	   quiescent.	  
However,	   the	   likelihood	   that	   both	   independent	   integrations	   similarly	   integrated	   into	  
such	  genomic	  regions	   is	   rather	  remote.	   	  Another	  possibility	  relates	  to	  plasmid	  vector	  
sequences	   that	  were	   not	   removed	   prior	   to	   pronuclear	   injection,	   and	   that	   remaining	  
plasmid	  sequences	  could	  inhibit	  gene	  transcription.	  Such	  negative	  regulatory	  effect	  of	  
plasmid	   sequence	   have	   previously	   been	   reported.	   A	   last,	   possibility	   is	   that	   the	  
enhancer	   is	   lacking	   DNA	   regions	   required	   for	   its	   expression	   and/or	   may	   contain	  
repressor	  regions	  negatively	  regulating	  its	  ability	  to	  control	  expression.	  	  
	  
Careful	  comparison	  of	  the	  restriction	  map	  of	  the	  7F7R	  Fgf10	  enhancer	  to	  the	  map	  of	  
the	  large	  enhancer	  Ohuchi	  identified	  (2005)	  revealed	  that	  the	  7F7R	  enhancer	  fragment	  
was	   lacking	   a	   2kb	   5’region,	   whilst	   including	   an	   additional	   promoter-­‐proximal	   700bp	  
region	   (Figure	   4.2).	   	   Analysis	   of	   this	   700bp	   region	   revealed	   the	   presence	   of	   8	  
repetitions	  of	  ETSF	  factors	  followed	  by	  21	  repetitions	  of	  VZF07	  Zinc	  finger	  protein	  263	  
sites,	   followed	  by	  17	  more	  sites	   for	  ETSF	   factors.	  Although	  a	   review	  of	   the	   literature	  
did	   not	   reveal	   whether	   these	   factors	   could	   negatively	   regulate	   gene	   expression,	   it	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cannot	   be	   ruled	   out	   that	   this	   apparently	   unusual	   stretch	   of	   DNA	   repeats	   might	  
interfere	   with	   Fgf10	   expression.	   The	   presence	   of	   2	   conserved	   elements	   upstream	  
Fgf10	   not	   included	   in	  7F7R	  was	  also	  envisaged	  as	   a	  possibility	   to	  explain	   the	   lack	  of	  
DsRed	  expression.	  However,	  the	  3F3R	  fragment	  was	  later	  shown	  to	  drive	  the	  early	  and	  
late	  patterns	  of	  inner	  ear	  expression	  (Economou	  et	  al.,	  2012).	  	  Thus,	  whilst	  additional	  
neural	   domains	   that	   have	   never	   been	   intensively	   studied	   for	   any	   of	   these	   reporters	  
could	  be	  present	   in	  these	  missing	  domains,	  the	  ability	  of	  3F3R-­‐ZsGreen	   to	  drive	  early	  
inner	  ear	  expression	  suggests	  that	  the	  7F7R-­‐DsRed	  transgene	  should	  have	  worked.	  The	  
technical	   issues	  raised	   in	  the	  previous	  paragraphs	  are	  thus	  the	  more	   likely	  to	  explain	  
the	  lack	  of	  7F7R-­‐DsRed	  expression.	  
	  
5.2.2 Investigating	  Fgf10	  regulation	  in	  chick	  
A	  quick	   review	  of	   the	   literature	   shows	   that	   the	   chick	  has	  been	   successfully	   used	   for	  
testing	   mouse	   enhancer	   regulatory	   activity	   (Saitsu	   et	   al.,	   2006).	   The	   ex-­‐utero	  
development	   of	   the	   chicken	   embryo	  makes	   it	   easy	   to	   incubate	   the	   embryo	   until	   an	  
appropriate	   time	   of	   development,	   to	   access	   the	   embryo	   to	   electroporate	   reporter-­‐
constructs	   and	   subsequently	   analyse	   embryos	   for	   transgene	   expression	   after	   just	   1	  
more	  day	  of	   incubation.	  Thus	   this	  method	   theoretically	  allows	   testing	   the	   regulatory	  
potential	  of	  any	  enhancer	  in	  4	  days	  and	  at	  low	  cost.	  In	  addition,	  the	  analysis	  of	  mouse	  
Fgf10	  regulation	  in	  the	  chicken	  inner	  ear	  also	  aimed	  at	  uncovering	  potential	  similarities	  
and	  differences	  between	  Fgf10	  regulation	  in	  chick	  and	  in	  mouse.	  	  
	  
Electroporation	   of	   7F7R-­‐ZsGreen,	   3F3R-­‐Zgreen	   and	   3F7R-­‐ZsGreen	   constructs	   lead	   to	  
ZsGreen	   expression	   in	   a	   couple	   of	   embryos	   for	   each	   construct,	   showing	   that	   all	   the	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enhancer	   fragments	   tested	  were	  able	   to	  drive	  Fgf10	   expression	   in	   the	   chicken	   inner	  
ear.	   Importantly,	   this	  also	  demonstrates	   that	   the	  7F7R	   fragment	   that	  had	  been	  used	  
for	  the	  generation	  of	  the	  two	  transgenic	  mouse	  lines	  that	  did	  not	  exhibit	  any	  inner	  ear	  
expression	   was	   however	   functional	   in	   the	   chicken.	   Although	   the	   relatively	   small	  
number	  of	   chicken	  embryos	  expressing	   the	   transgene	  did	  not	  allow	  me	   to	  draw	  any	  
firm	  conclusions,	  it	  seemed	  that	  the	  larger	  the	  construct,	  the	  stronger	  the	  fluorescence	  
and	   the	   larger	   the	  area	  of	  expressing	  cells.	  This	  could	  be	   interpreted	   that	  7F7R	  does	  
contain	   additional	   domains	   positively	   regulating	   its	   expression	   in	   the	   chick	   embryo,	  
and	  would	  be	  interesting	  to	  explore	  further.	  
	  
In	  an	  independent	  project	  in	  the	  lab,	  the	  generation	  and	  characterization	  of	  a	  minimal	  
Fgf10	  ear	  enhancer	  recapitulating	  most,	  if	  not	  all	  of	  Fgf10	  expression	  in	  the	  inner	  ear,	  
was	  completed	  and	  shown	   to	   lie	  within	   the	  3F3R	  enhancer	   (Economou	  et	  al.,	  2012).	  
Furthermore,	  the	  Fgf10	  pattern	  of	  expression	  in	  electroporated	  chicken	  embryos	  was	  
compared	   against	   mouse	   transgenic	   reporter	   embryos.	   In	   mice,	   the	   3F3R-­‐Zsgreen	  
pattern	  of	  expression	  was	  strictly	  restricted	  to	  the	   inner	  ear,	  whereas	   in	  chick,	  3F3R-­‐
ZsGreen	   is	   expressed	   in	   the	   otic	   epithelium	  and	   in	   addition	   other	   regions	   of	   surface	  
ectoderm	  in	  (this	  study	  and	  A.Economou,	  personal	  communications).	  Also,	  mutation	  of	  
the	   3	   GATA3	   sites	   of	   3F3R	   resulted	   in	   loss	   of	   Fgf10	   expression	   in	   all	   mouse	   lines	  
examined	  (Economou	  et	  al.,	  2012),	  whereas	  reporter	  expression	  was	  still	  detected	   in	  
chick	  (A.	  Economou	  personnal	  communications).	  All	  together	  this	  suggests	  that	  some	  
aspects	  of	  molecular	  mechanisms	  underlying	  Fgf10	   regulation	  are	  different	  between	  
chick	  and	  mouse	  inner	  ear.	  	  It	  would	  be	  interesting	  to	  test	  the	  constructs	  containing	  all	  
four	   conserved	   regions	   to	   see	  whether	   inner	   ear	   specificity	   is	   regained.	   	   But	   in	   the	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opposite	  fashion,	  expression	  of	  the	  reporter	  does	  show	  that	  Fgf10	  reporter	  constructs	  
can	   be	   tested	   for	   functionality	   in	   the	   chicken	   embryo,	   with	   the	   caveat	   that	   otic	  
specificity	  may	  be	  lost.	  	  	  
	  
Thus,	   the	   present	  work	  modulates	  what	   had	  been	  previously	   postulated	   (Timmer	   et	  
al.,	   2001),	   and	   indicates	   that	   although	   chick	   electroporation	  may	   indeed	   be	   used	   to	  
analyse	   the	   regulatory	   potential	   of	   enhancer	   regions	   for	   some	   mouse	   genes,	   this	  
cannot	   be	   extended	   to	   all	   mouse	   genes.	   Therefore,	   an	   analysis	   of	   mouse	   enhancer	  
regulation	  in	  chick	  should	  not	  stand	  on	  its	  own	  but	  always	  need	  to	  be	  corroborated	  by	  
data	  in	  mice.	  	  
	  
5.2.3 Regulation	  of	  Fgf10	  by	  the	  Neurogenin	  pathway	  
In	  order	  to	  identify	  putative	  upstream	  regulators	  of	  Fgf10,	  bioinformatic	  analysis	  of	  the	  
6.9kb	  region	  upstream	  of	  Fgf10	  reported	  by	  Ohuchi	  et	  al.	  (2005)	  was	  performed	  using	  
MatInspector	   (Quandt	   et	   al.,	   1995).	   This	   analysis	   showed	   the	   presence	   of	   1294	  
putative	   transcription	   factor	   binding	   sites.	   	   Some	  of	   these	   factors	  were	  of	   particular	  
interest,	  as	  they	  are	  known	  to	  be	  active	  in	  the	  early	  inner	  ear	  around	  the	  time	  of	  Fgf10	  
onset	   of	   expression.	   This	   includes	   putative	   binding	   sites	   for	   members	   of	   the	  
Neurogenin	   pathway,	   Ngn1	   and	   NeuroD.	   Ngn1	   and	   NeuroD	   are	   proneural	   genes	  
expressed	   in	   the	   anteroventral	   wall	   of	   the	   otic	   vesicle	   and	   are	   required	   for	  
neurogenesis	   in	  the	   inner	  ear	  (Abello	  and	  Alsina,	  2007;	  Ma	  et	  al.,	  1998).	  Accordingly,	  
Ngn1	  mutants	  fail	  to	  form	  the	  proximal	  cranial	  sensory	  ganglia	  and	  targeted	  mutation	  
of	  NeuroD	   results	   in	   a	   severe	   loss	   of	   inner	   ear	   sensory	   neurons	   (Abello	   and	   Alsina,	  
2007;	  Ma	  et	  al.,	  1998).	  The	  number	  of	  otic	  neurons	  was	  also	  reduced	  in	  Fgf10	  null	  mice	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(Pirvola	   et	   al.,	   2000),	   thus	   suggesting	  Fgf10	  may	  be	  one	  of	   the	   genes	  mediating	   the	  
effect	  of	  the	  Neurogenin	  pathway.	  
	  
The	  presence	  of	  a	  binding	  site	  alone	  is	  only	  a	  first	  step	  in	  the	  identification	  of	  an	  in	  vivo	  
functional	   regulator	   of	   Fgf10	   expression,	   because	   consensus	   sequences	   may	   occur	  
randomly	  within	  the	  genome	  by	  chance	  alone.	  However	  two	  additional	  organizational	  
traits	   suggest	   functionality	   in	   vivo.	   First,	   the	   Ngn1/NeuroD	   sites	   lie	   in	   a	   region	   of	  
homology	  conserved	  between	  mice,	  chick	  and	  humans	  (Ohuchi	  et	  al.	  2005).	  In	  addition	  
these	   sites	   form	   a	   cluster	   in	   the	   3’	   region	   of	   the	   enhancer,	   and	   previous	   studies	  
suggest	   that	   clustered	   binding	   sites	   identified	   by	   bioinformatic	   strategies	   are	   more	  
likely	   to	   be	   functionally	   relevant	   in	   vivo	   (Gotea	   et	   al.,	   2010;	   Lifanov	   et	   al.,	   2003).	  
Comparative	  analysis	  of	  NeuroD	  and	  Fgf10	  expression	  also	  supported	  the	  Neurogenin	  
pathway	  as	  a	  candidate	  for	  direct	  regulation	  of	  Fgf10.	  	  
	  
In	   order	   to	   test	   the	   functionality	   in	   vivo	   of	   these	   sites,	   several	   enhancer	   fragments	  
containing	  all	  or	  part	  of	  the	  clustered	  neurogenic	  family	  of	  sites	  were	  constructed.	  At	  
the	  time	  of	  writing	  they	  were	  not	  tested	  but	  they	  will	   likely	  be	  the	  starting	  point	   for	  
further	  studies.	  	  
	  
5.2.4 Regulation	  of	  Fgf10	  by	  Gata3	  
The	  bioinformatic	  analysis	  of	  the	  7.0kb	  region	  upstream	  Fgf10	  revealed	  the	  presence	  
of	   9	   putative	   GATA3	   binding	   sites.	  Gata3	   is	   a	   transcription	   factor	   expressed	   in	   the	  
developing	  inner	  ear	  (Lawoko-­‐Kerali	  et	  al.,	  2002;	  Lawoko-­‐Kerali	  et	  al.,	  2004;	  Nardelli	  et	  
al.,	  1999;	  Pauley	  et	  al.,	  2003)	  and,	  interestingly,	  Fgf10	  expression	  is	  downregulated	  in	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Gata3	   null	   mice	   (Lillevali	   et	   al.,	   2006).	   All	   together	   these	   elements	   suggested	   that	  
Gata3	  was	  a	  strong	  candidate	  for	  direct	  Fgf10	   regulation.	  As	  part	  of	   this	  project,	   the	  
onset	  of	  Gata3	  and	  Fgf10	  expression	  were	  examined	  and	  compared.	  This	  comparative	  
analysis	  revealed	  their	  expression	  is	  initiated	  in	  similar	  areas	  of	  the	  inner	  ear.	  
	  
Other	   experiments	   performed	   independently	   in	   the	   lab	   then	   confirmed	   the	   direct	  
regulation	  of	  Fgf10	  by	  Gata3.	  EMSA	  experiments	  were	  performed	  on	  the	  3	  GATA3	  sites	  
located	   in	   3F3R	   and	   revealed	   the	   GATA3	   protein	   could	   bind	   all	   three	   sites	   but	  with	  
different	  affinity	   (Economou	  et	  al.,	  2012).	  The	  functional	  significance	  of	  these	  GATA3	  
binding	   sites	   was	   then	   tested	   in	   vivo,	   and	   GATA3	   site2	   was	   the	   only	   binding	   site	  
absolutely	  required	  for	  Fgf10	  expression	  in	  the	  inner	  ear	  (Economou	  et	  al.,	  2012).	  	  
	  
5.2.5 Regulation	  of	  Fgf10	  by	  Retinoids	  
The	  3F3R	  Fgf10	  enhancer	   contains	   two	  putative	   retinoic	   acid	  binding	   sites,	   and	   thus	  
analysis	  of	  3F3R-­‐ZsGreen	  transgenic	  mice	  was	  used	  to	  gauge	  the	  response	  of	  Fgf10	  to	  
RA.	  Using	  a	  dose	  that	  gave	  maximum	  response	  of	  Fgf3,	  25mg/kg	  of	  RA	  at	  8.5dpc	  lead	  
to	   different	   spatial	   changes	   to	   Fgf10	   than	   those	   found	   for	   Fgf3.	   Fgf10	   expression	  
appeared	  more	  dorsally	   localized,	  while	   lost	  and	  downregulated	   in	   the	  anteroventral	  
wall	   of	   the	   otic	   vesicle	   in	   half	   of	   the	   embryos.	   In	   the	   remaining	   embryos,	   Fgf10	  
expression	  appeared	  unchanged.	  Interestingly,	  embryos	  where	  expression	  was	  shifted	  
and	  downregulated,	   also	  displayed	  abnormal	  brain	  phenotypes,	   such	  as	  open	  neural	  
tube	   defects,	   that	   are	   characteristic	   of	   embryos	   exposed	   to	   RA	   prior	   to	   hindbrain	  
patterning.	  Perhaps	  then	  exposure	  at	  7.75dpc	  and	  during	  hindbrain	  patterning	  affects	  
Fgf10	   expression,	   through	  dorsalisation	  and	  downregulation,	  but	  exposure	  at	  8.5dpc	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does	  not.	  Based	  on	  this	  hypothesis,	  I	  designed	  an	  additional	  set	  of	  RA	  treatments	  that	  
were	   carried	   out	   by	   A.	   Economou	   during	   the	   writing	   of	   my	   thesis.	   When	   RA	   is	  
administered	  at	  7.75dpc,	  Fgf10	  expression	  becomes	  more	  dorsally	  localized	  in	  the	  otic	  
vesicle	  and	  appears	  lost	  or	  downregulated	  in	  the	  anteroventral	  region,	  but	  when	  RA	  is	  
administered	  at	  8.5dpc	  the	  spatiotemporal	  pattern	  of	  Fgf10	  is	  no	  longer	  dorsalized	  but	  
just	  downregulated	  (Economou	  et	  al.,	  2012).	  The	  downregulation	  of	  Fgf10	  expression	  
following	   exposure	   to	   25mg/kg	   of	   RA	   extends	   previous	   RT-­‐PCR	   studies	   (Frenz	   et	   al.,	  
2010)	  where	  the	  spatial	  dynamics	  of	  changes	  in	  expression	  are	  now	  revealed.	  	  	  	  
	  
5.2.6 Differences	   and	   similarities	   in	   Fgf10	   and	   Fgf3	   regulation	   by	  
Retinoids	  
Regulation	  of	  Fgf10	  by	  retinoids	  shows	  similarities	  and	  differences	  with	  Fgf3.	  Similar	  to	  
Fgf3,	   Fgf10	   expression	   is	   downregulated	   in	   the	   antero-­‐ventral	   wall	   of	   the	   otocyst	  
following	   RA	   administration.	   	   Both	   also	   exhibit	   spatial	   changes,	   although	   along	  
different	  otic	  axes.	  	  Timing	  of	  administration	  appears	  to	  be	  important	  for	  both	  genes.	  	  
Fgf3	  expression	  is	  shifted	  posteriorly	  and	  becomes	  lateralized	  in	  embryos	  exposed	  to	  
RA	  before	  hindbrain	  patterning	  but	   is	  only	  downregulated	   in	  embryos	  exposed	  to	  RA	  
after	   hindbrain	   patterning	   (Cadot	   et	   al.,	   2012).	   However,	   for	   Fgf10,	   the	   remaining	  
patch	  of	  expression	  is	  dorsal	  whereas	  for	  Fgf3	  it	  is	  ventral.	  In	  addition,	  there	  were	  clear	  
RA	  response	  differences	  in	  the	  incidence	  and	  extent	  of	  reporter	  downregulation,	  with	  
only	  30%	  of	  the	  Fgf10	  reporter	  embryos	  showing	  some	  downregulation	  when	  exposed	  
to	  25mg/kg	  of	  RA	   (Economou	  et	  al.,	   2012),	  whereas	  more	   than	  90%	  of	   the	  embryos	  
presented	   a	   downregulation	   of	   Fgf3	   expression	  when	   exposed	   to	   a	   similar	   RA	   dose	  
(Cadot	  et	  al.,	  2012).	  However,	  these	  results	  may	  not	  be	  directly	  comparable	  since	  no	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quantitative	   analysis	   of	   Fgf3/Fgf10	   expression	   was	   performed,	   the	   reporters	   are	  
different	   and	   the	   dose-­‐response	   of	   Fgf10	   to	   RA	   was	   not	   analysed	   in	   detail.	   Such	  
experiments	  would	  be	  useful	  to	  confirm	  these	  conclusions.	  	  	  
	  
The	   relocation	   of	   Fgf10	   expression	   following	   exposure	   of	   embryos	   at	   7.75dpc	  
(Economou	  et	   al.,	   2012)	   also	   confirms	   the	  plasticity	   of	   otic	   vesicle	   patterning	   at	   this	  
stage	   of	   development	   as	   initially	   suggested	   following	   the	   detailed	   analysis	   of	   Fgf3	  
expression.	   	  Reprogramming	  the	  spatial	  expression	  of	   two	  different	   Fgfs	   in	   the	   inner	  
ear	  unequivocally	  demonstrates	  that	  at	  7.75dpc	  the	  otic	  vesicle	  is	  able	  to	  reprogram	  its	  
spatial	  gene	  expression	  pattern.	  These	  contrasts	  with	  the	  downregulated	  but	  spatially	  
unaltered	  domain	  of	  Fgf10	  and	  Fgf3	  expression	  following	  RA	  administration	  at	  8.5dpc,	  
showing	   that	   at	   this	   stage,	   the	   otic	   vesicle	   seems	   to	   have	   become	   resistant	   to	   re-­‐
patterning.	  
	  
Different	   spatial	   responses	   of	   Fgf3	   and	   Fgf10	   to	   RA	   may	   also	   reflect	   underlying	  
differences	  in	  the	  regulation	  of	  the	  two	  ligands;	  and/or	  their	  functions	  within	  the	  otic	  
epithelium	  that	  have	  not	  yet	  been	  fully	  defined.	   Indeed	  as	  part	  of	   this	  project,	   I	  also	  
showed	  that	   the	  Fgf3	  pattern	  of	  expression	   is	  unchanged	   in	  Fgf10	  mutants	  and	   thus	  
Fgf3	  could	  in	  part	  compensate	  for	  the	  lack	  of	  Fgf10	  in	  vivo	  at	  the	  ligand	  level,	  however	  
the	   functionality	  of	  Fgf3/Fgf10	   redundancy	  within	   the	  otic	  epithelium	  and	  vestibulo-­‐
acoustic	  ganglion	  has	  not	  yet	  been	  investigated.	  	  
	  
The	  major	  alteration	   in	  Fgf3/Fgf10	   spatial	   expression	  happens	   following	  exposure	   to	  
RA	   during	   hindbrain	   patterning.	   Since	   otic	   vesicle	   formation	   is	   under	   the	   control	   of	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signalling	  from	  the	  hindbrain	  	  (Alvarez	  et	  al.,	  2003)	  this	  raises	  the	  possibility	  that	  this	  
repatterning	  may	  all	  or	  partly	  be	  due	  to	  the	  repatterning	  of	  the	  hindbrain.	  	  However,	  
the	  presence	  of	  RAREs	  in	  both	  Fgf	  enhancers,	  and	  the	  ability	  of	  RA	  to	  bind	  Fgf3	  RAREs	  
(Frenz	   et	   al.,	   2010)	   raise	   the	   possibility	   of	   a	   direct	   regulatory	   control.	   It	   will	   be	  
interesting	   to	   define	   the	   extent	   of	   the	   RA	   response	   that	   is	   indirect,	   and	   due	   to	  
alterations	   in	   hindbrain	   patterning,	   or	   direct	   through	   directly	   repressing	   Fgf3	   and	  
Fgf10	  expression	  through	  binding	  the	  RAREs	  located	  in	  the	  two	  enhancers.	  
	  
5.3 Conclusions	  
Regulatory	  mechanisms	   involved	   in	   the	   formation	   of	   sensory	   neurons	   and	   hair	   cells	  
during	  inner	  ear	  development	  are	  still	  poorly	  understood	  and	  this	  is	  an	  obstacle	  to	  the	  
generation	  of	  gene	  or	  stem	  cell	   therapies	   to	   treat	  deafness	  and	  hearing	   impairment.	  
Fgf3,	   Fgf10	   and	   RA	   have	   long	   been	   known	   to	   play	   crucial	   roles	   in	   inner	   ear	  
development	  and	  there	  has	  been	  accumulating	  evidence	  that	  they	  could	  be	  involved	  in	  
hair	  cell	  differentiation	  (Kelley	  et	  al.,	  1993;	  Chen	  et	  al.,	  2012).	  	  
	  
Using	  an	  Fgf3-­‐lacZ	  transgenic	  line	  a	  detailed	  analysis	  of	  the	  effect	  of	  excess	  RA	  on	  Fgf3	  
expression	   was	   performed	   (Cadot	   et	   al.,	   2012).	   This	   showed	   that	   RA	   differentially	  
affects	  Fgf3	  expression	  depending	  on	  administration	  timing	  and	  dose.	  Administration	  
of	   increasing	   doses	   of	   RA	   at	   7.75dpc	   leads	   to	   a	   dose-­‐dependent	   downregulation	   of	  
Fgf3	  in	  the	  otic	  vesicle,	  as	  well	  as	  changes	  in	  hindbrain	  expression.	  Detailed	  analysis	  of	  
the	   otic	   vesicle	   at	   9.5dpc	   also	   showed	   a	   lateralization	   of	   Fgf3	   expression	   with	  
increasing	  dose	  of	  RA.	  Administration	  of	  RA	  at	  8.5dpc	  also	  leads	  to	  a	  dose-­‐dependent	  
downregulation	  of	  RA	  in	  the	  inner	  ear	  at	  higher	  doses	  than	  required	  at	  7.75dpc	  but	  no	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spatial	   changes	   of	   expression;	   otic	   Fgf3	   expression	   was	   evenly	   downregulated	  
throughout	   the	   otic	   vesicle,	   suggesting	   that	   otic	   patterning	   is	   underway	   at	   7.75dpc	  
whereas	  the	  AP	  axis	  is	  fixed	  at	  8.5dpc.	  	  
	  
Fgf10	  enhancer-­‐constructs	  were	  made	  and	  tested	  both	   in	  mice	  and	  chick	  embryos	   in	  
order	  to	  identify	  fragments	  controlling	  all	  or	  part	  of	  Fgf10	  expression	  in	  the	  inner	  ear.	  
Comparative	   analysis	   between	   electroporated	   chick	   inner	   ears	   and	   a	   Fgf10-­‐ZsGreen	  
transgenic	  mouse	   line	   (3F3R-­‐ZsGreen;	   Economou	  et	   al.,	   2012)	   suggests	   that	   some	  of	  
the	  molecular	  mechanisms	  underlying	  Fgf10	   regulation	  are	  different	  between	  mouse	  
and	   chick	   inner	   ear.	   Using	   the	   3F3R-­‐ZsGreen	   transgenic	   mouse	   line	   shown	   to	  
recapitulate	  Fgf10	  endogenous	  expression	  in	  all	  area	  of	  the	  inner	  ear	  (Economou	  et	  al.,	  
2012).	   A	   preliminary	   analysis	   of	   Fgf10	   regulation	   by	   retinoids	   was	   performed	   and	  
showed	  similarities	  with	  Fgf3	  regulation,	  with	  both	  time	  and	  dose	  differently	  affecting	  
otic	   Fgf10	   expression.	   However,	   the	   change	   in	   spatial	   expression	   following	   RA	  
administration	   at	   7.75dpc	   and	   the	   dose	   required	   to	   induce	   it	  was	   different	   than	   for	  
Fgf3.	   	   The	   differential	   responses	   of	   Fgf3	   and	   Fgf10	   to	   RA	   suggest	   these	   genes	   are	  
unlikely	   to	   be	   fully	   redundant	   in	   the	   development	   of	   structures	   from	   the	   otic	  
epithelium.	   	   The	   development	   of	   conditional	   double	   null	   alleles	   will	   be	   of	   some	  
interest	   to	   explore	   functional	   redundancy	   and	   examine	   how	   this	   reflects	   the	  
divergence	   of	   upstream	   molecular	   mechanisms.	   	   Moreover,	   the	   identification	   of	  
whether	   the	   RA	   inputs	   to	   regulate	   Fgf3/10	   is	   direct	   or	   indirect	   is	   another	   goal	   that	  
needs	   to	   be	   established	   in	   drawing	   up	   the	  molecular	   programme	   of	   early	   inner	   ear	  



























































































































































































































Table	  S1	  –	  Range	  of	  all-­‐trans	  retinoic	  acid	  doses	  administrated	  to	  pregnant	  mice	  via	  

































of	  defects	  	   References	  10	   -­‐-­‐	   (Wang	  et	  al.,	  2009)	  7dpc	   100	   -­‐-­‐	   (Wang	  et	  al.,	  2009)	  
25	   0-­‐17%*	   	  (Kochhar	  et	  al.,	  1984)	  
50	   8-­‐27%*	   (Kochhar	  et	  al.,	  1984)	  
100	   28-­‐46%*	  40%	   (Kochhar	  et	  al.,	  1984)	  (Abbott	  et	  al.,	  2005)	  10dpc	   200	   54%	   (Kochhar	  et	  al.,	  1984)	  
2,5	   0,5%	   (Campbell	  et	  al.,	  2004)	  
10	   7,6%	   (Campbell	  et	  al.,	  2004)	  
25	   33%	   (Kochhar	  et	  al.,	  1984)	  
30	   26,3%	   (Campbell	  et	  al.,	  2004)	  
50	   82%	   (Kochhar	  et	  al.,	  1984)	  
60	   42,4%	   (Campbell	  et	  al.,	  2004)	  
100	   65-­‐75%	  73,7%	  82%	   (Abbott	  et	  al.,	  2005)	  (Campbell	  et	  al.,	  2004)	  (Kochhar	  et	  al.,	  1984)	  
11dpc	  	  
200	   94%	   (Kochhar	  et	  al.,	  1984)	  
70	   -­‐-­‐	  -­‐-­‐	   (Degitz	  et	  al.,	  1998)	  (Zhang	  et	  al.,	  2003),	  (Dempsey,	  1983)	  
	  
PALATE	  
12dpc	  	   100	   0-­‐50%	  94,1%	   (Abbott	  et	  al.,	  2005)	  (Wang	  et	  al.,	  2009)	  10	   60	   (Wasiak	  and	  Lohnes,	  1999)	  7dpc	   100	   100	   (Wasiak	  and	  Lohnes,	  1999)	  
	  
HEART	  
8dpc	   70IP	   51-­‐67%	   (Ratajska	  et	  al.,	  2005)	  
6dpc	   20	   12-­‐60%	   (Simeone	  et	  al.,	  1995)	  
7dpc	   20	   58-­‐90%	  -­‐-­‐	   (Simeone	  et	  al.,	  1995)	  (Avantaggiato	  et	  al.,	  1996)	  
	  
FOREBRAIN	  
8dpc	   20	   68-­‐72%	   	  (Simeone	  et	  al.,	  1995)	  
	  













of	  defects	  	   References	  10	   -­‐-­‐	   (Morriss-­‐Kay	  et	  al.,	  1991),	  (Mahmood	  et	  al.,	  1996)	  12	   -­‐-­‐	   (Morriss-­‐Kay	  et	  al.,	  1991),	  (Mahmood	  et	  al.,	  1996)	  (Wood	  et	  al.,	  1994)	  20	   -­‐-­‐	   	  (Conlon	  and	  Rossant,	  1992),	  (Marshall	  et	  al.,	  1992)	  7dpc	   25	   -­‐-­‐	   (Leonard	  et	  al.,	  1995)	  
10	   -­‐-­‐	   (Morriss-­‐Kay	  et	  al.,	  1991),	  (Mahmood	  et	  al.,	  1996)	  12	   -­‐-­‐	   (Morriss-­‐Kay	  et	  al.,	  1991),	  (Mahmood	  et	  al.,	  1996)	  (Wood	  et	  al.,	  1994)	  8dpc	   20	   -­‐-­‐	   (Folberg	  et	  al.,	  1999)	  
	  
HINDBRAIN	  
9dpc	   20	   -­‐-­‐	   (Folberg	  et	  al.,	  1999)	  
9dpc	   80	   3%	   (Kochhar,	  1973)	  
25	   0-­‐15%*	   (Kochhar	  et	  al.,	  1984)	  
50	   7-­‐76%*	   (Kochhar	  et	  al.,	  1984)	  
80	   0%	   (Kochhar,	  1973)	  
100	   21-­‐91%*	  95,1%	  -­‐-­‐	   (Kochhar	  et	  al.,	  1984)	  (Cusic	  and	  Dagg,	  1985)	  (Bynum,	  1991)	  
10dpc	  
200	   90%	   (Kochhar	  et	  al.,	  1984)	  
20	   64-­‐82,6%	   (Kwasigroch	  et	  al.,	  1984)	  
40	   100%	   (Kwasigroch	  et	  al.,	  1984)	  
60	   100%	   (Anson	  et	  al.,	  1991)	  
80	   100%	   (Kwasigroch	  et	  al.,	  1984),	  (Kochhar,	  1973)	  11dpc	  
100	   -­‐-­‐	  87,6%	  100%	  	  
	  (Hayes	  and	  Morriss-­‐Kay,	  2001)	  
	  (Cusic	  and	  Dagg,	  1985)	  
(Kwasigroch	  and	  Neubert,	  1980),	  (Alles	  
and	  Sulik,	  1989),	  (Anson	  et	  al.,	  1991)	  12dpc	   80	   84%	   (Kochhar,	  1973)	  
13dpc	   80	   61%	   (Kochhar,	  1973)	  
	  
LIMB	  
14-­‐15dpc	   80	   0%	   (Kochhar,	  1973)	  













of	  defects	  	   References	  1IP	   0%	   (Lee	  et	  al.,	  2006)	  
3IP	   5,3%	   (Lee	  et	  al.,	  2006)	  
5IP	   2,9%	   (Lee	  et	  al.,	  2006)	  
7,5IP	   5,3%	   (Lee	  et	  al.,	  2006)	  
9dpc	  
50IP	   -­‐-­‐	   (Shimizu	  et	  al.,	  2007)	  
10dpc	   100	   40%	   	  (Abbott	  et	  al.,	  2005)	  
2,5	   4,9%	   (Campbell	  et	  al.,	  2004)	  
10	   26,3%	   (Campbell	  et	  al.,	  2004)	  
30	   83%	   (Campbell	  et	  al.,	  2004)	  
60	   93,3%	   (Campbell	  et	  al.,	  2004)	  
11dpc	  
100	   65-­‐75%	  93,2%	  100%	   (Abbott	  et	  al.,	  2005)	  (Campbell	  et	  al.,	  2004)	  (Kochhar	  et	  al.,	  1984)	  
	  
FORELIMB	  
12dpc	   100	   0-­‐50%	   (Abbott	  et	  al.,	  2005)	  
20	   -­‐-­‐	   (Kawanishi	  et	  al.,	  2003)	  6dpc	  	   30	   -­‐-­‐	   (Kawanishi	  et	  al.,	  2003)	  
10	   -­‐-­‐	   (Iulianella	  and	  Lohnes,	  1997)	  7dpc	   20	   -­‐-­‐	   (Kawanishi	  et	  al.,	  2003)	  




10-­‐11dpc	   100	   -­‐-­‐	   (Iulianella	  and	  Lohnes,	  1997)	  
0,313	   8,1%	   (Sulik	  et	  al.,	  1995)	  
0,625	   12,9%	   (Sulik	  et	  al.,	  1995)	  




12,5IP	   95,5%	   (Ozeki	  and	  Shirai,	  1998)	  













of	  defects	  	   References	  5IP	   14-­‐22%	   (Juriloff	  et	  al.,	  1991)	  
3	  x	  5	   0%	   (Ehlers	  et	  al.,	  1992)	  
3	  x	  12,5	   58%	   (Ehlers	  et	  al.,	  1992)	  
3	  x	  15	   60%	   (Ehlers	  et	  al.,	  1992)	  
20IP	   25,7-­‐100%*	   (Kuno	  et	  al.,	  1999)	  
30IP	   40,6-­‐92%*	   (Kuno	  et	  al.,	  1999)	  
3	  x	  30	   100%	   (Ehlers	  et	  al.,	  1992)	  
40IP	   57,1-­‐94%*	  -­‐-­‐	   (Kuno	  et	  al.,	  1999)	  (Yasuda	  et	  al.,	  1990)	  50IP	   94,4%	  -­‐-­‐	   (Kuno	  et	  al.,	  1999)	  (Dempsey	  and	  Trasler,	  1983)	  60	   -­‐-­‐	   (Yasuda	  et	  al.,	  1990)	  
53IP	   -­‐-­‐	   (Kapron-­‐Bras	  and	  Trasler,	  1988)	  
	  




80	   -­‐-­‐	   (Tibbles	  and	  Wiley,	  1988)	  
20	   0%	   (Frenz	  et	  al.,	  1996)	  6dpc	   25	   0%	   (Frenz	  et	  al.,	  1996)	  
15	   0%	   (Frenz	  et	  al.,	  1996)	  
20	   0%	   (Frenz	  et	  al.,	  1996)	  
25	   0%	   (Frenz	  et	  al.,	  1996)	  7dpc	  
50	   -­‐-­‐	   (Bok	  et	  al.,	  2011)	  
2	  x	  12,5	   0%	   (Frenz	  et	  al.,	  1996)	  
25	   5%	   (Frenz	  et	  al.,	  1996)	  










9dpc	   25	   -­‐-­‐	   (Frenz	  et	  al.,	  1996)	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of	  defects	  	   References	  10	   -­‐-­‐	   (Mahmood	  et	  al.,	  1996)	  7dpc	   12	   -­‐-­‐	   (Mahmood	  et	  al.,	  1996)	  
5	   -­‐-­‐	   (Taylor	  et	  al.,	  1995)	  
10	   -­‐-­‐	   (Mahmood	  et	  al.,	  1996)	  
12	   -­‐-­‐	   (Mahmood	  et	  al.,	  1996)	  
60	   -­‐-­‐	   (Vanmuylder	  et	  al.,	  2004)	  
8dpc	  




9dpc	   60	   -­‐-­‐	   (Vanmuylder	  et	  al.,	  2004)	  
7dpc	   10	   -­‐-­‐	   (Mallo	  and	  Brandlin,	  1997)	  
10	   -­‐-­‐	   (Mulder	  et	  al.,	  2000)	  
25	   -­‐-­‐	   (Mulder	  et	  al.,	  2000)	  





100	   -­‐-­‐	   (Mulder	  et	  al.,	  2000)	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